<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="1063" width="918">
	<fontspec id="0" size="25" family="Times" color="#000000"/>
	<fontspec id="1" size="13" family="Times" color="#000000"/>
	<fontspec id="2" size="13" family="Times" color="#0000ff"/>
	<fontspec id="3" size="13" family="Helvetica" color="#000000"/>
	<fontspec id="4" size="13" family="Times" color="#000000"/>
<text top="103" left="105" width="252" height="37" font="0">Accepted Manuscript</text>
<text top="189" left="105" width="528" height="21" font="1">2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease</text>
<text top="230" left="105" width="564" height="21" font="1">WRITING COMMITTEE MEMBERS, Donna K. Arnett, PhD, MSPH, FAHA, Co-Chair,</text>
<text top="248" left="105" width="538" height="21" font="1">Roger S. Blumenthal, MD, FACC, FAHA, Co-Chair, Michelle A. Albert, MD, MPH,</text>
<text top="266" left="105" width="545" height="21" font="1">FAHA, Erin D. Michos, MD, MHS, FACC, FAHA, Andrew B. Buroker, Esq, Michael</text>
<text top="284" left="105" width="525" height="21" font="1">D. Miedema, MD, MPH, Zachary D. Goldberger, MD, MS, FACC, FAHA, Daniel</text>
<text top="302" left="105" width="560" height="21" font="1">Muñoz, MD, MPA, FACC, Ellen J. Hahn, PhD, RN, Sidney C. Smith, Jr., MD, MACC,</text>
<text top="320" left="105" width="526" height="21" font="1">FAHA, Cheryl D. Himmelfarb, PhD, RN, ANP, FAHA, Salim S. Virani, MD, PhD,</text>
<text top="338" left="105" width="567" height="21" font="1">FACC, FAHA, Amit Khera, MD, MSc, FACC, FAHA, Kim A. Williams, Sr., MD, MACC,</text>
<text top="356" left="105" width="531" height="21" font="1">FAHA, Donald Lloyd-Jones, MD, SCM, FACC, FAHA, Joseph Yeboah, MD, MS,</text>
<text top="374" left="105" width="545" height="21" font="1">FACC, FAHA, J. William McEvoy, MBBCh, MEd, MHS, Boback Ziaeian, MD, PhD,</text>
<text top="392" left="105" width="556" height="21" font="1">FACC, FAHA, ACC/AHA TASK FORCE MEMBERS, Patrick T. O’Gara, MD, MACC,</text>
<text top="410" left="105" width="539" height="21" font="1">FAHA, Chair, Joshua A. Beckman, MD, MS, FAHA, Chair-Elect, Glenn N. Levine,</text>
<text top="428" left="105" width="529" height="21" font="1">MD, FACC, FAHA, Immediate Past Chair, Sana M. Al-Khatib, MD, MHS, FACC,</text>
<text top="446" left="105" width="568" height="21" font="1">FAHA, Mark A. Hlatky, MD, FACC, FAHA, Kim K. Birtcher, PharmD, MS, AACC, John</text>
<text top="464" left="105" width="550" height="21" font="1">Ikonomidis, MD, PhD, FAHA, Joaquin E. Cigarroa, MD, FACC, José A. Joglar, MD,</text>
<text top="482" left="105" width="566" height="21" font="1">FACC, FAHA, Anita Deswal, MD, MPH, FACC, FAHA, Laura Mauri, MD, MSc, FAHA,</text>
<text top="500" left="105" width="536" height="21" font="1">Lee A. Fleisher, MD, FACC, FAHA, Mariann R. Piano, RN, PhD, FAHA, Federico</text>
<text top="518" left="105" width="549" height="21" font="1">Gentile, MD, FACC, Barbara Riegel, PhD, RN, FAHA, Zachary D. Goldberger, MD,</text>
<text top="536" left="105" width="371" height="21" font="1">MS, FACC, FAHA, Duminda N. Wijeysundera, MD, PhD</text>
<text top="614" left="105" width="22" height="21" font="1">PII:</text>
<text top="614" left="216" width="165" height="21" font="1">S0735-1097(19)33877-X</text>
<text top="642" left="105" width="31" height="21" font="1">DOI:</text>
<text top="642" left="216" width="275" height="21" font="2"><a href="https://doi.org/10.1016/j.jacc.2019.03.010">https://doi.org/10.1016/j.jacc.2019.03.010</a></text>
<text top="671" left="105" width="73" height="21" font="1">Reference:</text>
<text top="671" left="216" width="74" height="21" font="1">JAC 26029</text>
<text top="719" left="105" width="88" height="21" font="1">To appear in:</text>
<text top="723" left="216" width="306" height="14" font="3"><i>Journal of the American College of Cardiology</i></text>
<text top="836" left="105" width="672" height="21" font="1">Please cite this article as: WRITING COMMITTEE MEMBERS, Arnett DK, Blumenthal RS, Albert MA,</text>
<text top="854" left="105" width="670" height="21" font="1">Michos ED, Buroker AB, Miedema MD, Goldberger ZD, Muñoz D, Hahn EJ, Smith Jr SC, Himmelfarb</text>
<text top="872" left="105" width="641" height="21" font="1">CD, Virani SS, Khera A, Williams Sr KA, Lloyd-Jones D, Yeboah J, McEvoy JW, Ziaeian B, ACC/</text>
<text top="890" left="105" width="670" height="21" font="1">AHA TASK FORCE MEMBERS, O’Gara PT, Beckman JA, Levine GN, Chair IP, Al-Khatib SM, Hlatky</text>
<text top="908" left="105" width="649" height="21" font="1">MA, Birtcher KK, Ikonomidis J, Cigarroa JE, Joglar JA, Deswal A, Mauri L, Fleisher LA, Piano MR,</text>
<text top="926" left="105" width="640" height="21" font="1">Gentile F, Riegel B, Goldberger ZD, Wijeysundera DN, 2019 ACC/AHA Guideline on the Primary</text>
<text top="944" left="105" width="645" height="21" font="1">Prevention of Cardiovascular Disease, <i>Journal of the American College of Cardiology</i> (2019), doi:</text>
<text top="962" left="105" width="275" height="21" font="2"><a href="https://doi.org/10.1016/j.jacc.2019.03.010">https://doi.org/10.1016/j.jacc.2019.03.010</a></text>
<text top="962" left="380" width="4" height="21" font="1"><a href="https://doi.org/10.1016/j.jacc.2019.03.010">.</a></text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1063" width="918">
<text top="106" left="105" width="654" height="21" font="1">This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to</text>
<text top="124" left="105" width="641" height="21" font="1">our customers we are providing this early version of the manuscript. The manuscript will undergo</text>
<text top="142" left="105" width="675" height="21" font="1">copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please</text>
<text top="160" left="105" width="687" height="21" font="1">note that during the production process errors may be discovered which could affect the content, and all</text>
<text top="178" left="105" width="325" height="21" font="1">legal disclaimers that apply to the journal pertain.</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="5" size="67" family="Times" color="#e5e5e5"/>
	<fontspec id="6" size="18" family="Times" color="#ffffff"/>
	<fontspec id="7" size="14" family="Times" color="#000000"/>
	<fontspec id="8" size="14" family="Times" color="#000000"/>
	<fontspec id="9" size="12" family="Times" color="#000000"/>
	<fontspec id="10" size="21" family="Times" color="#000000"/>
	<fontspec id="11" size="15" family="Times" color="#000000"/>
	<fontspec id="12" size="15" family="Times" color="#000000"/>
	<fontspec id="13" size="14" family="Times" color="#000000"/>
	<fontspec id="14" size="14" family="Times" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="406" width="84" height="13" font="9">Page 1 of 101 </text>
<text top="169" left="108" width="683" height="21" font="10"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular </b></text>
<text top="198" left="410" width="74" height="21" font="10"><b>Disease</b></text>
<text top="202" left="484" width="4" height="16" font="11"> </text>
<text top="237" left="119" width="659" height="16" font="12"><b>A Report of the American College of Cardiology/American Heart Association Task Force on </b></text>
<text top="258" left="349" width="199" height="16" font="12"><b>Clinical Practice Guidelines </b></text>
<text top="279" left="105" width="4" height="14" font="13"> </text>
<text top="310" left="118" width="661" height="14" font="14"><i>Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, the American </i></text>
<text top="330" left="122" width="652" height="14" font="14"><i>Geriatrics Society, the American Society of Preventive Cardiology, and the Preventive Cardiovascular </i></text>
<text top="349" left="386" width="126" height="14" font="14"><i>Nurses Association</i> </text>
<text top="381" left="105" width="4" height="14" font="13"> </text>
<text top="412" left="336" width="224" height="15" font="7"><b>WRITING COMMITTEE MEMBERS </b></text>
<text top="432" left="296" width="296" height="14" font="13">Donna K. Arnett, PhD, MSPH, FAHA, <i>Co-Chair</i> </text>
<text top="451" left="286" width="316" height="14" font="13">Roger S. Blumenthal, MD, FACC, FAHA, <i>Co-Chair</i> </text>
<text top="471" left="138" width="247" height="14" font="13">Michelle A. Albert, MD, MPH, FAHA*  </text>
<text top="471" left="480" width="261" height="14" font="13">Erin D. Michos, MD, MHS, FACC, FAHA* </text>
<text top="490" left="138" width="165" height="14" font="13">Andrew B. Buroker, Esq† </text>
<text top="490" left="480" width="218" height="14" font="13">Michael D. Miedema, MD, MPH* </text>
<text top="510" left="138" width="303" height="14" font="13">Zachary D. Goldberger, MD, MS, FACC, FAHA‡ </text>
<text top="510" left="480" width="217" height="14" font="13">Daniel Muñoz, MD, MPA, FACC*  </text>
<text top="530" left="138" width="155" height="14" font="13">Ellen J. Hahn, PhD, RN* </text>
<text top="530" left="480" width="253" height="14" font="13">Sidney C. Smith, Jr, MD, MACC, FAHA* </text>
<text top="549" left="138" width="292" height="14" font="13">Cheryl D. Himmelfarb, PhD, RN, ANP, FAHA* </text>
<text top="549" left="480" width="254" height="14" font="13">Salim S. Virani, MD, PhD, FACC, FAHA* </text>
<text top="569" left="138" width="236" height="14" font="13">Amit Khera, MD, MSc, FACC, FAHA* </text>
<text top="569" left="480" width="256" height="14" font="13">Kim A. Williams, Sr, MD, MACC, FAHA* </text>
<text top="590" left="138" width="291" height="14" font="13">Donald Lloyd-Jones, MD, SCM, FACC, FAHA* </text>
<text top="590" left="480" width="254" height="14" font="13">Joseph Yeboah, MD, MS, FACC, FAHA* </text>
<text top="610" left="138" width="261" height="14" font="13">J. William McEvoy, MBBCh, MEd, MHS* </text>
<text top="610" left="480" width="260" height="14" font="13">Boback Ziaeian, MD, PhD, FACC, FAHA§ </text>
<text top="629" left="105" width="4" height="14" font="13"> </text>
<text top="660" left="336" width="225" height="15" font="7"><b>ACC/AHA TASK FORCE MEMBERS </b></text>
<text top="680" left="312" width="278" height="14" font="13">Patrick T. O’Gara, MD, MACC, FAHA, <i>Chair </i></text>
<text top="700" left="296" width="310" height="14" font="13">Joshua A. Beckman, MD, MS, FAHA,<i> Chair-Elect </i></text>
<text top="719" left="260" width="367" height="14" font="13">Glenn N. Levine, MD, FACC, FAHA, <i>Immediate Past</i> <i>Chair</i></text>
<text top="716" left="626" width="15" height="20" font="13">║ </text>
<text top="739" left="138" width="275" height="14" font="13">Sana M. Al-Khatib, MD, MHS, FACC, FAHA </text>
<text top="739" left="480" width="216" height="14" font="13">Mark A. Hlatky, MD, FACC, FAHA </text>
<text top="758" left="138" width="233" height="14" font="13">Kim K. Birtcher, PharmD, MS, AACC </text>
<text top="758" left="480" width="215" height="14" font="13">John Ikonomidis, MD, PhD, FAHA</text>
<text top="755" left="694" width="15" height="20" font="13">║ </text>
<text top="778" left="138" width="201" height="14" font="13">Joaquin E. Cigarroa, MD, FACC </text>
<text top="778" left="480" width="207" height="14" font="13">José A. Joglar, MD, FACC, FAHA </text>
<text top="798" left="138" width="245" height="14" font="13">Anita Deswal, MD, MPH, FACC, FAHA </text>
<text top="798" left="480" width="190" height="14" font="13">Laura Mauri, MD, MSc, FAHA</text>
<text top="794" left="669" width="15" height="20" font="13">║ </text>
<text top="817" left="138" width="214" height="14" font="13">Lee A. Fleisher, MD, FACC, FAHA </text>
<text top="817" left="480" width="220" height="14" font="13">Mariann R. Piano, RN, PhD, FAHA </text>
<text top="837" left="138" width="184" height="14" font="13">Federico Gentile, MD, FACC </text>
<text top="837" left="480" width="199" height="14" font="13">Barbara Riegel, PhD, RN, FAHA</text>
<text top="834" left="679" width="15" height="20" font="13">║ </text>
<text top="856" left="138" width="303" height="14" font="13">Zachary D. Goldberger, MD, MS, FACC, FAHA‡ </text>
<text top="856" left="480" width="240" height="14" font="13">Duminda N. Wijeysundera, MD, PhD </text>
<text top="876" left="105" width="4" height="14" font="13"> </text>
<text top="896" left="105" width="4" height="14" font="13"> </text>
<text top="915" left="105" width="687" height="14" font="13">*ACC/AHA  Representative.  †Lay  Representative.  ‡ACC/AHA  Task  Force  on  Clinical  PracƟce  Guidelines </text>
<text top="935" left="105" width="416" height="14" font="13">Liaison.  §Task  Force  Performance  Measures  Representative. </text>
<text top="932" left="525" width="267" height="20" font="13">║Former  Task  Force  member;  current </text>
<text top="955" left="105" width="225" height="14" font="13">member during the writing effort. </text>
<text top="986" left="105" width="687" height="14" font="13">This document was approved by the American College of Cardiology Clinical Policy Approval Committee, </text>
<text top="1005" left="105" width="687" height="14" font="13">the American Heart Association Science Advisory and Coordinating Committee, and the American Heart </text>
<text top="1025" left="105" width="342" height="14" font="13">Association Executive Committee in February 2019.  </text>
<text top="1056" left="105" width="687" height="14" font="13">The  American  College  of  Cardiology  requests  that  this  document  be  cited  as  follows:  Arnett  DK, </text>
<text top="1076" left="105" width="687" height="14" font="13">Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, </text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="406" width="84" height="13" font="9">Page 2 of 101 </text>
<text top="167" left="105" width="687" height="14" font="13">McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian </text>
<text top="187" left="105" width="687" height="14" font="13">B.  2019  ACC/AHA  guideline  on  the  primary  prevention  of  cardiovascular  disease:  a  report  of  the </text>
<text top="207" left="105" width="687" height="14" font="13">American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J </text>
<text top="226" left="105" width="169" height="14" font="13">Am Coll Cardiol 2019;000:</text>
<text top="226" left="274" width="109" height="17" font="13">-. </text>
<text top="257" left="105" width="317" height="14" font="13">This article has been copublished in <i>Circulation</i>.  </text>
<text top="289" left="105" width="687" height="14" font="13">Copies: This document is available on the websites of the American College of Cardiology (www.acc.org) </text>
<text top="308" left="105" width="687" height="14" font="13">and  the  American  Heart  Association  (professional.heart.org/).  For  copies  of  this  document,  please </text>
<text top="328" left="105" width="672" height="14" font="13">contact the Elsevier Inc. Reprint Department via fax (212-633-3820) or e-mail (reprints@elsevier.com). </text>
<text top="359" left="105" width="687" height="14" font="13">Permissions:  Multiple  copies,  modification,  alteration,  enhancement,  and/or  distribution  of  this </text>
<text top="379" left="105" width="687" height="14" font="13">document  are  not  permitted  without  the  express  permission  of  the  American  College  of  Cardiology. </text>
<text top="398" left="105" width="63" height="14" font="13">Requests </text>
<text top="398" left="209" width="32" height="14" font="13">may </text>
<text top="398" left="281" width="20" height="14" font="13">be </text>
<text top="398" left="342" width="74" height="14" font="13">completed </text>
<text top="398" left="456" width="44" height="14" font="13">online </text>
<text top="398" left="542" width="22" height="14" font="13">via </text>
<text top="398" left="605" width="25" height="14" font="13">the </text>
<text top="398" left="670" width="54" height="14" font="13">Elsevier </text>
<text top="398" left="765" width="27" height="14" font="13">site </text>
<text top="418" left="105" width="554" height="14" font="13">(http://www.elsevier.com/about/policies/author-agreement/obtaining-permission). </text>
<text top="449" left="105" width="653" height="14" font="13">© 2019 by the American College of Cardiology Foundation and the American Heart Association, Inc. </text>
<text top="481" left="105" width="4" height="14" font="13"> </text>
<text top="512" left="105" width="4" height="14" font="13"> </text>
<text top="512" left="315" width="4" height="14" font="13"> </text>
</page>
<page number="5" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="15" size="18" family="Times" color="#000000"/>
	<fontspec id="16" size="18" family="Times" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="406" width="84" height="13" font="9">Page 3 of 101 </text>
<text top="168" left="372" width="154" height="19" font="15"><b>Table of Contents</b> </text>
<text top="195" left="105" width="4" height="14" font="13"> </text>
<text top="228" left="105" width="686" height="14" font="13">Top 10 Take-Home Messages for the Primary Prevention of Cardiovascular Disease ............................... 4 </text>
<text top="248" left="105" width="686" height="14" font="13">Preamble ................................................................................................................................................. 5 </text>
<text top="267" left="105" width="686" height="14" font="13">1. Introduction ........................................................................................................................................ 6 </text>
<text top="287" left="121" width="670" height="14" font="13">1.1. Methodology and Evidence Review ............................................................................................... 6 </text>
<text top="317" left="121" width="670" height="14" font="13">1.2. Organization of the Writing Committee ........................................................................................ 7 </text>
<text top="347" left="121" width="670" height="14" font="13">1.3. Document Review and Approval ................................................................................................... 8 </text>
<text top="376" left="121" width="670" height="14" font="13">1.4. Scope of the Guideline .................................................................................................................. 8 </text>
<text top="406" left="121" width="670" height="14" font="13">1.5. Class of Recommendation and Level of Evidence .......................................................................... 8 </text>
<text top="436" left="121" width="670" height="14" font="13">1.6. Abbreviations ............................................................................................................................. 10 </text>
<text top="466" left="105" width="686" height="14" font="13">2. Overarching Recommendations for ASCVD Prevention Efforts ........................................................... 11 </text>
<text top="486" left="121" width="670" height="14" font="13">2.1. Patient-Centered Approaches to Comprehensive ASCVD Prevention........................................... 11 </text>
<text top="515" left="121" width="670" height="14" font="13">2.2. Assessment of Cardiovascular Risk .............................................................................................. 14 </text>
<text top="545" left="105" width="686" height="14" font="13">3. Lifestyle Factors Affecting Cardiovascular Risk ................................................................................... 18 </text>
<text top="565" left="121" width="670" height="14" font="13">3.1. Nutrition and Diet ....................................................................................................................... 18 </text>
<text top="595" left="121" width="670" height="14" font="13">3.2. Exercise and Physical Activity ...................................................................................................... 21 </text>
<text top="625" left="105" width="686" height="14" font="13">4. Other Factors Affecting Cardiovascular Risk ....................................................................................... 24 </text>
<text top="644" left="121" width="670" height="14" font="13">4.1. Adults with Overweight and Obesity ........................................................................................... 24 </text>
<text top="674" left="121" width="670" height="14" font="13">4.2. Adults with Type 2 Diabetes Mellitus .......................................................................................... 26 </text>
<text top="704" left="121" width="670" height="14" font="13">4.3. Adults with High Blood Cholesterol ............................................................................................. 30 </text>
<text top="734" left="121" width="670" height="14" font="13">4.4. Adults with High Blood Pressure or Hypertension ....................................................................... 36 </text>
<text top="764" left="121" width="670" height="14" font="13">4.5. Treatment of Tobacco Use .......................................................................................................... 42 </text>
<text top="793" left="121" width="670" height="14" font="13">4.6. Aspirin Use.................................................................................................................................. 46 </text>
<text top="823" left="105" width="686" height="14" font="13">5. Cost and Value Considerations .......................................................................................................... 48 </text>
<text top="843" left="105" width="686" height="14" font="13">6. Conclusion ......................................................................................................................................... 49 </text>
<text top="862" left="105" width="686" height="14" font="13">Appendix 1. Search Criteria ................................................................................................................... 51 </text>
<text top="882" left="105" width="686" height="14" font="13">Appendix 2. Author Relationships With Industry and Other Entities (Relevant) ...................................... 59 </text>
<text top="902" left="105" width="686" height="14" font="13">Appendix 3. Reviewer Relationships With Industry and Other Entities (Comprehensive)........................ 64 </text>
<text top="921" left="105" width="686" height="14" font="13">References ............................................................................................................................................ 78 </text>
<text top="941" left="121" width="4" height="14" font="13"> </text>
<text top="971" left="105" width="4" height="14" font="13"> </text>
<text top="971" left="315" width="4" height="14" font="13"> </text>
</page>
<page number="6" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="17" size="14" family="Helvetica" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="406" width="84" height="13" font="9">Page 4 of 101 </text>
<text top="169" left="105" width="577" height="21" font="10"><b>Top 10 Take-Home Messages for the Primary Prevention of </b></text>
<text top="198" left="105" width="227" height="21" font="10"><b>Cardiovascular Disease </b></text>
<text top="227" left="105" width="12" height="14" font="13">1.</text>
<text top="227" left="117" width="4" height="15" font="17"> </text>
<text top="227" left="131" width="661" height="14" font="13">The  most  important  way  to  prevent  atherosclerotic  vascular  disease,  heart  failure,  and  atrial </text>
<text top="247" left="131" width="391" height="14" font="13">fibrillation is to promote a healthy lifestyle throughout life.  </text>
<text top="267" left="105" width="12" height="14" font="13">2.</text>
<text top="267" left="117" width="4" height="15" font="17"> </text>
<text top="267" left="131" width="661" height="14" font="13">A  team-based  care  approach  is  an  effective  strategy  for  the  prevention  of  cardiovascular  disease. </text>
<text top="286" left="131" width="661" height="14" font="13">Clinicians  should  evaluate  the  social  determinants  of  health  that  affect  individuals  to  inform </text>
<text top="306" left="131" width="138" height="14" font="13">treatment decisions. </text>
<text top="325" left="105" width="12" height="14" font="13">3.</text>
<text top="325" left="117" width="4" height="15" font="17"> </text>
<text top="325" left="131" width="661" height="14" font="13">Adults who are 40 to 75 years of age and are being evaluated for cardiovascular disease prevention </text>
<text top="345" left="131" width="661" height="14" font="13">should  undergo  10-year  atherosclerotic  cardiovascular  disease  (ASCVD)  risk  estimation  and  have  a </text>
<text top="365" left="131" width="661" height="14" font="13">clinician–patient  risk  discussion  before  starting  on  pharmacological  therapy,  such  as </text>
<text top="384" left="131" width="661" height="14" font="13">antihypertensive therapy, a statin, or aspirin. In addition, assessing for other risk-enhancing factors </text>
<text top="404" left="131" width="661" height="14" font="13">can help guide decisions about preventive interventions in select individuals, as can coronary artery </text>
<text top="423" left="131" width="119" height="14" font="13">calcium scanning. </text>
<text top="443" left="105" width="12" height="14" font="13">4.</text>
<text top="443" left="117" width="4" height="15" font="17"> </text>
<text top="443" left="131" width="661" height="14" font="13">All  adults  should  consume  a  healthy  diet  that  emphasizes  the  intake  of  vegetables,  fruits,  nuts, </text>
<text top="463" left="131" width="661" height="14" font="13">whole  grains,  lean  vegetable  or  animal  protein,  and  fish  and  minimizes  the  intake  of  <i>trans</i>  fats, </text>
<text top="482" left="131" width="661" height="14" font="13">processed meats, refined carbohydrates, and sweetened beverages. For adults with overweight and </text>
<text top="502" left="131" width="661" height="14" font="13">obesity, counseling  and  caloric  restriction  are  recommended  for  achieving  and  maintaining weight </text>
<text top="521" left="131" width="32" height="14" font="13">loss. </text>
<text top="541" left="105" width="12" height="14" font="13">5.</text>
<text top="541" left="117" width="4" height="15" font="17"> </text>
<text top="541" left="131" width="661" height="14" font="13">Adults should engage in at least 150 minutes per week of accumulated moderate-intensity physical </text>
<text top="561" left="131" width="458" height="14" font="13">activity or 75 minutes per week of vigorous-intensity physical activity. </text>
<text top="580" left="105" width="12" height="14" font="13">6.</text>
<text top="580" left="117" width="4" height="15" font="17"> </text>
<text top="580" left="131" width="661" height="14" font="13">For  adults  with  type  2  diabetes  mellitus,  lifestyle  changes,  such  as  improving  dietary  habits  and </text>
<text top="600" left="131" width="661" height="14" font="13">achieving  exercise  recommendations,  are  crucial.  If  medication  is  indicated,  metformin  is  first-line </text>
<text top="619" left="131" width="661" height="14" font="13">therapy, followed by consideration of a sodium-glucose cotransporter 2 inhibitor or a glucagon-like </text>
<text top="639" left="131" width="186" height="14" font="13">peptide-1 receptor agonist.  </text>
<text top="659" left="105" width="12" height="14" font="13">7.</text>
<text top="659" left="117" width="4" height="15" font="17"> </text>
<text top="659" left="131" width="661" height="14" font="13">All adults should be assessed at every healthcare visit for tobacco use, and those who use tobacco </text>
<text top="678" left="131" width="316" height="14" font="13">should be assisted and strongly advised to quit.  </text>
<text top="698" left="105" width="12" height="14" font="13">8.</text>
<text top="698" left="117" width="4" height="15" font="17"> </text>
<text top="698" left="131" width="661" height="14" font="13">Aspirin should be used infrequently in the routine primary prevention of ASCVD because of lack of </text>
<text top="717" left="131" width="80" height="14" font="13">net benefit. </text>
<text top="737" left="105" width="12" height="14" font="13">9.</text>
<text top="737" left="117" width="4" height="15" font="17"> </text>
<text top="737" left="131" width="657" height="14" font="13">Statin therapy is first-line treatment for primary prevention of ASCVD in patients with elevated low-</text>
<text top="757" left="131" width="661" height="14" font="13">density lipoprotein cholesterol levels (≥190 mg/dL), those with diabetes mellitus, who are 40 to 75 </text>
<text top="776" left="131" width="661" height="14" font="13">years  of  age,  and  those  determined  to  be  at  sufficient  ASCVD  risk  after  a  clinician–patient  risk </text>
<text top="796" left="131" width="74" height="14" font="13">discussion. </text>
<text top="815" left="105" width="20" height="14" font="13">10.</text>
<text top="815" left="125" width="4" height="15" font="17"> </text>
<text top="815" left="131" width="661" height="14" font="13">Nonpharmacological interventions are recommended for all adults with elevated blood pressure or </text>
<text top="835" left="131" width="661" height="14" font="13">hypertension.  For  those  requiring  pharmacological  therapy,  the  target  blood  pressure  should </text>
<text top="855" left="131" width="197" height="14" font="13">generally be &lt;130/80 mm Hg. </text>
<text top="886" left="105" width="4" height="14" font="13"> </text>
<text top="886" left="315" width="4" height="14" font="13"> </text>
</page>
<page number="7" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="406" width="84" height="13" font="9">Page 5 of 101 </text>
<text top="169" left="105" width="98" height="21" font="10"><b>Preamble </b></text>
<text top="199" left="105" width="687" height="14" font="13">Since  1980,  the  American  College  of  Cardiology  (ACC)  and  American  Heart  Association  (AHA)  have </text>
<text top="218" left="105" width="687" height="14" font="13">translated  scientific  evidence  into  clinical  practice  guidelines  with  recommendations  to  improve </text>
<text top="238" left="105" width="687" height="14" font="13">cardiovascular health. These guidelines, which are based on systematic methods to evaluate and classify </text>
<text top="258" left="105" width="687" height="14" font="13">evidence, provide a foundation for the delivery of quality cardiovascular care. The ACC and AHA sponsor </text>
<text top="277" left="105" width="687" height="14" font="13">the  development  and  publication  of  clinical  practice  guidelines  without  commercial  support,  and </text>
<text top="297" left="105" width="420" height="14" font="13">members volunteer their time to the writing and review efforts. </text>
<text top="316" left="105" width="4" height="14" font="13"> </text>
<text top="336" left="105" width="687" height="14" font="13">Clinical practice guidelines provide recommendations applicable to patients with or at risk of developing </text>
<text top="356" left="105" width="687" height="14" font="13">cardiovascular disease (CVD). The focus is on medical practice in the United States, but these guidelines </text>
<text top="375" left="105" width="687" height="14" font="13">are relevant to patients throughout the world. Although guidelines may be used to inform regulatory or </text>
<text top="395" left="105" width="687" height="14" font="13">payer decisions, the goals are to improve quality of care and align with patients’ interests. Guidelines are </text>
<text top="415" left="105" width="687" height="14" font="13">intended to define practices meeting the needs of patients in most but not all circumstances and should </text>
<text top="434" left="105" width="196" height="14" font="13">not replace clinical judgment. </text>
<text top="454" left="105" width="4" height="14" font="13"> </text>
<text top="473" left="105" width="687" height="14" font="13">Recommendations  for  guideline-directed  management  and  therapy,  which  encompasses  clinical </text>
<text top="493" left="105" width="687" height="14" font="13">evaluation, diagnostic testing, and both pharmacological and procedural treatments, are effective only </text>
<text top="512" left="105" width="687" height="14" font="13">when adopted by both practitioners and patients. Adherence to recommendations can be enhanced by </text>
<text top="532" left="105" width="687" height="14" font="13">shared  decision-making  between  clinicians  and  patients,  with  patient  engagement  in  selecting </text>
<text top="552" left="105" width="687" height="14" font="13">interventions  on  the  basis  of  individual  values,  preferences,  and  associated  conditions  and </text>
<text top="571" left="105" width="97" height="14" font="13">comorbidities. </text>
<text top="591" left="105" width="4" height="14" font="13"> </text>
<text top="611" left="105" width="687" height="14" font="13">The  ACC/AHA  Task  Force  on  Clinical  Practice  Guidelines  strives  to  ensure  that  the  guideline  writing </text>
<text top="630" left="105" width="687" height="14" font="13">committee  includes  requisite  expertise  and  is  representative  of  the  broader  medical  community  by </text>
<text top="650" left="105" width="687" height="14" font="13">selecting experts from a broad array of backgrounds, representing different geographic regions, sexes, </text>
<text top="669" left="105" width="687" height="14" font="13">races, ethnicities, intellectual perspectives/biases, and scopes of clinical practice. The ACC and AHA have </text>
<text top="689" left="105" width="687" height="14" font="13">rigorous  policies  and  methods  to  ensure  that  documents  are  developed  without  bias  or  improper </text>
<text top="709" left="105" width="687" height="14" font="13">influence.  The  complete  policy  on  relationships  with  industry  and  other  entities  (RWI)  can  be  found </text>
<text top="728" left="105" width="52" height="14" font="13">online.  </text>
<text top="748" left="105" width="4" height="14" font="13"> </text>
<text top="767" left="105" width="687" height="14" font="13">Beginning  in  2017,  numerous  modifications  to  the  guidelines  have  been  and  continue  to  be </text>
<text top="787" left="105" width="687" height="14" font="13">implemented  to  make  guidelines  shorter  and  enhance  “user  friendliness.”  Guidelines  are  written  and </text>
<text top="807" left="105" width="687" height="14" font="13">presented  in  a  modular  knowledge  chunk  format,  in  which  each  chunk  includes  a  table  of </text>
<text top="826" left="105" width="687" height="14" font="13">recommendations,  a  brief  synopsis,  recommendation-specific  supportive  text  and,  when  appropriate, </text>
<text top="846" left="105" width="687" height="14" font="13">flow  diagrams  or  additional  tables.  Hyperlinked  references  are  provided  for  each  modular  knowledge </text>
<text top="865" left="105" width="687" height="14" font="13">chunk  to  facilitate  quick  access  and  review.  More  structured  guidelines—including  word  limits </text>
<text top="885" left="105" width="687" height="14" font="13">(“targets”)  and  a  web  guideline  supplement  for  useful  but  noncritical  tables  and  figures—are  2  such </text>
<text top="905" left="105" width="604" height="14" font="13">changes. This Preamble is an abbreviated version, with the detailed version available online. </text>
<text top="924" left="105" width="4" height="14" font="13"> </text>
<text top="944" left="105" width="241" height="14" font="14"><i>Patrick T. O’Gara, MD, MACC, FAHA  </i></text>
<text top="964" left="105" width="376" height="14" font="14"><i>Chair, ACC/AHA Task Force on Clinical Practice Guidelines </i></text>
<text top="983" left="105" width="4" height="14" font="13"> </text>
</page>
<page number="8" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="18" size="24" family="Times" color="#000000"/>
	<fontspec id="19" size="21" family="Times" color="#000000"/>
	<fontspec id="20" size="19" family="Times" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="406" width="84" height="13" font="9">Page 6 of 101 </text>
<text top="186" left="105" width="145" height="21" font="10"><b>1. Introduction</b></text>
<text top="185" left="250" width="6" height="24" font="18"> </text>
<text top="216" left="105" width="687" height="14" font="13">Although  there  has  been  substantial  improvement  in  atherosclerotic  cardiovascular  disease  (ASCVD) </text>
<text top="236" left="105" width="683" height="14" font="13">outcomes in recent decades, ASCVD remains the leading cause of morbidity and mortality globally (S1-</text>
<text top="256" left="105" width="687" height="14" font="13">1–S1-3).  In  the  United  States,  it  is  also  the  leading  cause  of  death  for  people  of  most  racial/ethnic </text>
<text top="275" left="105" width="687" height="14" font="13">groups,  with  an  estimated  cost  of  &gt;$200  billion  annually  in  healthcare  services,  medications,  and  lost </text>
<text top="295" left="105" width="687" height="14" font="13">productivity.  Much  of  this  is  attributable  to  suboptimal  implementation  of  prevention  strategies  and </text>
<text top="314" left="105" width="359" height="14" font="13">uncontrolled ASCVD risk factors in many adults (S1-2).  </text>
<text top="346" left="105" width="687" height="14" font="13">Most  Americans  who  have  had  a  myocardial  infarction  (MI)  had  unfavorable  levels  of  at  least  1 </text>
<text top="365" left="105" width="687" height="14" font="13">cardiovascular  risk  factor  before  their  ASCVD  event  (S1-4).  In  2010,  the  AHA  defined  a  new  model  of </text>
<text top="385" left="105" width="687" height="14" font="13">“ideal cardiovascular health,” referred to as Life’s Simple 7 (S1-5). Clinicians will find the 2018 Journal of </text>
<text top="404" left="105" width="687" height="14" font="13">American  College  of  Cardiology  (JACC)  Cardiovascular  Health  Promotion  Series  very  helpful  in </text>
<text top="424" left="105" width="687" height="14" font="13">approaching  the  various  aspects  of  prevention  with  patients  (S1-6).  An  increasing  number  of  ideal </text>
<text top="444" left="105" width="687" height="14" font="13">cardiovascular  health  factors  have  been  associated  with  a  lower  prevalence  and  incidence  of  ASCVD </text>
<text top="463" left="105" width="687" height="14" font="13">events, heart failure, atrial fibrillation, cancer,  depression, and cognitive impairment  (S1-7). Therefore, </text>
<text top="483" left="105" width="687" height="14" font="13">moving  individuals  toward  ideal  cardiovascular  health  is  critically  important  for  prevention  of  many </text>
<text top="503" left="105" width="194" height="14" font="13">important health conditions.  </text>
<text top="534" left="105" width="687" height="14" font="13">The ACC/AHA Task Force on Clinical Practice Guidelines has commissioned this guideline to consolidate </text>
<text top="553" left="105" width="687" height="14" font="13">existing  recommendations  and  various  recent  scientific  statements,  expert  consensus  documents,  and </text>
<text top="573" left="105" width="687" height="14" font="13">clinical  practice  guidelines  into  a  single  guidance  document  focused  on  the  primary  prevention  of </text>
<text top="593" left="105" width="687" height="14" font="13">ASCVD.  However,  this  guideline  also  includes  newly  generated  recommendations  for  aspirin  use, </text>
<text top="612" left="105" width="687" height="14" font="13">exercise and physical activity, and tobacco use, in addition to recommendations related to team-based </text>
<text top="632" left="105" width="687" height="14" font="13">care,  shared  decision-making,  and  assessment  of  social  determinants  of  health,  to  create  a </text>
<text top="651" left="105" width="687" height="14" font="13">comprehensive  yet  targeted  ACC/AHA  guideline  on  the  prevention  of  ASCVD.  This  guideline  has  been </text>
<text top="671" left="105" width="555" height="14" font="13">formatted in the modular chunk format to facilitate readability and future updating.  </text>
<text top="702" left="105" width="687" height="14" font="13">Prevention  strategies  occur  at the  population level  but  must  also engage individual  adults  to  slow  the </text>
<text top="722" left="105" width="687" height="14" font="13">development  of  ASCVD.  The  most  important  way  to  prevent  ASCVD  is  to  promote  a  healthy  lifestyle </text>
<text top="742" left="105" width="687" height="14" font="13">throughout  life.  Prevention  strategies  must  include  a  strong  focus  on  lifestyle  optimization </text>
<text top="761" left="105" width="687" height="14" font="13">(improvements  in  diet,  physical  activity,  and  avoidance  of  tobacco  use  and  exposure  to  secondhand </text>
<text top="781" left="105" width="348" height="14" font="13">smoke) to minimize the risk of future ASCVD events.  </text>
<text top="812" left="105" width="687" height="14" font="13">A comprehensive patient-centered approach that addresses all aspects of a patient’s lifestyle habits and </text>
<text top="832" left="105" width="687" height="14" font="13">estimated risk of a future ASCVD event is the first step in  deciding on where there may be  a  need for </text>
<text top="851" left="105" width="687" height="14" font="13">pharmacotherapy.  Even  if  a  blood  pressure  (BP)–reducing  medication,  lipid-lowering  medication,  or </text>
<text top="871" left="105" width="687" height="14" font="13">diabetes  medication  is  ultimately  prescribed,  lifestyle  goals  should  be  emphasized  on  a  regular  basis. </text>
<text top="890" left="105" width="687" height="14" font="13">Only when a person’s risk is sufficiently high should medications to reduce ASCVD risk be considered as </text>
<text top="910" left="105" width="687" height="14" font="13">part of a shared decision-making process for optimal treatment. In summary, clinicians and individuals </text>
<text top="930" left="105" width="687" height="14" font="13">should  focus  attention  on  living  a  healthy  lifestyle  by  referring  to  these  evidence-based </text>
<text top="949" left="105" width="283" height="14" font="13">recommendations to help prevent ASCVD.  </text>
<text top="974" left="105" width="5" height="21" font="19"> </text>
<text top="1005" left="105" width="363" height="20" font="20"><b>1.1. Methodology and Evidence Review </b></text>
<text top="1030" left="105" width="687" height="14" font="13">This guideline continues the ACC and AHA effort to design a comprehensive yet succinct compilation of </text>
<text top="1050" left="105" width="687" height="14" font="13">practical  guidance  for  the  primary  prevention  of  ASCVD  and  to  promote  optimal  dissemination  of </text>
<text top="1069" left="105" width="687" height="14" font="13">information by using concise language and formatting. The recommendations listed in this guideline are </text>
<text top="1089" left="105" width="687" height="14" font="13">evidence  based  and  supported  by  an  extensive  evidence  review.  A  search  for  literature  derived  from </text>
</page>
<page number="9" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="406" width="84" height="13" font="9">Page 7 of 101 </text>
<text top="167" left="105" width="687" height="14" font="13">research  involving  human  subjects,  published  in  English,  and  indexed  in  Ovid  MEDLINE,  PubMed, </text>
<text top="187" left="105" width="687" height="14" font="13">Cochrane Library, National Institute for Health and Care Excellence (NICE), and other selected databases </text>
<text top="207" left="105" width="687" height="14" font="13">relevant  to  this  guideline, was  conducted  between  May  and July  2018.  For  specific  search  terms  used </text>
<text top="226" left="105" width="366" height="14" font="13">and years searched per section, please see Appendix 1.  </text>
<text top="257" left="105" width="687" height="14" font="13">Randomized  controlled  trials  (RCTs),  systematic  reviews  of  RCTs,  meta-analyses,  and  large,  United </text>
<text top="277" left="105" width="687" height="14" font="13">States–based,  high-quality  cohort  studies,  as  well  as  observational  studies  and  systematic  reviews  of </text>
<text top="297" left="105" width="687" height="14" font="13">observational studies, were evaluated for their content on the prevention of ASCVD outcomes related to </text>
<text top="316" left="105" width="687" height="14" font="13">the following 9 topic areas: risk assessment, diet, exercise/physical activity, obesity and weight loss, type </text>
<text top="336" left="105" width="687" height="14" font="13">2  diabetes  mellitus  (T2DM),  blood  cholesterol,  hypertension,  smoking  cessation,  and  aspirin  use. </text>
<text top="355" left="105" width="687" height="14" font="13">Previous ACC/AHA guidelines, as well as U.S. Preventive Services Task Force (USPSTF) reviews and other </text>
<text top="375" left="105" width="687" height="14" font="13">guidance relevant to this guideline, were also assessed. The final evidence tables included in the Online </text>
<text top="395" left="105" width="687" height="14" font="13">Data  Supplement  summarize  the  evidence  used  to  formulate  recommendations.  References  selected </text>
<text top="414" left="105" width="472" height="14" font="13">and published in this document are representative and not all-inclusive. </text>
<text top="446" left="105" width="687" height="14" font="13">Avalere  Health,  a  healthcare  advisory  services  firm  contracted  by  ACC/AHA,  served  as  the  document </text>
<text top="465" left="105" width="687" height="14" font="13">manager  for  this  guideline  to  facilitate  its  development  process.  Avalere  Health  commissioned  the </text>
<text top="485" left="105" width="687" height="14" font="13">Pacific Northwest  Evidence-based Practice Center at Oregon Health  and Science University to perform </text>
<text top="505" left="105" width="687" height="14" font="13">rapid systematic evidence reviews for 5 of the key topics: aspirin use, T2DM, nutrition and diet, obesity </text>
<text top="524" left="105" width="687" height="14" font="13">and weight loss, and tobacco use. In parallel, an independent health data and epidemiology expert, Lee </text>
<text top="544" left="105" width="687" height="14" font="13">Ann  Prebil,  conducted  a  systematic  evidence  review  for  the  key  topic  of  exercise  and  physical  activity </text>
<text top="563" left="105" width="687" height="14" font="13">and  conducted  targeted  literature  searches  to  support  this  document’s  discussion  of  patient-centered </text>
<text top="583" left="105" width="687" height="14" font="13">approaches, including team-based care, shared decision-making, and assessment of social determinants </text>
<text top="602" left="105" width="687" height="14" font="13">of  health.  A  targeted  literature  search  was  also  conducted  for  this  guideline’s  cost  and  value </text>
<text top="622" left="105" width="107" height="14" font="13">considerations.  </text>
<text top="653" left="105" width="687" height="14" font="13">Recommendations  and  supportive  text  relevant  to  cardiovascular  risk,  blood  cholesterol,  and  high  BP </text>
<text top="673" left="105" width="687" height="14" font="13">were  taken  directly  from  2  recently  released  ACC/AHA  guidelines,  the  2017  Hypertension  Clinical </text>
<text top="693" left="105" width="687" height="14" font="13">Practice  Guidelines  (S1.1-1)  and  the  2018  Cholesterol  Clinical  Practice  Guideline<i>  </i>(S1.1-2),<i>  </i>and  were </text>
<text top="712" left="105" width="687" height="14" font="13">adapted  for  the  present  guideline,  which  aims  to  provide  an  overview  of  the  primary  prevention  of </text>
<text top="732" left="105" width="687" height="14" font="13">ASCVD among adults. Recommendations that were adapted from previous publications are noted in the </text>
<text top="751" left="105" width="687" height="14" font="13">recommendation tables, and both the original published recommendation and the adapted version are </text>
<text top="771" left="105" width="174" height="14" font="13">provided in the guideline . </text>
<text top="802" left="105" width="687" height="14" font="13">The  results of these evidence reviews were evaluated  by the writing  committee for incorporation into </text>
<text top="822" left="105" width="687" height="14" font="13">the  present  guideline.  (See  Table  S1  in  the  Web  Supplement  for  a  list  of  relevant  publications  and </text>
<text top="841" left="105" width="687" height="14" font="13">statements  used  in  support  of  the  guideline’s  recommendations.)  Each  topic  area  was  assigned  a </text>
<text top="861" left="105" width="687" height="14" font="13">primary  writer,  as  well  as  a  primary,  and  sometimes  secondary,  reviewer.  These  assignments  were </text>
<text top="881" left="105" width="687" height="14" font="13">based on areas of particular expertise of writing committee members. All recommendations were fully </text>
<text top="900" left="105" width="687" height="14" font="13">reviewed and discussed among the full committee to allow for diverse perspectives and considerations </text>
<text top="920" left="105" width="687" height="14" font="13">for  this  guideline.  Recommendations  were  then  voted  upon,  with  a  modified  Delphi  process  used  to </text>
<text top="939" left="105" width="115" height="14" font="13">reach consensus. </text>
<text top="972" left="105" width="399" height="20" font="20"><b>1.2. Organization of the Writing Committee </b></text>
<text top="998" left="105" width="687" height="14" font="13">The writing committee consisted of clinicians, cardiologists, health services researchers, epidemiologists, </text>
<text top="1017" left="105" width="687" height="14" font="13">internists,  nurses,  and  a  lay  representative.  The  writing  committee  included  representatives  from  the </text>
<text top="1037" left="105" width="687" height="14" font="13">ACC and AHA. Appendix 2 of the present document lists writing committee members’ relevant RWI. For </text>
<text top="1056" left="105" width="687" height="14" font="13">the  purposes  of  full  transparency,  the  writing  committee  members’  comprehensive  disclosure </text>
<text top="1076" left="105" width="205" height="14" font="13">information is available online. </text>
</page>
<page number="10" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="406" width="84" height="13" font="9">Page 8 of 101 </text>
<text top="169" left="105" width="337" height="20" font="20"><b>1.3. Document Review and Approval </b></text>
<text top="194" left="105" width="687" height="14" font="13">This document was  reviewed  by  5 official reviewers nominated by  the  ACC and AHA (1 reviewer from </text>
<text top="214" left="105" width="687" height="14" font="13">the ACC/AHA Task  Force for  Practice Guidelines, 2 reviewers from the AHA, and  2 reviewers from the </text>
<text top="233" left="105" width="687" height="14" font="13">ACC);  3  reviewers  on  behalf  of  the  American  Association  of  Cardiovascular  and  Pulmonary </text>
<text top="253" left="105" width="687" height="14" font="13">Rehabilitation,  the  American  Society  for  Nutrition,  and  the  American  Society  of  Preventive  Medicine; </text>
<text top="272" left="105" width="687" height="14" font="13">and  23  individual  content  reviewers.  Reviewers’  RWI  information  was  distributed  to  the  writing </text>
<text top="292" left="105" width="687" height="14" font="13">committee and is published in this document (Appendix 3). This document was approved for publication </text>
<text top="312" left="105" width="297" height="14" font="13">by the governing bodies of the ACC and AHA. </text>
<text top="344" left="105" width="249" height="20" font="20"><b>1.4. Scope of the Guideline </b></text>
<text top="370" left="105" width="687" height="14" font="13">This  guideline  is  intended  to  be  a  resource  for  the  clinical  and  public  health  practice  communities.  It </text>
<text top="389" left="105" width="687" height="14" font="13">addresses the primary  prevention of CVD in adults (≥18  years  of age), focused  on outcomes  of ASCVD </text>
<text top="409" left="105" width="687" height="14" font="13">(i.e.,  acute  coronary  syndromes,  MI,  stable  or  unstable  angina,  arterial  revascularization,  stroke, </text>
<text top="429" left="105" width="687" height="14" font="13">transient ischemic attack, or peripheral arterial disease of atherosclerotic origin), as well as heart failure </text>
<text top="448" left="105" width="687" height="14" font="13">and  atrial  fibrillation.  The  guideline  presents  recommendations  to  prevent  CVD  that  are  related  to </text>
<text top="468" left="105" width="687" height="14" font="13">lifestyle factors (e.g., diet and exercise or physical activity), other factors affecting CVD risk (e.g., obesity, </text>
<text top="487" left="105" width="683" height="14" font="13">diabetes,  blood  cholesterol,  high  BP,  smoking,  aspirin  use),  patient-centered  approaches  (e.g.,  team-</text>
<text top="507" left="105" width="687" height="14" font="13">based care, shared decision-making, assessment of social determinants of health), and considerations of </text>
<text top="527" left="105" width="274" height="14" font="13">the cost and value of primary prevention. </text>
<text top="559" left="105" width="481" height="20" font="20"><b>1.5. Class of Recommendation and Level of Evidence </b></text>
<text top="585" left="105" width="687" height="14" font="13">Recommendations are designated with both a Class of Recommendation (COR) and a Level of Evidence </text>
<text top="604" left="105" width="687" height="14" font="13">(LOE). The COR indicates the strength of recommendation, encompassing the estimated magnitude and </text>
<text top="624" left="105" width="687" height="14" font="13">certainty of benefit in proportion to risk. The LOE rates the quality of scientific evidence supporting the </text>
<text top="643" left="105" width="687" height="14" font="13">intervention  on  the  basis  of  the  type,  quantity,  and  consistency  of  data  from  clinical  trials  and  other </text>
<text top="663" left="105" width="172" height="14" font="13">sources (Table 1) (S1.5-1). </text>
<text top="663" left="484" width="4" height="14" font="13"> </text>
</page>
<page number="11" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="406" width="84" height="13" font="9">Page 9 of 101 </text>
<text top="167" left="105" width="683" height="15" font="7"><b>Table 1. Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, </b></text>
<text top="187" left="105" width="488" height="15" font="7"><b>Treatments, or Diagnostic Testing in Patient Care (Updated August 2015) </b></text>
<text top="981" left="863" width="4" height="15" font="7"><b> </b></text>
<text top="1010" left="105" width="5" height="21" font="19"> </text>
<text top="1010" left="315" width="5" height="21" font="19"> </text>
</page>
<page number="12" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 10 of 101 </text>
<text top="169" left="105" width="171" height="20" font="20"><b>1.6. Abbreviations </b></text>
<text top="195" left="105" width="91" height="15" font="7"><b>Abbreviation </b></text>
<text top="195" left="236" width="115" height="15" font="7"><b>Meaning/Phrase </b></text>
<text top="215" left="105" width="48" height="14" font="13">ASCVD </text>
<text top="215" left="236" width="255" height="14" font="13">atherosclerotic cardiovascular disease  </text>
<text top="236" left="105" width="23" height="14" font="13">AU </text>
<text top="236" left="236" width="98" height="14" font="13">Agatston units </text>
<text top="256" left="105" width="30" height="14" font="13">BMI </text>
<text top="256" left="236" width="112" height="14" font="13">body mass index </text>
<text top="276" left="105" width="21" height="14" font="13">BP </text>
<text top="276" left="236" width="101" height="14" font="13">blood pressure </text>
<text top="296" left="105" width="32" height="14" font="13">CHD </text>
<text top="296" left="236" width="153" height="14" font="13">coronary heart disease </text>
<text top="317" left="105" width="30" height="14" font="13">CKD </text>
<text top="317" left="236" width="151" height="14" font="13">chronic kidney disease </text>
<text top="337" left="105" width="31" height="14" font="13">CVD </text>
<text top="337" left="236" width="150" height="14" font="13">cardiovascular disease </text>
<text top="357" left="105" width="40" height="14" font="13">DASH </text>
<text top="357" left="236" width="275" height="14" font="13">Dietary Approaches to Stop Hypertension </text>
<text top="378" left="105" width="31" height="14" font="13">DBP </text>
<text top="378" left="236" width="159" height="14" font="13">diastolic blood pressure </text>
<text top="398" left="105" width="27" height="14" font="13">DM </text>
<text top="398" left="236" width="115" height="14" font="13">diabetes mellitus </text>
<text top="419" left="105" width="39" height="14" font="13">ENDS </text>
<text top="419" left="236" width="237" height="14" font="13">electronic nicotine delivery systems </text>
<text top="439" left="105" width="30" height="14" font="13">FDA </text>
<text top="439" left="236" width="230" height="14" font="13">U.S. Food and Drug Administration </text>
<text top="459" left="105" width="51" height="14" font="13">GLP-1R </text>
<text top="459" left="236" width="217" height="14" font="13">glucagon-like peptide-1 receptor </text>
<text top="479" left="105" width="46" height="14" font="13">HbA1c </text>
<text top="479" left="236" width="109" height="14" font="13">hemoglobin A1c </text>
<text top="500" left="105" width="44" height="14" font="13">HDL-C </text>
<text top="500" left="236" width="237" height="14" font="13">high-density lipoprotein cholesterol </text>
<text top="520" left="105" width="46" height="14" font="13">HbA1c </text>
<text top="520" left="236" width="109" height="14" font="13">hemoglobin A1c </text>
<text top="541" left="105" width="40" height="14" font="13">LDL-C </text>
<text top="541" left="236" width="232" height="14" font="13">low-density lipoprotein cholesterol </text>
<text top="561" left="105" width="21" height="14" font="13">MI </text>
<text top="561" left="236" width="143" height="14" font="13">myocardial infarction </text>
<text top="581" left="105" width="28" height="14" font="13">PCE </text>
<text top="581" left="236" width="164" height="14" font="13">pooled cohort equations </text>
<text top="602" left="105" width="29" height="14" font="13">RCT </text>
<text top="602" left="236" width="182" height="14" font="13">randomized controlled trial </text>
<text top="622" left="105" width="28" height="14" font="13">SBP </text>
<text top="622" left="236" width="153" height="14" font="13">systolic blood pressure </text>
<text top="642" left="105" width="49" height="14" font="13">SGLT-2 </text>
<text top="642" left="236" width="211" height="14" font="13">sodium-glucose cotransporter 2 </text>
<text top="663" left="105" width="43" height="14" font="13">T2DM </text>
<text top="663" left="236" width="160" height="14" font="13">type 2 diabetes mellitus </text>
<text top="683" left="105" width="52" height="14" font="13">USPSTF </text>
<text top="683" left="236" width="232" height="14" font="13">U.S. Preventive Services Task Force </text>
<text top="721" left="71" width="12" height="14" font="13">1 </text>
</page>
<page number="13" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="21" size="14" family="Helvetica" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 11 of 101 </text>
<text top="195" left="105" width="621" height="21" font="10"><b>2. Overarching Recommendations for ASCVD Prevention Efforts </b></text>
<text top="226" left="105" width="656" height="20" font="20"><b>2.1. Patient-Centered Approaches to Comprehensive ASCVD Prevention </b></text>
<text top="252" left="147" width="604" height="15" font="7"><b>Recommendations for Patient-Centered Approaches to Comprehensive ASCVD Prevention </b></text>
<text top="272" left="127" width="643" height="14" font="13">Referenced studies that support recommendations are summarized in Online Data Supplements 1 </text>
<text top="292" left="426" width="44" height="14" font="13">and 2. </text>
<text top="312" left="124" width="32" height="15" font="7"><b>COR </b></text>
<text top="312" left="194" width="29" height="15" font="7"><b>LOE </b></text>
<text top="312" left="453" width="129" height="15" font="7"><b>Recommendations </b></text>
<text top="342" left="136" width="8" height="15" font="7"><b>I </b></text>
<text top="342" left="202" width="14" height="15" font="7"><b>A </b></text>
<text top="332" left="251" width="13" height="15" font="7"><b>1.</b></text>
<text top="332" left="263" width="4" height="15" font="21"><b> </b></text>
<text top="332" left="277" width="506" height="15" font="7"><b>A team-based care approach is recommended for the control of risk factors </b></text>
<text top="352" left="277" width="273" height="15" font="7"><b>associated with ASCVD (S2.1-1</b>–<b>S2.1-14). </b></text>
<text top="386" left="136" width="8" height="15" font="7"><b>I </b></text>
<text top="386" left="195" width="27" height="15" font="7"><b>B-R </b></text>
<text top="372" left="251" width="13" height="15" font="7"><b>2.</b></text>
<text top="372" left="263" width="4" height="15" font="21"><b> </b></text>
<text top="372" left="277" width="500" height="15" font="7"><b>Shared decision-making should guide discussions about the best strategies </b></text>
<text top="392" left="277" width="272" height="15" font="7"><b>to reduce ASCVD risk (S2.1-15–S2.1-18)</b>.<b>  </b></text>
<text top="439" left="136" width="8" height="15" font="7"><b>I </b></text>
<text top="439" left="190" width="37" height="15" font="7"><b>B-NR </b></text>
<text top="420" left="251" width="13" height="15" font="7"><b>3.</b></text>
<text top="420" left="263" width="4" height="15" font="21"><b> </b></text>
<text top="420" left="277" width="481" height="15" font="7"><b>Social determinants of health should inform optimal implementation of </b></text>
<text top="439" left="277" width="485" height="15" font="7"><b>treatment recommendations for the prevention of ASCVD (S2.1-19–S2.1-</b></text>
<text top="459" left="277" width="29" height="15" font="7"><b>25). </b></text>
<text top="479" left="105" width="4" height="14" font="13"> </text>
<text top="499" left="105" width="61" height="15" font="7"><b>Synopsis </b></text>
<text top="519" left="105" width="683" height="14" font="13">This 2019 ACC/AHA Guideline on the Primary Prevention of CVD aims to promote the delivery of patient-</text>
<text top="538" left="105" width="687" height="14" font="13">centered care, which the writing committee felt was foundational to the guidance provided throughout. </text>
<text top="558" left="105" width="687" height="14" font="13">These  patient-centered  recommendations  emphasize  the  importance  of  team-based  care  delivery, </text>
<text top="577" left="105" width="687" height="14" font="13">shared  decision-making,  and  the  evaluation  of  social  determinants  of  health  in  ASCVD  prevention </text>
<text top="597" left="105" width="687" height="14" font="13">efforts.  These  recommendations  apply  to  all  aspects  of  clinical  practice  for  the  primary  prevention  of </text>
<text top="616" left="105" width="52" height="14" font="13">ASCVD. </text>
<text top="636" left="105" width="4" height="14" font="13"> </text>
<text top="656" left="105" width="287" height="15" font="7"><b>Recommendation-Specific Supportive Text </b></text>
<text top="675" left="105" width="687" height="14" font="13">1.  Team-based  care  makes  use  of  multidisciplinary  health  professionals  to  improve  the  quality  and </text>
<text top="695" left="131" width="657" height="14" font="13">maintenance  of  ASCVD  prevention.  It  is  a  multifaceted  approach  that  supports  clinical  decision-</text>
<text top="715" left="131" width="661" height="14" font="13">making (i.e., treatment algorithms), collaboration among different clinicians, and patient and family </text>
<text top="734" left="131" width="661" height="14" font="13">member  participation  to  facilitate  the  treatment  goals  of  patients  (S2.1-26).  RCTs  and  systematic </text>
<text top="754" left="131" width="661" height="14" font="13">reviews  with  meta-analyses  demonstrated  greater  reduction  of  ASCVD  risk  with  team-based  care </text>
<text top="773" left="131" width="661" height="14" font="13">than with usual care in patients with hypertension, diabetes, and hyperlipidemia (S2.1-1–S2.1-14). A </text>
<text top="793" left="131" width="661" height="14" font="13">team-based  approach  to  ASCVD  prevention  may  result  in  significant  improvements  in  patient </text>
<text top="812" left="131" width="657" height="14" font="13">outcomes  (S2.1-27)  and  often  meets  patient  needs  better  than  standard  care,  especially  in  low-</text>
<text top="832" left="131" width="661" height="14" font="13">resource  settings  and  among  vulnerable  populations.  In  a  team-based  care  model  that  compared </text>
<text top="852" left="131" width="661" height="14" font="13">patients  enrolled  in  a  preventive  cardiology  clinic  staffed  by  advanced  practice  providers  with  a </text>
<text top="871" left="131" width="661" height="14" font="13">propensity-matched cohort of patients enrolled in primary care clinics, a reduction in cardiovascular </text>
<text top="891" left="131" width="661" height="14" font="13">risk  was  demonstrated  through  effective  risk  stratification  and  preventive  management  (S2.1-28). </text>
<text top="911" left="131" width="661" height="14" font="13">Other  successful  interventions  that  have  used  team-based  care  include  telehealth  monitoring, </text>
<text top="930" left="131" width="368" height="14" font="13">follow-up support aids, and patient education (S2.1-27). </text>
<text top="950" left="105" width="687" height="14" font="13">2.  Decisions  about  primary  prevention  should  be  collaborative  between  a  clinician  and  a  patient. </text>
<text top="969" left="131" width="661" height="14" font="13">Shared  decision-making  occurs  when  practitioners  engage  patients  in  discussions  about </text>
<text top="989" left="131" width="661" height="14" font="13">personalized  ASCVD  risk  estimates  and  their  implications  for  the  perceived  benefits  of  preventive </text>
<text top="1009" left="131" width="661" height="14" font="13">strategies, including lifestyle habits, goals, and medical therapies. Collaborative decisions are more </text>
<text top="1028" left="131" width="661" height="14" font="13">likely  to  address  potential  barriers  to  treatment  options,  compared  with  treatment  and  guidance </text>
<text top="1048" left="131" width="319" height="14" font="13">offered without patient input (S2.1-15–S2.1-18). </text>
<text top="1067" left="105" width="687" height="14" font="13">3.  Socioeconomic  inequalities  are  strong  determinants  of  CVD  risk  internationally  (S2.1-21,  S2.1-24). </text>
<text top="1087" left="131" width="661" height="14" font="13">Therefore, the clinician should tailor advice to a patient’s socioeconomic and educational status, as </text>
</page>
<page number="14" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="22" size="14" family="Symbol" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 12 of 101 </text>
<text top="167" left="131" width="661" height="14" font="13">well  as  cultural,  work,  and  home  environments  (S2.1-23).  The  Centers  for  Medicare  &amp;  Medicaid </text>
<text top="187" left="131" width="657" height="14" font="13">Services  has  developed  a  screening  tool  (https://nam.edu/standardized-screening-for-health-</text>
<text top="207" left="131" width="616" height="14" font="13">related-social-needs-in-clinical-settings-the-accountable-health-communities-screening-tool/) </text>
<text top="207" left="774" width="17" height="14" font="13">to </text>
<text top="226" left="131" width="661" height="14" font="13">assess 5 domains of non–health-related measures  that  affect health outcomes: housing instability, </text>
<text top="246" left="131" width="657" height="14" font="13">food  insecurity,  transportation  difficulties,  utility  assistance  needs,  and  interpersonal  safety  (S2.1-</text>
<text top="265" left="131" width="661" height="14" font="13">29).  ASCVD  prevention  could  benefit  from  such  screening.  ASCVD  risk  begins  early  in  life,  with </text>
<text top="285" left="131" width="661" height="14" font="13">heightened  susceptibility  tied  to  low  socioeconomic  status  (S2.1-25).  Examples  of  upstream  social </text>
<text top="305" left="131" width="661" height="14" font="13">determinants  of  health  that  affect  treatment  adherence  and  ASCVD  health  outcomes  include </text>
<text top="324" left="131" width="661" height="14" font="13">comorbid  mental  illness,  lack  of  health  literacy,  exposure  to  adversity  (e.g.,  home/community </text>
<text top="344" left="131" width="661" height="14" font="13">violence, trauma exposures, safety concerns), financial strain, inadequate housing conditions, lack of </text>
<text top="363" left="131" width="657" height="14" font="13">food  security  (i.e.,  access  to  affordable  and  nutritious  food),  and  inadequate  social  support  (S2.1-</text>
<text top="383" left="131" width="661" height="14" font="13">30). Systems of care should evaluate social determinants of health that affect care delivery for the </text>
<text top="403" left="131" width="617" height="14" font="13">primary prevention of ASCVD (e.g., transportation barriers, the availability of health services).  </text>
<text top="422" left="131" width="4" height="14" font="13"> </text>
<text top="422" left="158" width="634" height="14" font="13">Important  considerations  related  to  socioeconomic  disadvantage  are  not  captured  by  existing </text>
<text top="442" left="131" width="661" height="14" font="13">CVD risk equations (S2.1-31). Addressing unmet social needs improves management of BP and lipids </text>
<text top="461" left="131" width="661" height="14" font="13">(S2.1-32),  which  highlights  the  importance  of  dietary  counseling  and  encouraging  physical  activity </text>
<text top="481" left="131" width="661" height="14" font="13">(S2.1-19).  More  time  may  be  required  to  address  ASCVD  prevention  with  adults  of  low  health </text>
<text top="501" left="131" width="343" height="14" font="13">literacy or disadvantaged educational backgrounds.  </text>
<text top="520" left="131" width="4" height="14" font="13"> </text>
<text top="520" left="158" width="634" height="14" font="13">Differential cardiovascular outcomes persist by important sociodemographic characteristics that </text>
<text top="540" left="131" width="661" height="14" font="13">include  but  are  not  limited  to  age,  sex,  and  race/ethnicity  (S2.1-22,  S2.1-33–S2.1-35).  Failure  to </text>
<text top="559" left="131" width="661" height="14" font="13">address  the  impact  of  social  determinants  of  health  impedes  efficacy  of  proven  prevention </text>
<text top="579" left="131" width="661" height="14" font="13">recommendations. Table 2 outlines key considerations related to social determinants of health and </text>
<text top="599" left="131" width="127" height="14" font="13">ASCVD prevention. </text>
<text top="618" left="105" width="4" height="14" font="13"> </text>
<text top="638" left="105" width="681" height="15" font="7"><b>Table 2. Example Considerations for Addressing Social Determinants of Health to Help Prevent ASCVD </b></text>
<text top="657" left="105" width="48" height="15" font="7"><b>Events </b></text>
<text top="677" left="105" width="99" height="15" font="7"><b>Topic/Domain</b> </text>
<text top="677" left="447" width="164" height="15" font="7"><b>Example Considerations</b> </text>
<text top="698" left="105" width="126" height="14" font="13">Cardiovascular risk </text>
<text top="694" left="284" width="7" height="21" font="22">•</text>
<text top="699" left="291" width="4" height="15" font="17"> </text>
<text top="699" left="310" width="435" height="14" font="13">Adults should be routinely assessed for psychosocial stressors and </text>
<text top="719" left="310" width="315" height="14" font="13">provided with appropriate counseling (S2.1-31). </text>
<text top="734" left="284" width="7" height="21" font="22">•</text>
<text top="739" left="291" width="4" height="15" font="17"> </text>
<text top="739" left="310" width="402" height="14" font="13">Health literacy should be assessed every 4 to 6 y to maximize </text>
<text top="759" left="310" width="273" height="14" font="13">recommendation effectiveness (S2.1-36). </text>
<text top="779" left="105" width="31" height="14" font="13">Diet </text>
<text top="775" left="284" width="7" height="21" font="22">•</text>
<text top="780" left="291" width="4" height="15" font="17"> </text>
<text top="780" left="310" width="406" height="14" font="13">In addition to the prescription of diet modifications, body size </text>
<text top="799" left="310" width="408" height="14" font="13">perception, as well as social and cultural influences, should be </text>
<text top="819" left="310" width="187" height="14" font="13">assessed (S2.1-37, S2.1-38).  </text>
<text top="834" left="284" width="7" height="21" font="22">•</text>
<text top="839" left="291" width="4" height="15" font="17"> </text>
<text top="839" left="310" width="414" height="14" font="13">Potential barriers to adhering to a heart-healthy diet should be </text>
<text top="859" left="310" width="444" height="14" font="13">assessed, including food access and economic factors; these factors </text>
<text top="878" left="310" width="453" height="14" font="13">may be particularly relevant to persons from vulnerable populations, </text>
<text top="898" left="310" width="455" height="14" font="13">such as individuals residing in either inner-city or rural environments, </text>
<text top="918" left="310" width="439" height="14" font="13">those at socioeconomic disadvantage, and those of advanced age* </text>
<text top="937" left="310" width="66" height="14" font="13">(S2.1-39). </text>
<text top="957" left="105" width="141" height="14" font="13">Exercise and physical </text>
<text top="977" left="105" width="51" height="14" font="13">activity </text>
<text top="953" left="284" width="7" height="21" font="22">•</text>
<text top="958" left="291" width="4" height="15" font="17"> </text>
<text top="958" left="310" width="461" height="14" font="13">In addition to the prescription of exercise, neighborhood environment </text>
<text top="978" left="310" width="447" height="14" font="13">and access to facilities for physical activity should be assessed (S2.1- </text>
<text top="997" left="310" width="142" height="14" font="13">30, S2.1-40, S2.1-41). </text>
<text top="1017" left="105" width="158" height="14" font="13">Obesity and weight loss </text>
<text top="1013" left="284" width="7" height="21" font="22">•</text>
<text top="1018" left="291" width="4" height="15" font="17"> </text>
<text top="1018" left="310" width="453" height="14" font="13">Lifestyle counseling for weight loss should include assessment of and </text>
<text top="1038" left="310" width="431" height="14" font="13">interventional recommendations for psychosocial stressors, sleep </text>
<text top="1057" left="310" width="398" height="14" font="13">hygiene, and other individualized barriers (S2.1-42–S2.1-44). </text>
</page>
<page number="15" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="23" size="12" family="Times" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 13 of 101 </text>
<text top="168" left="105" width="99" height="15" font="7"><b>Topic/Domain</b> </text>
<text top="168" left="447" width="164" height="15" font="7"><b>Example Considerations</b> </text>
<text top="185" left="284" width="7" height="21" font="22">•</text>
<text top="189" left="291" width="4" height="15" font="17"> </text>
<text top="189" left="310" width="382" height="14" font="13">Weight maintenance should be promoted in patients with </text>
<text top="209" left="310" width="455" height="14" font="13">overweight/obesity who are unable to achieve recommended weight </text>
<text top="228" left="310" width="36" height="14" font="13">loss.  </text>
<text top="250" left="105" width="117" height="14" font="13">Diabetes mellitus </text>
<text top="246" left="284" width="7" height="21" font="22">•</text>
<text top="251" left="291" width="4" height="15" font="17"> </text>
<text top="251" left="310" width="376" height="14" font="13">In addition to the prescription of type 2 diabetes mellitus </text>
<text top="270" left="310" width="424" height="14" font="13">interventions, environmental and psychosocial factors, including </text>
<text top="290" left="310" width="405" height="14" font="13">depression, stress, self-efficacy, and social support, should be </text>
<text top="309" left="310" width="453" height="14" font="13">assessed to improve achievement of glycemic control and adherence </text>
<text top="329" left="310" width="211" height="14" font="13">to treatment (S2.1-45–S2.1-48). </text>
<text top="349" left="105" width="135" height="14" font="13">High blood pressure </text>
<text top="345" left="284" width="7" height="21" font="22">•</text>
<text top="350" left="291" width="4" height="15" font="17"> </text>
<text top="350" left="310" width="459" height="14" font="13">Short sleep duration (&lt;6 h) and poor-quality sleep are associated with </text>
<text top="369" left="310" width="429" height="14" font="13">high blood pressure and should be considered (S2.1-49). Because </text>
<text top="389" left="310" width="449" height="14" font="13">other lifestyle habits can impact blood pressure, access to a healthy, </text>
<text top="409" left="310" width="387" height="14" font="13">low-sodium diet and viable exercise options should also be </text>
<text top="428" left="310" width="84" height="14" font="13">considered.  </text>
<text top="448" left="105" width="128" height="14" font="13">Tobacco treatment </text>
<text top="444" left="284" width="7" height="21" font="22">•</text>
<text top="449" left="291" width="4" height="15" font="17"> </text>
<text top="449" left="310" width="417" height="14" font="13">Social support is another potential determinant of tobacco use. </text>
<text top="469" left="310" width="460" height="14" font="13">Therefore, in adults who use tobacco, assistance and arrangement for </text>
<text top="488" left="310" width="457" height="14" font="13">individualized and group social support counseling are recommended </text>
<text top="508" left="310" width="123" height="14" font="13">(S2.1-50, S2.1-51). </text>
<text top="527" left="105" width="294" height="13" font="23">*Advanced age generally refers to age ≥75 years. </text>
<text top="545" left="105" width="329" height="13" font="23">ASCVD indicates atherosclerotic cardiovascular disease.</text>
<text top="564" left="71" width="12" height="14" font="13">1 </text>
<text top="595" left="71" width="12" height="14" font="13">2 </text>
</page>
<page number="16" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 14 of 101 </text>
<text top="169" left="105" width="356" height="20" font="20"><b>2.2. Assessment of Cardiovascular Risk </b></text>
<text top="195" left="248" width="388" height="15" font="7"><b>Recommendations for Assessment of Cardiovascular Risk  </b></text>
<text top="215" left="120" width="640" height="14" font="13">Referenced studies that support recommendations are summarized in Online Data Supplement 3.<b> </b></text>
<text top="235" left="115" width="32" height="15" font="7"><b>COR </b></text>
<text top="235" left="181" width="29" height="15" font="7"><b>LOE </b></text>
<text top="235" left="441" width="129" height="15" font="7"><b>Recommendations </b></text>
<text top="275" left="127" width="8" height="15" font="7"><b>I </b></text>
<text top="275" left="177" width="37" height="15" font="7"><b>B-NR </b></text>
<text top="255" left="234" width="13" height="15" font="7"><b>1.</b></text>
<text top="255" left="247" width="4" height="15" font="21"><b> </b></text>
<text top="255" left="260" width="515" height="15" font="7"><b>For adults 40 to 75 years of age, clinicians should routinely assess traditional </b></text>
<text top="275" left="260" width="516" height="15" font="7"><b>cardiovascular risk factors and calculate 10-year risk of ASCVD by using the </b></text>
<text top="294" left="260" width="315" height="15" font="7"><b>pooled cohort equations (PCE) (S2.2-1, S2.2-2). </b></text>
<text top="324" left="121" width="20" height="15" font="7"><b>IIa </b></text>
<text top="324" left="177" width="37" height="15" font="7"><b>B-NR </b></text>
<text top="315" left="234" width="13" height="15" font="7"><b>2.</b></text>
<text top="315" left="247" width="4" height="15" font="21"><b> </b></text>
<text top="315" left="260" width="516" height="15" font="7"><b>For adults 20 to 39 years of age, it is reasonable to assess traditional ASCVD </b></text>
<text top="334" left="260" width="360" height="15" font="7"><b>risk factors at least every 4 to 6 years (S2.2-1–S2.2-3). </b></text>
<text top="384" left="121" width="20" height="15" font="7"><b>IIa </b></text>
<text top="384" left="177" width="37" height="15" font="7"><b>B-NR </b></text>
<text top="354" left="234" width="13" height="15" font="7"><b>3.</b></text>
<text top="355" left="247" width="4" height="15" font="21"><b> </b></text>
<text top="354" left="260" width="515" height="15" font="7"><b>In adults at borderline risk (5% to &lt;7.5% 10-year ASCVD risk) or intermediate </b></text>
<text top="374" left="260" width="515" height="15" font="7"><b>risk  (≥7.5%  to  &lt;20%  10-year  ASCVD  risk),  it  is  reasonable  to  use  additional </b></text>
<text top="394" left="260" width="515" height="15" font="7"><b>risk-enhancing  factors  to  guide  decisions  about  preventive  interventions </b></text>
<text top="413" left="260" width="260" height="15" font="7"><b>(e.g., statin therapy) (S2.2-4</b>–<b>S2.2-14).  </b></text>
<text top="473" left="121" width="20" height="15" font="7"><b>IIa </b></text>
<text top="473" left="177" width="37" height="15" font="7"><b>B-NR </b></text>
<text top="434" left="234" width="13" height="15" font="7"><b>4.</b></text>
<text top="434" left="247" width="4" height="15" font="21"><b> </b></text>
<text top="434" left="260" width="515" height="15" font="7"><b>In  adults  at  intermediate  risk  (≥7.5%  to  &lt;20%  10-year  ASCVD  risk)  or </b></text>
<text top="453" left="260" width="512" height="15" font="7"><b>selected  adults  at  borderline  risk  (5%  to  &lt;7.5%  10-year ASCVD  risk), if risk-</b></text>
<text top="473" left="260" width="515" height="15" font="7"><b>based  decisions  for  preventive  interventions  (e.g.,  statin  therapy)  remain </b></text>
<text top="492" left="260" width="515" height="15" font="7"><b>uncertain,  it  is  reasonable  to  measure  a  coronary  artery  calcium  score  to </b></text>
<text top="512" left="260" width="379" height="15" font="7"><b>guide clinician–patient risk discussion (S2.2-15</b>–<b>S2.2-31). </b></text>
<text top="552" left="121" width="21" height="15" font="7"><b>IIb </b></text>
<text top="552" left="177" width="37" height="15" font="7"><b>B-NR </b></text>
<text top="532" left="234" width="13" height="15" font="7"><b>5.</b></text>
<text top="532" left="247" width="4" height="15" font="21"><b> </b></text>
<text top="532" left="260" width="515" height="15" font="7"><b>For adults 20 to 39 years of age and for those 40 to 59 years of age who have </b></text>
<text top="552" left="260" width="515" height="15" font="7"><b>&lt;7.5% 10-year ASCVD risk, estimating lifetime or 30-year ASCVD risk may be </b></text>
<text top="571" left="260" width="300" height="15" font="7"><b>considered (S2.2-1, S2.2-2, S2.2-32</b>–<b>S2.2-35). </b></text>
<text top="592" left="105" width="4" height="14" font="13"> </text>
<text top="611" left="105" width="61" height="15" font="7"><b>Synopsis </b></text>
<text top="631" left="105" width="687" height="14" font="13">Assessment of ASCVD risk remains the foundation of primary prevention. Although all individuals should </text>
<text top="651" left="105" width="687" height="14" font="13">be encouraged to follow a heart-healthy lifestyle, estimating an individual’s 10-year absolute ASCVD risk </text>
<text top="670" left="105" width="687" height="14" font="13">enables  matching  the  intensity  of  preventive  interventions  to  the  patient’s  absolute  risk,  to  maximize </text>
<text top="690" left="105" width="687" height="14" font="13">anticipated benefit and minimize potential harm from overtreatment. The 10-year ASCVD risk estimate </text>
<text top="710" left="105" width="687" height="14" font="13">is used to guide decision-making for many preventive interventions, including lipid management (S2.2-4, </text>
<text top="729" left="105" width="687" height="14" font="13">S2.2-36) and BP management (S2.2-37); it should be the start of a conversation with the patient about </text>
<text top="749" left="105" width="687" height="14" font="13">risk-reducing  strategies  (the  “clinician–patient  discussion”)  and  not  the  sole  decision  factor  for  the </text>
<text top="768" left="105" width="687" height="14" font="13">initiation  of  pharmacotherapy  (S2.2-4,  S2.2-36,  S2.2-38).  All  risk  estimation  tools  have  inherent </text>
<text top="788" left="105" width="687" height="14" font="13">limitations,  and  population-based  risk  scores  must  be  interpreted  in light  of  specific  circumstances  for </text>
<text top="808" left="105" width="687" height="14" font="13">individual  patients.  The  PCE  have  been  shown  to  overestimate  (S2.2-15,  S2.2-39–S2.2-47)  or </text>
<text top="827" left="105" width="687" height="14" font="13">underestimate  (S2.2-12,  S2.2-48–S2.2-51)  ASCVD  risk  for  certain  subgroups.  Thus,  after  calculation  of </text>
<text top="847" left="105" width="687" height="14" font="13">the  PCE,  it  is  reasonable  to  use  additional  risk-enhancing  factors  to  guide  decisions  about  preventive </text>
<text top="867" left="105" width="687" height="14" font="13">interventions  for  borderline-  or  intermediate-risk  adults  (S2.2-4–S2.2-14).  However,  the  value  of </text>
<text top="886" left="105" width="687" height="14" font="13">preventive  therapy  may  remain  uncertain  for  many  individuals  with  borderline  or  intermediate </text>
<text top="906" left="105" width="687" height="14" font="13">estimated  10-year  risk,  and  some  patients  may  be  reluctant  to  take  medical  therapy  without  clearer </text>
<text top="925" left="105" width="687" height="14" font="13">evidence of increased ASCVD risk. For these individuals, the assessment of coronary artery calcium is a </text>
<text top="945" left="105" width="687" height="14" font="13">reasonable  tool  to  reclassify  risk  either  upward  or  downward,  as  part  of  shared  decision-making.  For </text>
<text top="965" left="105" width="687" height="14" font="13">younger adults 20 to 59 years of age, estimation of lifetime risk may be considered. For adults &gt;75 years </text>
<text top="984" left="105" width="687" height="14" font="13">of age, the clinician and patient should engage in a discussion about the possible benefits of preventive </text>
<text top="1004" left="105" width="596" height="14" font="13">therapies appropriate to the age group in the context of comorbidities and life expectancy. </text>
<text top="1023" left="105" width="4" height="14" font="13"> </text>
<text top="1043" left="105" width="4" height="15" font="7"><b> </b></text>
<text top="1043" left="315" width="4" height="15" font="7"><b> </b></text>
</page>
<page number="17" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 15 of 101 </text>
<text top="167" left="105" width="287" height="15" font="7"><b>Recommendation-Specific Supportive Text </b></text>
<text top="187" left="105" width="687" height="14" font="13">1.  To  facilitate  decisions  about  preventive  interventions,  it  is  recommended  to  screen  for  traditional </text>
<text top="207" left="131" width="661" height="14" font="13">ASCVD  risk  factors  and  apply  the  race-  and  sex-specific  PCE  (ASCVD  Risk  Estimator: </text>
<text top="226" left="131" width="661" height="14" font="13">http://tools.acc.org/ldl/ascvd_risk_estimator/index.html#!/calulate/estimator/) to estimate 10-year </text>
<text top="246" left="131" width="661" height="14" font="13">ASCVD risk for asymptomatic adults 40 to 75 years of age (S2.2.1, S2.2.2). For management of stage </text>
<text top="265" left="131" width="661" height="14" font="13">1 hypertension (BP 130–139 / 80–89 mm Hg), adults should be categorized as &lt;10% or &gt;10% 10-year </text>
<text top="285" left="131" width="661" height="14" font="13">ASCVD  risk  for  therapeutic  decisions  (see  Section  4.4  Figure  4).  For  management  of  blood </text>
<text top="305" left="131" width="661" height="14" font="13">cholesterol,  adults  should  be  categorized  as  having  low  (&lt;5%),  borderline  (5%  to  &lt;7.5%), </text>
<text top="324" left="131" width="661" height="14" font="13">intermediate  (≥7.5%  to  &lt;20%),  or  high  (≥20%)  10-year  risk  (S2.2-4).  The  PCE  are  best  validated </text>
<text top="344" left="131" width="661" height="14" font="13">among  non-Hispanic  whites  and  non-Hispanic  blacks  living  in  the  United  States  (S2.2-1,  S2.2-39, </text>
<text top="363" left="131" width="661" height="14" font="13">S2.2-48,  S2.2-49,  S2.2-52).  In  other  racial/ethnic  groups  (S2.2-53,  S2.2-54)  or  in  some  non-U.S. </text>
<text top="383" left="131" width="661" height="14" font="13">populations  (S2.2-40,  S2.2-41,  S2.2-53,  S2.2-54),  the  PCE  may  overestimate  or  underestimate  risk. </text>
<text top="403" left="131" width="661" height="14" font="13">Therefore, clinicians may consider the use of another risk prediction tool as an alternative to the PCE </text>
<text top="422" left="131" width="661" height="14" font="13">if  the  tool  was  validated  in  a  population  with  characteristics  similar  to  those  of  the  evaluated </text>
<text top="442" left="131" width="661" height="14" font="13">patient. Examples include the general Framingham CVD risk score (S2.2-55), the Reynolds risk scores </text>
<text top="461" left="131" width="661" height="14" font="13">(S2.2-56,  S2.2-57),  SCORE  (Systematic  COronary  Risk  Evaluation)  (S2.2-58),  and  the  QRISK/JBS3 </text>
<text top="481" left="131" width="661" height="14" font="13">(S2.2-59) tools. Other professional  societies have incorporated some of these  alternative validated </text>
<text top="501" left="131" width="661" height="14" font="13">risk  scores  into  their lipid  management  guidelines  or  have  considered  different  risk  thresholds  for </text>
<text top="520" left="131" width="661" height="14" font="13">preventive  interventions  (S2.2-58–S2.2-63).  Although  slight  differences  exist  across  organizational </text>
<text top="540" left="131" width="661" height="14" font="13">guidelines, they are all very similar in their overarching goal of matching the intensity of preventive </text>
<text top="559" left="131" width="533" height="14" font="13">therapies to the absolute (generally 10-year) risk of the patient (S2.2-58–S2.2-63) </text>
<text top="579" left="105" width="687" height="14" font="13">2.  After  age  20  years,  it  is  reasonable  to  measure  traditional  risk  factors  at  least  every  4  to  6  years </text>
<text top="599" left="131" width="661" height="14" font="13">(S2.2-1, S2.2-3). For adults 20 to 39 years of age, limited data exist on the performance and utility of </text>
<text top="618" left="131" width="661" height="14" font="13">10-year risk estimation tools (S2.2-64). Because age is a major driver of risk, most in this age range </text>
<text top="638" left="131" width="661" height="14" font="13">(&lt;40  years)  are  unlikely  to  have  a  sufficiently  elevated  10-year  risk  to  warrant  pharmacological </text>
<text top="658" left="131" width="661" height="14" font="13">therapy with a statin (with some exceptions, such as in familial hypercholesterolemia). Nevertheless, </text>
<text top="677" left="131" width="661" height="14" font="13">periodic assessment of risk factors (e.g., at least every 4 to 6 years in younger adults 20 to 39 years </text>
<text top="697" left="131" width="661" height="14" font="13">of age) is important to guide discussions about intensity of lifestyle interventions, frequency of risk </text>
<text top="716" left="131" width="661" height="14" font="13">factor  monitoring,  treatment  of  nonlipid  risk  factors,  and  consideration  of  30-year  or  lifetime  risk </text>
<text top="736" left="131" width="184" height="14" font="13">estimation (S2.2-1–S2.2-3).  </text>
<text top="755" left="105" width="687" height="14" font="13">3.  No  single  risk  calculator  is  appropriate  for  all  patients.  In  certain  populations,  the  PCE  have </text>
<text top="775" left="131" width="661" height="14" font="13">reasonable  calibration  (S2.2-1,  S2.2-65–S2.2-67).  However,  some  studies  have  found </text>
<text top="795" left="131" width="661" height="14" font="14"><i>underestimation  </i>of  risk  (and  potential  for  undertreatment)  among  individuals  with  chronic </text>
<text top="814" left="131" width="661" height="14" font="13">inflammatory  conditions  (e.g.,  autoimmune  disease  (S2.2-50),  HIV  infection  (S2.2-12))  or </text>
<text top="834" left="131" width="661" height="14" font="13">socioeconomic disadvantage (S2.2-48, S2.2-49, S2.2-51) not captured in current risk scoring models. </text>
<text top="854" left="131" width="661" height="14" font="13">Patients  with  familial  hypercholesterolemia  are  at  significant  risk  of  having  an  early  ASCVD  event, </text>
<text top="873" left="131" width="661" height="14" font="13">and  the  use  of  risk  calculators  is  not  applicable  to  these  patients.  In  contrast,  other  studies  have </text>
<text top="893" left="131" width="661" height="14" font="13">found  <i>overestimation</i>  of  risk  with  the  PCE,  particularly  among  those  with  higher  socioeconomic </text>
<text top="912" left="131" width="661" height="14" font="13">position  and  those  with  continual  access  to  care  and  preventive  services,  which  could  lead  to </text>
<text top="932" left="131" width="661" height="14" font="13">overtreatment  of  individuals  less  likely  to  receive  net  benefit  from  preventive  pharmacotherapies </text>
<text top="952" left="131" width="661" height="14" font="13">over  the  next  decade (S2.2-15,  S2.2-39–S2.2-47).  The  PCE  may  be  suboptimally  calibrated in more </text>
<text top="971" left="131" width="661" height="14" font="13">modern  populations  as  compared  with  the  older  cohorts  from  which  they  were  derived  (S2.2-68). </text>
<text top="991" left="131" width="661" height="14" font="13">Therefore,  among  adults  at  borderline  (5%  to  &lt;7.5%)  and  intermediate  (≥7.5%  to  &lt;20%)<b>  </b>risk,  one </text>
<text top="1010" left="131" width="661" height="14" font="13">may consider additional individual risk-enhancing clinical factors (Table 3) that can be used to revise </text>
<text top="1030" left="131" width="661" height="14" font="13">the  10-year  ASCVD  risk  estimate  (S2.2-4).  These  factors  may  include  having  a  family  history  of </text>
<text top="1050" left="131" width="657" height="14" font="13">premature ASCVD (S2.2-5), chronic inflammatory disease [rheumatoid arthritis (S2.2-6), lupus (S2.2-</text>
<text top="1069" left="131" width="661" height="14" font="13">7), or HIV infection (S2.2-12)], South Asian ancestry (S2.2-13), a history of preeclampsia (S2.2-8) or </text>
</page>
<page number="18" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 16 of 101 </text>
<text top="167" left="131" width="661" height="14" font="13">preterm delivery (S2.2-9), early menopause (S2.2-10), erectile dysfunction (S2.2-11), chronic kidney </text>
<text top="187" left="131" width="661" height="14" font="13">disease  (CKD),  metabolic  syndrome,  persistently  elevated  inflammatory  markers  (S2.2-14),  or </text>
<text top="207" left="131" width="661" height="14" font="13">elevated  lipid  biomarkers<b>  </b>(S2.2-4).<b>  </b>After  these  clinically  available  risk-enhancing  factors  have  been </text>
<text top="226" left="131" width="661" height="14" font="13">considered, if there is still uncertainty about the reliability of the risk estimate for individuals in the </text>
<text top="246" left="131" width="661" height="14" font="13">borderline-  or  intermediate-risk  categories,  further  testing  to  document  subclinical  coronary </text>
<text top="265" left="131" width="661" height="14" font="13">atherosclerosis is  reasonable  to  more  accurately  reclassify  the  risk  estimate  upward  or  downward </text>
<text top="285" left="131" width="180" height="14" font="13">(S2.2-17–S2.2-19, S2.2-69). </text>
<text top="305" left="105" width="687" height="14" font="13">4.  For individuals with intermediate predicted risk (≥7.5% to &lt;20%) by the PCE or for select adults with </text>
<text top="324" left="131" width="661" height="14" font="13">borderline (5% to &lt;7.5%) predicted risk, coronary artery calcium measurement can be a useful tool </text>
<text top="344" left="131" width="661" height="14" font="13">in  refining  risk  assessment  for  preventive  interventions  (e.g.,  statin  therapy)  (S2.2-4).  In  these </text>
<text top="363" left="131" width="661" height="14" font="13">groups,  coronary  artery  calcium  measurement  can  reclassify  risk  upward  (particularly  if  coronary </text>
<text top="383" left="131" width="661" height="14" font="13">artery calcium score is ≥100 Agatston units (AU) or ≥75th age/sex/race percentile) or downward (if </text>
<text top="403" left="131" width="661" height="14" font="13">coronary  artery  calcium  is  zero)  in  a  significant  proportion  of  individuals  (S2.2-15).  The  extent  of </text>
<text top="422" left="131" width="661" height="14" font="13">reclassification is sufficient to provide confidence that borderline- or intermediate-risk patients with </text>
<text top="442" left="131" width="661" height="14" font="13">elevated  coronary  artery  calcium  will  have  event  rates  that  clearly  exceed  benefit  thresholds  (i.e., </text>
<text top="461" left="131" width="661" height="14" font="13">≥7.5%  in  10  years)  and  those  with  coronary  artery  calcium  scores  of  zero  will  have  event  rates </text>
<text top="481" left="131" width="661" height="14" font="13">&lt;7.5%,  which  can  help  guide  shared  decision-making  about  statins  (S2.2-15,  S2.2-16,  S2.2-21)  or </text>
<text top="501" left="131" width="661" height="14" font="13">potentially  even  aspirin  (S2.2-70).  In  observational  data,  the  presence  and  severity  of  coronary </text>
<text top="520" left="131" width="661" height="14" font="13">artery calcium have been shown to be associated with the likelihood of benefit from statin therapy </text>
<text top="540" left="131" width="661" height="14" font="13">for ASCVD risk reduction (S2.2-71). Coronary artery calcium scoring has superior discrimination and </text>
<text top="559" left="131" width="661" height="14" font="13">risk  reclassification  as  compared  with  other  subclinical  imaging  markers  or  biomarkers  (S2.2-22, </text>
<text top="579" left="131" width="661" height="14" font="13">S2.2-27). In the MESA (Multi-Ethnic Study of Atherosclerosis) trial, the coronary artery calcium score </text>
<text top="599" left="131" width="661" height="14" font="13">was  strongly  associated  with  10-year  ASCVD  risk  in  a  graded  manner  across  age,  sex,  and </text>
<text top="618" left="131" width="661" height="14" font="13">racial/ethnic groups, independent of traditional risk factors (S2.2-17). Coronary artery calcium may </text>
<text top="638" left="131" width="661" height="14" font="13">even  refine  ASCVD  risk  estimates  among  lower-risk  women  (&lt;7.5%  10-year  risk)  (S2.2-7),  younger </text>
<text top="658" left="131" width="661" height="14" font="13">adults (&lt;45 years of age) (S2.2-20), and older adults (≥75 years of age) (S2.2-26), but more data are </text>
<text top="677" left="131" width="661" height="14" font="13">needed  to  support  its  use  in  these  subgroups.  A  coronary  artery  calcium  score  of  zero  identifies </text>
<text top="697" left="131" width="657" height="14" font="13">individuals at lower risk of ASCVD events and death over a ≥10-year period (S2.2-15, S2.2-17, S2.2-</text>
<text top="716" left="131" width="661" height="14" font="13">25), who appear to derive little or no benefit from statins for ASCVD risk reduction (S2.2-71). Thus, </text>
<text top="736" left="131" width="661" height="14" font="13">the absence of coronary artery calcium could reclassify a patient downward into a lower risk group </text>
<text top="755" left="131" width="661" height="14" font="13">in which preventive interventions (e.g., statins) could be postponed (S2.2-22). Note that the absence </text>
<text top="775" left="131" width="661" height="14" font="13">of  coronary  artery  calcium  does  not  rule  out  noncalcified  plaque,  and  clinical judgment  about  risk </text>
<text top="795" left="131" width="661" height="14" font="13">should prevail. Coronary artery calcium might also be considered in refining risk for selected low-risk </text>
<text top="814" left="131" width="661" height="14" font="13">adults  (&lt;5%  10-year  risk),  such  as  those  with  a  strong  family  history  of  premature  coronary  heart </text>
<text top="834" left="131" width="661" height="14" font="13">disease  (CHD)  (S2.2-23).  MESA  (S2.2-28)  and  Astro-CHARM  (Astronaut  Cardiovascular  Health  and </text>
<text top="854" left="131" width="661" height="14" font="13">Risk Modification) (S2.2-29) are risk estimation tools that incorporate both risk factors and coronary </text>
<text top="873" left="131" width="661" height="14" font="13">artery  calcium  for  estimating  10-year  CHD  and  ASCVD  risk,  respectively.  Coronary  artery  calcium </text>
<text top="893" left="131" width="661" height="14" font="13">measurement is not intended as a “screening” test for all but rather may be used as a decision aid in </text>
<text top="912" left="131" width="405" height="14" font="13">select adults to facilitate the clinician–patient risk discussion.  </text>
<text top="932" left="105" width="664" height="14" font="13">5.  For adults 20 to 39 years of age (who are not included in the PCE) and those 40 to 59 years of age </text>
<text top="952" left="131" width="649" height="14" font="13">who are not already at elevated (≥7.5%)<b> </b>10-year risk, estimating a lifetime or 30-year risk of ASCVD </text>
<text top="971" left="131" width="281" height="14" font="13">may be considered (ASCVD Risk Estimator: </text>
<text top="991" left="131" width="642" height="14" font="13">http://tools.acc.org/ldl/ascvd_risk_estimator/index.html#!/calulate/estimator/) (S2.2-2). Younger </text>
<text top="1010" left="131" width="653" height="14" font="13">individuals often have low estimated 10-year risk, but the presence of at least 1 major risk factor by </text>
<text top="1030" left="131" width="642" height="14" font="13">middle age is associated with increased lifetime ASCVD risk and reduced survival free of morbidity </text>
<text top="1050" left="131" width="659" height="14" font="13">compared with those with optimal risk factors (S2.2-32–S2.2-34). Calculation of lifetime risk with the </text>
<text top="1069" left="131" width="656" height="14" font="13">ACC/AHA 30-year/lifetime risk estimator for those 20 to 59 years of age (not at high short-term risk) </text>
</page>
<page number="19" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="24" size="8" family="Times" color="#000000"/>
	<fontspec id="25" size="14" family="Courier" color="#000000"/>
	<fontspec id="26" size="12" family="Times" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 17 of 101 </text>
<text top="167" left="131" width="638" height="14" font="13">may be reasonable to consider as a communication strategy for reinforcing adherence to lifestyle </text>
<text top="187" left="131" width="181" height="14" font="13">recommendations (S2.2-2). </text>
<text top="207" left="105" width="4" height="14" font="13"> </text>
<text top="226" left="105" width="456" height="15" font="7"><b>Table 3. Risk-Enhancing Factors for Clinician–Patient Risk Discussion </b></text>
<text top="261" left="105" width="156" height="15" font="7"><b>Risk-Enhancing Factors </b></text>
<text top="298" left="105" width="7" height="21" font="22">•</text>
<text top="303" left="112" width="4" height="15" font="17"> </text>
<text top="303" left="131" width="490" height="15" font="7"><b>Family history of premature ASCVD</b> (males, age &lt;55 y; females, age &lt;65 y) </text>
<text top="319" left="105" width="7" height="21" font="22">•</text>
<text top="323" left="112" width="4" height="15" font="17"> </text>
<text top="323" left="131" width="620" height="15" font="7"><b>Primary hypercholesterolemia</b> (LDL-C, 160–189 mg/dL [4.1–4.8 mmol/L]; non–HDL-C 190–219 </text>
<text top="343" left="131" width="175" height="14" font="13">mg/dL [4.9–5.6 mmol/L])* </text>
<text top="358" left="105" width="7" height="21" font="22">•</text>
<text top="363" left="112" width="4" height="15" font="17"> </text>
<text top="363" left="131" width="655" height="15" font="7"><b>Metabolic syndrome</b> (increased waist circumference [by ethnically appropriate cutpoints], elevated </text>
<text top="383" left="131" width="638" height="14" font="13">triglycerides [&gt;150 mg/dL, nonfasting], elevated blood pressure, elevated glucose, and low HDL-C </text>
<text top="402" left="131" width="568" height="14" font="13">[&lt;40 mg/dL in men; &lt;50 mg/dL in women] are factors; a tally of 3 makes the diagnosis) </text>
<text top="418" left="105" width="7" height="21" font="22">•</text>
<text top="423" left="112" width="4" height="15" font="17"> </text>
<text top="423" left="131" width="345" height="15" font="7"><b>Chronic kidney disease</b> (eGFR 15–59 mL/min/1.73 m</text>
<text top="420" left="476" width="5" height="9" font="24">2</text>
<text top="423" left="481" width="306" height="14" font="13"> with or without albuminuria; not treated with </text>
<text top="443" left="131" width="224" height="14" font="13">dialysis or kidney transplantation) </text>
<text top="458" left="105" width="7" height="21" font="22">•</text>
<text top="463" left="112" width="4" height="15" font="17"> </text>
<text top="463" left="131" width="492" height="15" font="7"><b>Chronic inflammatory conditions,</b> such as psoriasis, RA, lupus, or HIV/AIDS </text>
<text top="479" left="105" width="7" height="21" font="22">•</text>
<text top="483" left="112" width="4" height="15" font="17"> </text>
<text top="483" left="131" width="660" height="15" font="7"><b>History of premature menopause (before age 40 y) and history of pregnancy-associated conditions </b></text>
<text top="503" left="131" width="351" height="15" font="7"><b>that increase later ASCVD risk, such as preeclampsia </b></text>
<text top="519" left="105" width="7" height="21" font="22">•</text>
<text top="524" left="112" width="4" height="15" font="17"> </text>
<text top="523" left="131" width="341" height="15" font="7"><b>High-risk race/ethnicity</b> (e.g., South Asian ancestry) </text>
<text top="539" left="105" width="7" height="21" font="22">•</text>
<text top="544" left="112" width="4" height="15" font="17"> </text>
<text top="544" left="131" width="375" height="15" font="7"><b>Lipids/biomarkers</b>: associated with increased ASCVD risk </text>
<text top="565" left="132" width="10" height="13" font="25">o</text>
<text top="564" left="141" width="4" height="15" font="17"> </text>
<text top="564" left="158" width="510" height="14" font="13">Persistently elevated* primary hypertriglyceridemia (≥175 mg/dL, nonfasting) </text>
<text top="585" left="132" width="10" height="13" font="25">o</text>
<text top="583" left="141" width="4" height="15" font="17"> </text>
<text top="583" left="158" width="86" height="14" font="13">If measured: </text>
<text top="603" left="158" width="7" height="17" font="13"></text>
<text top="603" left="165" width="4" height="15" font="17"> </text>
<text top="603" left="184" width="368" height="15" font="7"><b>Elevated high-sensitivity C-reactive protein</b> (≥2.0 mg/L)<b> </b></text>
<text top="622" left="158" width="7" height="17" font="13"></text>
<text top="622" left="165" width="4" height="15" font="17"> </text>
<text top="622" left="184" width="570" height="15" font="7"><b>Elevated Lp(a): </b>A relative indication for its measurement is family history of premature </text>
<text top="642" left="184" width="604" height="14" font="13">ASCVD. An Lp(a) ≥50 mg/dL or ≥125 nmol/L constitutes a risk-enhancing factor, especially at </text>
<text top="662" left="184" width="147" height="14" font="13">higher levels of Lp(a). <b> </b></text>
<text top="681" left="158" width="7" height="17" font="13"></text>
<text top="681" left="165" width="4" height="15" font="17"> </text>
<text top="681" left="184" width="607" height="15" font="7"><b>Elevated apoB</b> (≥130 mg/dL): A relative indication for its measurement would be triglyceride </text>
<text top="701" left="184" width="601" height="14" font="13">≥200 mg/dL. A level ≥130 mg/dL corresponds to an LDL-C &gt;160 mg/dL and constitutes a risk-</text>
<text top="721" left="184" width="114" height="14" font="13">enhancing factor </text>
<text top="740" left="158" width="7" height="17" font="13"></text>
<text top="740" left="165" width="4" height="15" font="17"> </text>
<text top="740" left="184" width="68" height="15" font="7"><b>ABI</b> (&lt;0.9) </text>
<text top="766" left="105" width="181" height="13" font="23">*Optimally, 3 determinations.<b> </b></text>
<text top="784" left="105" width="687" height="13" font="23">ABI  indicates  ankle-brachial  index;  AIDS,  acquired  immunodeficiency  syndrome;  apoB,  apolipoprotein  B;  ASCVD, </text>
<text top="802" left="105" width="687" height="13" font="23">atherosclerotic cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein </text>
<text top="819" left="105" width="687" height="13" font="23">cholesterol; HIV, human immunodeficiency virus; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); </text>
<text top="837" left="105" width="176" height="13" font="23">and RA, rheumatoid arthritis. </text>
<text top="855" left="105" width="687" height="13" font="23">Reproduced with permission from Grundy et al. (S2.2-4). Copyright © 2018, American Heart Association, Inc., and </text>
<text top="873" left="105" width="264" height="13" font="23">American College of Cardiology Foundation. </text>
</page>
<page number="20" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="27" size="14" family="Times" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 18 of 101 </text>
<text top="186" left="105" width="471" height="21" font="10"><b>3. Lifestyle Factors Affecting Cardiovascular Risk </b></text>
<text top="218" left="105" width="209" height="20" font="20"><b>3.1. Nutrition and Diet </b></text>
<text top="244" left="302" width="277" height="15" font="7"><b>Recommendations for Nutrition and Diet </b></text>
<text top="263" left="119" width="643" height="14" font="13">Referenced studies that support recommendations are summarized in Online Data Supplements 4 </text>
<text top="283" left="418" width="44" height="14" font="13">and 5. </text>
<text top="303" left="116" width="32" height="15" font="7"><b>COR </b></text>
<text top="303" left="179" width="29" height="15" font="7"><b>LOE </b></text>
<text top="303" left="438" width="129" height="15" font="7"><b>Recommendations </b></text>
<text top="345" left="128" width="8" height="15" font="7"><b>I </b></text>
<text top="345" left="181" width="27" height="15" font="7"><b>B-R </b></text>
<text top="335" left="229" width="13" height="15" font="7"><b>1.</b></text>
<text top="335" left="242" width="4" height="15" font="21"><b> </b></text>
<text top="335" left="256" width="509" height="15" font="7"><b>A diet emphasizing intake of vegetables, fruits, legumes, nuts, whole grains, </b></text>
<text top="355" left="256" width="495" height="15" font="7"><b>and fish is recommended to decrease ASCVD risk factors (S3.1-1–S3.1-11). </b></text>
<text top="407" left="122" width="20" height="15" font="7"><b>IIa </b></text>
<text top="407" left="175" width="37" height="15" font="7"><b>B-NR </b></text>
<text top="387" left="229" width="13" height="15" font="7"><b>2.</b></text>
<text top="387" left="242" width="4" height="15" font="21"><b> </b></text>
<text top="387" left="256" width="437" height="15" font="7"><b>Replacement of saturated fat with dietary monounsaturated and </b></text>
<text top="407" left="256" width="498" height="15" font="7"><b>polyunsaturated fats can be beneficial to reduce ASCVD risk (S3.1-12, S3.1-</b></text>
<text top="426" left="256" width="29" height="15" font="7"><b>13). </b></text>
<text top="477" left="122" width="20" height="15" font="7"><b>IIa </b></text>
<text top="477" left="175" width="37" height="15" font="7"><b>B-NR </b></text>
<text top="458" left="229" width="13" height="15" font="7"><b>3.</b></text>
<text top="458" left="242" width="4" height="15" font="21"><b> </b></text>
<text top="458" left="256" width="462" height="15" font="7"><b>A diet containing reduced amounts of cholesterol and sodium can be </b></text>
<text top="478" left="256" width="400" height="15" font="7"><b>beneficial to decrease ASCVD risk (S3.1-9, S3.1-14–S3.1-16). </b></text>
<text top="547" left="122" width="20" height="15" font="7"><b>IIa </b></text>
<text top="547" left="175" width="37" height="15" font="7"><b>B-NR </b></text>
<text top="528" left="229" width="13" height="15" font="7"><b>4.</b></text>
<text top="528" left="242" width="4" height="15" font="21"><b> </b></text>
<text top="528" left="256" width="456" height="15" font="7"><b>As a part of a healthy diet, it is reasonable to minimize the intake of </b></text>
<text top="547" left="256" width="471" height="15" font="7"><b>processed meats, refined carbohydrates, and sweetened beverages to </b></text>
<text top="567" left="256" width="251" height="15" font="7"><b>reduce ASCVD risk (S3.1-17–S3.1-24). </b></text>
<text top="599" left="121" width="21" height="15" font="7"><b>III: </b></text>
<text top="618" left="111" width="40" height="15" font="7"><b>Harm </b></text>
<text top="609" left="175" width="37" height="15" font="7"><b>B-NR </b></text>
<text top="599" left="229" width="13" height="15" font="7"><b>5.</b></text>
<text top="599" left="242" width="4" height="15" font="21"><b> </b></text>
<text top="599" left="256" width="479" height="15" font="7"><b>As a part of a healthy diet, the intake of <i>trans</i></b><b> fats should be avoided to </b></text>
<text top="618" left="256" width="365" height="15" font="7"><b>reduce ASCVD risk (S3.1-12, S3.1-17, S3.1-25–S3.1-27). </b></text>
<text top="639" left="105" width="4" height="14" font="13"> </text>
<text top="658" left="105" width="61" height="15" font="7"><b>Synopsis </b></text>
<text top="678" left="105" width="687" height="14" font="13">Approximately  630,000  Americans  died  from  heart  disease  in  2015,  of  whom  366,000  died  from </text>
<text top="698" left="105" width="687" height="14" font="13">coronary artery disease. After 4 decades of decline, heart disease deaths rose in 2015 by 1% (S3.1-28). </text>
<text top="717" left="105" width="687" height="14" font="13">This trend  has  been  attributed  to  the  obesity epidemic.  Healthy  nutrition  has an  important impact  on </text>
<text top="737" left="105" width="687" height="14" font="13">ASCVD  and  its  risk  factors  (see  recommendations  in  the  individual  sections),  potentially  reversing  or </text>
<text top="757" left="105" width="687" height="14" font="13">reducing obesity, high cholesterol, diabetes, and hypertension. The cardiovascular nutrition literature is </text>
<text top="776" left="105" width="687" height="14" font="13">limited by the paucity of large-scale prospective randomized trials with ASCVD outcomes. Although RCTs </text>
<text top="796" left="105" width="687" height="14" font="13">focused on hard endpoints are limited, multiple observational studies have focused on the association of </text>
<text top="815" left="105" width="687" height="14" font="13">CVD  mortality  with  dietary  patterns—specifically,  sugar,  low-calorie  sweeteners,  high-carbohydrate </text>
<text top="835" left="105" width="687" height="14" font="13">diets, low-carbohydrate diets, refined grains, <i>trans</i> fat, saturated fat, sodium, red meat, and processed </text>
<text top="855" left="105" width="473" height="14" font="13">red meat (e.g., bacon, salami, ham, hot dogs, sausage) (S3.1-1<b>–</b>S3.1-24). </text>
<text top="874" left="105" width="4" height="14" font="13"> </text>
<text top="894" left="105" width="287" height="15" font="7"><b>Recommendation-Specific Supportive Text </b></text>
<text top="913" left="105" width="687" height="14" font="13">1.  Plant-based and Mediterranean diets, along  with increased fruit, nut,  vegetable,  legume, and lean </text>
<text top="933" left="131" width="661" height="14" font="13">vegetable or animal protein (preferably fish) consumption, with the inherent soluble and insoluble </text>
<text top="953" left="131" width="661" height="14" font="13">vegetable fiber, have consistently been associated with lower risk of all-cause mortality than control </text>
<text top="972" left="131" width="661" height="14" font="13">or  standard  diets  (S3.1-1<b>–</b>S3.1-10,  S3.1-29,  S3.1-30)  in  observational  studies.  The  PREDIMED </text>
<text top="992" left="131" width="661" height="14" font="13">(Prevención  con  Dieta  Mediterránea)  trial  randomized  participants  to  a  Mediterranean  diet </text>
<text top="1011" left="131" width="661" height="14" font="13">supplemented with either extra-virgin olive oil or nuts and demonstrated 30% and 28% reductions, </text>
<text top="1031" left="131" width="661" height="14" font="13">respectively, in the combined endpoint  (MI,  stroke, or cardiovascular mortality), but  the improved </text>
<text top="1051" left="131" width="661" height="14" font="13">outcome  was  driven  largely  by  the  reduction  in  stroke,  with  no  significant  improvement  over  the </text>
<text top="1070" left="131" width="661" height="14" font="13">control diet for mortality or MI (S3.1-1). When  the PREDIMED cohort  was reanalyzed post hoc for </text>
</page>
<page number="21" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 19 of 101 </text>
<text top="167" left="131" width="661" height="14" font="13">the  “provegetarian”  food  pattern  (more  vegetable  consumption  versus  animal,  egg,  fish,  dairy,  or </text>
<text top="187" left="131" width="661" height="14" font="13">meat product consumption), a significant mortality rate reduction (41%) was noted in the 2 quintiles </text>
<text top="207" left="131" width="661" height="14" font="13">with  the  highest  vegetarian  score  (S3.1-11).  A  comparison  of  plant  and  animal  protein  from  the </text>
<text top="226" left="131" width="661" height="14" font="13">Adventist  Health  Study-2  cohort  (S3.1-10)  similarly  indicated  that  using  meat  for  protein  was </text>
<text top="246" left="131" width="661" height="14" font="13">associated with a 61% increase in mortality rate, whereas replacing meat with nuts and seeds was </text>
<text top="265" left="131" width="661" height="14" font="13">associated with a 40% reduction in mortality rate. Similarly, the graded risk published by Song et al. </text>
<text top="285" left="131" width="661" height="14" font="13">indicated that lower mortality rate was associated with replacing animal protein of different origins </text>
<text top="305" left="131" width="661" height="14" font="13">with plant protein (S3.1-9). The evidence is mixed with regard to the effectiveness of dairy intake to </text>
<text top="324" left="131" width="661" height="14" font="13">reduce  ASCVD  risk  factors,  which  is  why  it  is  not  included  in  the  listed  foods  for  this </text>
<text top="344" left="131" width="661" height="14" font="13">recommendation.  Although  the  DASH  (Dietary  Approaches  to  Stop  Hypertension)  diet,  which </text>
<text top="363" left="131" width="661" height="14" font="13">includes low-fat dairy products, was shown to reduce BP (S3.1-14), and the PURE (Prospective Urban </text>
<text top="383" left="131" width="661" height="14" font="13">Rural  Epidemiology)  study  indicated  that  dairy  intake  was  associated  with  a  23%  lower  mortality </text>
<text top="403" left="131" width="661" height="14" font="13">rate  (S3.1-31),  Song  et  al.  indicated  an  11%  increase  in  cardiovascular  mortality  rate  with  dairy </text>
<text top="422" left="131" width="382" height="14" font="13">consumption as compared with vegetable protein S3.1-9). </text>
<text top="442" left="105" width="687" height="14" font="13">2.  <i>Trans</i>  and saturated  fats  have  been  associated with  a  higher  risk  of  total  and cause-specific  death </text>
<text top="461" left="131" width="661" height="14" font="13">(S3.1-12).  However,  observational  data  from  the  PURE  trial  suggested  that,  when  used  instead  of </text>
<text top="481" left="131" width="661" height="14" font="13">refined  carbohydrates,  saturated  and  unsaturated  fats  were  associated  with  reduced  stroke  and </text>
<text top="501" left="131" width="130" height="14" font="13">mortality (S3.1-13). </text>
<text top="520" left="105" width="687" height="14" font="13">3.  Dietary sodium reduction was found to reduce BP and cardiovascular events in the DASH trial and in </text>
<text top="540" left="131" width="661" height="14" font="13">TOHP  (Trials  of  Hypertension  Prevention)  (S3.1-14,  S3.1-15).  Data  from  NHANES  (National  Health </text>
<text top="559" left="131" width="661" height="14" font="13">and Nutrition Examination Surveys) (S3.1-16) suggest that high consumption of sodium (&gt;2,000 mg </text>
<text top="579" left="131" width="661" height="14" font="13">daily),  red  meat  (&gt;14  g/d),  and  sugar-sweetened  beverages  and  processed  red  meat  consumption </text>
<text top="599" left="131" width="661" height="14" font="13">were  associated  with  cardiovascular  death.  A  prospective  cohort  study  of  U.S.  healthcare </text>
<text top="618" left="131" width="661" height="14" font="13">professionals  (S3.1-9)  with  at  least  1  risk  factor  indicated  that  replacement  of  animal  protein </text>
<text top="638" left="131" width="661" height="14" font="13">(sources  of  cholesterol,  saturated  fat,  heme  iron  and  precursors  of  trimethylamine-N-oxide)  with </text>
<text top="658" left="131" width="661" height="14" font="13">plant  protein  was  associated  with  reduced  cardiovascular  mortality  rate.  In  that  study,  compared </text>
<text top="677" left="131" width="661" height="14" font="13">with plant protein, poultry and fish were associated with a 6% higher mortality rate, dairy with an </text>
<text top="697" left="131" width="661" height="14" font="13">8% higher mortality rate, unprocessed red meat with a 12% higher mortality rate, eggs with a 19% </text>
<text top="716" left="131" width="661" height="14" font="13">higher  mortality  rate,  and  processed  red  meat  with  a  34%  higher  mortality  rate.  Overall,  plant </text>
<text top="736" left="131" width="661" height="14" font="13">protein  was  associated  with  a  reduction  in  mortality  rate  of  10%  for  every  3%  energy  increment </text>
<text top="755" left="131" width="207" height="14" font="13">replacement of animal protein. </text>
<text top="775" left="105" width="687" height="14" font="13">4.  Intake of several food products has been shown to be potentially harmful or increase risk of ASCVD. </text>
<text top="795" left="131" width="661" height="14" font="13">Sugar-sweetened  and  artificially  sweetened  beverages  have  been  correlated  with  increasing  the </text>
<text top="814" left="131" width="661" height="14" font="13">development  of  T2DM  and  with  ASCVD  risk,  with  a  20%  increase  in  the  frequency  of  diabetes </text>
<text top="834" left="131" width="661" height="14" font="13">mellitus  with  1  daily  serving  of  these  sweetened  beverages  (S3.1-18).  In  large  cohort  studies, </text>
<text top="854" left="131" width="661" height="14" font="13">consumption of added sugar at &gt;10% of daily calories has been associated with increased mortality </text>
<text top="873" left="131" width="661" height="14" font="13">rate  (S3.1-19).  However,  adults  who  are  habitually  high  consumers  of  sugar-sweetened  beverages </text>
<text top="893" left="131" width="661" height="14" font="13">and utilize low calorie sweetened beverages as a replacement strategy that provides a sweet taste </text>
<text top="912" left="131" width="661" height="14" font="13">while  reducing  caloric intake may  find  this  useful in  the  transition  to  water  (S3.1-20).  In REGARDS </text>
<text top="932" left="131" width="661" height="14" font="13">(REasons  for  Geographic  and  Racial  Differences  in  Stroke)  (S3.1-21),  the  Southern  dietary  pattern </text>
<text top="952" left="131" width="661" height="14" font="13">was  identified  as  substantially  increasing  health  risks,  including  a  56%  higher  risk  of  heart  disease </text>
<text top="971" left="131" width="661" height="14" font="13">and  a  30%  higher  risk  of  stroke.  This  pattern  consisted  of  more  fried  food,  added  fats,  organ  and </text>
<text top="991" left="131" width="661" height="14" font="13">processed  meats,  and  sugar-sweetened  beverages.  Consuming  a  diet  (S3.1-4)  with  juices  and </text>
<text top="1010" left="131" width="661" height="14" font="13">sweetened  beverages,  refined  grains,  potatoes/fries,  and  sweets  resulted  in  a  greater  increase  in </text>
<text top="1030" left="131" width="661" height="14" font="13">coronary events than the increase seen with consumption of animal products. Given the additional </text>
<text top="1050" left="131" width="661" height="14" font="13">risk  associated  with  intake  of  these  various  food  products,  clinicians  would  do  well  to  counsel </text>
<text top="1069" left="131" width="661" height="14" font="13">individuals  about  their  associated  harm  and  advise  them  to  avoid  these  foods  when  possible. </text>
</page>
<page number="22" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 20 of 101 </text>
<text top="167" left="131" width="661" height="14" font="13">Furthermore,  longstanding  dietary  patterns  that  focus  on  low  intake  of  carbohydrates  and  a  high </text>
<text top="187" left="131" width="661" height="14" font="13">intake of animal fat and protein are associated with increased cardiac and noncardiac mortality rate </text>
<text top="207" left="131" width="661" height="14" font="13">(S3.1-22<b>–</b>S3.1-24). In 1 meta-analysis (S3.1-23), low-carbohydrate diets were associated with a 31% </text>
<text top="226" left="131" width="661" height="14" font="13">higher risk of all-cause death, with increased cardiac mortality rate. Population data from the ARIC </text>
<text top="246" left="131" width="657" height="14" font="13">(Atherosclerosis  Risk  in  Communities)  study  indicated  an  18%  increase  in  mortality  rate  with  low-</text>
<text top="265" left="131" width="661" height="14" font="13">carbohydrate  diets  using  animal-derived  protein  and  fat  sources  (e.g.,  lamb,  beef,  pork,  chicken) </text>
<text top="285" left="131" width="661" height="14" font="13">(S3.1-22),  but  plant  sources  (e.g.,  vegetables,  nuts,  peanut  butter,  whole-grain  breads)  were </text>
<text top="305" left="131" width="661" height="14" font="13">associated  with  lower  mortality  rate.  In  addition,  the  ARIC  investigators  noted  a  23%  increase  in </text>
<text top="324" left="131" width="661" height="14" font="13">mortality  rate  associated  with  high-carbohydrate  diets,  with  the  optimal  carbohydrate  intake </text>
<text top="344" left="131" width="190" height="14" font="13">observed to be 50% to 55%.  </text>
<text top="363" left="105" width="687" height="14" font="13">5.  Intake  of  <i>trans  </i>fat  has  been  shown  to  be  harmful  and  increase  risk  of  ASCVD.  <i>Trans</i>  fat  was </text>
<text top="383" left="131" width="661" height="14" font="13">associated with higher all-cause mortality rate in the REGARDS U.S. healthcare professionals cohort </text>
<text top="403" left="131" width="661" height="14" font="13">studies (S3.1-12, S3.1-17). Additionally, regulations to curb use of <i>trans</i> fat in the food industry have </text>
<text top="422" left="131" width="661" height="14" font="13">been associated with a decrease in stroke and MI (S3.1-25). <i>Trans</i> fats have adverse effects on lipid </text>
<text top="442" left="131" width="661" height="14" font="13">and  lipoproteins  and  promote  endothelial  dysfunction,  insulin  resistance,  inflammation,  and </text>
<text top="461" left="131" width="661" height="14" font="13">arrhythmias (S3.1-26). Since partially hydrogenated oils are optional food additives, their elimination </text>
<text top="481" left="131" width="280" height="14" font="13">has been a public health priority (S3.1-27). </text>
<text top="501" left="71" width="12" height="14" font="13">1 </text>
<text top="532" left="71" width="12" height="14" font="13">2 </text>
<text top="563" left="71" width="12" height="14" font="13">3 </text>
<text top="583" left="105" width="4" height="14" font="13"> </text>
<text top="583" left="315" width="4" height="14" font="13"> </text>
</page>
<page number="23" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 21 of 101 </text>
<text top="169" left="105" width="309" height="20" font="20"><b>3.2. Exercise and Physical Activity </b></text>
<text top="195" left="265" width="350" height="15" font="7"><b>Recommendations for Exercise and Physical Activity </b></text>
<text top="215" left="119" width="643" height="14" font="13">Referenced studies that support recommendations are summarized in Online Data Supplements 6 </text>
<text top="234" left="418" width="44" height="14" font="13">and 7. </text>
<text top="254" left="113" width="32" height="15" font="7"><b>COR </b></text>
<text top="254" left="177" width="29" height="15" font="7"><b>LOE </b></text>
<text top="254" left="439" width="129" height="15" font="7"><b>Recommendations </b></text>
<text top="290" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="290" left="178" width="27" height="15" font="7"><b>B-R </b></text>
<text top="275" left="231" width="13" height="15" font="7"><b>1.</b></text>
<text top="275" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="275" left="257" width="519" height="15" font="7"><b>Adults  should  be  routinely  counseled  in  healthcare  visits  to  optimize  a </b></text>
<text top="294" left="257" width="277" height="15" font="7"><b>physically active lifestyle (S3.2-1, S3.2-2). </b></text>
<text top="354" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="354" left="173" width="37" height="15" font="7"><b>B-NR </b></text>
<text top="325" left="231" width="13" height="15" font="7"><b>2.</b></text>
<text top="325" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="325" left="257" width="519" height="15" font="7"><b>Adults  should  engage  in  at  least  150  minutes  per  week  of  accumulated </b></text>
<text top="345" left="257" width="519" height="15" font="7"><b>moderate-intensity  or  75  minutes  per  week  of  vigorous-intensity  aerobic </b></text>
<text top="364" left="257" width="519" height="15" font="7"><b>physical  activity  (or  an  equivalent  combination  of  moderate  and  vigorous </b></text>
<text top="384" left="257" width="310" height="15" font="7"><b>activity) to reduce ASCVD risk (S3.2-3–S3.2-8). </b></text>
<text top="453" left="119" width="20" height="15" font="7"><b>IIa </b></text>
<text top="453" left="173" width="37" height="15" font="7"><b>B-NR </b></text>
<text top="404" left="231" width="13" height="15" font="7"><b>3.</b></text>
<text top="404" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="404" left="257" width="519" height="15" font="7"><b>For  adults  unable  to  meet  the  minimum  physical  activity recommendations </b></text>
<text top="424" left="257" width="519" height="15" font="7"><b>(at  least  150  minutes  per  week  of  accumulated  moderate-intensity  or  75 </b></text>
<text top="443" left="257" width="519" height="15" font="7"><b>minutes per week of vigorous-intensity aerobic physical activity), engaging in </b></text>
<text top="463" left="257" width="519" height="15" font="7"><b>some moderate- or vigorous-intensity physical activity, even if less than this </b></text>
<text top="483" left="257" width="515" height="15" font="7"><b>recommended amount, can be beneficial to reduce ASCVD risk (S3.2-5, S3.2-</b></text>
<text top="502" left="257" width="21" height="15" font="7"><b>6). </b></text>
<text top="532" left="119" width="21" height="15" font="7"><b>IIb </b></text>
<text top="532" left="175" width="34" height="15" font="7"><b>C-LD </b></text>
<text top="523" left="231" width="13" height="15" font="7"><b>4.</b></text>
<text top="523" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="523" left="257" width="519" height="15" font="7"><b>Decreasing sedentary behavior in adults may be reasonable to reduce ASCVD </b></text>
<text top="542" left="257" width="193" height="15" font="7"><b>risk (S3.2-3, S3.2-9–S3.2-11). </b></text>
<text top="563" left="105" width="4" height="14" font="13"> </text>
<text top="582" left="105" width="65" height="15" font="7"><b>Synopsis </b> </text>
<text top="602" left="105" width="687" height="14" font="13">The numerous health benefits of regular physical activity have been well established (S3.2-12–S3.2-15), </text>
<text top="621" left="105" width="687" height="14" font="13">and  physical  activity  is  a  cornerstone  of  maintaining  and  improving  cardiovascular  health  (S3.2-6). </text>
<text top="641" left="105" width="687" height="14" font="13">Nevertheless,  approximately  half  of  adults  in  the  United  States  do  not  meet  the  minimum  physical </text>
<text top="661" left="105" width="687" height="14" font="13">activity  recommendations  (S3.2-12).  Strategies  are  needed  to  increase  physical  activity  at  both  the </text>
<text top="680" left="105" width="359" height="14" font="13">individual and the population levels (S3.2-16, S3.2-17). </text>
<text top="700" left="105" width="4" height="14" font="13"> </text>
<text top="700" left="131" width="661" height="14" font="13">Extensive observational data from meta-analyses and systematic reviews support recommendations </text>
<text top="719" left="105" width="687" height="14" font="13">for  aerobic  physical  activity  to  lower  ASCVD  risk  (S3.2-3–S3.2-8,  S3.2-12,  S3.2-18,  S3.2-19).  Resistance </text>
<text top="739" left="105" width="687" height="14" font="13">exercise should also be encouraged because of its several health benefits, including improving physical </text>
<text top="759" left="105" width="687" height="14" font="13">functioning (S3.2-20), improving glycemic control in individuals with diabetes (S3.2-21), and possibly BP </text>
<text top="778" left="105" width="569" height="14" font="13">lowering (S3.2-22). Whether resistance exercise lowers ASCVD risk is unclear (S3.2-12). </text>
<text top="798" left="105" width="4" height="14" font="13"> </text>
<text top="798" left="131" width="661" height="14" font="13">Aerobic physical activity is generally very safe (S3.2-23). However, sedentary individuals starting an </text>
<text top="817" left="105" width="687" height="14" font="13">exercise  program  should  initiate  exercise  at  a  lower  intensity  (e.g.,  slow  walking)  and  duration  and </text>
<text top="837" left="105" width="687" height="14" font="13">progress gradually to recommended levels (S3.2-24). It is uncertain whether an upper limit of habitual </text>
<text top="857" left="105" width="687" height="14" font="13">exercise, either in amount or intensity, may have adverse cardiovascular consequences (S3.2-25). But, in </text>
<text top="876" left="105" width="687" height="14" font="13">discussions with patients, it should be mentioned that these very high levels of physical activity (i.e., &gt;10 </text>
<text top="896" left="105" width="687" height="14" font="13">times the minimum recommended amount) pertain to only a small fraction of the population (S3.2-12). </text>
<text top="915" left="105" width="687" height="14" font="13">Individuals  with  significant  functional  impairments  may  need  modifications  to  and  more  specific </text>
<text top="935" left="105" width="425" height="14" font="13">guidance on the type, duration, and intensity of physical activity. </text>
<text top="955" left="105" width="4" height="14" font="13"> </text>
<text top="974" left="105" width="287" height="15" font="7"><b>Recommendation-Specific Supportive Text </b></text>
<text top="994" left="105" width="687" height="14" font="13">1.  Physical  activity  assessment  and  counseling  in  the  healthcare  setting  have  important </text>
<text top="1013" left="131" width="661" height="14" font="13">complementary  roles  in  promoting  increased  physical  activity  (S3.2-16).  Ascertaining  physical </text>
<text top="1033" left="131" width="661" height="14" font="13">activity patterns during a standard clinical visit is the first step toward effective counseling and can </text>
<text top="1053" left="131" width="661" height="14" font="13">be  accomplished  through  several  available  simple  assessment  tools  (S3.2-16). The  results  of  these </text>
<text top="1072" left="131" width="661" height="14" font="13">tools can be recorded in the electronic health record, along with parameters such as weight and BP </text>
</page>
<page number="24" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 22 of 101 </text>
<text top="167" left="131" width="661" height="14" font="13">(S3.2-16).  Physical  activity  counseling  by  clinicians  can  result  in  modest  improvements  in  physical </text>
<text top="187" left="131" width="661" height="14" font="13">activity  levels,  with  a  number  needed  to  counsel  as  low  as  12  for  an  individual  to  achieve </text>
<text top="207" left="131" width="661" height="14" font="13">recommended  physical  activity  levels  (S3.2-1,  S3.2-2).  This  counseling  might  include  an  exercise </text>
<text top="226" left="131" width="661" height="14" font="13">prescription  that  consists  of  recommended  frequency,  intensity,  time  (duration),  and  type  of </text>
<text top="246" left="131" width="61" height="14" font="13">exercise. </text>
<text top="265" left="105" width="687" height="14" font="13">2.  There is a consistent, strong, inverse dose–response relationship between the amount of moderate </text>
<text top="285" left="131" width="661" height="14" font="13">to  vigorous  physical  activity  and  incident  ASCVD  events  and  death  (S3.2-3–S3.2-8,  S3.2-12).  The </text>
<text top="305" left="131" width="661" height="14" font="13">shape  of  the  dose–response  relationship  is  curvilinear,  with  significant  benefit  observed  when </text>
<text top="324" left="131" width="661" height="14" font="13">comparing those engaging in little or no physical activity with those performing moderate amounts </text>
<text top="344" left="131" width="661" height="14" font="13">(S3.2-5, S3.2-6, S3.2-12). All adults should engage in at least 150 minutes per week of accumulated </text>
<text top="363" left="131" width="661" height="14" font="13">moderate-intensity  aerobic  physical  activity  or  75  minutes  per  week  of  vigorous-intensity  aerobic </text>
<text top="383" left="131" width="661" height="14" font="13">physical activity (or  an equivalent combination of moderate  and vigorous activity) to lower ASCVD </text>
<text top="403" left="131" width="661" height="14" font="13">risk (Table 4). These recommendations are in line with those of other health organizations (S3.2-26). </text>
<text top="422" left="131" width="657" height="14" font="13">Shorter durations of exercise seem to be as beneficial as longer ones (e.g., ≥10-minute bouts) (S3.2-</text>
<text top="442" left="131" width="661" height="14" font="13">27, S3.2-28), and thus the focus of physical activity  counseling should be on the total accumulated </text>
<text top="461" left="131" width="661" height="14" font="13">amount.  Additional  reduction  in  ASCVD  risk  is  seen  in  those  achieving  higher  amounts  of  aerobic </text>
<text top="481" left="131" width="661" height="14" font="13">physical  activity  (&gt;300  minutes  per  week  of  moderate-intensity  aerobic  physical  activity  or  150 </text>
<text top="501" left="131" width="661" height="14" font="13">minutes  per  week  of  vigorous-intensity  aerobic  physical  activity)  (S3.2-5,  S3.2-6,  S3.2-12,  S3.2-14). </text>
<text top="520" left="131" width="661" height="14" font="13">There is a continued but diminishing additive benefit of  further increasing physical activity to very </text>
<text top="540" left="131" width="237" height="14" font="13">high levels (S3.2-5, S3.2-6, S3.2-12).</text>
<text top="537" left="368" width="2" height="9" font="24"> </text>
<text top="540" left="372" width="421" height="14" font="13">Specific exercise recommendations for the prevention of heart </text>
<text top="559" left="131" width="661" height="14" font="13">failure  may  differ  slightly  because  the  dose–response  relationship  with  increasing  physical  activity </text>
<text top="579" left="131" width="199" height="14" font="13">levels may be linear (S3.2-29). </text>
<text top="599" left="105" width="687" height="14" font="13">3.  There  is  likely  no  lower  limit  on  the  quantity  of  moderate-to-vigorous  physical  activity  at  which </text>
<text top="618" left="131" width="661" height="14" font="13">benefits for ASCVD risk start to accrue (S3.2-6). All efforts should be made to promote achievement </text>
<text top="638" left="131" width="661" height="14" font="13">of  the  minimum  recommended  amount  of  physical  activity  by  all  adults.  However,  for  individuals </text>
<text top="658" left="131" width="661" height="14" font="13">unable to achieve this minimum, encouraging at least some moderate-to-vigorous physical activity </text>
<text top="677" left="131" width="661" height="14" font="13">among  those  who  are  inactive  (i.e.,  no  moderate-to-vigorous  physical  activity)  or  increasing  the </text>
<text top="697" left="131" width="657" height="14" font="13">amount in those who are insufficiently active is still likely beneficial to reduce ASCVD risk (S3.2-6).</text>
<text top="694" left="788" width="2" height="9" font="24"> </text>
<text top="716" left="131" width="661" height="14" font="13">Strategies to further increase physical activity in those achieving less than targeted amounts should </text>
<text top="736" left="131" width="115" height="14" font="13">be implemented. </text>
<text top="755" left="105" width="687" height="14" font="13">4.  Despite the focus on moderate- and vigorous-intensity physical activity, such activity accounts for a </text>
<text top="775" left="131" width="661" height="14" font="13">small proportion of  individuals’  daily time as compared with other  forms of activity. Other activity </text>
<text top="795" left="131" width="661" height="14" font="13">states that comprise a 24-hour period for an average individual include sleep, light-intensity physical </text>
<text top="814" left="131" width="661" height="14" font="13">activity,  and  sedentary  behavior  (Figure  1).  <i>Sedentary  behavior</i>  refers  to  waking  behavior  with  an </text>
<text top="834" left="131" width="661" height="14" font="13">energy  expenditure  of  ≤1.5  metabolic  equivalents  while  in  a  sitting  or  reclining  posture  (Table  4) </text>
<text top="854" left="131" width="661" height="14" font="13">(S3.2-30).  Increased  sedentary  behavior  is  associated  with  worse  health  parameters,  including </text>
<text top="873" left="131" width="661" height="14" font="13">cardiometabolic  risk  factors  (S3.2-3,  S3.2-9–S3.2-11). Sedentary  behavior may  be  most  deleterious </text>
<text top="893" left="131" width="661" height="14" font="13">to  ASCVD  risk  for  individuals  who  engage  in  the  least  amount  of  moderate  to  vigorous  physical </text>
<text top="912" left="131" width="661" height="14" font="13">activity  (S3.2-3,  S3.2-10,  S3.2-12).  Thus,  strategies  to  reduce  sedentary  behavior,  particularly  in </text>
<text top="932" left="131" width="661" height="14" font="13">those  not  achieving  current  recommended  physical  activity  levels,  may  be  beneficial  for  lowering </text>
<text top="952" left="131" width="661" height="14" font="13">ASCVD risk. However, data on the value of reducing or modifying sedentary behavior over time to </text>
<text top="971" left="131" width="661" height="14" font="13">reduce ASCVD risk are sparse, and whether replacing sedentary behavior with light-intensity activity </text>
<text top="991" left="131" width="661" height="14" font="13">(e.g., slow walking, light work) is beneficial for ASCVD prevention is unclear (S3.2-31). The strength </text>
<text top="1010" left="131" width="661" height="14" font="13">and  specificity  of  the  recommendation  to  reduce  sedentary  behavior  are  limited  by  uncertainty </text>
<text top="1030" left="131" width="635" height="14" font="13">about the appropriate limits of and optimal approach to modifying sedentary behavior (S3.2-30).<b> </b></text>
<text top="1050" left="105" width="4" height="14" font="13"> </text>
<text top="1081" left="105" width="4" height="15" font="7"><b> </b></text>
<text top="1081" left="315" width="4" height="15" font="7"><b> </b></text>
</page>
<page number="25" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="28" size="12" family="Times" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 23 of 101 </text>
<text top="167" left="105" width="516" height="15" font="7"><b>Table 4. Definitions and Examples of Different Intensities of Physical Activity  </b></text>
<text top="204" left="104" width="62" height="15" font="7"><b>Intensity </b></text>
<text top="204" left="288" width="40" height="15" font="7"><b>METs </b></text>
<text top="204" left="420" width="67" height="15" font="7"><b>Examples </b></text>
<text top="240" left="104" width="139" height="14" font="13">Sedentary behavior* </text>
<text top="240" left="288" width="40" height="14" font="13">1–1.5 </text>
<text top="240" left="420" width="298" height="14" font="13">Sitting, reclining, or lying; watching television </text>
<text top="295" left="104" width="36" height="14" font="13">Light </text>
<text top="295" left="288" width="52" height="14" font="13">1.6–2.9 </text>
<text top="295" left="420" width="271" height="14" font="13">Walking slowly, cooking, light housework </text>
<text top="341" left="104" width="69" height="14" font="13">Moderate </text>
<text top="341" left="288" width="56" height="14" font="13">3.0 –5.9 </text>
<text top="341" left="420" width="352" height="14" font="13">Brisk  walking  (2.4–4  mph),  biking  (5–9  mph), </text>
<text top="361" left="420" width="63" height="14" font="13">ballroom </text>
<text top="361" left="499" width="59" height="14" font="13">dancing, </text>
<text top="361" left="575" width="43" height="14" font="13">active </text>
<text top="361" left="634" width="39" height="14" font="13">yoga, </text>
<text top="361" left="689" width="82" height="14" font="13">recreational </text>
<text top="380" left="420" width="70" height="14" font="13">swimming </text>
<text top="413" left="104" width="61" height="14" font="13">Vigorous </text>
<text top="413" left="288" width="20" height="14" font="13">≥6 </text>
<text top="413" left="420" width="352" height="14" font="13">Jogging/running,  biking  (≥10  mph),  singles  tennis, </text>
<text top="433" left="420" width="100" height="14" font="13">swimming laps </text>
<text top="465" left="105" width="687" height="13" font="23">*<i>Sedentary behavior</i> is defined as any waking behavior characterized by an energy expenditure ≤1.5 METs while in </text>
<text top="483" left="105" width="687" height="13" font="23">a  sitting,  reclining,  or  lying  posture.  Standing  is  a  sedentary  activity  in  that  it  involves  ≤1.5  METs,  but  it  is  not </text>
<text top="501" left="105" width="291" height="13" font="23">considered a component of sedentary behavior.  </text>
<text top="519" left="105" width="371" height="13" font="23">MET indicates metabolic equivalent; and mph, miles per hour. </text>
<text top="537" left="105" width="4" height="14" font="13"> </text>
<text top="557" left="105" width="4" height="14" font="13"> </text>
<text top="576" left="105" width="4" height="14" font="13"> </text>
<text top="596" left="105" width="389" height="15" font="7"><b>Figure 1. Hours Per Day Spent in Various States of Activity </b></text>
<text top="615" left="105" width="4" height="14" font="13"> </text>
<text top="635" left="447" width="4" height="14" font="13"> </text>
<text top="654" left="447" width="4" height="14" font="13"> </text>
<text top="674" left="447" width="4" height="14" font="13"> </text>
<text top="694" left="447" width="323" height="14" font="13">U.S. adults spend &gt;7 h/d on average in sedentary </text>
<text top="713" left="447" width="307" height="14" font="13">activities. Replacing sedentary time with other </text>
<text top="733" left="447" width="276" height="14" font="13">physical activity involves increasing either </text>
<text top="753" left="447" width="336" height="14" font="13">moderate- to vigorous-intensity physical activity or </text>
<text top="772" left="447" width="208" height="14" font="13">light-intensity physical activity.  </text>
<text top="792" left="447" width="278" height="14" font="13">Data modified from Young et al. (S3.2-30). </text>
<text top="811" left="447" width="4" height="14" font="13"> </text>
<text top="831" left="447" width="4" height="14" font="13"> </text>
<text top="850" left="447" width="4" height="14" font="13"> </text>
<text top="899" left="447" width="4" height="14" font="13"> </text>
<text top="948" left="447" width="4" height="14" font="13"> </text>
<text top="971" left="105" width="4" height="14" font="13"> </text>
<text top="1005" left="105" width="5" height="21" font="10"><b> </b></text>
<text top="1005" left="315" width="5" height="21" font="10"><b> </b></text>
</page>
<page number="26" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 24 of 101 </text>
<text top="169" left="105" width="447" height="21" font="10"><b>4. Other Factors Affecting Cardiovascular Risk </b></text>
<text top="200" left="105" width="377" height="20" font="20"><b>4.1. Adults With Overweight and Obesity </b></text>
<text top="226" left="240" width="400" height="15" font="7"><b>Recommendations for Adults With Overweight and Obesity </b></text>
<text top="246" left="119" width="643" height="14" font="13">Referenced studies that support recommendations are summarized in Online Data Supplements 8 </text>
<text top="265" left="418" width="44" height="14" font="13">and 9. </text>
<text top="286" left="113" width="32" height="15" font="7"><b>COR </b></text>
<text top="286" left="177" width="29" height="15" font="7"><b>LOE </b></text>
<text top="286" left="439" width="129" height="15" font="7"><b>Recommendations </b></text>
<text top="316" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="316" left="178" width="27" height="15" font="7"><b>B-R </b></text>
<text top="306" left="231" width="13" height="15" font="7"><b>1.</b></text>
<text top="306" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="306" left="257" width="519" height="15" font="7"><b>In  individuals with  overweight  and  obesity, weight loss  is  recommended  to </b></text>
<text top="326" left="257" width="312" height="15" font="7"><b>improve the ASCVD risk factor profile (S4.1-1). </b></text>
<text top="366" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="366" left="178" width="27" height="15" font="7"><b>B-R </b></text>
<text top="346" left="231" width="13" height="15" font="7"><b>2.</b></text>
<text top="346" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="346" left="257" width="519" height="15" font="7"><b>Counseling  and  comprehensive  lifestyle  interventions,  including  calorie </b></text>
<text top="366" left="257" width="519" height="15" font="7"><b>restriction,  are  recommended  for  achieving  and  maintaining  weight  loss  in </b></text>
<text top="385" left="257" width="347" height="15" font="7"><b>adults with overweight and obesity (S4.1-1, S4.1-2). </b></text>
<text top="425" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="425" left="174" width="36" height="15" font="7"><b>C-EO </b></text>
<text top="406" left="231" width="13" height="15" font="7"><b>3.</b></text>
<text top="406" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="406" left="257" width="519" height="15" font="7"><b>Calculating  body  mass  index  (BMI)  is  recommended  annually  or  more </b></text>
<text top="425" left="257" width="519" height="15" font="7"><b>frequently  to  identify  adults  with  overweight  and  obesity  for  weight  loss </b></text>
<text top="445" left="257" width="106" height="15" font="7"><b>considerations. </b></text>
<text top="475" left="119" width="20" height="15" font="7"><b>IIa </b></text>
<text top="475" left="173" width="37" height="15" font="7"><b>B-NR </b></text>
<text top="465" left="231" width="13" height="15" font="7"><b>4.</b></text>
<text top="465" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="465" left="257" width="519" height="15" font="7"><b>It  is  reasonable  to  measure  waist  circumference  to  identify  those  at  higher </b></text>
<text top="485" left="257" width="251" height="15" font="7"><b>cardiometabolic risk (S4.1-3–S4.1-6).  </b></text>
<text top="505" left="105" width="4" height="14" font="13"> </text>
<text top="525" left="105" width="61" height="15" font="7"><b>Synopsis </b></text>
<text top="544" left="105" width="687" height="14" font="13">The  increased  availability  of  affordable,  palatable,  and  high-calorie  foods  and  the  decreased  physical </text>
<text top="564" left="105" width="687" height="14" font="13">demands  of  many  jobs  have  fueled  the  epidemic  of  obesity  and  the  consequent  increases  in </text>
<text top="584" left="105" width="499" height="14" font="13">hypertension and T2DM (S4.1-7). Adults diagnosed as obese (BMI ≥30 kg/m</text>
<text top="581" left="604" width="5" height="9" font="24">2</text>
<text top="584" left="609" width="183" height="14" font="13">) or overweight (BMI=25 to </text>
<text top="603" left="105" width="66" height="14" font="13">29.9 kg/m</text>
<text top="600" left="172" width="5" height="9" font="24">2</text>
<text top="603" left="177" width="615" height="14" font="13">) are at increased risk of ASCVD, heart failure, and atrial fibrillation, compared with those of a </text>
<text top="623" left="105" width="687" height="14" font="13">normal  weight  (S4.1-8,  S4.1-9).  The  nutritional  aspects  of  obesity  revolve  around  the  principle  of </text>
<text top="642" left="105" width="687" height="14" font="13">balancing caloric intake with caloric expenditure. Following the 2013 Guideline for the Management of </text>
<text top="662" left="105" width="687" height="14" font="13">Overweight  and  Obesity  in  Adults  from  the  AHA,  ACC,  and  The  Obesity  Society  (TOS),  adults  with </text>
<text top="682" left="105" width="687" height="14" font="13">overweight/obesity  are  advised  to  participate  in  comprehensive  lifestyle  programs  of  ≥6  months’ </text>
<text top="701" left="105" width="687" height="14" font="13">duration that assist participants in adhering to a low-calorie diet (800 to 1,500 kcal/day) and increased </text>
<text top="721" left="105" width="687" height="14" font="13">physical  activity.  Existing  clinical  guidance  strongly  recommends  face-to-face  or  telephone-delivered </text>
<text top="740" left="105" width="687" height="14" font="13">weight-loss  maintenance  programs  that  provide  regular  contact  (at  least  monthly)  with  a  trained </text>
<text top="760" left="105" width="687" height="14" font="13">interventionist to help participants engage in high levels of physical activity (200 to 300 minutes/week), </text>
<text top="780" left="105" width="620" height="14" font="13">monitor body weight regularly (at least weekly), and consume a reduced-calorie diet (S4.1-10). </text>
<text top="799" left="105" width="4" height="14" font="13"> </text>
<text top="799" left="131" width="661" height="14" font="13">U.S. Food and Drug Administration (FDA)–approved pharmacological therapies (S4.1-1, S4.1-11) and </text>
<text top="819" left="105" width="687" height="14" font="13">bariatric  surgery  (S4.1-12),  adjunctive  to  complementary  lifestyle  interventions,  additionally  reduce </text>
<text top="838" left="105" width="687" height="14" font="13">weight and may have a role in weight loss for select patients. The present guideline document focuses </text>
<text top="858" left="105" width="687" height="14" font="13">primarily  on  lifestyle  interventions  for  overweight  and  obesity,  as  outlined  in  the  2013  AHA/ACC/TOS </text>
<text top="878" left="105" width="687" height="14" font="13">Guideline for the Management of Overweight and Obesity in Adults (S4.1-10). Weight loss interventions </text>
<text top="897" left="105" width="687" height="14" font="13">should  be  cautiously  implemented  and  individualized,  especially  in  older  adults,  to  avoid  detrimental </text>
<text top="917" left="105" width="609" height="14" font="13">effects, such as loss of lean body/muscle mass and nutritional deficiencies (S4.1-13–S4.1-15). </text>
<text top="937" left="105" width="4" height="14" font="13"> </text>
<text top="956" left="105" width="287" height="15" font="7"><b>Recommendation-Specific Supportive Text </b></text>
<text top="976" left="105" width="687" height="14" font="13">1.  Clinically  meaningful  weight  loss  (≥5%  initial  weight)  is  associated  with  moderate  improvement  in </text>
<text top="995" left="131" width="661" height="14" font="13">BP,  low-density  lipoprotein  cholesterol  (LDL-C),  triglyceride,  and  glucose  levels  among  individuals </text>
<text top="1015" left="131" width="661" height="14" font="13">with  overweight/obesity  (S4.1-1).  Weight  loss  reduces  or  delays  the  development  of  T2DM  in </text>
<text top="1034" left="131" width="661" height="14" font="13">persons  with  obesity  (S4.1-1,  S4.1-16,  S4.1-17).  High-intensity  (≥14  sessions  in  6  months) </text>
<text top="1054" left="131" width="661" height="14" font="13">comprehensive weight-loss interventions provided by a trained interventionist work best (S4.1-10). </text>
</page>
<page number="27" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 25 of 101 </text>
<text top="167" left="131" width="661" height="14" font="13">However, other modalities, such as electronically delivered weight-loss programs with personalized </text>
<text top="187" left="131" width="559" height="14" font="13">feedback and some commercial-based programs, have also shown moderate results.  </text>
<text top="207" left="105" width="683" height="14" font="13">2.  Comprehensive lifestyle intervention consists  of  a structured  program, which includes regular self-</text>
<text top="226" left="131" width="661" height="14" font="13">monitoring  of  food  intake,  physical  activity,  and  weight.  Increased  physical  activity,  preferably </text>
<text top="246" left="131" width="661" height="14" font="13">aerobic physical activity (e.g., brisk walking) for  ≥150 minutes/week (equal to ≥30 minutes/day  on </text>
<text top="265" left="131" width="492" height="14" font="13">most  days  of  the  week),  is  recommended  for initial weight loss  (S4.1-10).</text>
<text top="262" left="623" width="2" height="9" font="24"> </text>
<text top="265" left="627" width="165" height="14" font="13">Higher levels  of  physical </text>
<text top="285" left="131" width="661" height="14" font="13">activity,  approximately  200  to  300  minutes/week,  are  recommended  to  maintain  weight  loss  or </text>
<text top="305" left="131" width="661" height="14" font="13">minimize weight regain after 1 year. Adults with obesity are also typically prescribed a diet designed </text>
<text top="324" left="131" width="661" height="14" font="13">to  reduce  caloric  intake  by  ≥500  kcal/day  from  baseline,  which  often  can  be  attained  by  limiting </text>
<text top="344" left="131" width="661" height="14" font="13">women to 1,200 to 1,500 kcal/day and men to 1,500 to 1,800 kcal/day (S4.1-10). A very-low-calorie </text>
<text top="363" left="131" width="661" height="14" font="13">diet  (defined  as  &lt;800  kcal/day)  should  be  prescribed  only  in  limited  circumstances  and  only  by </text>
<text top="383" left="131" width="661" height="14" font="13">trained  clinicians  in  a  medical  care  setting  with  the  patient  under  medical  supervision  (S4.1-10). </text>
<text top="403" left="131" width="661" height="14" font="13">Comprehensive lifestyle intervention has been shown to produce on average 8 kg of weight loss (5% </text>
<text top="422" left="131" width="661" height="14" font="13">to  10%  of  initial  body  weight)  in  the  short  term  (≤6  months)  and  intermediate  term  (6  to  12 </text>
<text top="442" left="131" width="349" height="14" font="13">months), compared with usual care (S4.1-1, S4.1-10).</text>
<text top="439" left="480" width="2" height="9" font="24"> </text>
<text top="442" left="483" width="309" height="14" font="13">However, longer interventions after 1 year are </text>
<text top="461" left="131" width="661" height="14" font="13">associated  with  gradual  weight  gain  of  1  or  2  kg/year  (on  average),  compared  with  usual  care. </text>
<text top="481" left="131" width="661" height="14" font="13">Weight loss of  5% to 10% of initial weight, achieved  through comprehensive lifestyle intervention, </text>
<text top="501" left="131" width="661" height="14" font="13">has been shown  to improve BP, delay the  onset of T2DM, improve glycemic  control in T2DM, and </text>
<text top="520" left="131" width="243" height="14" font="13">improve lipid profile (S4.1-1, S4.1-2). </text>
<text top="540" left="105" width="687" height="14" font="13">3.  Measures  used  to  estimate  body  fat  and  quantify  the  associated  health  risks  include  BMI,  waist </text>
<text top="559" left="131" width="657" height="14" font="13">circumference,  waist–hip  ratio,  bioimpedance,  and  dual-energy  X-ray  absorptiometry  (DXA)  (S4.1-</text>
<text top="579" left="131" width="661" height="14" font="13">18). BMI, waist circumference, and waist–hip ratio are easily measured and therefore are the most </text>
<text top="599" left="131" width="661" height="14" font="13">widely used in clinical practice. A USPSTF document found good evidence supporting the use of BMI </text>
<text top="618" left="131" width="661" height="14" font="13">to  identify  adults  at  increased  risk  of  future  morbidity  and  mortality  (S4.1-18).  Because </text>
<text top="638" left="131" width="661" height="14" font="13">obesity/overweight defined by BMI is the most studied and standardized approach, we recommend </text>
<text top="658" left="131" width="661" height="14" font="13">its  measurement  for  primary  screening  of  individuals  needing  weight  loss.  BMI  should  be </text>
<text top="677" left="131" width="661" height="14" font="13">interpreted  with  caution  in  persons  of  Asian  ancestry,  older  adults,  and  muscular  adults  (S4.1-19, </text>
<text top="697" left="131" width="61" height="14" font="13">S4.1-20). </text>
<text top="716" left="105" width="687" height="14" font="13">4.  Increased waist circumference has been associated with increased cardiometabolic and ASCVD risk </text>
<text top="736" left="131" width="661" height="14" font="13">(S4.1-3–S4.1-6). Central adiposity, captured by using waist circumference, has been associated with </text>
<text top="755" left="131" width="661" height="14" font="13">ASCVD risk and may be missed when BMI is used as the only measure of obesity (S4.1-21, S4.1-22). </text>
<text top="775" left="131" width="596" height="14" font="13">Waist  circumference  measurement  is  recommended  in  all  patients  with  BMI  &lt;35  kg/m</text>
<text top="772" left="727" width="5" height="9" font="24">2</text>
<text top="775" left="732" width="60" height="14" font="13">  (S4.1-9, </text>
<text top="795" left="131" width="661" height="14" font="13">S4.1-19,  S4.1-23).  Ethnic  differences  in  waist  circumference  thresholds  associated  with </text>
<text top="814" left="131" width="661" height="14" font="13">cardiometabolic  risk  have  been  reported.  Waist  circumference  may  be  more  useful  than  BMI  in </text>
<text top="834" left="131" width="661" height="14" font="13">persons  with  abdominal  obesity  (central  adiposity)  (S4.1-24).  Definitions  of  elevated  waist </text>
<text top="854" left="131" width="661" height="14" font="13">circumference  as  ≥40  inches  (≥102  cm)  in  men  and  ≥35  inches  (≥88  cm)  in  women  were </text>
<text top="873" left="131" width="661" height="14" font="13">recommended by the 1998 National Heart, Lung, and Blood Institute Obesity Initiative Expert Panel </text>
<text top="893" left="131" width="661" height="14" font="13">(S4.1-25)  and  were  adopted  by  the  2013  AHA/ACC/TOS  writing  committee  (S4.1-1).  Furthermore, </text>
<text top="912" left="131" width="661" height="14" font="13">waist  circumference  assessment  is  needed  for  the  diagnosis  of  metabolic  syndrome.  Thus, </text>
<text top="932" left="131" width="661" height="14" font="13">combining waist circumference and BMI may be the best approach for assessing obesity-related risk. </text>
<text top="952" left="131" width="661" height="14" font="13">Counseling  and  comprehensive  lifestyle  interventions,  including  calorie  restriction  and  adjunctive </text>
<text top="971" left="131" width="661" height="14" font="13">therapies  (e.g.,  FDA–approved  drugs,  bariatric  surgery),  have  all  been  associated  with  significant </text>
<text top="991" left="131" width="657" height="14" font="13">reductions  in  waist  circumference  and  improvement  in  cardiometabolic  risk  profiles  (S4.1-1).</text>
</page>
<page number="28" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 26 of 101 </text>
<text top="199" left="71" width="12" height="14" font="13">1 </text>
<text top="223" left="105" width="381" height="20" font="20"><b>4.2. Adults With Type 2 Diabetes Mellitus </b></text>
<text top="248" left="105" width="669" height="14" font="13">See Figure 2 for an algorithm for treatment of T2DM for primary prevention of cardiovascular disease. </text>
<text top="280" left="239" width="403" height="15" font="7"><b>Recommendations for Adults With Type 2 Diabetes Mellitus </b></text>
<text top="300" left="116" width="649" height="14" font="13">Referenced studies that support recommendations are summarized in Online Data Supplement 10.<b> </b></text>
<text top="320" left="113" width="32" height="15" font="7"><b>COR </b></text>
<text top="320" left="177" width="29" height="15" font="7"><b>LOE </b></text>
<text top="320" left="439" width="129" height="15" font="7"><b>Recommendations </b></text>
<text top="370" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="370" left="185" width="13" height="15" font="7"><b>A </b></text>
<text top="340" left="231" width="13" height="15" font="7"><b>1.</b></text>
<text top="340" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="340" left="257" width="515" height="15" font="7"><b>For  all  adults  with  T2DM,  a  tailored  nutrition  plan  focusing  on  a  heart-</b></text>
<text top="360" left="257" width="519" height="15" font="7"><b>healthy  dietary  pattern  is  recommended  to  improve  glycemic  control, </b></text>
<text top="379" left="257" width="519" height="15" font="7"><b>achieve weight loss if needed, and improve other ASCVD risk factors (S4.2-1, </b></text>
<text top="399" left="257" width="54" height="15" font="7"><b>S4.2-2). </b></text>
<text top="449" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="449" left="185" width="13" height="15" font="7"><b>A </b></text>
<text top="419" left="231" width="13" height="15" font="7"><b>2.</b></text>
<text top="419" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="419" left="257" width="519" height="15" font="7"><b>Adults  with  T2DM  should  perform  at  least  150  minutes  per  week  of </b></text>
<text top="439" left="257" width="519" height="15" font="7"><b>moderate-intensity  physical  activity  or  75  minutes  of  vigorous-intensity </b></text>
<text top="458" left="257" width="519" height="15" font="7"><b>physical activity to improve glycemic control, achieve weight loss if needed, </b></text>
<text top="478" left="257" width="363" height="15" font="7"><b>and improve other ASCVD risk factors (S4.2-3, S4.2-4). </b></text>
<text top="523" left="119" width="20" height="15" font="7"><b>IIa </b></text>
<text top="523" left="178" width="27" height="15" font="7"><b>B-R </b></text>
<text top="498" left="231" width="13" height="15" font="7"><b>3.</b></text>
<text top="499" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="498" left="257" width="519" height="15" font="7"><b>For  adults  with  T2DM,  it  is  reasonable  to  initiate  metformin  as  first-line </b></text>
<text top="518" left="257" width="519" height="15" font="7"><b>therapy  along  with  lifestyle  therapies  at  the  time  of  diagnosis  to  improve </b></text>
<text top="538" left="257" width="376" height="15" font="7"><b>glycemic control and reduce ASCVD risk (S4.2-5–S4.2-8). </b></text>
<text top="607" left="119" width="21" height="15" font="7"><b>IIb </b></text>
<text top="607" left="178" width="27" height="15" font="7"><b>B-R </b></text>
<text top="567" left="231" width="13" height="15" font="7"><b>4.</b></text>
<text top="567" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="567" left="257" width="515" height="15" font="7"><b>For adults with T2DM and additional ASCVD risk factors who require glucose-</b></text>
<text top="587" left="257" width="519" height="15" font="7"><b>lowering therapy despite initial lifestyle modifications and metformin, it may </b></text>
<text top="607" left="257" width="519" height="15" font="7"><b>be reasonable to initiate a sodium-glucose cotransporter 2 (SGLT-2) inhibitor </b></text>
<text top="626" left="257" width="519" height="15" font="7"><b>or  a  glucagon-like  peptide-1  receptor  (GLP-1R)  agonist  to  improve  glycemic </b></text>
<text top="646" left="257" width="305" height="15" font="7"><b>control and reduce CVD risk (S4.2-9–S4.2-14). </b></text>
<text top="666" left="105" width="4" height="14" font="13"> </text>
<text top="686" left="105" width="61" height="15" font="7"><b>Synopsis </b></text>
<text top="705" left="105" width="687" height="14" font="13">T2DM,  defined  as  a  hemoglobin  A1c  (HbA1c)  &gt;6.5%,  is  a  metabolic  disorder  characterized  by  insulin </text>
<text top="725" left="105" width="687" height="14" font="13">resistance leading to hyperglycemia. Unlike type 1 diabetes mellitus (an autoimmune condition largely </text>
<text top="745" left="105" width="687" height="14" font="13">unrelated  to  lifestyle  factors),  the  development  and  progression  of  T2DM  are  heavily  influenced  by </text>
<text top="764" left="105" width="687" height="14" font="13">dietary pattern, physical activity, and body weight. Approximately 12% of U.S. adults have diabetes, 90% </text>
<text top="784" left="105" width="687" height="14" font="13">to  95%  of  whom  have  T2DM,  with  significant  heterogeneity  according  to  age,  sex,  race/ethnicity,  and </text>
<text top="803" left="105" width="687" height="14" font="13">socioeconomic status (S4.2-15). Alarmingly, more than one-third of U.S. adults (≈80 million adults) have </text>
<text top="823" left="105" width="82" height="14" font="13">prediabetes </text>
<text top="823" left="224" width="28" height="14" font="13">and </text>
<text top="823" left="290" width="25" height="14" font="13">are </text>
<text top="823" left="352" width="17" height="14" font="13">at </text>
<text top="823" left="406" width="27" height="14" font="13">risk </text>
<text top="823" left="470" width="17" height="14" font="13">of </text>
<text top="823" left="524" width="76" height="14" font="13">developing </text>
<text top="823" left="637" width="43" height="14" font="13">T2DM </text>
<text top="823" left="718" width="70" height="14" font="13">(S4.2-15).*</text>
<text top="1071" left="105" width="214" height="14" font="13">                                                            </text>
<text top="1090" left="105" width="482" height="13" font="23">*An HbA1c is the optimal screening method, with a level ≥6.5% indicating T2DM. </text>
</page>
<page number="29" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 27 of 101 </text>
<text top="167" left="105" width="4" height="14" font="13"> </text>
<text top="167" left="131" width="661" height="14" font="13">Although  contemporary  data  have  shown  a  significant  decrease in  ASCVD  rates  in individuals  with </text>
<text top="187" left="105" width="687" height="14" font="13">T2DM (S4.2-15), T2DM remains a highly prevalent disease and a major ASCVD risk factor. An aggressive, </text>
<text top="207" left="105" width="687" height="14" font="13">comprehensive  approach  to  ASCVD  risk  factor  treatment  in  adults  with  T2DM  reduces  ASCVD  events </text>
<text top="226" left="105" width="687" height="14" font="13">(S4.2-16). Management of cholesterol and hypertension in adults with T2DM is discussed in the relevant </text>
<text top="246" left="105" width="399" height="14" font="13">sections of the present guideline (see Sections 4.3. and 4.4.). </text>
<text top="265" left="105" width="4" height="14" font="13"> </text>
<text top="285" left="105" width="287" height="15" font="7"><b>Recommendation-Specific Supportive Text </b></text>
<text top="305" left="105" width="687" height="14" font="13">1.  A heart-healthy dietary pattern is a key intervention in the treatment of T2DM. The Mediterranean, </text>
<text top="324" left="131" width="661" height="14" font="13">DASH,  and  vegetarian/vegan  diets  have  all  been  shown  to  help  in  the  achievement  of  weight loss </text>
<text top="344" left="131" width="661" height="14" font="13">and  improve  glycemic  control  in  T2DM  (S4.2-1,  S4.2-2).  Prospective  cohorts  have  demonstrated  a </text>
<text top="363" left="131" width="661" height="14" font="13">significantly  lower  likelihood  of  CVD  events  and  CVD  death  in  adults  with  T2DM  who  follow  a </text>
<text top="383" left="131" width="661" height="14" font="13">healthy  dietary  pattern  (S4.2-17).  However,  an  RCT  targeting  aggressive  lifestyle  interventions  in </text>
<text top="403" left="131" width="661" height="14" font="13">T2DM  was  unable  to  show  a  reduction  in  ASCVD  events  despite  early  success  in  achieving  weight </text>
<text top="422" left="131" width="95" height="14" font="13">loss (S4.2-18). </text>
<text top="442" left="105" width="4" height="14" font="13"> </text>
<text top="442" left="131" width="4" height="14" font="13"> </text>
<text top="442" left="158" width="634" height="14" font="13">The quality of carbohydrate intake is especially important for control of T2DM, and focus should </text>
<text top="461" left="131" width="661" height="14" font="13">be placed on the intake of fiber-rich whole grains and avoidance of refined carbohydrates (S4.2-19). </text>
<text top="481" left="131" width="661" height="14" font="13">Additionally, red meat consumption has  been shown to increase the risk of T2DM, and decreasing </text>
<text top="501" left="131" width="661" height="14" font="13">intake  of  red  meat  can  improve  glycemic  control  (S4.2-20,  S4.2-21).  Weight  loss  is  an  essential </text>
<text top="520" left="131" width="661" height="14" font="13">treatment  component  for  T2DM,  and  dietary  recommendations  should  be  adjusted  to  achieve </text>
<text top="540" left="131" width="661" height="14" font="13">meaningful  weight  loss,  if  needed.  Establishing  an  appropriate  nutrition  plan  requires  time  and </text>
<text top="559" left="131" width="661" height="14" font="13">effort and is best accomplished with assistance from a registered dietitian-nutritionist or a diabetes </text>
<text top="579" left="131" width="133" height="14" font="13">education program. </text>
<text top="599" left="105" width="687" height="14" font="13">2.  Initiation of an exercise program for those with T2DM has been shown to improve glycemic control, </text>
<text top="618" left="131" width="661" height="14" font="13">with a prior meta-analysis showing a significant reduction in mean HbA1c (7.65%  versus 8.31%) in </text>
<text top="638" left="131" width="661" height="14" font="13">individuals  assigned  to  an  exercise  program  versus  control  groups  (S4.2-22).  The  combination  of </text>
<text top="658" left="131" width="661" height="14" font="13">aerobic  and  resistance  training  further  improves  glycemic  control  and  facilitates  weight  loss  more </text>
<text top="677" left="131" width="661" height="14" font="13">than  either  type  of  exercise  alone  (S4.2-3,  S4.2-4).  Prospective  cohort  studies  have  provided </text>
<text top="697" left="131" width="661" height="14" font="13">supportive data for the benefits of physical activity in individuals with T2DM, with increased levels of </text>
<text top="716" left="131" width="552" height="14" font="13">physical activity associated with lower rates of CVD events and CVD death (S4.2-17). </text>
<text top="736" left="105" width="4" height="14" font="13"> </text>
<text top="736" left="131" width="4" height="14" font="13"> </text>
<text top="736" left="158" width="634" height="14" font="13">How  to  best  promote  physical  activity  in  individuals  with  T2DM  remains  unclear.  For  older </text>
<text top="755" left="131" width="661" height="14" font="13">individuals with other comorbidities, a simple walking program may be ideal, whereas for younger, </text>
<text top="775" left="131" width="661" height="14" font="13">healthier  individuals,  a  variety  of  activities  should  be  encouraged.  In  addition  to  a  structured </text>
<text top="795" left="131" width="661" height="14" font="13">exercise program, a general increase in physical activity throughout the day (e.g., taking the stairs, </text>
<text top="814" left="131" width="572" height="14" font="13">walking or biking to work, avoiding prolonged periods of sitting) should be encouraged. </text>
<text top="834" left="105" width="687" height="14" font="13">3.  Metformin decreases hepatic glucose production and increases peripheral insulin sensitivity, leading </text>
<text top="854" left="131" width="661" height="14" font="13">to a reduction in hyperglycemia in adults with T2DM. In a substudy of the UKPDS (United Kingdom </text>
<text top="873" left="131" width="661" height="14" font="13">Prospective  Diabetes  Study),  metformin,  compared  with  conventional  therapy  (i.e.,  lifestyle </text>
<text top="893" left="131" width="657" height="14" font="13">modifications  alone),  resulted  in  a  32%  reduction  in  microvascular  and  macrovascular  diabetes-</text>
<text top="912" left="131" width="661" height="14" font="13">related outcomes, a 39% reduction in MI, and a 36% reduction in all-cause mortality rate (S4.2-5). A </text>
<text top="932" left="131" width="661" height="14" font="13">2016  systematic  review  and  meta-analysis  of  glucose-lowering  therapies  for  T2DM  supported  the </text>
<text top="952" left="131" width="661" height="14" font="13">use of metformin as first-line therapy for T2DM because of its beneficial effects on HbA1c, weight, </text>
<text top="971" left="131" width="661" height="14" font="13">and  improved  ASCVD  outcomes  (compared  with  sulfonylureas),  as  well  as  its  acceptable  safety </text>
<text top="991" left="131" width="661" height="14" font="13">profile  and  low  cost.  However,  a  separate  systematic  review  found  no  evidence  of  reduced  CVD </text>
<text top="1010" left="131" width="661" height="14" font="13">events or CVD deaths with metformin (S4.2-8). Metformin carries a small risk of lactic acidosis and </text>
<text top="1030" left="131" width="661" height="14" font="13">must  be  used  with  caution  in  patients  with  CKD.  For  younger  individuals  or  those  with  a  mildly </text>
<text top="1050" left="131" width="661" height="14" font="13">elevated HbA1c at the time of diagnosis of T2DM, clinicians can consider a trial of lifestyle therapies </text>
<text top="1069" left="131" width="365" height="14" font="13">for 3 to 6 months before reconsideration of metformin. </text>
</page>
<page number="30" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 28 of 101 </text>
<text top="168" left="105" width="687" height="14" font="13">4.  Several classes of medications have been shown to effectively lower blood glucose but may or may </text>
<text top="187" left="132" width="661" height="14" font="13">not  affect  ASCVD  risk  (S4.2-23<b>–</b>S4.2-26).  However,  2  classes  of  glucose-lowering  medications  have </text>
<text top="207" left="132" width="661" height="14" font="13">recently been demonstrated to reduce CVD events in adults with T2DM and high ASCVD risk. SGLT-2 </text>
<text top="226" left="132" width="661" height="14" font="13">inhibitors act in the proximal tubule to increase urinary excretion of glucose and sodium, leading to </text>
<text top="246" left="132" width="661" height="14" font="13">a reduction in HbA1c, body weight, and BP. Three RCTs have shown a significant reduction in ASCVD </text>
<text top="266" left="132" width="661" height="14" font="13">events  and  heart  failure  with  use  of  an  SGLT-2  inhibitor  (S4.2-9,  S4.2-10,  S4.2-12).  Although  most </text>
<text top="285" left="132" width="661" height="14" font="13">patients studied had established CVD at baseline, the reduction in heart failure has been shown to </text>
<text top="305" left="132" width="661" height="14" font="13">extend  to  primary  prevention  populations  (S4.2-12,  S4.2-27).  The  GLP-1R  agonists  increase  insulin </text>
<text top="324" left="132" width="661" height="14" font="13">and  glucagon  production  in  the  liver,  increase  glucose  uptake  in  muscle  and  adipose  tissue,  and </text>
<text top="344" left="132" width="661" height="14" font="13">decrease hepatic glucose production. Three GLP-1R agonists have been found to significantly reduce </text>
<text top="364" left="132" width="661" height="14" font="13">the  risk  of  ASCVD  in  adults  with  T2DM  who  are  at  high  ASCVD  risk  (S4.2-11,  S4.2-13,  S4.2-14).  As </text>
<text top="383" left="132" width="661" height="14" font="13">opposed to a reduction in heart failure with SGLT-2 inhibitors, the benefit of the GLP-1R agonists has </text>
<text top="403" left="132" width="627" height="14" font="13">been a reduction in ASCVD events though the majority of patients studied had established CVD. </text>
<text top="422" left="105" width="4" height="14" font="13"> </text>
<text top="422" left="132" width="4" height="14" font="13"> </text>
<text top="422" left="158" width="626" height="14" font="13">In patients with T2DM and additional risk factors for CVD, it may be reasonable to initiate these </text>
<text top="442" left="132" width="366" height="14" font="13">2 classes of medications for primary prevention of CVD. </text>
<text top="462" left="105" width="4" height="14" font="13"> </text>
<text top="481" left="105" width="4" height="14" font="13"> </text>
<text top="501" left="105" width="527" height="15" font="7"><b>Figure 2. Treatment of T2DM for Primary Prevention of Cardiovascular Disease </b></text>
<text top="1053" left="861" width="4" height="15" font="7"><b> </b></text>
</page>
<page number="31" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 29 of 101 </text>
<text top="167" left="105" width="687" height="13" font="23">CVD  indicates  cardiovascular disease; GLP-1R, glucagon-like  peptide-1 receptor; HbA1c, hemoglobin A1c;  SGLT-2, </text>
<text top="185" left="105" width="413" height="13" font="23">sodium-glucose cotransporter 2; and T2DM, type 2 diabetes mellitus. </text>
<text top="215" left="105" width="4" height="14" font="13"> </text>
<text top="215" left="315" width="4" height="14" font="13"> </text>
</page>
<page number="32" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 30 of 101 </text>
<text top="169" left="105" width="365" height="20" font="20"><b>4.3. Adults With High Blood Cholesterol </b></text>
<text top="194" left="105" width="646" height="14" font="13">Recommendations from the 2018 Cholesterol Clinical Practice Guidelines (S4.3-1) are included and </text>
<text top="214" left="105" width="105" height="14" font="13">adapted below. </text>
<text top="246" left="245" width="391" height="15" font="7"><b>Recommendations for Adults With High Blood Cholesterol </b></text>
<text top="265" left="115" width="651" height="14" font="13">Referenced studies that support recommendations are summarized in Online Data Supplements 11 </text>
<text top="285" left="414" width="52" height="14" font="13">and 12. </text>
<text top="305" left="113" width="32" height="15" font="7"><b>COR </b></text>
<text top="305" left="177" width="29" height="15" font="7"><b>LOE </b></text>
<text top="305" left="439" width="129" height="15" font="7"><b>Recommendations </b></text>
<text top="384" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="384" left="185" width="13" height="15" font="7"><b>A </b></text>
<text top="325" left="231" width="13" height="15" font="7"><b>1.</b></text>
<text top="326" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="325" left="257" width="519" height="15" font="7"><b>In  adults  at  intermediate  risk  (≥7.5%  to  &lt;20%  10-year  ASCVD  risk),  statin </b></text>
<text top="345" left="257" width="519" height="15" font="7"><b>therapy  reduces  risk  of  ASCVD,  and  in  the  context  of  a  risk  discussion,  if  a </b></text>
<text top="365" left="257" width="519" height="15" font="7"><b>decision  is  made  for  statin  therapy,  a  moderate-intensity  statin  should  be </b></text>
<text top="384" left="257" width="209" height="15" font="7"><b>recommended (S4.3-2–S4.3-9). </b></text>
<text top="404" left="255" width="4" height="14" font="13"> </text>
<text top="424" left="255" width="479" height="14" font="13">Adapted from recommendations in the 2018 Cholesterol Clinical Practice </text>
<text top="443" left="255" width="131" height="14" font="13">Guidelines (S4.3-1). </text>
<text top="522" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="522" left="185" width="13" height="15" font="7"><b>A </b></text>
<text top="463" left="231" width="13" height="15" font="7"><b>2.</b></text>
<text top="464" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="463" left="257" width="519" height="15" font="7"><b>In  intermediate  risk  (≥7.5%  to  &lt;20%  10-year  ASCVD  risk)  patients,  LDL-C </b></text>
<text top="483" left="257" width="519" height="15" font="7"><b>levels  should  be  reduced  by  30%  or  more,  and  for  optimal  ASCVD  risk </b></text>
<text top="503" left="257" width="519" height="15" font="7"><b>reduction,  especially  in  patients  at  high  risk  (≥20%  10-year  ASCVD  risk), </b></text>
<text top="522" left="257" width="443" height="15" font="7"><b>levels should be reduced by 50% or more (S4.3-2, S4.3-5–S4.3-10). </b></text>
<text top="542" left="255" width="4" height="14" font="13"> </text>
<text top="562" left="255" width="479" height="14" font="13">Adapted from recommendations in the 2018 Cholesterol Clinical Practice </text>
<text top="581" left="255" width="131" height="14" font="13">Guidelines (S4.3-1).<b> </b></text>
<text top="641" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="641" left="185" width="13" height="15" font="7"><b>A </b></text>
<text top="601" left="231" width="13" height="15" font="7"><b>3.</b></text>
<text top="602" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="601" left="257" width="519" height="15" font="7"><b>In adults 40 to 75 years of age with diabetes, regardless of estimated 10-year </b></text>
<text top="621" left="257" width="515" height="15" font="7"><b>ASCVD risk, moderate-intensity statin therapy is indicated (S4.3-11–S4.3-19). </b></text>
<text top="641" left="255" width="4" height="14" font="13"> </text>
<text top="660" left="255" width="480" height="14" font="13">Included from recommendations in the 2018 Cholesterol Clinical Practice </text>
<text top="680" left="255" width="131" height="14" font="13">Guidelines (S4.3-1).<b> </b></text>
<text top="749" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="749" left="178" width="27" height="15" font="7"><b>B-R </b></text>
<text top="700" left="231" width="13" height="15" font="7"><b>4.</b></text>
<text top="700" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="700" left="257" width="519" height="15" font="7"><b>In  patients  20  to  75  years  of  age  with  an  LDL-C  level  of  190  mg/dL  (≥4.9 </b></text>
<text top="720" left="257" width="519" height="15" font="7"><b>mmol/L)  or  higher,  maximally  tolerated  statin  therapy  is  recommended </b></text>
<text top="739" left="257" width="174" height="15" font="7"><b>(S4.3-2, S4.3-20–S4.3-25). </b></text>
<text top="759" left="255" width="4" height="14" font="13"> </text>
<text top="779" left="255" width="480" height="14" font="13">Included from recommendations in the 2018 Cholesterol Clinical Practice </text>
<text top="798" left="255" width="131" height="14" font="13">Guidelines (S4.3-1).<b> </b></text>
<text top="867" left="119" width="20" height="15" font="7"><b>IIa </b></text>
<text top="867" left="178" width="27" height="15" font="7"><b>B-R </b></text>
<text top="818" left="231" width="13" height="15" font="7"><b>5.</b></text>
<text top="819" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="818" left="257" width="519" height="15" font="7"><b>In  adults  with  diabetes  mellitus  who  have  multiple  ASCVD  risk  factors,  it is </b></text>
<text top="838" left="257" width="519" height="15" font="7"><b>reasonable to prescribe high-intensity statin therapy with the aim to reduce </b></text>
<text top="858" left="257" width="299" height="15" font="7"><b>LDL-C levels by 50% or more (S4.3-2, S4.3-7). </b></text>
<text top="877" left="255" width="4" height="14" font="13"> </text>
<text top="897" left="255" width="480" height="14" font="13">Included from recommendations in the 2018 Cholesterol Clinical Practice </text>
<text top="917" left="255" width="131" height="14" font="13">Guidelines (S4.3-1).<b> </b></text>
<text top="986" left="119" width="20" height="15" font="7"><b>IIa </b></text>
<text top="986" left="178" width="27" height="15" font="7"><b>B-R </b></text>
<text top="937" left="231" width="13" height="15" font="7"><b>6.</b></text>
<text top="937" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="937" left="257" width="515" height="15" font="7"><b>In  intermediate-risk  (≥7.5%  to  &lt;20%  10-year  ASCVD  risk)  adults,  risk-</b></text>
<text top="957" left="257" width="519" height="15" font="7"><b>enhancing factors favor initiation or intensification of statin therapy (S4.3-7, </b></text>
<text top="976" left="257" width="120" height="15" font="7"><b>S4.3-26–S4.3-33). </b></text>
<text top="996" left="255" width="4" height="14" font="13"> </text>
<text top="1016" left="255" width="479" height="14" font="13">Adapted from recommendations in the 2018 Cholesterol Clinical Practice </text>
<text top="1035" left="255" width="131" height="14" font="13">Guidelines (S4.3-1).<b> </b></text>
</page>
<page number="33" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 31 of 101 </text>
<text top="311" left="119" width="20" height="15" font="7"><b>IIa </b></text>
<text top="311" left="173" width="37" height="15" font="7"><b>B-NR </b></text>
<text top="168" left="231" width="13" height="15" font="7"><b>7.</b></text>
<text top="168" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="168" left="257" width="519" height="15" font="7"><b>In  intermediate-risk  (≥7.5%  to  &lt;20%  10-year  ASCVD  risk)  adults  or  selected </b></text>
<text top="188" left="257" width="519" height="15" font="7"><b>borderline-risk (5% to &lt;7.5% 10-year ASCVD risk) adults in whom a coronary </b></text>
<text top="207" left="257" width="519" height="15" font="7"><b>artery  calcium  score  is  measured  for  the  purpose  of  making  a  treatment </b></text>
<text top="227" left="257" width="97" height="15" font="7"><b>decision, AND </b></text>
<text top="251" left="261" width="7" height="21" font="22">•</text>
<text top="256" left="269" width="4" height="15" font="17"> </text>
<text top="256" left="287" width="488" height="15" font="7"><b>If the coronary artery calcium score is zero, it is reasonable to withhold </b></text>
<text top="276" left="287" width="488" height="15" font="7"><b>statin  therapy  and  reassess  in  5  to  10  years,  as  long  as  higher-risk </b></text>
<text top="295" left="287" width="488" height="15" font="7"><b>conditions  are  absent  (e.g.,  diabetes,  family  history of  premature  CHD, </b></text>
<text top="315" left="287" width="136" height="15" font="7"><b>cigarette smoking);  </b></text>
<text top="331" left="261" width="7" height="21" font="22">•</text>
<text top="335" left="269" width="4" height="15" font="17"> </text>
<text top="335" left="287" width="488" height="15" font="7"><b>If  coronary  artery  calcium  score  is  1  to  99,  it  is  reasonable  to  initiate </b></text>
<text top="355" left="287" width="299" height="15" font="7"><b>statin therapy for patients ≥55 years of age;  </b></text>
<text top="371" left="261" width="7" height="21" font="22">•</text>
<text top="375" left="269" width="4" height="15" font="17"> </text>
<text top="375" left="287" width="488" height="15" font="7"><b>If coronary artery calcium score is 100 or higher or in the 75th percentile </b></text>
<text top="395" left="287" width="464" height="15" font="7"><b>or higher, it is reasonable to initiate statin therapy (S4.3-28, S4.3-34). </b></text>
<text top="415" left="255" width="4" height="14" font="13"> </text>
<text top="434" left="255" width="479" height="14" font="13">Adapted from recommendations in the 2018 Cholesterol Clinical Practice </text>
<text top="454" left="255" width="131" height="14" font="13">Guidelines (S4.3-1).<b> </b></text>
<text top="523" left="119" width="21" height="15" font="7"><b>IIb </b></text>
<text top="523" left="178" width="27" height="15" font="7"><b>B-R </b></text>
<text top="474" left="231" width="13" height="15" font="7"><b>8.</b></text>
<text top="474" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="474" left="257" width="519" height="15" font="7"><b>In  patients  at  borderline  risk  (5%  to  &lt;7.5%  10-year  ASCVD  risk),  in  risk </b></text>
<text top="494" left="257" width="519" height="15" font="7"><b>discussion,  the  presence  of  risk-enhancing  factors  may  justify  initiation  of </b></text>
<text top="513" left="257" width="354" height="15" font="7"><b>moderate-intensity statin therapy (S4.3-28, S4.3-35). </b></text>
<text top="533" left="255" width="4" height="14" font="13"> </text>
<text top="553" left="255" width="479" height="14" font="13">Adapted from recommendations in the 2018 Cholesterol Clinical Practice </text>
<text top="572" left="255" width="131" height="14" font="13">Guidelines (S4.3-1).<b> </b></text>
<text top="593" left="105" width="4" height="14" font="13"> </text>
<text top="612" left="105" width="61" height="15" font="7"><b>Synopsis </b></text>
<text top="632" left="105" width="687" height="14" font="13">Primary ASCVD prevention requires attention to ASCVD risk factors beginning early in life (Figure 3). This </text>
<text top="651" left="105" width="687" height="14" font="13">guideline  addresses  major  issues  related  to  cholesterol  management  and  primary  ASCVD  prevention, </text>
<text top="671" left="105" width="687" height="14" font="13">which are also addressed in the recently published 2018 Cholesterol Clinical Practice Guidelines (S4.3-1). </text>
<text top="691" left="105" width="687" height="14" font="13">Therefore,  the  relevant  subset  of  those  recommendations  is  presented  here,  along  with  its </text>
<text top="710" left="105" width="687" height="14" font="13">accompanying supportive text. This writing  committee  agrees  that for young adults (20 to 39 years of </text>
<text top="730" left="105" width="687" height="14" font="13">age), priority should be given to estimating lifetime risk and promoting a healthy lifestyle. Only in select </text>
<text top="749" left="105" width="687" height="14" font="13">patients with moderately high  LDL-C (≥160 mg/dL) or  those with very  high LDL-C (≥190 mg/dL) is  drug </text>
<text top="769" left="105" width="687" height="14" font="13">therapy  indicated.  In  adults  40  to  75  years  of  age,  10-year  ASCVD  risk  should  guide  therapeutic </text>
<text top="789" left="105" width="687" height="14" font="13">considerations.  The  higher  the  estimated  risk,  the  more  likely  the  patient  is  to  benefit  from  statin </text>
<text top="808" left="105" width="687" height="14" font="13">treatment. For patients &gt;75 years of age, assessment of risk status and a clinician patient risk discussion </text>
<text top="828" left="105" width="687" height="14" font="13">are needed to decide whether to continue or initiate statin treatment. For a detailed discussion of statin </text>
<text top="847" left="105" width="687" height="14" font="13">safety  and  management  of  statin-associated  side  effects,  please  refer  to  Section  5  of  the  2018 </text>
<text top="867" left="105" width="314" height="14" font="13">Cholesterol Clinical Practice Guidelines (S4.3-1). </text>
<text top="887" left="105" width="4" height="14" font="13"> </text>
<text top="906" left="105" width="287" height="15" font="7"><b>Recommendation-Specific Supportive Text </b></text>
<text top="926" left="105" width="687" height="14" font="13">1.  Large-scale RCTs in primary prevention demonstrated ASCVD risk reduction with moderate-intensity </text>
<text top="946" left="131" width="661" height="14" font="13">(S4.3-6,  S4.3-36)  and  high-intensity  statin  therapy  (S4.3-7)  that  outweighed  the  observable  risks. </text>
<text top="965" left="131" width="661" height="14" font="13">Subsequently,  a  large-scale  RCT  in  an  ethnically  and  racially  diverse  population  confirmed  statin </text>
<text top="985" left="131" width="661" height="14" font="13">benefit  from  a  moderate-intensity  statin  therapy,  as  compared  with  placebo,  in  intermediate-risk </text>
<text top="1004" left="131" width="661" height="14" font="13">patients.  That  RCT  enrolled  men  ≥55  years  of  age  and  women  ≥65  years  of  age  with  at  least  1 </text>
<text top="1024" left="131" width="661" height="14" font="13">cardiovascular risk factor. In the placebo group, the 10-year risk of “hard ASCVD” was 8.7%, and the </text>
<text top="1044" left="131" width="661" height="14" font="13">risk  of  the  expanded  ASCVD  endpoint  that  included  coronary  revascularization  was  10%  (S4.3-9). </text>
<text top="1063" left="131" width="661" height="14" font="13">After  5.6  years,  those  assigned  to  rosuvastatin  10  mg  per  day  showed  significant  absolute  risk </text>
<text top="1083" left="131" width="661" height="14" font="13">reduction  in  both  co-primary  endpoints,  with  an  acceptable  safety  record.  By  comparison,  after  a </text>
</page>
<page number="34" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 32 of 101 </text>
<text top="167" left="131" width="661" height="14" font="13">median follow-up of 1.9 years, those assigned to a high-intensity statin dose of rosuvastatin in the </text>
<text top="187" left="131" width="661" height="14" font="13">JUPITER  (Justification  for  the  Use  of  Statins  in  Prevention:  an  Intervention  Trial  Evaluating </text>
<text top="207" left="131" width="661" height="14" font="13">Rosuvastatin)  RCT  achieved  greater  LDL-C  lowering  and  greater  reductions  in  ASCVD  outcomes </text>
<text top="226" left="131" width="657" height="14" font="13">(S4.3-7). This corroborates meta-analyses demonstrating that in those at risk, net benefit of LDL-C–</text>
<text top="246" left="131" width="508" height="14" font="13">lowering therapy is greater with greater reductions in LDL-C (S4.3-2, S4.3-10). </text>
<text top="265" left="105" width="687" height="14" font="13">2.  If in the context of a risk discussion, maximal ASCVD risk reduction is desired, it is reasonable to use </text>
<text top="285" left="131" width="657" height="14" font="13">a high-intensity statin to lower LDL-C by ≥50%. This provides increased benefit, especially when 10-</text>
<text top="305" left="131" width="661" height="14" font="13">year ASCVD risk is ≥20%. JUPITER enrolled men ≥50 years of age and women ≥60 years of age with </text>
<text top="324" left="131" width="661" height="14" font="13">high-sensitivity  C-reactive  protein  values  ≥2.0  mg/L  and  LDL-C  &lt;130  mg/dL.  Participants  randomly </text>
<text top="344" left="131" width="661" height="14" font="13">assigned to 20 mg per day of rosuvastatin achieved a median LDL-C reduction of 50% and a highly </text>
<text top="363" left="131" width="661" height="14" font="13">significant  ASCVD  risk  reduction  at  1.9  years  (S4.3-7).  Importantly,  the  magnitude  of  the  percent </text>
<text top="383" left="131" width="661" height="14" font="13">LDL-C  reduction  achieved  determined  benefit  (S4.3-29).  The  USPSTF  systematic  review  of  statin </text>
<text top="403" left="131" width="661" height="14" font="13">therapy in primary prevention showed a reduced risk of all-cause and cardiovascular mortality and </text>
<text top="422" left="131" width="661" height="14" font="13">ASCVD  events  and  noted  greater  absolute  benefits  in  those  at  greater  baseline  risk  (S4.3-5), </text>
<text top="442" left="131" width="661" height="14" font="13">consistent  with  other  high-quality  systematic  reviews  and  meta-analyses  (S4.3-2,  S4.3-8,  S4.3-35). </text>
<text top="461" left="131" width="661" height="14" font="13">This underscores the need for aggressive and safe risk reduction in the highest-risk groups and the </text>
<text top="481" left="131" width="661" height="14" font="13">need  for  follow-up  LDL-C  testing  to  determine  adherence  and  adequacy  of  effect  of  the  statin </text>
<text top="501" left="131" width="131" height="14" font="13">prescribed (S4.3-1). </text>
<text top="520" left="105" width="683" height="14" font="13">3.  Most patients 40 to 75 years of age  with diabetes are at intermediate  or  high  risk (PCE ≥7.5% 10-</text>
<text top="540" left="131" width="661" height="14" font="13">year risk) of ASCVD events (S4.3-15, S4.3-16, S4.3-18). Three of 4 double-blinded primary-prevention </text>
<text top="559" left="131" width="661" height="14" font="13">RCTs of moderate statin therapy in large cohorts with diabetes in this age range showed significant </text>
<text top="579" left="131" width="661" height="14" font="13">reductions  in  ASCVD  events  (S4.3-11,  S4.3-12,  S4.3-14,  S4.3-17).  A  meta-analysis  of  these  trials </text>
<text top="599" left="131" width="661" height="14" font="13">found that moderate-intensity statin therapy was associated with a risk reduction of 25% (S4.3-13), </text>
<text top="618" left="131" width="661" height="14" font="13">similar  to  people  without  diabetes  and  with  no  apparent  difference  in  benefit  between  type  1 </text>
<text top="638" left="131" width="661" height="14" font="13">diabetes  mellitus  and  T2DM. Therefore,  moderate-intensity  statin  therapy is  indicated  for  primary </text>
<text top="658" left="131" width="384" height="14" font="13">prevention in patients 40 to 75 years of age with diabetes. </text>
<text top="677" left="105" width="687" height="14" font="13">4.  Patients with primary severe hypercholesterolemia  (LDL-C ≥190 mg/dL  [≥4.9 mmol/L]) have a high </text>
<text top="697" left="131" width="661" height="14" font="13">risk  of  ASCVD  (S4.3-23)  and  premature  and  recurrent  coronary  events.  Although  no  randomized, </text>
<text top="716" left="131" width="661" height="14" font="13">placebo-controlled  trials  of  statin  therapy  have  been  done  exclusively  in  subjects  with  LDL-C  ≥190 </text>
<text top="736" left="131" width="657" height="14" font="13">mg/dL, a placebo-controlled primary-prevention study performed in men with a mean baseline LDL-</text>
<text top="755" left="131" width="661" height="14" font="13">C  of  192±17  mg/dL  demonstrated  a  reduced  incidence  of  MI  and  cardiovascular  death  in  those </text>
<text top="775" left="131" width="661" height="14" font="13">receiving pravastatin 40 mg daily (S4.3-24). These findings were extended in a post hoc analysis of </text>
<text top="795" left="131" width="661" height="14" font="13">2,560  exclusively  primary-prevention  subjects in  that  RCT  and in  a 20-year  observational  post-trial </text>
<text top="814" left="131" width="661" height="14" font="13">long-term follow-up study (S4.3-37). Because moderate- or high-intensity statins have been shown </text>
<text top="834" left="131" width="661" height="14" font="13">to reduce ASCVD risk and because high-intensity statins provide greater ASCVD risk reduction than </text>
<text top="854" left="131" width="661" height="14" font="13">do  moderate-intensity  statins  or  placebo  (S4.3-2),  maximally  tolerated  statin  therapy  should  be </text>
<text top="873" left="131" width="661" height="14" font="13">administered  to  patients  with  LDL-C  ≥190  mg/dL.  Please  refer  to  the  2018  cholesterol  guideline </text>
<text top="893" left="131" width="541" height="14" font="13">(S4.3-1) for recommendations on the use of non-statin therapies in these patients. </text>
<text top="912" left="105" width="687" height="14" font="13">5.  The occurrence of a first ASCVD event in patients 40 to 75 years of age with diabetes is associated </text>
<text top="932" left="131" width="661" height="14" font="13">with  increased  morbidity  and  mortality  compared  with  those  without  diabetes,  which  places  a </text>
<text top="952" left="131" width="661" height="14" font="13">particularly  high  premium  on  primary  prevention  in  individuals  with  diabetes  in  that  age  range. </text>
<text top="971" left="131" width="661" height="14" font="13">Although  trials  using  moderate-intensity  statin  therapy  have  demonstrated  significant  benefit  in </text>
<text top="991" left="131" width="661" height="14" font="13">such individuals, the residual risk in the statin treatment groups in these trials remained high. (e.g., </text>
<text top="1010" left="131" width="661" height="14" font="13">8.5%  had  major  cardiovascular  events  in  3.8  years)  (S4.3-13).  The  benefit  from  statin  therapy  is </text>
<text top="1030" left="131" width="661" height="14" font="13">related to both global risk and intensity of treatment (S4.3-2), and  no RCTs of high-intensity statin </text>
<text top="1050" left="131" width="661" height="14" font="13">therapy have been carried out in cohorts of patients exclusively with diabetes. On the basis of these </text>
<text top="1069" left="131" width="661" height="14" font="13">considerations and the fact that patients with diabetes have a higher trajectory of lifetime risk than </text>
</page>
<page number="35" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 33 of 101 </text>
<text top="167" left="131" width="661" height="14" font="13">do  those  without  diabetes,  high-intensity  statin  therapy  is  preferred  in  patients  with  diabetes  as </text>
<text top="187" left="131" width="245" height="14" font="13">they develop risk modifiers (Table 5). </text>
<text top="207" left="105" width="687" height="14" font="13">6.  Knowledge  of  risk-enhancing  factors  (Table  3  in  Section  2.2.)  is  useful  for  all  individuals  but </text>
<text top="226" left="131" width="661" height="14" font="13">particularly  for  those  at  intermediate  risk  (ASCVD  risk  of  7.5%  to  ≤20%).  For  example,  in  an  RCT </text>
<text top="246" left="131" width="661" height="14" font="13">(S4.3-38),  a  family  history  of  premature  ASCVD  identified  women  ≥60  years  of  age  with  elevated </text>
<text top="265" left="131" width="661" height="14" font="13">hsCRP  and  without  ASCVD  who  benefitted  from  high-intensity  statin  therapy.  Those  with  primary </text>
<text top="285" left="131" width="661" height="14" font="13">LDL-C elevations of ≥160 mg/dL (≥4.1 mmol/L) have elevated lifetime ASCVD risk and benefit from </text>
<text top="305" left="131" width="661" height="14" font="13">statin  therapy (S4.3-33,  S4.3-36). Increased  ASCVD risk is  seen with metabolic syndrome (S4.3-31); </text>
<text top="324" left="131" width="661" height="14" font="13">inflammatory diseases, including psoriasis (S4.3-39) and rheumatoid arthritis; and HIV when treated </text>
<text top="344" left="131" width="661" height="14" font="13">with protease inhibitors (S4.3-40). The presence of risk-enhancing factors may affect the threshold </text>
<text top="363" left="131" width="661" height="14" font="13">for statin initiation or intensification. Lipoprotein (a) levels, especially in those with a family history </text>
<text top="383" left="131" width="661" height="14" font="13">of  premature  ASCVD,  can  increase  risk  (S4.3-27).  However,  no  available  RCT  evidence  supports </text>
<text top="403" left="131" width="657" height="14" font="13">lipoprotein (a) levels as a target of therapy. Moderate primary elevations of triglycerides, non–HDL-</text>
<text top="422" left="131" width="661" height="14" font="13">C (total cholesterol – HDL-C), and, if measured, apolipoprotein B can improve selection of those at </text>
<text top="442" left="131" width="207" height="14" font="13">increased ASCVD risk (S4.3-33). </text>
<text top="461" left="105" width="687" height="14" font="13">7.  In  adults  at  intermediate  risk,  coronary  artery  calcium  measurement  can  be  effective  for </text>
<text top="481" left="131" width="661" height="14" font="13">meaningfully  reclassifying  risk  in  a  large  proportion  of  individuals  (S4.3-41–S4.3-55).  In  such </text>
<text top="501" left="131" width="661" height="14" font="13">intermediate-risk adults,  those with coronary artery calcium ≥100  AU or coronary artery  calcium ≥ </text>
<text top="520" left="131" width="661" height="14" font="13">75th percentile have ASCVD event rates for which initiation of statin therapy is reasonable (S4.3-41). </text>
<text top="540" left="131" width="661" height="14" font="13">Those  with  coronary  artery  calcium  scores  of  zero  appear  to  have  10-year  event  rates  in  a  lower </text>
<text top="559" left="131" width="661" height="14" font="13">range  for  which  statin  therapy  may  be  of  limited  value.  For  those  with  coronary  artery  calcium </text>
<text top="579" left="131" width="661" height="14" font="13">scores of 1 to 99 AU, 10-year ASCVD event rates are 3.8%, 6.5%, and 8.3% for adults 45 to 54, 55 to </text>
<text top="599" left="131" width="661" height="14" font="13">64, and 65 to 74 years of age, respectively (S4.3-34), indicating that risk reclassification is modest for </text>
<text top="618" left="131" width="661" height="14" font="13">individuals  with  coronary  artery  calcium  scores  of  1  to  99.  Therefore,  for  patients  with  coronary </text>
<text top="638" left="131" width="661" height="14" font="13">artery  calcium  scores  of  1  to  99,  it  is  reasonable  to  repeat  the  risk  discussion.  If  these  patients </text>
<text top="658" left="131" width="661" height="14" font="13">remain  untreated,  repeat  coronary  artery  calcium  measurement  in  5  years  may  have  some  value, </text>
<text top="677" left="131" width="661" height="14" font="13">but  data  are  limited  (S4.3-56,  S4.3-57).  Selected  examples  of  candidates  who  might  benefit  from </text>
<text top="697" left="131" width="661" height="14" font="13">knowing that their coronary artery calcium scores are zero are listed in Table 6. Clinicians should not </text>
<text top="716" left="131" width="661" height="14" font="13">downclassify risk in patients who have coronary artery calcium scores of zero but who are persistent </text>
<text top="736" left="131" width="661" height="14" font="13">cigarette  smokers,  have  diabetes,  have  a  family  history  of  ASCVD,  or,  possibly,  have  chronic </text>
<text top="755" left="131" width="661" height="14" font="13">inflammatory conditions. In the presence of these conditions, a coronary artery calcium of zero does </text>
<text top="775" left="131" width="546" height="14" font="13">not rule out risk from noncalcified plaque or increased risk of thrombosis (S4.3-58). </text>
<text top="795" left="105" width="687" height="14" font="13">8.  Benefit  from  statin  therapy  is  also  seen  in  lower-risk  individuals  (S4.3-35).  For  those  in  the  5%  to </text>
<text top="814" left="131" width="661" height="14" font="13">&lt;7.5%  risk  range,  available  generic  statins  are  cost-effective  (S4.3-59).  Nonetheless,  the  challenge </text>
<text top="834" left="131" width="661" height="14" font="13">among those in a lower ASCVD risk category is to include those who would benefit, yet avoid casting </text>
<text top="854" left="131" width="661" height="14" font="13">too  wide  a  net,  to  minimize  treating  those  who  would  derive  little  benefit  from  statins.  This  risk </text>
<text top="873" left="131" width="660" height="14" font="13">group benefits greatly from a clinician–patient risk discussion. Clinicians should assess priorities for </text>
<text top="893" left="131" width="661" height="14" font="13">health  care,  perceived  ASCVD  risk,  and  prior  risk  reduction  experiences  and  should  use  best </text>
<text top="912" left="131" width="661" height="14" font="13">practices for communicating risk to arrive at a shared risk decision. The presence of risk-enhancing </text>
<text top="932" left="131" width="661" height="14" font="13">factors  is  probably  the  best  indicator  favoring  initiation  of  statin  therapy  (Table  3  in  Section  2.2.) </text>
<text top="952" left="131" width="661" height="14" font="13">(S4.3-60).  Although  a  coronary  artery  calcium  score  can  be  useful  in  select  individuals,  it  will  be </text>
<text top="971" left="131" width="661" height="14" font="13">positive less often in this lower-risk group than in those with higher levels of ASCVD risk and is not </text>
<text top="991" left="131" width="228" height="14" font="13">recommended routinely (S4.3-41).<b> </b></text>
<text top="991" left="566" width="4" height="14" font="13"> </text>
</page>
<page number="36" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 34 of 101 </text>
<text top="167" left="105" width="194" height="15" font="7"><b>Figure 3. Primary Prevention </b></text>
<text top="680" left="802" width="4" height="14" font="13"> </text>
<text top="695" left="105" width="3" height="13" font="23"> </text>
<text top="724" left="105" width="349" height="13" font="23">Colors correspond to Class of Recommendation in Table 1. </text>
<text top="742" left="105" width="687" height="13" font="23">ABI  indicates  ankle-brachial  index;  apoB,  apolipoprotein  B;  ASCVD,  atherosclerotic  cardiovascular  disease;  CAC, </text>
<text top="760" left="105" width="687" height="13" font="23">coronary artery calcium; CHD, coronary heart disease; HIV, human immunodeficiency virus; hs-CRP, high-sensitivity </text>
<text top="778" left="105" width="523" height="13" font="23">C-reactive protein; LDL-C, low-density lipoprotein cholesterol; and Lp(a), lipoprotein (a). </text>
<text top="796" left="105" width="677" height="13" font="23">Reproduced with permission from Grundy et al. (S4.3-1). Copyright © 2018, American Heart Association, Inc., and </text>
<text top="813" left="105" width="264" height="13" font="23">American College of Cardiology Foundation. </text>
<text top="832" left="105" width="4" height="14" font="13"> </text>
<text top="851" left="105" width="4" height="15" font="7"><b> </b></text>
<text top="851" left="315" width="4" height="15" font="7"><b> </b></text>
</page>
<page number="37" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 35 of 101 </text>
<text top="167" left="105" width="649" height="15" font="7"><b>Table 5. Diabetes-Specific Risk Enhancers That Are Independent of Other Risk Factors in Diabetes </b></text>
<text top="187" left="105" width="62" height="15" font="7"><b>Mellitus  </b></text>
<text top="227" left="105" width="236" height="15" font="7"><b>Risk Enhancers in Diabetic Patients</b> </text>
<text top="254" left="105" width="7" height="21" font="22">•</text>
<text top="258" left="112" width="4" height="15" font="17"> </text>
<text top="258" left="131" width="445" height="14" font="13">Long duration (≥10 years for T2DM (S4.3-61) or ≥20 years for type 1 </text>
<text top="278" left="131" width="186" height="14" font="13">diabetes mellitus (S4.3-16))  </text>
<text top="294" left="105" width="7" height="21" font="22">•</text>
<text top="299" left="112" width="4" height="15" font="17"> </text>
<text top="299" left="131" width="358" height="14" font="13">Albuminuria ≥30 mcg albumin/mg creatinine (S4.3-62) </text>
<text top="314" left="105" width="7" height="21" font="22">•</text>
<text top="319" left="113" width="4" height="15" font="17"> </text>
<text top="319" left="131" width="168" height="14" font="13">eGFR &lt;60 mL/min/1.73 m</text>
<text top="316" left="299" width="8" height="9" font="24">2 </text>
<text top="319" left="307" width="62" height="14" font="13">(S4.3-62) </text>
<text top="335" left="105" width="7" height="21" font="22">•</text>
<text top="339" left="112" width="4" height="15" font="17"> </text>
<text top="339" left="131" width="146" height="14" font="13">Retinopathy (S4.3-63) </text>
<text top="355" left="105" width="7" height="21" font="22">•</text>
<text top="360" left="112" width="4" height="15" font="17"> </text>
<text top="360" left="131" width="144" height="14" font="13">Neuropathy (S4.3-64) </text>
<text top="376" left="105" width="7" height="21" font="22">•</text>
<text top="380" left="112" width="4" height="15" font="17"> </text>
<text top="380" left="131" width="177" height="14" font="13">ABI &lt;0.9 (S4.3-65, S4.3-66) </text>
<text top="401" left="105" width="680" height="13" font="23">ABI indicates ankle-brachial index; eGFR, estimated glomerular filtration rate; and T2DM, type 2 diabetes mellitus. </text>
<text top="419" left="105" width="687" height="13" font="23">Reproduced with permission from Grundy et al. (S4.3-1). Copyright © 2018, American Heart Association, Inc., and </text>
<text top="437" left="105" width="264" height="13" font="23">American College of Cardiology Foundation. </text>
<text top="455" left="105" width="4" height="14" font="13"> </text>
<text top="474" left="105" width="4" height="14" font="13"> </text>
<text top="494" left="105" width="646" height="15" font="7"><b>Table 6. Selected Examples of Candidates for Coronary Artery Calcium Measurement Who Might </b></text>
<text top="514" left="105" width="446" height="15" font="7"><b>Benefit From Knowing Their Coronary Artery Calcium Score Is Zero </b></text>
<text top="549" left="105" width="675" height="15" font="7"><b>Coronary Artery Calcium Measurement Candidates Who Might Benefit from Knowing Their Coronary </b></text>
<text top="569" left="105" width="191" height="15" font="7"><b>Artery Calcium Score Is Zero</b> </text>
<text top="598" left="105" width="7" height="21" font="22">•</text>
<text top="603" left="112" width="4" height="15" font="17"> </text>
<text top="603" left="131" width="653" height="14" font="13">Patients reluctant to initiate statin who wish to understand their risk and potential for benefit more </text>
<text top="622" left="131" width="61" height="14" font="13">precisely </text>
<text top="638" left="105" width="7" height="21" font="22">•</text>
<text top="643" left="112" width="4" height="15" font="17"> </text>
<text top="643" left="131" width="597" height="14" font="13">Patients concerned about need to reinstitute statin therapy after discontinuation for statin-</text>
<text top="662" left="131" width="144" height="14" font="13">associated symptoms </text>
<text top="678" left="105" width="7" height="21" font="22">•</text>
<text top="683" left="112" width="4" height="15" font="17"> </text>
<text top="683" left="131" width="635" height="14" font="13">Older patients (men 55–80 y of age; women 60–80 y of age) with low burden of risk factors (S4.3-</text>
<text top="702" left="131" width="434" height="14" font="13">53) who question whether they would benefit from statin therapy </text>
<text top="718" left="105" width="7" height="21" font="22">•</text>
<text top="723" left="112" width="4" height="15" font="17"> </text>
<text top="723" left="131" width="633" height="14" font="13">Middle-aged adults (40–55 y of age) with PCE-calculated 10-year risk of ASCVD 5% to &lt;7.5% with </text>
<text top="742" left="131" width="545" height="14" font="13">factors that increase their ASCVD risk, although they are in a borderline risk group.<b> </b> </text>
<text top="769" left="105" width="687" height="13" font="23">Caveats: If patient is at intermediate risk and if a risk decision is uncertain and a coronary artery calcium<b> </b>score is </text>
<text top="787" left="105" width="687" height="13" font="23">obtained, it is reasonable to withhold statin therapy unless higher-risk conditions, such as cigarette smoking, family </text>
<text top="805" left="105" width="687" height="13" font="23">history of premature ASCVD, or diabetes mellitus, are present and to reassess coronary artery calcium<b> </b>score in 5 to </text>
<text top="822" left="105" width="687" height="13" font="23">10  years.  Moreover,  if  coronary  artery  calcium<b> </b>scoring is recommended,  it  should  be  performed in facilities  that </text>
<text top="840" left="105" width="473" height="13" font="23">have current technology and expertise to deliver the lowest radiation possible.  </text>
<text top="858" left="105" width="687" height="13" font="23">ASCVD  indicates  atherosclerotic  cardiovascular  disease;  LDL-C,  low-density  lipoprotein  cholesterol;  and  PCE, </text>
<text top="876" left="105" width="153" height="13" font="23">pooled cohort equations. </text>
<text top="894" left="105" width="687" height="13" font="23">Reproduced with permission from Grundy et al. (S4.3-1). Copyright © 2018, American Heart Association, Inc., and </text>
<text top="912" left="105" width="264" height="13" font="23">American College of Cardiology Foundation. </text>
<text top="941" left="105" width="3" height="13" font="23"> </text>
<text top="959" left="105" width="3" height="13" font="23"> </text>
<text top="977" left="105" width="4" height="14" font="13"> </text>
</page>
<page number="38" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="29" size="15" family="Helvetica" color="#000000"/>
	<fontspec id="30" size="8" family="Times" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 36 of 101 </text>
<text top="169" left="105" width="492" height="20" font="20"><b>4.4. Adults With High Blood Pressure or Hypertension </b></text>
<text top="194" left="105" width="677" height="14" font="13">Recommendations from the 2017 Hypertension Clinical Practice Guidelines (S4.4-1) are adapted below. </text>
<text top="226" left="197" width="487" height="15" font="7"><b> Recommendations for Adults With High Blood Pressure or Hypertension </b></text>
<text top="246" left="115" width="651" height="14" font="13">Referenced studies that support recommendations are summarized in Online Data Supplements 13 </text>
<text top="265" left="414" width="52" height="14" font="13">and 14. </text>
<text top="285" left="113" width="32" height="15" font="7"><b>COR </b></text>
<text top="285" left="177" width="29" height="15" font="7"><b>LOE </b></text>
<text top="285" left="439" width="129" height="15" font="7"><b>Recommendations </b></text>
<text top="428" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="428" left="185" width="13" height="15" font="7"><b>A </b></text>
<text top="306" left="229" width="13" height="16" font="12"><b>1.</b></text>
<text top="306" left="242" width="5" height="16" font="29"><b> </b></text>
<text top="307" left="255" width="521" height="15" font="7"><b>In adults with elevated blood pressure (BP) or hypertension, including those </b></text>
<text top="327" left="255" width="521" height="15" font="7"><b>requiring  antihypertensive  medications  nonpharmacological  interventions </b></text>
<text top="346" left="255" width="318" height="15" font="7"><b>are recommended to reduce BP. These include: </b></text>
<text top="362" left="260" width="7" height="21" font="22">•</text>
<text top="367" left="268" width="4" height="15" font="17"> </text>
<text top="367" left="287" width="187" height="15" font="7"><b>weight loss (S4.4-2–S4.4-5); </b></text>
<text top="383" left="260" width="7" height="21" font="22">•</text>
<text top="387" left="268" width="4" height="15" font="17"> </text>
<text top="387" left="287" width="320" height="15" font="7"><b>a heart-healthy dietary pattern (S4.4-6–S4.4-8); </b></text>
<text top="403" left="260" width="7" height="21" font="22">•</text>
<text top="408" left="268" width="4" height="15" font="17"> </text>
<text top="408" left="287" width="238" height="15" font="7"><b>sodium reduction (S4.4-9–S4.4-13); </b></text>
<text top="424" left="260" width="7" height="21" font="22">•</text>
<text top="428" left="268" width="4" height="15" font="17"> </text>
<text top="428" left="287" width="367" height="15" font="7"><b>dietary potassium supplementation (S4.4-14–S4.4-18); </b></text>
<text top="444" left="261" width="7" height="21" font="22">•</text>
<text top="449" left="268" width="4" height="15" font="17"> </text>
<text top="449" left="287" width="489" height="15" font="7"><b>increased  physical  activity  with  a  structured  exercise  program  (S4.4-3, </b></text>
<text top="468" left="287" width="255" height="15" font="7"><b>S4.4-5, S4.4-11, S4.4-19–S4.4-23);</b> <b>and </b></text>
<text top="484" left="260" width="7" height="21" font="22">•</text>
<text top="489" left="268" width="4" height="15" font="17"> </text>
<text top="489" left="287" width="227" height="15" font="7"><b>limited alcohol (S4.4-24–S4.4-29). </b></text>
<text top="509" left="255" width="4" height="14" font="13"> </text>
<text top="528" left="255" width="493" height="14" font="13">Adapted from recommendations in the 2017 Hypertension Clinical Practice </text>
<text top="548" left="255" width="131" height="14" font="13">Guidelines (S4.4-1). </text>
<text top="630" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="583" left="175" width="37" height="15" font="7"><b>SBP:  </b></text>
<text top="603" left="185" width="13" height="15" font="7"><b>A </b></text>
<text top="571" left="229" width="13" height="16" font="12"><b>2.</b></text>
<text top="571" left="242" width="5" height="16" font="29"><b> </b></text>
<text top="572" left="255" width="521" height="15" font="7"><b>In  adults  with  an  estimated  10-year  ASCVD  risk*  of  10%  or  higher  and  an </b></text>
<text top="592" left="255" width="521" height="15" font="7"><b>average systolic BP (SBP) of 130 mm Hg or higher or an average diastolic BP </b></text>
<text top="611" left="255" width="521" height="15" font="7"><b>(DBP)  of  80  mm  Hg  or  higher,  use  of  BP-lowering  medications  is </b></text>
<text top="631" left="255" width="431" height="15" font="7"><b>recommended for primary prevention of CVD (S4.4-30–S4.4-38). </b></text>
<text top="650" left="255" width="4" height="14" font="13"> </text>
<text top="670" left="255" width="493" height="14" font="13">Adapted from recommendations in the 2017 Hypertension Clinical Practice </text>
<text top="690" left="255" width="131" height="14" font="13">Guidelines (S4.4-1).<b> </b></text>
<text top="653" left="174" width="39" height="15" font="7"><b>DBP:  </b></text>
<text top="672" left="174" width="36" height="15" font="7"><b>C-EO </b></text>
<text top="760" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="719" left="175" width="37" height="15" font="7"><b>SBP:  </b></text>
<text top="739" left="173" width="23" height="15" font="7"><b>B-R</b></text>
<text top="735" left="196" width="10" height="9" font="30"><b>SR</b></text>
<text top="739" left="207" width="4" height="15" font="7"><b> </b></text>
<text top="710" left="229" width="13" height="16" font="12"><b>3.</b></text>
<text top="710" left="242" width="5" height="16" font="29"><b> </b></text>
<text top="711" left="255" width="521" height="15" font="7"><b>In adults with confirmed hypertension and a 10-year ASCVD event risk of 10% </b></text>
<text top="731" left="255" width="521" height="15" font="7"><b>or higher, a BP target of less than 130/80 mm Hg is recommended (S4.4-33, </b></text>
<text top="751" left="255" width="120" height="15" font="7"><b>S4.4-39–S4.4-42). </b></text>
<text top="770" left="255" width="4" height="14" font="13"> </text>
<text top="790" left="255" width="493" height="14" font="13">Adapted from recommendations in the 2017 Hypertension Clinical Practice </text>
<text top="810" left="255" width="131" height="14" font="13">Guidelines (S4.4-1).<b> </b></text>
<text top="779" left="174" width="39" height="15" font="7"><b>DBP:  </b></text>
<text top="798" left="174" width="36" height="15" font="7"><b>C-EO </b></text>
<text top="870" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="835" left="175" width="37" height="15" font="7"><b>SBP:  </b></text>
<text top="854" left="173" width="23" height="15" font="7"><b>B-R</b></text>
<text top="851" left="196" width="10" height="9" font="30"><b>SR</b></text>
<text top="854" left="207" width="4" height="15" font="7"><b> </b></text>
<text top="830" left="229" width="13" height="16" font="12"><b>4.</b></text>
<text top="830" left="242" width="5" height="16" font="29"><b> </b></text>
<text top="831" left="255" width="521" height="15" font="7"><b>In  adults  with  hypertension  and  chronic  kidney  disease,  treatment  to  a  BP </b></text>
<text top="851" left="255" width="454" height="15" font="7"><b>goal of less than 130/80 mm Hg is recommended (S4.4-43–S4.4-48). </b></text>
<text top="870" left="229" width="4" height="14" font="13"> </text>
<text top="890" left="255" width="493" height="14" font="13">Adapted from recommendations in the 2017 Hypertension Clinical Practice </text>
<text top="910" left="255" width="131" height="14" font="13">Guidelines (S4.4-1).<b> </b></text>
<text top="885" left="174" width="39" height="15" font="7"><b>DBP:  </b></text>
<text top="904" left="174" width="36" height="15" font="7"><b>C-EO </b></text>
<text top="980" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="937" left="175" width="37" height="15" font="7"><b>SBP:  </b></text>
<text top="957" left="173" width="23" height="15" font="7"><b>B-R</b></text>
<text top="954" left="196" width="10" height="9" font="30"><b>SR</b></text>
<text top="957" left="207" width="4" height="15" font="7"><b> </b></text>
<text top="930" left="229" width="13" height="16" font="12"><b>5.</b></text>
<text top="930" left="242" width="5" height="16" font="29"><b> </b></text>
<text top="931" left="255" width="521" height="15" font="7"><b>In  adults  with  T2DM  and  hypertension,  antihypertensive  drug  treatment </b></text>
<text top="951" left="255" width="521" height="15" font="7"><b>should be initiated at a BP of 130/80 mm Hg or higher, with a treatment goal </b></text>
<text top="971" left="255" width="421" height="15" font="7"><b>of less than 130/80 mm Hg (S4.4-33, S4.4-47, S4.4-49–S4.4-54). </b></text>
<text top="990" left="255" width="4" height="14" font="13"> </text>
<text top="1010" left="255" width="493" height="14" font="13">Adapted from recommendations in the 2017 Hypertension Clinical Practice </text>
<text top="1030" left="255" width="131" height="14" font="13">Guidelines (S4.4-1).<b> </b></text>
<text top="997" left="174" width="39" height="15" font="7"><b>DBP:  </b></text>
<text top="1017" left="174" width="36" height="15" font="7"><b>C-EO </b></text>
<text top="1060" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="1060" left="175" width="34" height="15" font="7"><b>C-LD </b></text>
<text top="1050" left="229" width="13" height="16" font="12"><b>6.</b></text>
<text top="1050" left="242" width="5" height="16" font="29"><b> </b></text>
<text top="1051" left="255" width="521" height="15" font="7"><b>In adults with an estimated 10-year ASCVD risk &lt;10% and an SBP of 140 mm </b></text>
<text top="1070" left="255" width="517" height="15" font="7"><b>Hg  or  higher  or  a  DBP  of  90  mm  Hg  or  higher,  initiation  and  use  of  BP-</b></text>
</page>
<page number="39" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 37 of 101 </text>
<text top="168" left="255" width="449" height="15" font="7"><b>lowering medication are recommended (S4.4-36, S4.4-55–S4.4-58). </b></text>
<text top="188" left="255" width="4" height="14" font="13"> </text>
<text top="207" left="255" width="493" height="14" font="13">Adapted from recommendations in the 2017 Hypertension Clinical Practice </text>
<text top="227" left="255" width="131" height="14" font="13">Guidelines (S4.4-1).<b> </b></text>
<text top="297" left="119" width="21" height="15" font="7"><b>IIb </b></text>
<text top="256" left="166" width="47" height="15" font="7"><b>SBP: B-</b></text>
<text top="276" left="180" width="23" height="15" font="7"><b>NR </b></text>
<text top="248" left="229" width="13" height="16" font="12"><b>7.</b></text>
<text top="248" left="242" width="5" height="16" font="29"><b> </b></text>
<text top="249" left="255" width="521" height="15" font="7"><b>In  adults  with  confirmed  hypertension  without  additional  markers  of </b></text>
<text top="268" left="255" width="521" height="15" font="7"><b>increased  ASCVD  risk,  a  BP  target  of  less  than  130/80  mm  Hg  may  be </b></text>
<text top="288" left="255" width="202" height="15" font="7"><b>reasonable (S4.4-59–S4.4-62). </b></text>
<text top="308" left="230" width="4" height="14" font="13"> </text>
<text top="327" left="255" width="493" height="14" font="13">Adapted from recommendations in the 2017 Hypertension Clinical Practice </text>
<text top="347" left="255" width="131" height="14" font="13">Guidelines (S4.4-1).<b> </b></text>
<text top="316" left="165" width="49" height="15" font="7"><b>DBP: C-</b></text>
<text top="336" left="181" width="22" height="15" font="7"><b>EO </b></text>
<text top="367" left="105" width="425" height="13" font="23">*ACC/AHA pooled cohort equations to estimate 10-year risk of ASCVD.  </text>
<text top="385" left="105" width="4" height="14" font="13"> </text>
<text top="404" left="105" width="61" height="15" font="7"><b>Synopsis </b></text>
<text top="424" left="105" width="687" height="14" font="13">In the United States, hypertension accounts  for more ASCVD  deaths than  any other modifiable ASCVD </text>
<text top="444" left="105" width="687" height="14" font="13">risk  factor  (S4.4-63).  The  prevalence  of  hypertension  (defined  as  systolic  blood  pressure  [SBP]  ≥130 </text>
<text top="463" left="105" width="687" height="14" font="13">mm Hg or diastolic blood pressure [DBP] ≥80 mm Hg) among U.S. adults is 46%; is higher in blacks than </text>
<text top="483" left="105" width="687" height="14" font="13">in whites, Asians, and Hispanic Americans; and increases dramatically with increasing age (S4.4-64). In a </text>
<text top="503" left="105" width="687" height="14" font="13">meta-analysis of 61 prospective studies, a log-linear association was observed between SBP levels &lt;115 </text>
<text top="522" left="105" width="687" height="14" font="13">to &gt;180 mm Hg and DBP levels &lt;75 to 105 mm Hg and risk of ASCVD (S4.4-55). In that analysis, 20–mm </text>
<text top="542" left="105" width="687" height="14" font="13">Hg higher SBP and 10–mm Hg higher DBP were each associated with a doubling in the risk of death from </text>
<text top="561" left="105" width="687" height="14" font="13">stroke, heart disease, or other vascular disease. An increased risk of ASCVD associated with higher SBP </text>
<text top="581" left="105" width="687" height="14" font="13">and  DBP  has  been  reported  across  a  broad  age  spectrum,  from  30  to  &gt;80  years  of  age.  Although  the </text>
<text top="600" left="105" width="687" height="14" font="13">relative  risk  of  incident  CVD  associated  with  higher  SBP  and  DBP  is  smaller  at  older  ages,  the </text>
<text top="620" left="105" width="687" height="14" font="13">corresponding high BP-related increase in absolute  risk is larger in older persons (≥65 years) given the </text>
<text top="640" left="105" width="687" height="14" font="13">higher absolute risk of CVD at an older age (S4.4-55). See Figure 4 for the BP thresholds and treatment </text>
<text top="659" left="105" width="687" height="14" font="13">recommendations  algorithm  and  refer  to  the  2017  Hypertension  Clinical  Practice  Guidelines  for </text>
<text top="679" left="105" width="209" height="14" font="13">comprehensive details (S4.4-1). </text>
<text top="699" left="105" width="4" height="14" font="13"> </text>
<text top="718" left="105" width="287" height="15" font="7"><b>Recommendation-Specific Supportive Text </b></text>
<text top="738" left="105" width="687" height="14" font="13">1.  Nonpharmacological  interventions  are  effective  in  lowering  BP  and  may  be  sufficient  to  prevent </text>
<text top="757" left="131" width="661" height="14" font="13">hypertension and to achieve goal BP in some individuals with hypertension, and they are integral in </text>
<text top="777" left="131" width="657" height="14" font="13">the  management  of  those  on  antihypertensive  medication  (S4.4-2,  S4.4-3,  S4.4-6,  S4.4-7,  S4.4-9<b>–</b></text>
<text top="796" left="131" width="661" height="14" font="13">S4.4-11,  S4.4-14,  S4.4-15,  S4.4-19,  S4.4-20,  S4.4-24).  Furthermore,  combining  recommended </text>
<text top="816" left="131" width="661" height="14" font="13">nonpharmacological  interventions  has  been  shown  to  increase  impact  on  BP  reduction  (S4.4-65). </text>
<text top="836" left="131" width="661" height="14" font="13">Nonpharmacological  intervention  is  the  preferred  therapy  for  adults  with  elevated  BP  and  an </text>
<text top="855" left="131" width="661" height="14" font="13">appropriate first-line therapy for adults with stage  1 hypertension who have  an estimated  10-year </text>
<text top="875" left="131" width="661" height="14" font="13">ASCVD  risk  of  &lt;10%.  Adherence  to  and impact  of  nonpharmacological therapy should  be  assessed </text>
<text top="895" left="131" width="597" height="14" font="13">within 3 to 6 months. See Table 7 for recommended goals and approximate impact on SBP. </text>
<text top="914" left="105" width="687" height="14" font="13">2.  Meta-analyses  and  RCTs  provide  evidence  for  the  benefit  of  BP-lowering  medications  on  ASCVD </text>
<text top="934" left="131" width="661" height="14" font="13">prevention  in  adults  with  moderate  to  high  ASCVD  risk  and  SBP  ≥130  mm  Hg  or  DBP  ≥80  mm  Hg </text>
<text top="953" left="131" width="661" height="14" font="13">(S4.4-32,  S4.4-33,  S4.4-36,  S4.4-37,  S4.4-66),  with  significant  outcome  reductions  demonstrated  in </text>
<text top="973" left="131" width="657" height="14" font="13">stroke, heart failure, coronary events, and death. Significant reductions were seen in stroke and all-</text>
<text top="992" left="131" width="661" height="14" font="13">cause death at SBP &lt;130 mm Hg and in stroke at DBP &lt;80 mm Hg (S4.4-37). SPRINT (Systolic Blood </text>
<text top="1012" left="131" width="661" height="14" font="13">Pressure  Intervention  Trial)  provides  additional  support  for  the  use  of  BP-lowering  medications  in </text>
<text top="1032" left="131" width="385" height="14" font="13">patients without CVD at SBP levels ≥130 mm Hg (S4.4-34).  </text>
<text top="1051" left="105" width="4" height="14" font="13"> </text>
<text top="1051" left="131" width="4" height="14" font="13"> </text>
<text top="1051" left="158" width="634" height="14" font="13">Antihypertensive drug treatment that is based on overall ASCVD risk assessment combined with </text>
<text top="1071" left="131" width="657" height="14" font="13">BP levels may prevent more CVD events than treatment that is based on BP levels alone (S4.4-67<b>–</b></text>
</page>
<page number="40" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 38 of 101 </text>
<text top="167" left="131" width="661" height="14" font="13">S4.4-70).  These  meta-analyses  are  consistent  in  concluding  that  lowering  of  BP  results  in  larger </text>
<text top="187" left="131" width="661" height="14" font="13">absolute  risk  reduction  in  higher-risk  individuals,  regardless  of  baseline  treated  or  untreated  BP </text>
<text top="207" left="131" width="661" height="14" font="13">≥130/80 mm Hg and irrespective of the specific cause of elevated risk. These analyses indicate that </text>
<text top="226" left="131" width="578" height="14" font="13">the benefit of treatment outweighs the potential harm at threshold BP ≥130/80 mm Hg. </text>
<text top="246" left="105" width="687" height="14" font="13">3.  Meta-analyses  and  systematic  reviews  of  trials  that  compare  more  intensive  BP  reduction  to </text>
<text top="265" left="131" width="661" height="14" font="13">standard BP reduction report that more intense BP lowering significantly reduces the risk of stroke, </text>
<text top="285" left="131" width="657" height="14" font="13">coronary events, major cardiovascular events, and cardiovascular mortality (S4.4-33, S4.4-39, S4.4-</text>
<text top="305" left="131" width="661" height="14" font="13">47, S4.4-71). Achieving an additional 10–mm Hg reduction in SBP reduced CVD risk when compared </text>
<text top="324" left="131" width="661" height="14" font="13">with an average BP of 158/82 to 143/76 mm Hg, 144/85 to 137/81 mm Hg, and 134/79 to 125/76 </text>
<text top="344" left="131" width="584" height="14" font="13">mm Hg. Patients with diabetes mellitus and CKD were included in the analyses (S4.4-39).  </text>
<text top="363" left="105" width="687" height="14" font="13">4.  Most  patients  with  CKD  have  a  10-year  ASCVD  risk  ≥10%,  requiring  initiation  of  antihypertensive </text>
<text top="383" left="131" width="661" height="14" font="13">drug therapy at BP ≥130/80 mm Hg. In SPRINT, the participants with CKD who were randomized to </text>
<text top="403" left="131" width="661" height="14" font="13">intensive therapy (SBP target &lt;120 mm Hg) derived the same beneficial reduction in CVD events and </text>
<text top="422" left="131" width="661" height="14" font="13">all-cause mortality that was seen among in their counterparts without CKD, with no difference seen </text>
<text top="442" left="131" width="661" height="14" font="13">in the principal renal outcome (S4.4-34). Other RCTs (S4.4-43, S4.4-44) that evaluated the effect of </text>
<text top="461" left="131" width="661" height="14" font="13">differing  BP  goals  on  CKD  progression  in  patients  with  CKD  demonstrated  no  benefit  for  more </text>
<text top="481" left="131" width="661" height="14" font="13">intensive BP reduction, although post hoc follow-up analyses favored lower targets in patients with </text>
<text top="501" left="131" width="661" height="14" font="13">more  severe  proteinuria  (S4.4-72).  These  trials  were  underpowered  to  detect  differences  in  CVD </text>
<text top="520" left="131" width="661" height="14" font="13">event rates. Several meta-analyses and systematic reviews support more intensive BP treatment to </text>
<text top="540" left="131" width="661" height="14" font="13">reduce  cardiovascular  events  but  do  not  demonstrate  a  reduction  in  the  rate  of  progression  of </text>
<text top="559" left="131" width="661" height="14" font="13">kidney  disease  (S4.4-31,  S4.4-33,  S4.4-39).  More  intensive  BP  treatment  may  result  in  a  modest </text>
<text top="579" left="131" width="661" height="14" font="13">reduction  in  glomerular  filtration  rate,  which  is  thought  to  be  primarily  attributable  to  a </text>
<text top="599" left="131" width="661" height="14" font="13">hemodynamic  effect  and  may  be  reversible.  Electrolyte  abnormalities  are  also  more  likely  during </text>
<text top="618" left="131" width="162" height="14" font="13">intensive BP treatment.  </text>
<text top="638" left="105" width="687" height="14" font="13">5.  Most  adults  with  diabetes  mellitus  a  10-year  ASCVD  risk  ≥10%,  requiring  initiation  of </text>
<text top="658" left="131" width="657" height="14" font="13">antihypertensive drug therapy at BP ≥130/80 mm Hg and a treatment goal of &lt;130/80 mm Hg (S4.4-</text>
<text top="677" left="131" width="661" height="14" font="13">73). Several meta-analyses of RCTs included all trials with a difference in BP levels (S4.4-31, S4.4-71) </text>
<text top="697" left="131" width="657" height="14" font="13">and  supported  lowering  BP  to  &lt;130/80  mm Hg  among  those  with  diabetes  mellitus.  Two  meta-</text>
<text top="716" left="131" width="661" height="14" font="13">analyses  addressing  target  BP  in  adults  with  diabetes  mellitus  restricted  the  analysis  to  RCTs  that </text>
<text top="736" left="131" width="661" height="14" font="13">randomized patients to different BP levels (S4.4-33, S4.4-47). Target BP of 133/76 mm Hg provided </text>
<text top="755" left="131" width="661" height="14" font="13">significant benefit compared with that of 140/81 mm Hg for major cardiovascular events, MI, stroke, </text>
<text top="775" left="131" width="345" height="14" font="13">albuminuria, and retinopathy progression (S4.4-33).  </text>
<text top="795" left="105" width="4" height="14" font="13"> </text>
<text top="795" left="131" width="4" height="14" font="13"> </text>
<text top="795" left="158" width="634" height="14" font="13">In  the  ACCORD  (Action  to Control  Cardiovascular  Risk in  Diabetes)  trial (S4.4-51), lowering  the </text>
<text top="814" left="131" width="661" height="14" font="13">BP target (SBP &lt;120 mm Hg) did not reduce the rate of the composite outcome of fatal and nonfatal </text>
<text top="834" left="131" width="657" height="14" font="13">major  cardiovascular  events  and  was  associated  with  greater  risk  of  adverse  events,  such  as  self-</text>
<text top="854" left="131" width="661" height="14" font="13">reported hypotension and a reduction in estimated glomerular filtration rate. Secondary analyses of </text>
<text top="873" left="131" width="661" height="14" font="13">the  ACCORD  trial  demonstrated  a  significant  outcome  benefit  of  stroke  risk  reduction  in  the </text>
<text top="893" left="131" width="324" height="14" font="13">intensive BP/ standard glycemic group (S4.4-74).  </text>
<text top="912" left="105" width="687" height="14" font="13">6.  The  relationship  of  SBP  with  CVD  risk is  continuous  across  levels  of  SBP  and  similar  across  groups </text>
<text top="932" left="131" width="661" height="14" font="13">that differ in level of absolute risk (S4.4-55). The relative risk reduction attributable to BP-lowering </text>
<text top="952" left="131" width="661" height="14" font="13">medication  therapy  is  consistent  across  the  range  of  absolute  risk  observed  in  trials  (S4.4-36), </text>
<text top="971" left="131" width="661" height="14" font="13">suggesting  that  relative  risk  reduction  may  be  similar  at  lower  levels  of  absolute  risk.  Indirect </text>
<text top="991" left="131" width="661" height="14" font="13">support is also provided by evidence from trials using BP-lowering medications to reduce the risk of </text>
<text top="1010" left="131" width="661" height="14" font="13">developing  higher  levels  of  BP  (S4.4-75,  S4.4-76).  In  the  HOPE-3  (Heart  Outcomes  Prevention </text>
<text top="1030" left="131" width="661" height="14" font="13">Evaluation-3)  BP  Trial,  there  was  no  evidence  of  short-term  benefit  during  treatment  of  adults </text>
<text top="1050" left="131" width="661" height="14" font="13">(average  age  66  years)  with  a  relatively  low  risk  of  CVD  (3.8%  CVD  event  rate  during  5.6  years  of </text>
</page>
<page number="41" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 39 of 101 </text>
<text top="167" left="131" width="661" height="14" font="13">follow-up). However, subgroup analysis suggested benefit in those with an average SBP &gt;140 mm Hg </text>
<text top="187" left="131" width="446" height="14" font="13">(and a CVD risk of 6.5% during the 5.6 years of follow-up) (S4.4-59).  </text>
<text top="207" left="105" width="687" height="14" font="13">7.  The  treatment  of  patients  with  hypertension  without  elevated  risk  has  been  systematically </text>
<text top="226" left="131" width="661" height="14" font="13">understudied  because  lower-risk  groups  would  require  prolonged  follow-up  to  have  a  sufficient </text>
<text top="246" left="131" width="661" height="14" font="13">number of clinical events to provide useful outcomes data. Although there is clinical trial evidence </text>
<text top="265" left="131" width="661" height="14" font="13">that both drug and nondrug therapy will interrupt the progressive course of hypertension, there is </text>
<text top="285" left="131" width="661" height="14" font="13">no  trial  evidence  that  this  treatment  decreases  CVD  morbidity  and  mortality.  The  clinical  trial </text>
<text top="305" left="131" width="661" height="14" font="13">evidence is strongest for a target BP of 140/90 mm Hg in  this population. However,  observational </text>
<text top="324" left="131" width="661" height="14" font="13">studies  suggest  that  these  individuals  often  have  a  high  lifetime  risk  and  would  benefit  from  BP </text>
<text top="344" left="131" width="202" height="14" font="13">control earlier in life (S4.4-77). </text>
<text top="363" left="105" width="4" height="14" font="13"> </text>
<text top="383" left="105" width="4" height="14" font="13"> </text>
<text top="402" left="105" width="414" height="15" font="7"><b>Figure 4.</b> <b>BP Thresholds and Recommendations for Treatment </b></text>
<text top="422" left="105" width="4" height="15" font="7"><b> </b></text>
<text top="659" left="788" width="4" height="15" font="7"><b> </b></text>
<text top="674" left="105" width="4" height="14" font="13"> </text>
<text top="693" left="105" width="349" height="13" font="23">Colors correspond to Class of Recommendation in Table 1. </text>
<text top="711" left="105" width="369" height="13" font="23">BP indicates blood pressure; and CVD, cardiovascular disease. </text>
<text top="729" left="105" width="687" height="13" font="23">Adapted  with  permission  from  Whelton  et  al.  (S4.4-1).  Copyright  ©  2017,  American  College  of  Cardiology </text>
<text top="747" left="105" width="316" height="13" font="23">Foundation and the American Heart Association, Inc. </text>
<text top="765" left="105" width="3" height="13" font="23"> </text>
<text top="783" left="105" width="4" height="14" font="13"> </text>
<text top="802" left="105" width="4" height="15" font="7"><b> </b></text>
<text top="802" left="315" width="4" height="15" font="7"><b> </b></text>
</page>
<page number="42" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 40 of 101 </text>
<text top="167" left="105" width="595" height="15" font="7"><b>Table 7. Best Proven Nonpharmacological Interventions for Prevention and Treatment of </b></text>
<text top="187" left="105" width="102" height="15" font="7"><b>Hypertension* </b></text>
<text top="239" left="105" width="4" height="15" font="7"><b> </b></text>
<text top="220" left="199" width="142" height="15" font="7"><b>Nonpharmacological </b></text>
<text top="239" left="226" width="87" height="15" font="7"><b>Intervention </b></text>
<text top="239" left="399" width="34" height="15" font="7"><b>Goal </b></text>
<text top="219" left="545" width="190" height="15" font="7"><b>Approximate Impact on SBP </b></text>
<text top="239" left="492" width="206" height="15" font="7"><b>Hypertension  Normotension </b></text>
<text top="239" left="714" width="71" height="15" font="7"><b>Reference </b></text>
<text top="260" left="105" width="205" height="14" font="13">Weight loss<b>  </b>Weight/body fat<b> </b></text>
<text top="260" left="352" width="112" height="14" font="13">Best goal is ideal </text>
<text top="280" left="352" width="115" height="14" font="13">body weight, but </text>
<text top="299" left="352" width="113" height="14" font="13">aim for at least a </text>
<text top="319" left="352" width="114" height="14" font="13">1-kg reduction in </text>
<text top="338" left="352" width="107" height="14" font="13">body weight for </text>
<text top="358" left="352" width="112" height="14" font="13">most adults who </text>
<text top="378" left="352" width="107" height="14" font="13">are overweight. </text>
<text top="397" left="352" width="101" height="14" font="13">Expect about 1 </text>
<text top="417" left="352" width="113" height="14" font="13">mm Hg for every </text>
<text top="436" left="352" width="114" height="14" font="13">1-kg reduction in </text>
<text top="456" left="352" width="88" height="14" font="13">body weight.<b> </b></text>
<text top="260" left="492" width="67" height="14" font="13">-5 mm Hg<b> </b></text>
<text top="260" left="598" width="82" height="14" font="13">-2/3 mm Hg<b> </b></text>
<text top="260" left="710" width="54" height="14" font="13">(S4.4-2)<b> </b></text>
<text top="476" left="105" width="54" height="14" font="13">Healthy </text>
<text top="496" left="105" width="29" height="14" font="13">diet<b> </b></text>
<text top="476" left="199" width="90" height="14" font="13">DASH dietary </text>
<text top="496" left="199" width="61" height="14" font="13">pattern†<b> </b></text>
<text top="476" left="352" width="105" height="14" font="13">Consume a diet </text>
<text top="496" left="352" width="86" height="14" font="13">rich in fruits, </text>
<text top="515" left="352" width="122" height="14" font="13">vegetables, whole </text>
<text top="535" left="352" width="125" height="14" font="13">grains, and low-fat </text>
<text top="555" left="352" width="102" height="14" font="13">dairy products, </text>
<text top="574" left="352" width="90" height="14" font="13">with reduced </text>
<text top="594" left="352" width="72" height="14" font="13">content of </text>
<text top="613" left="352" width="95" height="14" font="13">saturated and </text>
<text top="633" left="352" width="60" height="14" font="13">total fat.<b> </b></text>
<text top="476" left="492" width="75" height="14" font="13">-11 mm Hg<b> </b></text>
<text top="476" left="598" width="67" height="14" font="13">-3 mm Hg<b> </b></text>
<text top="476" left="710" width="53" height="14" font="13">(S4.4-7, </text>
<text top="496" left="710" width="49" height="14" font="13">S4.4-8)<b> </b></text>
<text top="653" left="105" width="61" height="14" font="13">Reduced </text>
<text top="673" left="105" width="61" height="14" font="13">intake of </text>
<text top="693" left="105" width="50" height="14" font="13">dietary </text>
<text top="712" left="105" width="52" height="14" font="13">sodium<b> </b></text>
<text top="653" left="199" width="103" height="14" font="13">Dietary sodium<b> </b></text>
<text top="653" left="352" width="101" height="14" font="13">Optimal goal is </text>
<text top="673" left="352" width="113" height="14" font="13">&lt;1500 mg/d, but </text>
<text top="693" left="352" width="113" height="14" font="13">aim for at least a </text>
<text top="712" left="352" width="76" height="14" font="13">1000-mg/d </text>
<text top="732" left="352" width="119" height="14" font="13">reduction in most </text>
<text top="751" left="352" width="48" height="14" font="13">adults.<b> </b></text>
<text top="653" left="492" width="82" height="14" font="13">-5/6 mm Hg<b> </b></text>
<text top="653" left="598" width="82" height="14" font="13">-2/3 mm Hg<b> </b></text>
<text top="653" left="710" width="62" height="14" font="13">(S4.4-10, </text>
<text top="673" left="710" width="57" height="14" font="13">S4.4-12)<b> </b></text>
<text top="772" left="105" width="68" height="14" font="13">Enhanced </text>
<text top="791" left="105" width="61" height="14" font="13">intake of </text>
<text top="811" left="105" width="50" height="14" font="13">dietary </text>
<text top="831" left="105" width="71" height="14" font="13">potassium<b> </b></text>
<text top="772" left="199" width="122" height="14" font="13">Dietary potassium<b> </b></text>
<text top="772" left="352" width="93" height="14" font="13">Aim for 3500–</text>
<text top="791" left="352" width="79" height="14" font="13">5000 mg/d, </text>
<text top="811" left="352" width="91" height="14" font="13">preferably by </text>
<text top="831" left="352" width="118" height="14" font="13">consumption of a </text>
<text top="850" left="352" width="73" height="14" font="13">diet rich in </text>
<text top="870" left="352" width="75" height="14" font="13">potassium.<b> </b></text>
<text top="772" left="492" width="82" height="14" font="13">-4/5 mm Hg<b> </b></text>
<text top="772" left="598" width="67" height="14" font="13">-2 mm Hg<b> </b></text>
<text top="772" left="710" width="62" height="14" font="13">(S4.4-14)<b> </b></text>
<text top="890" left="105" width="4" height="14" font="13"> </text>
<text top="890" left="315" width="4" height="14" font="13"> </text>
</page>
<page number="43" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 41 of 101 </text>
<text top="168" left="105" width="56" height="14" font="13">Physical </text>
<text top="188" left="105" width="51" height="14" font="13">activity<b> </b></text>
<text top="168" left="199" width="54" height="14" font="13">Aerobic<b> </b></text>
<text top="164" left="352" width="7" height="21" font="22">•</text>
<text top="169" left="360" width="4" height="15" font="17"> </text>
<text top="169" left="379" width="53" height="14" font="13">90–150 </text>
<text top="189" left="379" width="54" height="14" font="13">min/wk </text>
<text top="204" left="352" width="7" height="21" font="22">•</text>
<text top="209" left="360" width="4" height="15" font="17"> </text>
<text top="209" left="379" width="67" height="14" font="13">65%–75% </text>
<text top="229" left="379" width="69" height="14" font="13">heart rate </text>
<text top="248" left="379" width="52" height="14" font="13">reserve<b> </b></text>
<text top="168" left="492" width="82" height="14" font="13">-5/8 mm Hg<b> </b></text>
<text top="168" left="598" width="82" height="14" font="13">-2/4 mm Hg<b> </b></text>
<text top="168" left="710" width="62" height="14" font="13">(S4.4-19, </text>
<text top="188" left="710" width="57" height="14" font="13">S4.4-20)<b> </b></text>
<text top="269" left="105" width="4" height="14" font="13"> </text>
<text top="269" left="199" width="130" height="14" font="13">Dynamic resistance<b> </b></text>
<text top="265" left="352" width="7" height="21" font="22">•</text>
<text top="269" left="360" width="4" height="15" font="17"> </text>
<text top="269" left="379" width="53" height="14" font="13">90–150 </text>
<text top="289" left="379" width="54" height="14" font="13">min/wk </text>
<text top="305" left="352" width="7" height="21" font="22">•</text>
<text top="309" left="360" width="4" height="15" font="17"> </text>
<text top="309" left="379" width="79" height="14" font="13">50%–80% 1 </text>
<text top="329" left="379" width="95" height="14" font="13">rep maximum </text>
<text top="345" left="352" width="7" height="21" font="22">•</text>
<text top="350" left="360" width="4" height="15" font="17"> </text>
<text top="350" left="379" width="91" height="14" font="13">6 exercises, 3 </text>
<text top="369" left="379" width="93" height="14" font="13">sets/exercise, </text>
<text top="389" left="379" width="20" height="14" font="13">10 </text>
<text top="408" left="379" width="97" height="14" font="13">repetitions/set</text>
<text top="408" left="476" width="4" height="15" font="7"><b> </b></text>
<text top="269" left="492" width="67" height="14" font="13">-4 mm Hg<b> </b></text>
<text top="269" left="598" width="67" height="14" font="13">-2 mm Hg<b> </b></text>
<text top="269" left="710" width="62" height="14" font="13">(S4.4-19)<b> </b></text>
<text top="429" left="105" width="4" height="14" font="13"> </text>
<text top="429" left="199" width="135" height="14" font="13">Isometric resistance<b> </b></text>
<text top="425" left="352" width="7" height="21" font="22">•</text>
<text top="430" left="360" width="4" height="15" font="17"> </text>
<text top="430" left="379" width="64" height="14" font="13">4 × 2 min </text>
<text top="449" left="379" width="91" height="14" font="13">(hand grip), 1 </text>
<text top="469" left="379" width="58" height="14" font="13">min rest </text>
<text top="488" left="379" width="62" height="14" font="13">between </text>
<text top="508" left="379" width="68" height="14" font="13">exercises, </text>
<text top="528" left="379" width="67" height="14" font="13">30%–40% </text>
<text top="547" left="379" width="69" height="14" font="13">maximum </text>
<text top="567" left="379" width="66" height="14" font="13">voluntary </text>
<text top="586" left="379" width="95" height="14" font="13">contraction, 3 </text>
<text top="606" left="379" width="82" height="14" font="13">sessions/wk </text>
<text top="622" left="352" width="7" height="21" font="22">•</text>
<text top="627" left="360" width="4" height="15" font="17"> </text>
<text top="627" left="379" width="59" height="14" font="13">8–10 wk<b> </b></text>
<text top="429" left="492" width="67" height="14" font="13">-5 mm Hg<b> </b></text>
<text top="429" left="598" width="67" height="14" font="13">-4 mm Hg<b> </b></text>
<text top="429" left="710" width="62" height="14" font="13">(S4.4-21, </text>
<text top="448" left="710" width="57" height="14" font="13">S4.4-78)<b> </b></text>
<text top="647" left="105" width="82" height="14" font="13">Moderation </text>
<text top="666" left="105" width="67" height="14" font="13">in alcohol </text>
<text top="686" left="105" width="44" height="14" font="13">intake<b> </b></text>
<text top="647" left="199" width="52" height="14" font="13">Alcohol </text>
<text top="666" left="199" width="89" height="14" font="13">consumption </text>
<text top="647" left="352" width="121" height="14" font="13">In individuals who </text>
<text top="666" left="352" width="92" height="14" font="13">drink alcohol, </text>
<text top="686" left="352" width="96" height="14" font="13">reduce alcohol</text>
<text top="687" left="449" width="7" height="13" font="23">‡</text>
<text top="686" left="456" width="4" height="14" font="13"> </text>
<text top="706" left="352" width="22" height="14" font="13">to: </text>
<text top="721" left="352" width="7" height="21" font="22">•</text>
<text top="726" left="360" width="4" height="15" font="17"> </text>
<text top="726" left="379" width="58" height="14" font="13">Men: ≤2 </text>
<text top="746" left="379" width="78" height="14" font="13">drinks daily </text>
<text top="762" left="352" width="7" height="21" font="22">•</text>
<text top="766" left="360" width="4" height="15" font="17"> </text>
<text top="766" left="379" width="80" height="14" font="13">Women: ≤1 </text>
<text top="786" left="379" width="71" height="14" font="13">drink daily </text>
<text top="647" left="492" width="67" height="14" font="13">-4 mm Hg </text>
<text top="647" left="598" width="67" height="14" font="13">-3 mm Hg </text>
<text top="647" left="710" width="62" height="14" font="13">(S4.4-20, </text>
<text top="666" left="710" width="57" height="14" font="13">S4.4-24, </text>
<text top="686" left="710" width="57" height="14" font="13">S4.4-25) </text>
<text top="806" left="105" width="542" height="13" font="23">*Type, dose, and expected impact on BP in adults with a normal BP and with hypertension. </text>
<text top="824" left="105" width="631" height="13" font="23">†Detailed information about the DASH diet is available via the NHLBI (S4.4-81) and Dashdiet.org (S4.4-82). </text>
<text top="842" left="105" width="687" height="13" font="23">‡In the United States, 1 “standard” drink contains roughly 14 g of pure alcohol, which is typically found in 12 oz of </text>
<text top="859" left="105" width="687" height="13" font="23">regular  beer  (usually  about  5%  alcohol),  5  oz  of  wine  (usually  about  12%  alcohol),  and  1.5  oz  of  distilled  spirits </text>
<text top="877" left="105" width="227" height="13" font="23">(usually about 40% alcohol) (S4.4-80). </text>
<text top="895" left="105" width="687" height="13" font="23">BP  indicates  blood  pressure;  DASH,  Dietary  Approaches  to  Stop  Hypertension;  NHLBI,  National  Heart,  Lung,  and </text>
<text top="913" left="105" width="292" height="13" font="23">Blood Institute; and SBP, systolic blood pressure. </text>
<text top="931" left="105" width="687" height="13" font="23">Reproduced  with  permission  from  Whelton  et  al.  (S4.4-1).  Copyright  ©  2017,  American  College  of  Cardiology </text>
<text top="948" left="105" width="316" height="13" font="23">Foundation and the American Heart Association, Inc. </text>
<text top="966" left="105" width="3" height="13" font="23"> </text>
<text top="984" left="105" width="4" height="14" font="13"> </text>
<text top="1005" left="105" width="5" height="20" font="20"><b> </b></text>
<text top="1005" left="315" width="5" height="20" font="20"><b> </b></text>
</page>
<page number="44" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 42 of 101 </text>
<text top="169" left="105" width="283" height="20" font="20"><b>4.5. Treatment of Tobacco Use </b></text>
<text top="195" left="275" width="331" height="15" font="7"><b>Recommendations for Treatment of Tobacco Use </b></text>
<text top="215" left="115" width="651" height="14" font="13">Referenced studies that support recommendations are summarized in Online Data Supplements 15 </text>
<text top="234" left="414" width="52" height="14" font="13">and 16. </text>
<text top="254" left="113" width="32" height="15" font="7"><b>COR </b></text>
<text top="254" left="177" width="29" height="15" font="7"><b>LOE </b></text>
<text top="254" left="439" width="129" height="15" font="7"><b>Recommendations </b></text>
<text top="294" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="294" left="185" width="13" height="15" font="7"><b>A </b></text>
<text top="275" left="231" width="13" height="15" font="7"><b>1.</b></text>
<text top="275" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="275" left="257" width="519" height="15" font="7"><b>All  adults  should  be  assessed  at  every  healthcare  visit  for  tobacco  use  and </b></text>
<text top="294" left="257" width="519" height="15" font="7"><b>their  tobacco  use  status  recorded  as  a  vital  sign  to  facilitate  tobacco </b></text>
<text top="314" left="257" width="125" height="15" font="7"><b>cessation (S4.5-1). </b></text>
<text top="344" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="344" left="185" width="13" height="15" font="7"><b>A </b></text>
<text top="334" left="231" width="13" height="15" font="7"><b>2.</b></text>
<text top="334" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="334" left="257" width="519" height="15" font="7"><b>To  achieve tobacco abstinence, all  adults who use tobacco should be firmly </b></text>
<text top="354" left="257" width="162" height="15" font="7"><b>advised to quit (S4.5-2). </b></text>
<text top="384" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="384" left="185" width="13" height="15" font="7"><b>A </b></text>
<text top="374" left="231" width="13" height="15" font="7"><b>3.</b></text>
<text top="374" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="374" left="257" width="519" height="15" font="7"><b>In  adults  who  use  tobacco,  a  combination  of  behavioral  interventions  plus </b></text>
<text top="394" left="257" width="499" height="15" font="7"><b>pharmacotherapy is recommended to maximize quit rates (S4.5-2, S4.5-3). </b></text>
<text top="424" left="125" width="8" height="15" font="7"><b>I </b></text>
<text top="424" left="173" width="37" height="15" font="7"><b>B-NR </b></text>
<text top="414" left="231" width="13" height="15" font="7"><b>4.</b></text>
<text top="414" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="414" left="257" width="519" height="15" font="7"><b>In  adults  who  use  tobacco,  tobacco  abstinence  is  recommended  to  reduce </b></text>
<text top="434" left="257" width="188" height="15" font="7"><b>ASCVD risk (S4.5-4, S4.5-5).  </b></text>
<text top="464" left="119" width="20" height="15" font="7"><b>IIa </b></text>
<text top="464" left="178" width="27" height="15" font="7"><b>B-R </b></text>
<text top="454" left="231" width="13" height="15" font="7"><b>5.</b></text>
<text top="454" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="454" left="257" width="519" height="15" font="7"><b>To  facilitate  tobacco  cessation,  it  is  reasonable  to  dedicate  trained  staff  to </b></text>
<text top="474" left="257" width="370" height="15" font="7"><b>tobacco treatment in every healthcare system (S4.5-1). </b></text>
<text top="494" left="119" width="21" height="15" font="7"><b>III: </b></text>
<text top="513" left="109" width="41" height="15" font="7"><b>Harm </b></text>
<text top="504" left="173" width="37" height="15" font="7"><b>B-NR </b></text>
<text top="494" left="231" width="13" height="15" font="7"><b>6.</b></text>
<text top="494" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="494" left="257" width="519" height="15" font="7"><b>All  adults  and  adolescents  should  avoid  secondhand  smoke  exposure  to </b></text>
<text top="513" left="257" width="185" height="15" font="7"><b>reduce ASCVD risk (S4.5-6). </b></text>
<text top="534" left="105" width="4" height="14" font="13"> </text>
<text top="553" left="105" width="61" height="15" font="7"><b>Synopsis </b></text>
<text top="573" left="105" width="683" height="14" font="13">Tobacco use is the leading preventable cause of disease, disability, and death in the United States (S4.5-</text>
<text top="593" left="105" width="687" height="14" font="13">7). Smoking and smokeless tobacco (e.g., chewing tobacco) use increases the risk of all-cause mortality </text>
<text top="612" left="105" width="687" height="14" font="13">and is a cause of ASCVD (S4.5-4, S4.5-5). Secondhand smoke is a cause of ASCVD and stroke (S4.5-6), and </text>
<text top="632" left="105" width="687" height="14" font="13">almost one-third of CHD deaths are attributable to smoking and exposure to secondhand smoke. Even </text>
<text top="652" left="105" width="687" height="14" font="13">low levels of smoking increase risks of acute MI; thus, reducing the number of cigarettes per day does </text>
<text top="671" left="105" width="687" height="14" font="13">not totally eliminate risk (S4.5-8). Healthy People 2020 recommends that cessation treatment in clinical </text>
<text top="691" left="105" width="687" height="14" font="13">care  settings  be  expanded,  with  access  to  proven  cessation  treatment  provided  to  all  tobacco  users </text>
<text top="710" left="105" width="687" height="14" font="13">(S4.5-9). Electronic Nicotine Delivery Systems (ENDS), often called e-cigarettes (S4.5-10), are a new class </text>
<text top="730" left="105" width="687" height="14" font="13">of tobacco product that emit aerosol containing fine and ultrafine particulates, nicotine, and toxic gases </text>
<text top="749" left="105" width="687" height="14" font="13">that  may  increase  risk  of  cardiovascular  and  pulmonary  diseases  (S4.5-11).  Arrhythmias  and </text>
<text top="769" left="105" width="687" height="14" font="13">hypertension  with  e-cigarette  use  have  also  been  reported  (S4.5-12).  Chronic  use  is  associated  with </text>
<text top="789" left="105" width="683" height="14" font="13">persistent increases in oxidative stress and sympathetic stimulation in young, healthy subjects (S4.5-13). </text>
<text top="808" left="105" width="4" height="14" font="13"> </text>
<text top="828" left="105" width="287" height="15" font="7"><b>Recommendation-Specific Supportive Text </b></text>
<text top="848" left="105" width="687" height="14" font="13">1.  On  the  basis  of  on  the U.S. Public  Health  Service’s  Clinical Practice Guideline  for  Treating  Tobacco </text>
<text top="867" left="131" width="661" height="14" font="13">Use  and  Dependence  (S4.5-14,  S4.5-15),  the  USPSTF  recommended  (Grade  A)  in  2003  and </text>
<text top="887" left="131" width="661" height="14" font="13">reaffirmed  in  2009  that  clinicians  ask  all  adults  about  tobacco  use  (S4.5-2).  Treating  tobacco  use </text>
<text top="906" left="131" width="661" height="14" font="13">status as a vital sign and recording tobacco use status in the health record at every healthcare visit </text>
<text top="926" left="131" width="661" height="14" font="13">not  only  increases  the  rate  of  tobacco  treatment  but  also  improves  tobacco  abstinence  (S4.5-15, </text>
<text top="946" left="131" width="661" height="14" font="13">S4.5-16).  Office-wide  screening  systems  (e.g.,  chart  stickers,  computer  prompts)  that  expand  the </text>
<text top="965" left="131" width="661" height="14" font="13">vital  signs  to  include  tobacco  use  status  (current,  former,  never)  can  facilitate  tobacco  cessation </text>
<text top="985" left="131" width="661" height="14" font="13">(S4.5-15). Because many people who use tobacco do not report it, using multiple questions to assess </text>
<text top="1005" left="131" width="661" height="14" font="13">tobacco use status may improve accuracy and disclosure. For example, clinicians <i>should ask</i>, “Have </text>
<text top="1024" left="131" width="661" height="14" font="13">you smoked any tobacco product in the past 30 days, even a puff?” “Have you vaped or ‘juuled’ in </text>
<text top="1044" left="131" width="661" height="14" font="13">the past 30 days, even a puff?” “Have you used any other tobacco product in the past 30 days?” If </text>
<text top="1063" left="131" width="661" height="14" font="13">these  questions  are  answered  with  “yes,”  the  patient  is  considered  a  current  smoker.  Clinicians </text>
</page>
<page number="45" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 43 of 101 </text>
<text top="167" left="131" width="661" height="14" font="13">should  <i>avoid  asking</i>  “Are  you  a  smoker?”  or  “Do  you  smoke?”  because  people  are  less  likely  to </text>
<text top="187" left="131" width="348" height="14" font="13">report tobacco use when asked in this way (S4.5-17). </text>
<text top="207" left="105" width="687" height="14" font="13">2.  Tobacco users are more likely to quit after 6 months when clinicians strongly advise adults to quit </text>
<text top="226" left="131" width="661" height="14" font="13">using tobacco than when clinicians give no advice or usual care (S4.5-2). To help patients quit, it is </text>
<text top="246" left="131" width="661" height="14" font="13">critically important to use language that is clear and strong, yet compassionate, nonjudgmental, and </text>
<text top="265" left="131" width="661" height="14" font="13">personalized, to urge every tobacco user to quit (S4.5-15). For example, “The most important thing </text>
<text top="285" left="131" width="661" height="14" font="13">you can do for your health is to quit tobacco use. I (we) can help.” The ASCVD benefits of quitting </text>
<text top="305" left="131" width="661" height="14" font="13">are immediate (S4.5-18). The  best  and most effective treatments are those  that are  acceptable to </text>
<text top="324" left="131" width="661" height="14" font="13">and feasible for an individual patient; clinicians should consider the patient’s specific medical history </text>
<text top="344" left="131" width="657" height="14" font="13">and preferences and offer to provide tailored strategies that work best for the patient (S4.5-3, S4.5-</text>
<text top="363" left="131" width="29" height="14" font="13">19). </text>
<text top="383" left="105" width="687" height="14" font="13">3.  In  alignment  with  previous  expert  consensus  regarding  strategies  for  tobacco  cessation  (S4.5-19), </text>
<text top="403" left="131" width="661" height="14" font="13">Table  8  summarizes  recommended  behavioral  interventions  and  pharmacotherapy  for  tobacco </text>
<text top="422" left="131" width="661" height="14" font="13">treatment.  There  are  7  FDA-approved  cessation  medications,  including  5  forms  of  nicotine </text>
<text top="442" left="131" width="661" height="14" font="13">replacement. <i>Note that the black box warnings about neuropsychiatric events have been removed by </i></text>
<text top="461" left="131" width="55" height="14" font="14"><i>the FDA </i></text>
<text top="461" left="187" width="605" height="14" font="13">(S4.5-20, 4.5-21). The net benefit of FDA-approved tobacco-cessation pharmacotherapy and </text>
<text top="481" left="131" width="661" height="14" font="13">behavioral  interventions  (even  just  3  minutes  of  practical  advice),  alone  or  combined,  in </text>
<text top="501" left="131" width="661" height="14" font="13">nonpregnant  adults  (≥18  years  of  age)  who  smoke  is  substantial.  The  net  benefit  of  behavioral </text>
<text top="520" left="131" width="661" height="14" font="13">interventions  for  tobacco  cessation  on  perinatal  outcomes  and  smoking  abstinence  in  pregnant </text>
<text top="540" left="131" width="661" height="14" font="13">women  who  smoke  is  substantial.  However,  the  evidence  on  pharmacotherapy  for  tobacco </text>
<text top="559" left="131" width="661" height="14" font="13">cessation  in  pregnant  women  is  insufficient;  the  balance  of  benefits  and  harms  cannot  be </text>
<text top="579" left="131" width="661" height="14" font="13">determined.  Among  hospitalized  adults  who  use  tobacco,  intensive  counseling  with  continued </text>
<text top="599" left="131" width="629" height="14" font="13">supportive follow-up contacts for at least one month after discharge is recommended (S4.5-22). </text>
<text top="618" left="105" width="4" height="14" font="13"> </text>
<text top="618" left="131" width="4" height="14" font="13"> </text>
<text top="618" left="158" width="634" height="14" font="13">ENDS  are  not  recommended  as  a  tobacco  treatment  method.  The  evidence  is  unclear  about </text>
<text top="638" left="131" width="661" height="14" font="13">whether ENDS are useful or effective for tobacco treatment, and they may be potentially harmful. </text>
<text top="658" left="131" width="661" height="14" font="13">The evidence on the use of ENDS as a smoking-cessation tool in adults (including pregnant women) </text>
<text top="677" left="131" width="661" height="14" font="13">and adolescents is insufficient (S4.5-23) or limited (S4.5-24). The USPSTF recommends that clinicians </text>
<text top="697" left="131" width="661" height="14" font="13">direct patients  who smoke tobacco  to  other cessation interventions with established effectiveness </text>
<text top="716" left="131" width="75" height="14" font="13">and safety. </text>
<text top="736" left="105" width="687" height="14" font="13">4.  Cigarette smoking remains a strong, independent risk factor for ASCVD events and premature death </text>
<text top="755" left="131" width="661" height="14" font="13">(S4.5-4).  Even  among  older  adults,  tobacco  cessation  is  beneficial  in  reducing  excess  risk  (S4.5-5). </text>
<text top="775" left="131" width="661" height="14" font="13">The risk of heart failure and death for most former smokers is similar to that of never smokers after </text>
<text top="795" left="131" width="661" height="14" font="13">&gt;15  years  of  tobacco  cessation  (S4.5-25).  In  the  National  Health  Interview  Survey,  smoking  was </text>
<text top="814" left="131" width="661" height="14" font="13">strongly associated with ASCVD in young people after adjustment for multiple risk factors (S4.5-26), </text>
<text top="834" left="131" width="397" height="14" font="13">which is why abstinence from an early age is recommended. </text>
<text top="854" left="105" width="687" height="14" font="13">5.  Tobacco  use  dependence  is  a  chronic  disease  that  requires  highly  skilled  chronic  disease </text>
<text top="873" left="131" width="661" height="14" font="13">management.  It  is  a  reasonable  expectation  that  every  health  system  or  practice  should  dedicate </text>
<text top="893" left="131" width="661" height="14" font="13">trained  staff  to  tobacco  treatment.  Healthcare  professionals  who  receive  training  in  tobacco </text>
<text top="912" left="131" width="661" height="14" font="13">treatment  are  more  likely  to  ask  about  tobacco  use,  offer  advice  to  quit,  provide  behavioral </text>
<text top="932" left="131" width="657" height="14" font="13">interventions, follow up with individuals, and increase the number of tobacco users who quit (S4.5-</text>
<text top="952" left="131" width="661" height="14" font="13">1).  Participants  who  earn  a  certificate  in  tobacco  treatment  practice  demonstrate  a  nationally </text>
<text top="971" left="131" width="661" height="14" font="13">recognized level of training and skill acquisition in treating tobacco dependence (s4.5-27). A Tobacco </text>
<text top="991" left="131" width="661" height="14" font="13">Treatment  Specialist is a professional who possesses the skills,  knowledge, and training to  provide </text>
<text top="1010" left="131" width="657" height="14" font="13">effective, evidence-based interventions for tobacco dependence across a range of intensities (S4.5-</text>
<text top="1030" left="131" width="661" height="14" font="13">28).  A  list  of  accredited  Tobacco  Treatment  Specialist  programs  is  available  here: </text>
<text top="1050" left="131" width="314" height="14" font="13">http://ctttp.org/accredited-programs (S4.5-29). </text>
</page>
<page number="46" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 44 of 101 </text>
<text top="167" left="105" width="687" height="14" font="13">6.  Secondhand  smoke  exposure  is  known  to  cause  CVD  (S4.5-6)  and  stroke  (S4.5-16)  in  nonsmokers, </text>
<text top="187" left="131" width="661" height="14" font="13">and  it can lead to immediate  adverse events (S4.5-30). There is  no safe lower limit of exposure to </text>
<text top="207" left="131" width="661" height="14" font="13">secondhand smoke (S4.5-31). Even brief exposure to secondhand smoke can trigger an MI (S4.5-30, </text>
<text top="226" left="131" width="661" height="14" font="13">S4.5-32).  Even  though  exposure  to  secondhand  smoke  has  steadily  decreased  over  time,  certain </text>
<text top="246" left="131" width="661" height="14" font="13">subgroups remain exposed to secondhand smoke in homes, vehicles, public places, and workplaces. </text>
<text top="265" left="131" width="661" height="14" font="13">It  is  estimated  that  41,000  preventable  deaths  per  year  occur  in  adult  nonsmokers  as  a  result  of </text>
<text top="285" left="131" width="661" height="14" font="13">exposure to secondhand smoke (S4.5-33). The U.S. Department of Housing and Urban Development </text>
<text top="305" left="131" width="660" height="14" font="13">prohibited  the  use  of  combustible  tobacco  products  in  all  public  housing  living  units,  indoor </text>
<text top="324" left="131" width="661" height="14" font="13">common areas, and public housing agency administrative office buildings, extending to all outdoor </text>
<text top="344" left="131" width="661" height="14" font="13">areas  up  to  25  feet  from  public  housing  buildings  (S4.5-34).  Therefore,  the  present  writing </text>
<text top="363" left="131" width="661" height="14" font="13">committee  recommends  that  clinicians  advise  patients  to  take  precautions  against  exposure  to </text>
<text top="383" left="131" width="661" height="14" font="13">secondhand  smoke  and  aerosol  from  all  tobacco  products,  such  as  by  instituting  smoking </text>
<text top="403" left="131" width="661" height="14" font="13">restrictions  (including  ENDS)  inside  all  homes  and  vehicles  and  within  25  feet  from  all  entryways, </text>
<text top="422" left="131" width="66" height="14" font="13">windows, </text>
<text top="422" left="353" width="28" height="14" font="13">and </text>
<text top="422" left="537" width="56" height="14" font="13">building </text>
<text top="422" left="749" width="40" height="14" font="13">vents.</text>
</page>
<page number="47" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 45 of 101 </text>
<text top="167" left="105" width="687" height="15" font="7"><b>Table 8. Highlights of Recommended Behavioral and Pharmacotherapy Tobacco Treatment Modalities </b></text>
<text top="187" left="105" width="109" height="15" font="7"><b>for Prescribers* </b></text>
<text top="215" left="104" width="220" height="13" font="26"><b>Timing of Behavioral Interventions† </b></text>
<text top="243" left="104" width="221" height="13" font="23">&lt;3 min of tobacco status assessment </text>
<text top="261" left="104" width="202" height="13" font="23">with cessation counseling at each </text>
<text top="279" left="104" width="98" height="13" font="23">clinic encounter<b> </b></text>
<text top="243" left="341" width="168" height="13" font="23">&gt;3-10 min of tobacco status </text>
<text top="261" left="341" width="227" height="13" font="23">assessment with cessation counseling </text>
<text top="279" left="341" width="145" height="13" font="23">at each clinic encounter<b> </b></text>
<text top="243" left="584" width="157" height="13" font="23">&gt;10 min of tobacco status </text>
<text top="261" left="584" width="160" height="13" font="23">assessment with cessation </text>
<text top="279" left="584" width="211" height="13" font="23">counseling at each clinic encounter<b> </b></text>
<text top="310" left="104" width="67" height="13" font="26"><b>Treatment </b></text>
<text top="301" left="404" width="52" height="13" font="26"><b>Dosing‡ </b></text>
<text top="319" left="428" width="3" height="13" font="23"> </text>
<text top="310" left="658" width="75" height="13" font="26"><b>Precautions </b></text>
<text top="341" left="104" width="36" height="13" font="26"><b>NRT* </b></text>
<text top="380" left="104" width="37" height="13" font="23">Patch </text>
<text top="362" left="288" width="44" height="13" font="23">21 mg, </text>
<text top="380" left="288" width="60" height="13" font="23">14 mg, or </text>
<text top="397" left="288" width="33" height="13" font="23">7 mg </text>
<text top="362" left="361" width="85" height="13" font="23">Starting dose: </text>
<text top="380" left="361" width="203" height="13" font="23">21 mg for &gt;10 CPD; 14 mg for &lt;10 </text>
<text top="397" left="361" width="28" height="13" font="23">CPD </text>
<text top="362" left="584" width="210" height="13" font="23">Local irritation possible; avoid with </text>
<text top="380" left="584" width="222" height="13" font="23">skin disorders; may remove for sleep </text>
<text top="397" left="584" width="59" height="13" font="23">if needed </text>
<text top="437" left="104" width="32" height="13" font="23">Gum </text>
<text top="428" left="288" width="59" height="13" font="23">2 mg or 4 </text>
<text top="446" left="288" width="22" height="13" font="23">mg </text>
<text top="415" left="361" width="89" height="13" font="23">Starting dose:  </text>
<text top="433" left="361" width="209" height="13" font="23">4 mg if first tobacco use is ≤30 min </text>
<text top="451" left="361" width="202" height="13" font="23">after waking; 2 mg if first tobacco </text>
<text top="469" left="361" width="169" height="13" font="23">use is &gt;30 min after waking; </text>
<text top="487" left="361" width="185" height="13" font="23">maximum of 20 lozenges or 24 </text>
<text top="505" left="361" width="103" height="13" font="23">pieces of gum/d. </text>
<text top="523" left="361" width="129" height="13" font="23">Chew and park gum* </text>
<text top="451" left="584" width="205" height="13" font="23">Hiccups/dyspepsia possible; avoid </text>
<text top="469" left="584" width="224" height="13" font="23">food or beverages 15 min before and </text>
<text top="487" left="584" width="59" height="13" font="23">after use  </text>
<text top="500" left="104" width="52" height="13" font="23">Lozenge </text>
<text top="491" left="288" width="59" height="13" font="23">2 mg or 4 </text>
<text top="509" left="288" width="22" height="13" font="23">mg </text>
<text top="559" left="104" width="71" height="13" font="23">Nasal spray </text>
<text top="550" left="288" width="18" height="13" font="23">10 </text>
<text top="567" left="288" width="48" height="13" font="23">mg/mL  </text>
<text top="541" left="361" width="89" height="13" font="23">Starting dose:  </text>
<text top="559" left="361" width="184" height="13" font="23">1-2 doses/h (1 dose=2 sprays); </text>
<text top="576" left="361" width="147" height="13" font="23">maximum of 40 doses/d </text>
<text top="550" left="584" width="210" height="13" font="23">Local irritation possible; avoid with </text>
<text top="567" left="584" width="202" height="13" font="23">nasal or reactive airway disorders </text>
<text top="621" left="104" width="73" height="13" font="23">Oral inhaler </text>
<text top="603" left="288" width="25" height="13" font="23">10,  </text>
<text top="621" left="288" width="41" height="13" font="23">10-mg </text>
<text top="639" left="288" width="57" height="13" font="23">cartridge </text>
<text top="595" left="361" width="89" height="13" font="23">Starting dose:  </text>
<text top="612" left="361" width="210" height="13" font="23">Puff for 20 min/cartridge every 1-2 </text>
<text top="630" left="361" width="187" height="13" font="23">h; maximum 6-16 cartridges/d; </text>
<text top="648" left="361" width="121" height="13" font="23">taper over 3-6 mo§  </text>
<text top="612" left="584" width="213" height="13" font="23">Cough possible; avoid with reactive </text>
<text top="630" left="584" width="101" height="13" font="23">airway disorders </text>
<text top="673" left="104" width="35" height="13" font="26"><b>Other</b></text>
<text top="670" left="140" width="14" height="18" font="26"><b>║ </b></text>
<text top="698" left="104" width="69" height="13" font="23">Bupropion  </text>
<text top="716" left="104" width="157" height="13" font="23">(Zyban [GlaxoSmithKline], </text>
<text top="734" left="104" width="85" height="13" font="23">Wellbutrin SR </text>
<text top="751" left="104" width="114" height="13" font="23">[GlaxoSmithKline]) </text>
<text top="716" left="288" width="47" height="13" font="23">150 mg </text>
<text top="734" left="288" width="21" height="13" font="23">SR  </text>
<text top="707" left="361" width="188" height="13" font="23">150 mg once daily (am) for 3 d; </text>
<text top="725" left="361" width="201" height="13" font="23">then 150 mg twice daily; may use </text>
<text top="743" left="361" width="206" height="13" font="23">in combination with NRT (S4.5-21) </text>
<text top="707" left="584" width="208" height="13" font="23">Avoid with history/risk of seizures, </text>
<text top="725" left="584" width="216" height="13" font="23">eating disorders, MAO inhibitors, or </text>
<text top="743" left="584" width="107" height="13" font="23">CYP 2D6 inhibitor </text>
<text top="805" left="104" width="70" height="13" font="23">Varenicline </text>
<text top="823" left="104" width="103" height="13" font="23">(Chantix [Pfizer]) </text>
<text top="805" left="288" width="60" height="13" font="23">0.5 mg or </text>
<text top="823" left="288" width="33" height="13" font="23">1 mg </text>
<text top="770" left="361" width="184" height="13" font="23">0.5 mg once daily (am) for 3 d; </text>
<text top="788" left="361" width="187" height="13" font="23">then 0.5 mg twice daily for 4 d; </text>
<text top="805" left="361" width="189" height="13" font="23">then 1 mg twice daily (use start </text>
<text top="823" left="361" width="183" height="13" font="23">pack followed by continuation </text>
<text top="841" left="361" width="101" height="13" font="23">pack) for 3-6 mo </text>
<text top="859" left="361" width="3" height="13" font="23"> </text>
<text top="788" left="584" width="200" height="13" font="23">Nausea common; take with food. </text>
<text top="805" left="584" width="212" height="13" font="23">Renal dosing required. Very limited </text>
<text top="823" left="584" width="197" height="13" font="23">drug interactions; near-exclusive </text>
<text top="841" left="584" width="98" height="13" font="23">renal clearance. </text>
<text top="877" left="105" width="720" height="13" font="23">*CPD can guide dosing. 1 CPD is ≈1-2 mg of nicotine. <i>Note: Use caution with all NRT products for patients with recent (≤2 </i></text>
<text top="895" left="105" width="598" height="13" font="28"><i>wk) MI, serious arrhythmia, or angina; patients who are pregnant or breastfeeding; and adolescents. </i></text>
<text top="913" left="105" width="287" height="13" font="23">†Timing of assessment relates to ICD-10 coding. </text>
<text top="930" left="105" width="419" height="13" font="23">‡Dose and duration can be titrated on the basis of response (S4.5-21). </text>
<text top="948" left="105" width="459" height="13" font="23">§See Rx for Change for greater detail: http://rxforchange.ucsf.edu) (S4.5-35). </text>
<text top="963" left="105" width="617" height="18" font="23">║The FDA has issued a removal of black box warnings about neuropsychiatric events (S4.5-20, S4.5-21). </text>
<text top="984" left="105" width="719" height="13" font="23">am indicates morning; CPD, cigarettes smoked  per  day; FDA, U.S. Food and  Drug  Administration; ICD-10,  <i>International </i></text>
<text top="1003" left="105" width="719" height="13" font="28"><i>Classification  of  Diseases,  Tenth  Revision</i>;  MAO,  monoamine  oxidase;  NRT,  nicotine  replacement;  and  SR,  sustained </text>
<text top="1022" left="105" width="50" height="13" font="23">release. </text>
<text top="1042" left="105" width="4" height="14" font="13"> </text>
<text top="1061" left="105" width="4" height="14" font="13"> </text>
<text top="1082" left="105" width="5" height="20" font="20"><b> </b></text>
<text top="1082" left="315" width="5" height="20" font="20"><b> </b></text>
</page>
<page number="48" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 46 of 101 </text>
<text top="169" left="105" width="147" height="20" font="20"><b>4.6. Aspirin Use </b></text>
<text top="195" left="325" width="231" height="15" font="7"><b>Recommendations for Aspirin Use </b></text>
<text top="215" left="115" width="651" height="14" font="13">Referenced studies that support recommendations are summarized in Online Data Supplements 17 </text>
<text top="234" left="414" width="52" height="14" font="13">and 18. </text>
<text top="254" left="113" width="32" height="15" font="7"><b>COR </b></text>
<text top="254" left="177" width="29" height="15" font="7"><b>LOE </b></text>
<text top="254" left="439" width="129" height="15" font="7"><b>Recommendations </b></text>
<text top="294" left="118" width="21" height="15" font="7"><b>IIb </b></text>
<text top="294" left="185" width="13" height="15" font="7"><b>A </b></text>
<text top="275" left="231" width="13" height="15" font="7"><b>1.</b></text>
<text top="275" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="275" left="257" width="519" height="15" font="7"><b>Low-dose  aspirin  (75-100  mg  orally  daily)  might  be  considered  for  the </b></text>
<text top="294" left="257" width="519" height="15" font="7"><b>primary prevention of ASCVD among select adults 40 to 70 years of age who </b></text>
<text top="314" left="257" width="500" height="15" font="7"><b>are at higher ASCVD risk but not at increased bleeding risk (S4.6-1–S4.6-8). </b></text>
<text top="344" left="118" width="21" height="15" font="7"><b>III: </b></text>
<text top="364" left="109" width="41" height="15" font="7"><b>Harm </b></text>
<text top="354" left="178" width="27" height="15" font="7"><b>B-R </b></text>
<text top="334" left="231" width="13" height="15" font="7"><b>2.</b></text>
<text top="334" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="334" left="257" width="519" height="15" font="7"><b>Low-dose  aspirin  (75-100  mg  orally  daily)  should  not  be  administered  on  a </b></text>
<text top="354" left="257" width="519" height="15" font="7"><b>routine basis for the primary prevention of ASCVD among adults &gt;70 years of </b></text>
<text top="373" left="257" width="90" height="15" font="7"><b>age (S4.6-9).  </b></text>
<text top="404" left="118" width="21" height="15" font="7"><b>III: </b></text>
<text top="423" left="109" width="41" height="15" font="7"><b>Harm </b></text>
<text top="413" left="175" width="34" height="15" font="7"><b>C-LD </b></text>
<text top="394" left="231" width="13" height="15" font="7"><b>3.</b></text>
<text top="394" left="243" width="4" height="15" font="21"><b> </b></text>
<text top="394" left="257" width="519" height="15" font="7"><b>Low-dose aspirin (75-100 mg orally daily) should not be administered for the </b></text>
<text top="413" left="257" width="519" height="15" font="7"><b>primary prevention of ASCVD among adults of any age who are at increased </b></text>
<text top="433" left="257" width="177" height="15" font="7"><b>risk of bleeding (S4.6-10).  </b></text>
<text top="453" left="105" width="4" height="14" font="13"> </text>
<text top="473" left="105" width="61" height="15" font="7"><b>Synopsis </b></text>
<text top="492" left="105" width="687" height="14" font="13">For  decades,  aspirin  has  been  widely  administered  for  ASCVD  prevention.  By  irreversibly  inhibiting </text>
<text top="512" left="105" width="687" height="14" font="13">platelet  function,  aspirin  reduces  risk  of  atherothrombosis  but  also  increases  risk  of  bleeding, </text>
<text top="532" left="105" width="687" height="14" font="13">particularly in the gastrointestinal tract (S4.6-11). Aspirin is well established for secondary prevention of </text>
<text top="551" left="105" width="687" height="14" font="13">ASCVD  (S4.6-12)  and  is  widely  recommended  for  this  indication  (S4.6-13).  However,  in  primary </text>
<text top="571" left="105" width="687" height="14" font="13">prevention, aspirin use is more controversial. Because persons without prior ASCVD are inherently less </text>
<text top="591" left="105" width="687" height="14" font="13">likely  to  have  future  ASCVD  events  than  are  those  with  a  prior  history,  it  is  more  challenging  for </text>
<text top="610" left="105" width="687" height="14" font="13">clinicians and patients to balance benefits and harms of prophylactic aspirin for primary prevention. This </text>
<text top="630" left="105" width="687" height="14" font="13">uncertainty is reflected in international guidelines, where, for example, aspirin is not recommended in </text>
<text top="649" left="105" width="687" height="14" font="13">European  guidelines  for  primary  ASCVD  prevention  (S4.6-13)  but  is  recommended  in  prior  U.S. </text>
<text top="669" left="105" width="687" height="14" font="13">guidelines  for  selected  primary  prevention  for  adults  who  have  elevated  risk  of  ASCVD  based  on </text>
<text top="689" left="105" width="687" height="14" font="13">traditional  risk  factors  (S4.6-14,  S4.6-15).  Adding  to  this  controversy  are  more  recently  conducted </text>
<text top="708" left="105" width="687" height="14" font="13">primary-prevention  trials  that,  in  contrast  to  older  trials  (S4.6-12),  have  shown  less  overall  benefit  of </text>
<text top="728" left="105" width="687" height="14" font="13">prophylactic aspirin alongside coadministration of contemporary ASCVD preventive treatments, such as </text>
<text top="748" left="105" width="586" height="14" font="13">evidence-based hypertension and cholesterol therapies (S4.6-5<b>–</b>S4.6-9, S4.6-16, S4.6-17). </text>
<text top="767" left="105" width="4" height="14" font="13"> </text>
<text top="787" left="105" width="287" height="15" font="7"><b>Recommendation-Specific Supportive Text </b></text>
<text top="806" left="105" width="687" height="14" font="13">1.  To balance the benefits and risks, prior U.S. guidelines have recommended prophylactic aspirin only </text>
<text top="826" left="131" width="661" height="14" font="13">in the setting of elevated ASCVD risk (e.g., as calculated by risk estimators like the PCE or based on </text>
<text top="845" left="131" width="661" height="14" font="13">the presence of specific ASCVD risk factors) (S4.6-14, S4.6-18). Meta-regression analyses of historical </text>
<text top="865" left="131" width="661" height="14" font="13">trials  show  that  observed  ASCVD  risk  tracks  reasonably  well  with  baseline-estimated  ASCVD  risk </text>
<text top="885" left="131" width="657" height="14" font="13">(S4.6-19).  In  contrast,  observed  bleeding  risk  on  aspirin  is  less  well  correlated  with  baseline-</text>
<text top="904" left="131" width="210" height="14" font="13">estimated ASCVD risk (S4.6-19).</text>
<text top="901" left="341" width="2" height="9" font="24"> </text>
<text top="904" left="345" width="447" height="14" font="13">(A nonexhaustive list of scenarios associated with increased risk of </text>
<text top="924" left="131" width="661" height="14" font="13">bleeding includes: a history of previous gastrointestinal bleeding or peptic ulcer disease or bleeding </text>
<text top="944" left="131" width="661" height="14" font="13">from other sites, age &gt;70 years, thrombocytopenia, coagulopathy, CKD, and concurrent use of other </text>
<text top="963" left="131" width="661" height="14" font="13">medications  that  increase  bleeding  risk,  such  as  nonsteroidal  anti-inflammatory  drugs,  steroids, </text>
<text top="983" left="131" width="661" height="14" font="13">direct oral anticoagulants, and warfarin.) In this context, post hoc study of older trials suggests that </text>
<text top="1002" left="131" width="661" height="14" font="13">the benefit–risk ratio for prophylactic aspirin generally becomes more favorable at &gt;10% estimated </text>
<text top="1022" left="131" width="661" height="14" font="13">10-year  ASCVD  risk  (S4.6-15,  S4.6-19).  However,  the  relative  benefits  of  aspirin,  specifically  in </text>
<text top="1041" left="131" width="661" height="14" font="13">preventing nonfatal MI and perhaps stroke (with a trend to lower mortality) have been less evident </text>
<text top="1061" left="131" width="661" height="14" font="13">in  more  recent  trials  (S4.6-9,  S4.6-16,  S4.6-17,  S4.6-20).  Similarly,  in  these  recent  trials,  the </text>
<text top="1081" left="131" width="661" height="14" font="13">estimated  ASCVD  risk  has  generally  exceeded  the  actual  risk  observed  during  follow-up  (S4.6-17). </text>
</page>
<page number="49" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 47 of 101 </text>
<text top="167" left="131" width="661" height="14" font="13">These  recent  data  are  the  rationale  for  the  lower  COR  for  prophylactic  aspirin  in  the  present </text>
<text top="187" left="131" width="661" height="14" font="13">guideline  (Class  IIb)  and  the  removal  of  a  specific  PCE  risk  threshold  as  an  inclusion  criterion  for </text>
<text top="207" left="131" width="661" height="14" font="13">aspirin  consideration.  These  changes  reflect  the  need  to  instead  consider  the  totality  of  available </text>
<text top="226" left="131" width="661" height="14" font="13">evidence  for  ASCVD  risk  [inclusive,  where  appropriate,  of  risk-enhancing  factors,  such  as  strong </text>
<text top="246" left="131" width="661" height="14" font="13">family  history  of  premature  MI,  inability  to  achieve  lipid  or  BP  or  glucose  targets,  or  significant </text>
<text top="265" left="131" width="661" height="14" font="13">elevation in coronary artery calcium<b> </b>score (S4.6-21)] and to also tailor decisions about prophylactic </text>
<text top="285" left="131" width="661" height="14" font="13">aspirin to patient and clinician preferences. Depending on risk factors present, a given patient and </text>
<text top="305" left="131" width="661" height="14" font="13">his/her  clinician  may  decide  that  lowering  the  risk  of  MI  (which  has  potentially  serious  long-term </text>
<text top="324" left="131" width="661" height="14" font="13">consequences not captured by clinical trials of 5 to 10 years’ duration) is worth a slight excess risk of </text>
<text top="344" left="131" width="661" height="14" font="13">serious  bleeding.  Recent  trials  show  that  absolute  risk  for  ASCVD  events  typically  exceeds  that  of </text>
<text top="363" left="131" width="661" height="14" font="13">bleeding  and,  although  the  gap  of  relative  benefit  to  relative  harm  for  aspirin  has  narrowed,  the </text>
<text top="383" left="131" width="661" height="14" font="13">number  needed  to  treat  to  prevent  an  ASCVD  event  remains  lower  than  the  number  needed  to </text>
<text top="403" left="131" width="661" height="14" font="13">harm  to  cause  bleeding.  Others  may  feel  that  the  benefit  of  prophylactic  aspirin  is  comparable  to </text>
<text top="422" left="131" width="661" height="14" font="13">the risk and may instead choose to focus on optimal control of other modifiable ASCVD risk factors. </text>
<text top="442" left="131" width="661" height="14" font="13">Therefore, a Class IIb recommendation remains more suitable than a Class III recommendation for </text>
<text top="461" left="131" width="661" height="14" font="13">adults  40  to  70  years  of  age.  Given  the  narrow  overall  balance  between  benefits  and  harms  of </text>
<text top="481" left="131" width="661" height="14" font="13">prophylactic aspirin, there is limited justification  to use aspirin  at doses &gt;100 mg daily for primary </text>
<text top="501" left="131" width="661" height="14" font="13">prevention.  Indeed,  meta-analyses  suggest  that  the  ASCVD  risk  benefit  for  low-dose  aspirin  is </text>
<text top="520" left="131" width="661" height="14" font="13">equivalent to that for high-dose aspirin, but the bleeding risk is higher with high-dose aspirin. Recent </text>
<text top="540" left="131" width="661" height="14" font="13">observational  studies motivate future  research  on  the  personalization  of  prophylactic  aspirin  dose </text>
<text top="559" left="131" width="661" height="14" font="13">according to patient-specific factors (e.g., weight) (S4.6-22), though we note that, regarding weight </text>
<text top="579" left="131" width="661" height="14" font="13">specifically,  there  was  no  evidence  low-dose  aspirin  was  any  more  effective  in  low-weight </text>
<text top="599" left="131" width="661" height="14" font="13">individuals  than  in  high-weight  individuals  in  the  more  recently  published  ASCEND  (A  Study  of </text>
<text top="618" left="131" width="661" height="14" font="13">Cardiovascular  Events iN Diabetes) trial  (S4.6-16),  trial.  Most  importantly,  recent  clinical  trials  also </text>
<text top="638" left="131" width="661" height="14" font="13">teach us that low-dose prophylactic aspirin may be best justified among persons at high ASCVD risk </text>
<text top="658" left="131" width="484" height="14" font="13">who cannot achieve optimal control of other ASCVD risk factors (S4.6-23). </text>
<text top="677" left="105" width="687" height="14" font="13">2.  Prophylactic aspirin in primary-prevention adults &gt;70 years of age is potentially harmful and, given </text>
<text top="697" left="131" width="661" height="14" font="13">the higher risk of bleeding in this age group, difficult to justify for routine use (S4.6-9). In addition, </text>
<text top="716" left="131" width="661" height="14" font="13">for adults  &lt;40 years of age, there is insufficient evidence to judge the risk–benefit  ratio of routine </text>
<text top="736" left="131" width="661" height="14" font="13">aspirin  for the  primary  prevention  of  ASCVD.  However,  one  caveat is  that,  although  routine  use  is </text>
<text top="755" left="131" width="661" height="14" font="13">not  recommended  in  these  settings,  there  is  also  insufficient  evidence  to  comment  on  whether </text>
<text top="775" left="131" width="661" height="14" font="13">there may be select circumstances in which physicians might discuss prophylactic aspirin with adults </text>
<text top="795" left="131" width="661" height="14" font="13">&lt;40 years of age or &gt;70 years of age in the context of other known ASCVD risk factors (e.g., strong </text>
<text top="814" left="131" width="661" height="14" font="13">family  history  of  premature  MI,  inability  to  achieve  lipid  or  BP  or  glucose  targets,  or  significant </text>
<text top="834" left="131" width="661" height="14" font="13">elevation in coronary artery calcium<b> </b>score). As inferred from the first recommendation, there is also </text>
<text top="854" left="131" width="661" height="14" font="13">no  justification  for  the  routine  administration  of  low-dose  aspirin  for  the  primary  prevention  of </text>
<text top="873" left="131" width="661" height="14" font="13">ASCVD  among  adults  at  low  estimated  ASCVD  risk.  For  example,  in  the  recent  ARRIVE  (A </text>
<text top="893" left="131" width="661" height="14" font="13">Randomized  Trial  of  Induction  Versus  Expectant  Management)  trial,  observed  average  10-year </text>
<text top="912" left="131" width="661" height="14" font="13">ASCVD  risk  was  &lt;10%,  and  the  overall  benefits  of  prophylactic  aspirin  by  intention-to-treat  were </text>
<text top="932" left="131" width="133" height="14" font="13">negligible (S4.6-17). </text>
<text top="952" left="105" width="687" height="14" font="13">3.  The  accumulated  trial  and  observational  data  to  date  support  avoiding  prophylactic  aspirin  in  the </text>
<text top="971" left="131" width="661" height="14" font="13">setting  of  known  risk  factors  for  increased  bleeding  outcomes  (S4.6-10).  A  nonexhaustive  list  of </text>
<text top="991" left="131" width="661" height="14" font="13">conditions  associated  with  increased  bleeding  risk  includes:  a  history  of  previous  gastrointestinal </text>
<text top="1010" left="131" width="661" height="14" font="13">bleeding  or  peptic  ulcer  disease  or  bleeding  at  other  sites,  age  &gt;70  years,  thrombocytopenia, </text>
<text top="1030" left="131" width="661" height="14" font="13">coagulopathy,  CKD,  and  concurrent  use  of  other  medications  that  increase  bleeding  risk,  such  as </text>
<text top="1050" left="131" width="657" height="14" font="13">nonsteroidal  anti-inflammatory  drugs,  steroids,  direct  oral  anticoagulants,  and  warfarin  (S4.6-10).</text>
</page>
<page number="50" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 48 of 101 </text>
<text top="198" left="105" width="329" height="21" font="10"><b>5. Cost and Value Considerations  </b></text>
<text top="228" left="105" width="687" height="14" font="13">The  growing need to consider value stems directly from the goal of achieving the best possible health </text>
<text top="248" left="105" width="687" height="14" font="13">outcomes with finite healthcare resources in the primary prevention of CVD (S5-1). <i>Value</i> in health care </text>
<text top="267" left="105" width="687" height="14" font="13">can be defined as the incremental health benefits of a therapy or procedure relative to its incremental </text>
<text top="287" left="105" width="687" height="14" font="13">net long-term costs. The consideration of cost and value in the guideline development process supports </text>
<text top="307" left="105" width="687" height="14" font="13">key  goals,  including:  1)  enhancing  overall  value  in  the  delivery  of  cardiovascular  care  and  2)  involving </text>
<text top="326" left="105" width="687" height="14" font="13">healthcare  professionals  in  the  challenging  care  decisions  that  must  be  made  to  increase  value  in  the </text>
<text top="346" left="105" width="202" height="14" font="13">U.S. healthcare system (S5-2).  </text>
<text top="377" left="105" width="687" height="14" font="13">The  integration  of  value  assessments  into  our  national  guidelines  involves  inherent  methodological </text>
<text top="397" left="105" width="687" height="14" font="13">challenges, including: 1) variability in costs across different healthcare settings, 2) variability in costs and </text>
<text top="416" left="105" width="687" height="14" font="13">benefits  across  different  patient  subgroups,  3)  variability  over  time,  4)  variability  in  who  bears  the </text>
<text top="436" left="105" width="687" height="14" font="13">burden of the health outcome (i.e., typically the individual patient) versus who bears the burden of the </text>
<text top="455" left="105" width="687" height="14" font="13">healthcare  cost  (e.g.,  often  spread  beyond  the  individual  to  third-party  payers,  taxpayers),  and  5)  an </text>
<text top="475" left="105" width="687" height="14" font="13">inadequate literature base on which to render a sound,  evidence-based assessment of certain specific </text>
<text top="495" left="105" width="147" height="14" font="13">therapies (S5-1,S5-2).  </text>
<text top="526" left="105" width="687" height="14" font="13">There  are  additional  challenges  specific  to  the  prevention  realm.  As  described  in  the  2011  AHA  policy </text>
<text top="545" left="105" width="469" height="14" font="13">statement, “Value of Primordial and Primary Prevention in CVD” (S5-1): </text>
<text top="586" left="158" width="634" height="14" font="14"><i>“Assessing the value of prevention in apparently healthy patients is generally more difficult than </i></text>
<text top="605" left="158" width="634" height="14" font="14"><i>evaluating therapy for established disease because the time horizon to the clinical manifestation </i></text>
<text top="625" left="158" width="634" height="14" font="14"><i>of disease is generally long—many decades in the young. Thus, it is difficult, perhaps impossible, </i></text>
<text top="644" left="158" width="634" height="14" font="14"><i>to  assess  long-term  effectiveness  in  terms  of  survival  or  quality-adjusted  life-years  (QALYs)  or </i></text>
<text top="664" left="158" width="634" height="14" font="14"><i>associated costs because of increasing uncertainty  about outcome the further  one tries to look </i></text>
<text top="683" left="158" width="98" height="14" font="14"><i>into the future.</i></text>
<text top="683" left="256" width="10" height="14" font="13">” </text>
<text top="724" left="105" width="687" height="14" font="13">Furthermore, the principle of <i>discounting</i>, which places relative emphasis on current costs and benefits </text>
<text top="743" left="105" width="687" height="14" font="13">while  deemphasizing  downstream  costs  and  benefits,  creates  disadvantages  for  prevention  because </text>
<text top="763" left="105" width="687" height="14" font="13">costs often accrue in the present while the benefit may only be fully realized long into the future. These </text>
<text top="782" left="105" width="687" height="14" font="13">methodological challenges notwithstanding, prior AHA statements have highlighted the public policies, </text>
<text top="802" left="105" width="687" height="14" font="13">community efforts, and pharmacological interventions that are likely to be cost-effective and, at times, </text>
<text top="821" left="105" width="687" height="14" font="13">cost-saving  prevention  tactics  compared  with  common  benchmarks.  For  example,  robust  evidence </text>
<text top="841" left="105" width="687" height="14" font="13">suggests that both antihypertensive therapy (S5-3<b>–</b>S5-6) and statin therapy (S5-7<b>–</b>S5-9), particularly with </text>
<text top="861" left="105" width="687" height="14" font="13">low-cost generic drug formulations, are high-value interventions across a wide spectrum of risk and age </text>
<text top="880" left="105" width="49" height="14" font="13">strata.  </text>
<text top="920" left="105" width="687" height="14" font="13">The incorporation of the value category into clinical practice guidelines is one of several considerations </text>
<text top="940" left="105" width="687" height="14" font="13">in  medical  decision-making  and  resource  allocation.  Clinicians,  researchers,  and  policymakers  must </text>
<text top="960" left="105" width="687" height="14" font="13">continue  to  place  cost-effective  analyses  in  the  proper  context,  extracting  key  value  determinations </text>
<text top="979" left="105" width="687" height="14" font="13">while acknowledging the challenges in fully characterizing and incorporating the downstream benefits of </text>
<text top="999" left="105" width="687" height="14" font="13">a  given  therapeutic  prevention  tactic.  Further  research  and  methodological  advances  are  needed  to </text>
<text top="1018" left="105" width="687" height="14" font="13">comprehensively  characterize  the  full  spectrum  of  benefits  produced  by  the  prevention  approach, </text>
<text top="1038" left="105" width="683" height="14" font="13">thereby  rendering  cost-effectiveness  assessments  more  consequential  to  clinical  practice.</text>
</page>
<page number="51" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 49 of 101 </text>
<text top="186" left="105" width="134" height="21" font="10"><b>6. Conclusion </b></text>
<text top="216" left="105" width="687" height="14" font="13">Most  ASCVD  events  are  avoidable  through  primordial  prevention  (i.e.,  the  prevention  of  risk  factor </text>
<text top="236" left="105" width="687" height="14" font="13">development)  and control  of  traditional  cardiovascular  risk  factors.  Tobacco  avoidance  is  critically </text>
<text top="256" left="105" width="687" height="14" font="13">important for ASCVD prevention, and all adults should strive to engage in regular brisk physical activity </text>
<text top="275" left="105" width="687" height="14" font="13">most days of the week and adhere to a healthy dietary pattern to help lower future ASCVD risk. A diet </text>
<text top="295" left="105" width="687" height="14" font="13">high in fruits, vegetables, and whole grains is best. Fish, legumes, and poultry are the preferred sources </text>
<text top="314" left="105" width="687" height="14" font="13">of  protein.  Minimizing  the  consumption  of  <i>trans</i>  fats,  added  sugars  (including  sugar-sweetened </text>
<text top="334" left="105" width="687" height="14" font="13">beverages),  red  meats,  sodium,  and  saturated  fats  is  also  important.  Clinicians  should  work  in </text>
<text top="354" left="105" width="687" height="14" font="13">partnership  with  patients  to  assess  their  readiness  for  sustained  lifestyle  improvements,  identify </text>
<text top="373" left="105" width="687" height="14" font="13">potential  barriers  to  change,  and  encourage them  to  try to  achieve  measurable  goals  and  continue  to </text>
<text top="393" left="105" width="687" height="14" font="13">monitor  their  progress  (S6-1).  Finally,  social  determinants  of  ASCVD  risk—and  their  impact  on  the </text>
<text top="413" left="105" width="687" height="14" font="13">patient’s ability to prevent or treat risk factors—must be taken into account. Clinicians need to consider </text>
<text top="432" left="105" width="687" height="14" font="13">patients’  health literacy and education levels and  assess patients’ motivation to improve their lifestyle </text>
<text top="452" left="105" width="51" height="14" font="13">habits.  </text>
<text top="483" left="105" width="687" height="14" font="13">The goal of the clinician is to match the intensity of preventive efforts with an individual’s absolute risk </text>
<text top="503" left="105" width="687" height="14" font="13">of  a  future  ASCVD  event  and  with  the  individual’s  willingness  and  capacity  to  implement  preventive </text>
<text top="522" left="105" width="687" height="14" font="13">strategies. Risk estimation is imperfect and based on group averages that are then applied to individual </text>
<text top="542" left="105" width="687" height="14" font="13">patients. The clinician must balance an understanding of a patient’s estimated ASCVD risk with potential </text>
<text top="561" left="105" width="687" height="14" font="13">benefits and adverse risk from pharmacological therapy in the context of a risk discussion. To determine </text>
<text top="581" left="105" width="687" height="14" font="13">the  appropriateness  of  pharmacological  therapy  after  quantitative  risk  estimation  in  cases  that  are </text>
<text top="600" left="105" width="687" height="14" font="13">unclear,  risk-enhancing  factors  or  selective  use  of  a  coronary  artery  calcium<b>  </b>measurement  can  inform </text>
<text top="620" left="105" width="687" height="14" font="13">decision-making  for  cholesterol-lowering  or  antihypertensive  medication  use  in  intermediate-risk </text>
<text top="640" left="105" width="81" height="14" font="13">individuals.  </text>
<text top="671" left="105" width="687" height="14" font="13">This  primary-prevention  guideline  strives  to  provide  clinicians  with  the  information  they  need  to  help </text>
<text top="691" left="105" width="687" height="14" font="13">their patients reduce their risk of ASCVD and encourage them to make healthier lifestyle changes when </text>
<text top="710" left="105" width="61" height="14" font="13">needed.  </text>
<text top="742" left="105" width="4" height="14" font="13"> </text>
<text top="773" left="105" width="4" height="14" font="13"> </text>
</page>
<page number="52" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 50 of 101 </text>
<text top="167" left="105" width="137" height="15" font="7"><b>Presidents and Staff </b></text>
<text top="199" left="105" width="213" height="15" font="27"><i><b>American College of Cardiology</b></i> </text>
<text top="218" left="105" width="280" height="14" font="13">C. Michael Valentine, MD, FACC, President </text>
<text top="238" left="105" width="386" height="14" font="13">Timothy W. Attebery, MBA, FACHE, Chief Executive Officer </text>
<text top="257" left="105" width="684" height="14" font="13">William J. Oetgen, MD, MBA, FACC, Executive Vice President, Science, Education, Quality, and Publishing </text>
<text top="277" left="105" width="540" height="14" font="13">MaryAnne Elma, MPH, Senior Director, Science, Education, Quality, and Publishing </text>
<text top="297" left="105" width="569" height="14" font="13">Amelia Scholtz, PhD, Publications Manager, Science, Education, Quality, and Publishing </text>
<text top="316" left="105" width="4" height="14" font="13"> </text>
<text top="336" left="105" width="405" height="15" font="27"><i><b>American College of Cardiology/American Heart Association</b></i> </text>
<text top="355" left="105" width="472" height="14" font="13">Katherine A. Sheehan, PhD, Director, Guideline Strategy and Operations </text>
<text top="375" left="105" width="386" height="14" font="13">Abdul R. Abdullah, MD, Senior Manager, Guideline Science </text>
<text top="395" left="105" width="358" height="14" font="13">Thomas S.D. Getchius, Manager, Guideline Operations </text>
<text top="414" left="105" width="4" height="14" font="13"> </text>
<text top="434" left="105" width="189" height="15" font="27"><i><b>American Heart Association</b></i> </text>
<text top="453" left="105" width="239" height="14" font="13">Ivor Benjamin, MD, FAHA, President </text>
<text top="473" left="105" width="246" height="14" font="13">Nancy Brown, Chief Executive Officer </text>
<text top="493" left="105" width="458" height="14" font="13">Rose Marie Robertson, MD, FAHA, Chief Science and Medicine Officer </text>
<text top="512" left="105" width="608" height="14" font="13">Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice President, Office of Science Operations </text>
<text top="532" left="105" width="592" height="14" font="13">Cammie Marti, PhD, MPH, RN, Science and Medicine Advisor, Office of Science Operations </text>
<text top="551" left="105" width="679" height="14" font="13">Jody Hundley, Production and Operations Manager, Scientific Publications, Office of Science Operations </text>
<text top="571" left="105" width="4" height="14" font="13"> </text>
<text top="591" left="105" width="323" height="15" font="7"><b>Key Words</b>: ACC/AHA Clinical Practice Guidelines </text>
<text top="588" left="428" width="331" height="20" font="13">■ guidelines ■ antihypertensive agents ■ aspirin ■ </text>
<text top="611" left="105" width="102" height="14" font="13">atherosclerosis </text>
<text top="607" left="208" width="561" height="20" font="13">■ atherosclerotic cardiovascular disease ■ atrial fibrillation ■ behavior modification ■ </text>
<text top="630" left="105" width="116" height="14" font="13">behavior therapy </text>
<text top="627" left="221" width="534" height="20" font="13">■ blood cholesterol ■ blood pressure ■ body mass ■ index ■ cardiovascular team-</text>
<text top="650" left="105" width="74" height="14" font="13">based care </text>
<text top="646" left="179" width="603" height="20" font="13">■ cardiovascular ■ cardiovascular disease ■ cholesterol ■ chronic kidney disease ■ coronary </text>
<text top="669" left="105" width="136" height="14" font="13">artery calcium score </text>
<text top="666" left="241" width="515" height="20" font="13">■ coronary disease ■ coronary heart disease ■ cost ■ diet ■ dietary patterns ■ </text>
<text top="689" left="105" width="78" height="14" font="13">dietary fats </text>
<text top="686" left="183" width="594" height="20" font="13">■ dietary sodium ■ dyslipidemia ■ e-cigarettes ■ exercise ■ healthcare disparities ■ health </text>
<text top="708" left="105" width="137" height="14" font="13">services accessibility </text>
<text top="705" left="242" width="529" height="20" font="13">■ heart failure ■ hypertension ■ LDL-cholesterol ■ diabetes mellitus ■ lifestyle ■ </text>
<text top="728" left="105" width="38" height="14" font="13">lipids </text>
<text top="725" left="143" width="642" height="20" font="13">■ measurement ■ myocardial infarction ■ nicotine ■ nonpharmacological treatment ■ nutrition ■ </text>
<text top="748" left="105" width="107" height="14" font="13">physical activity </text>
<text top="745" left="212" width="563" height="20" font="13">■ prejudice ■ primary prevention ■ psychosocial deprivation ■ public health ■ quality </text>
<text top="767" left="105" width="68" height="14" font="13">indicators </text>
<text top="764" left="174" width="565" height="20" font="13">■ quality measurement ■ risk assessment ■ risk-enhancing factors ■ risk factors ■ risk </text>
<text top="787" left="105" width="67" height="14" font="13">reduction </text>
<text top="784" left="172" width="565" height="20" font="13">■ risk reduction discussion ■ risk treatment discussion ■ secondhand smoke ■ sleep ■ </text>
<text top="807" left="105" width="58" height="14" font="13">smoking </text>
<text top="803" left="163" width="628" height="20" font="13">■ smoking cessation ■ social determinants of health ■ socioeconomic factors ■ statin therapy ■ </text>
<text top="826" left="105" width="105" height="14" font="13">systems of care </text>
<text top="823" left="210" width="569" height="20" font="13">■ tobacco ■ tobacco smoke pollution ■ treatment adherence ■ treatment outcomes ■ </text>
<text top="846" left="105" width="160" height="14" font="13">type 2 diabetes mellitus </text>
<text top="842" left="265" width="239" height="20" font="13">■ waist circumference ■ weight loss </text>
<text top="865" left="105" width="4" height="14" font="13"> </text>
<text top="885" left="105" width="4" height="14" font="13"> </text>
<text top="885" left="315" width="4" height="14" font="13"> </text>
</page>
<page number="53" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 51 of 101 </text>
<text top="169" left="105" width="269" height="21" font="10"><b>Appendix 1. Search Criteria </b></text>
<text top="199" left="105" width="682" height="14" font="13">The rapid review conducted by the Evidence-based Practice Center to complete this literature search, in </text>
<text top="218" left="105" width="688" height="14" font="13">the limited timeframe provided, built on existing systematic reviews conducted on behalf of the USPSTF.  </text>
<text top="250" left="105" width="175" height="15" font="7"><b>Medical Subject Headings </b></text>
<text top="270" left="105" width="102" height="15" font="7"><b>(MeSH) Terms  </b></text>
<text top="250" left="328" width="76" height="15" font="7"><b>Key Words </b></text>
<text top="290" left="105" width="125" height="15" font="27"><i><b>Nutrition and Diet </b></i></text>
<text top="290" left="328" width="4" height="14" font="14"><i> </i></text>
<text top="311" left="105" width="215" height="14" font="13">Search since the 2017 review (1)<i> </i></text>
<text top="331" left="105" width="64" height="14" font="13">exp Diet/ </text>
<text top="331" left="328" width="37" height="14" font="13">diet* </text>
<text top="351" left="105" width="121" height="14" font="13">exp Diet Therapy/ </text>
<text top="351" left="328" width="101" height="14" font="13">cardiovascular  </text>
<text top="372" left="105" width="85" height="14" font="13">Healthy Diet </text>
<text top="372" left="328" width="62" height="14" font="13">coronary </text>
<text top="392" left="105" width="136" height="14" font="13">Primary Prevention/ </text>
<text top="392" left="328" width="39" height="14" font="13">heart </text>
<text top="413" left="105" width="4" height="14" font="13"> </text>
<text top="413" left="328" width="143" height="14" font="13">myocardial infarction </text>
<text top="433" left="105" width="4" height="14" font="13"> </text>
<text top="433" left="328" width="21" height="14" font="13">MI </text>
<text top="453" left="105" width="4" height="14" font="13"> </text>
<text top="453" left="328" width="31" height="14" font="13">CVD </text>
<text top="473" left="105" width="4" height="14" font="13"> </text>
<text top="473" left="328" width="32" height="14" font="13">CHD </text>
<text top="494" left="105" width="4" height="14" font="13"> </text>
<text top="494" left="328" width="108" height="14" font="13">cerebrovascular </text>
<text top="514" left="105" width="4" height="14" font="13"> </text>
<text top="514" left="328" width="45" height="14" font="13">stroke </text>
<text top="534" left="105" width="4" height="14" font="13"> </text>
<text top="534" left="328" width="94" height="14" font="13">microvascular </text>
<text top="555" left="105" width="4" height="14" font="13"> </text>
<text top="555" left="328" width="64" height="14" font="13">mortality </text>
<text top="575" left="105" width="4" height="14" font="13"> </text>
<text top="575" left="328" width="63" height="14" font="13">prevent* </text>
<text top="595" left="105" width="167" height="15" font="27"><i><b>Obesity and Weight Loss </b></i></text>
<text top="595" left="328" width="4" height="14" font="13"> </text>
<text top="616" left="105" width="215" height="14" font="13">Search since the 2018 review (2) </text>
<text top="636" left="105" width="86" height="14" font="13">exp Obesity/ </text>
<text top="636" left="328" width="43" height="14" font="13">obes* </text>
<text top="656" left="105" width="109" height="14" font="13">exp Weight Loss </text>
<text top="656" left="328" width="78" height="14" font="13">overweight </text>
<text top="677" left="105" width="136" height="14" font="13">Primary Prevention/ </text>
<text top="677" left="328" width="48" height="14" font="13">weight </text>
<text top="697" left="105" width="4" height="14" font="13"> </text>
<text top="697" left="328" width="101" height="14" font="13">cardiovascular  </text>
<text top="717" left="105" width="4" height="14" font="13"> </text>
<text top="717" left="328" width="62" height="14" font="13">coronary </text>
<text top="738" left="105" width="4" height="14" font="13"> </text>
<text top="738" left="328" width="39" height="14" font="13">heart </text>
<text top="758" left="105" width="4" height="14" font="13"> </text>
<text top="758" left="328" width="143" height="14" font="13">myocardial infarction </text>
<text top="778" left="105" width="4" height="14" font="13"> </text>
<text top="778" left="328" width="21" height="14" font="13">MI </text>
<text top="799" left="105" width="4" height="14" font="13"> </text>
<text top="799" left="328" width="31" height="14" font="13">CVD </text>
<text top="819" left="105" width="4" height="14" font="13"> </text>
<text top="819" left="328" width="32" height="14" font="13">CHD </text>
<text top="839" left="105" width="4" height="14" font="13"> </text>
<text top="839" left="328" width="108" height="14" font="13">cerebrovascular </text>
<text top="860" left="105" width="4" height="14" font="13"> </text>
<text top="860" left="328" width="45" height="14" font="13">stroke </text>
<text top="880" left="105" width="4" height="14" font="13"> </text>
<text top="880" left="328" width="94" height="14" font="13">microvascular </text>
<text top="900" left="105" width="4" height="14" font="13"> </text>
<text top="900" left="328" width="64" height="14" font="13">mortality </text>
<text top="921" left="105" width="4" height="14" font="13"> </text>
<text top="921" left="328" width="63" height="14" font="13">prevent* </text>
<text top="941" left="105" width="167" height="15" font="27"><i><b>Type 2 Diabetes Mellitus</b></i> </text>
<text top="961" left="105" width="215" height="14" font="13">Search since the 2015 review (3) </text>
<text top="982" left="105" width="202" height="14" font="13">exp Diabetes Mellitus, Type 2/ </text>
<text top="982" left="328" width="166" height="14" font="13">impaired fasting glucose  </text>
<text top="1002" left="105" width="121" height="14" font="13">Prediabetic State/ </text>
<text top="1002" left="328" width="181" height="14" font="13">impaired glucose tolerance </text>
<text top="1023" left="105" width="140" height="14" font="13">Glucose Intolerance/ </text>
<text top="1023" left="328" width="20" height="14" font="13">Ifg </text>
<text top="1043" left="105" width="136" height="14" font="13">Primary Prevention/ </text>
<text top="1043" left="328" width="21" height="14" font="13">Igt </text>
<text top="1063" left="105" width="4" height="14" font="13"> </text>
<text top="1063" left="328" width="90" height="14" font="13">prediabetes* </text>
<text top="1084" left="105" width="4" height="14" font="13"> </text>
<text top="1084" left="328" width="98" height="14" font="13">type 2 diabet* </text>
</page>
<page number="54" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 52 of 101 </text>
<text top="168" left="105" width="175" height="15" font="7"><b>Medical Subject Headings </b></text>
<text top="188" left="105" width="102" height="15" font="7"><b>(MeSH) Terms  </b></text>
<text top="168" left="328" width="76" height="15" font="7"><b>Key Words </b></text>
<text top="208" left="105" width="4" height="14" font="13"> </text>
<text top="208" left="328" width="27" height="14" font="13">DM </text>
<text top="228" left="105" width="4" height="14" font="13"> </text>
<text top="228" left="328" width="101" height="14" font="13">cardiovascular  </text>
<text top="249" left="105" width="4" height="14" font="13"> </text>
<text top="249" left="328" width="62" height="14" font="13">coronary </text>
<text top="269" left="105" width="4" height="14" font="13"> </text>
<text top="269" left="328" width="39" height="14" font="13">heart </text>
<text top="289" left="105" width="4" height="14" font="13"> </text>
<text top="289" left="328" width="143" height="14" font="13">myocardial infarction </text>
<text top="310" left="105" width="4" height="14" font="13"> </text>
<text top="310" left="328" width="21" height="14" font="13">MI </text>
<text top="330" left="105" width="4" height="14" font="13"> </text>
<text top="330" left="328" width="31" height="14" font="13">CVD </text>
<text top="350" left="105" width="4" height="14" font="13"> </text>
<text top="350" left="328" width="32" height="14" font="13">CHD </text>
<text top="371" left="105" width="4" height="14" font="13"> </text>
<text top="371" left="328" width="108" height="14" font="13">cerebrovascular </text>
<text top="391" left="105" width="4" height="14" font="13"> </text>
<text top="391" left="328" width="45" height="14" font="13">stroke </text>
<text top="411" left="105" width="4" height="14" font="13"> </text>
<text top="411" left="328" width="94" height="14" font="13">microvascular </text>
<text top="432" left="105" width="4" height="14" font="13"> </text>
<text top="432" left="328" width="64" height="14" font="13">mortality </text>
<text top="452" left="105" width="4" height="14" font="13"> </text>
<text top="452" left="328" width="63" height="14" font="13">prevent* </text>
<text top="472" left="105" width="87" height="15" font="27"><i><b>Tobacco Use </b></i></text>
<text top="472" left="328" width="4" height="14" font="13"> </text>
<text top="493" left="105" width="215" height="14" font="13">Search since the 2015 review (4) </text>
<text top="513" left="105" width="66" height="14" font="13">Smoking/ </text>
<text top="513" left="210" width="4" height="14" font="13"> </text>
<text top="513" left="328" width="58" height="14" font="13">smoking </text>
<text top="533" left="105" width="199" height="14" font="13">exp &#34;Tobacco Use Cessation&#34;/ </text>
<text top="533" left="328" width="70" height="14" font="13">cigarette* </text>
<text top="554" left="105" width="165" height="14" font="13">&#34;Tobacco Use Disorder&#34;/ </text>
<text top="554" left="328" width="56" height="14" font="13">tobacco </text>
<text top="574" left="105" width="144" height="14" font="13">Electronic Cigarettes/ </text>
<text top="574" left="328" width="57" height="14" font="13">nicotine </text>
<text top="595" left="105" width="136" height="14" font="13">Primary Prevention/ </text>
<text top="595" left="328" width="35" height="14" font="13">vape </text>
<text top="615" left="105" width="4" height="14" font="13"> </text>
<text top="615" left="328" width="47" height="14" font="13">vaping </text>
<text top="635" left="105" width="4" height="14" font="13"> </text>
<text top="635" left="328" width="75" height="14" font="13">e-cigarette </text>
<text top="656" left="105" width="4" height="14" font="13"> </text>
<text top="656" left="328" width="130" height="14" font="13">electronic cigarette </text>
<text top="676" left="105" width="4" height="14" font="13"> </text>
<text top="676" left="328" width="238" height="14" font="13">electronic nicotine delivery system* </text>
<text top="696" left="105" width="4" height="14" font="13"> </text>
<text top="696" left="328" width="39" height="14" font="13">ENDS </text>
<text top="716" left="105" width="4" height="14" font="13"> </text>
<text top="716" left="328" width="101" height="14" font="13">cardiovascular  </text>
<text top="737" left="105" width="4" height="14" font="13"> </text>
<text top="737" left="328" width="62" height="14" font="13">coronary </text>
<text top="757" left="105" width="4" height="14" font="13"> </text>
<text top="757" left="328" width="39" height="14" font="13">heart </text>
<text top="777" left="105" width="4" height="14" font="13"> </text>
<text top="777" left="328" width="143" height="14" font="13">myocardial infarction </text>
<text top="798" left="105" width="4" height="14" font="13"> </text>
<text top="798" left="328" width="21" height="14" font="13">MI </text>
<text top="818" left="105" width="4" height="14" font="13"> </text>
<text top="818" left="328" width="31" height="14" font="13">CVD </text>
<text top="838" left="105" width="4" height="14" font="13"> </text>
<text top="838" left="328" width="32" height="14" font="13">CHD </text>
<text top="859" left="105" width="4" height="14" font="13"> </text>
<text top="859" left="328" width="108" height="14" font="13">cerebrovascular </text>
<text top="879" left="105" width="4" height="14" font="13"> </text>
<text top="879" left="328" width="45" height="14" font="13">stroke </text>
<text top="900" left="105" width="4" height="14" font="13"> </text>
<text top="900" left="328" width="94" height="14" font="13">microvascular </text>
<text top="920" left="105" width="4" height="14" font="13"> </text>
<text top="920" left="328" width="64" height="14" font="13">mortality </text>
<text top="940" left="105" width="4" height="14" font="13"> </text>
<text top="940" left="328" width="63" height="14" font="13">prevent* </text>
<text top="960" left="105" width="79" height="15" font="27"><i><b>Aspirin Use</b></i> </text>
<text top="981" left="105" width="215" height="14" font="13">Search since the 2016 review (5) </text>
<text top="1001" left="105" width="49" height="14" font="13">Aspirin </text>
<text top="1001" left="328" width="51" height="14" font="13">aspirin  </text>
<text top="1021" left="105" width="345" height="14" font="13">exp Cerebrovascular Disorders/  acetylsalicylic acid </text>
<text top="1042" left="105" width="192" height="14" font="13">exp Cardiovascular Diseases/ </text>
<text top="1042" left="328" width="77" height="14" font="13">clopidogrel </text>
<text top="1062" left="105" width="136" height="14" font="13">Primary Prevention/ </text>
<text top="1062" left="328" width="101" height="14" font="13">cardiovascular  </text>
<text top="1082" left="105" width="4" height="14" font="13"> </text>
<text top="1082" left="328" width="62" height="14" font="13">coronary </text>
</page>
<page number="55" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 53 of 101 </text>
<text top="168" left="105" width="175" height="15" font="7"><b>Medical Subject Headings </b></text>
<text top="188" left="105" width="102" height="15" font="7"><b>(MeSH) Terms  </b></text>
<text top="168" left="328" width="76" height="15" font="7"><b>Key Words </b></text>
<text top="208" left="105" width="4" height="14" font="13"> </text>
<text top="208" left="328" width="39" height="14" font="13">heart </text>
<text top="228" left="105" width="4" height="14" font="13"> </text>
<text top="228" left="328" width="143" height="14" font="13">myocardial infarction </text>
<text top="249" left="105" width="4" height="14" font="13"> </text>
<text top="249" left="328" width="21" height="14" font="13">MI </text>
<text top="269" left="105" width="4" height="14" font="13"> </text>
<text top="269" left="328" width="31" height="14" font="13">CVD </text>
<text top="289" left="105" width="4" height="14" font="13"> </text>
<text top="289" left="328" width="32" height="14" font="13">CHD </text>
<text top="310" left="105" width="4" height="14" font="13"> </text>
<text top="310" left="328" width="108" height="14" font="13">cerebrovascular </text>
<text top="330" left="105" width="4" height="14" font="13"> </text>
<text top="330" left="328" width="45" height="14" font="13">stroke </text>
<text top="350" left="105" width="4" height="14" font="13"> </text>
<text top="350" left="328" width="94" height="14" font="13">microvascular </text>
<text top="371" left="105" width="4" height="14" font="13"> </text>
<text top="371" left="328" width="64" height="14" font="13">mortality </text>
<text top="391" left="105" width="4" height="14" font="13"> </text>
<text top="391" left="328" width="63" height="14" font="13">prevent* </text>
<text top="412" left="105" width="175" height="15" font="7"><b>Medical Subject Headings </b></text>
<text top="432" left="105" width="102" height="15" font="7"><b>(MeSH) Terms  </b></text>
<text top="412" left="328" width="76" height="15" font="7"><b>Key Words </b></text>
<text top="452" left="105" width="203" height="15" font="27"><i><b>Social Determinants of Health </b></i></text>
<text top="474" left="105" width="456" height="14" font="13">Search limited to English. No date restrictions (conducted 7/11/2018) </text>
<text top="493" left="105" width="461" height="14" font="13">Similar articles searches were also conducted where potentially highly </text>
<text top="513" left="105" width="185" height="14" font="13">relevant papers were found<b> </b></text>
<text top="533" left="105" width="200" height="14" font="13">NONE SPECIFIED, BUT DUE TO </text>
<text top="553" left="105" width="195" height="14" font="13">AUTOMATIC TERM MAPPING </text>
<text top="573" left="105" width="171" height="14" font="13">IN PUBMED, SOME MeSH </text>
<text top="592" left="105" width="162" height="14" font="13">TERMS MAY HAVE BEEN </text>
<text top="612" left="105" width="80" height="14" font="13">EMPLOYED  </text>
<text top="533" left="328" width="196" height="14" font="13">Social determinants of health </text>
<text top="632" left="105" width="4" height="14" font="13"> </text>
<text top="632" left="328" width="45" height="14" font="13">Equity </text>
<text top="652" left="105" width="4" height="14" font="13"> </text>
<text top="652" left="328" width="84" height="14" font="13">Social status </text>
<text top="673" left="105" width="4" height="14" font="13"> </text>
<text top="673" left="328" width="120" height="14" font="13">Social deprivation </text>
<text top="693" left="105" width="4" height="14" font="13"> </text>
<text top="693" left="328" width="98" height="14" font="13">Neighborhood </text>
<text top="713" left="105" width="4" height="14" font="13"> </text>
<text top="713" left="328" width="170" height="14" font="13">Neighborhood conditions </text>
<text top="734" left="105" width="4" height="14" font="13"> </text>
<text top="734" left="328" width="71" height="14" font="13">Uninsured </text>
<text top="754" left="105" width="4" height="14" font="13"> </text>
<text top="754" left="328" width="57" height="14" font="13">Housing </text>
<text top="775" left="105" width="4" height="14" font="13"> </text>
<text top="775" left="328" width="84" height="14" font="13">Immigration </text>
<text top="795" left="105" width="4" height="14" font="13"> </text>
<text top="795" left="328" width="172" height="14" font="13">Adverse childhood events </text>
<text top="815" left="105" width="4" height="14" font="13"> </text>
<text top="815" left="328" width="100" height="14" font="13">Social gradient </text>
<text top="835" left="105" width="4" height="14" font="13"> </text>
<text top="835" left="328" width="123" height="14" font="13">Educational status </text>
<text top="856" left="105" width="4" height="14" font="13"> </text>
<text top="856" left="328" width="79" height="14" font="13">Inequalities </text>
<text top="876" left="105" width="4" height="14" font="13"> </text>
<text top="876" left="328" width="62" height="14" font="13">Sexuality </text>
<text top="897" left="105" width="4" height="14" font="13"> </text>
<text top="897" left="328" width="104" height="14" font="13">Atherosclerosis </text>
<text top="917" left="105" width="4" height="14" font="13"> </text>
<text top="917" left="328" width="98" height="14" font="13">cardiovascular </text>
<text top="937" left="105" width="119" height="15" font="27"><i><b>Team Based Care </b></i></text>
<text top="959" left="105" width="467" height="14" font="13">Search limited to English, 1/1/2010-10/14/2018 (though earlier articles </text>
<text top="978" left="105" width="377" height="14" font="13">may have been identified through related articles search) </text>
<text top="998" left="105" width="466" height="14" font="13">Related articles searches were also conducted where potentially highly </text>
<text top="1018" left="105" width="185" height="14" font="13">relevant papers were found<b> </b></text>
<text top="1038" left="105" width="200" height="14" font="13">NONE SPECIFIED, BUT DUE TO </text>
<text top="1058" left="105" width="195" height="14" font="13">AUTOMATIC TERM MAPPING </text>
<text top="1077" left="105" width="171" height="14" font="13">IN PUBMED, SOME MeSH </text>
<text top="1038" left="328" width="37" height="14" font="13">team </text>
</page>
<page number="56" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 54 of 101 </text>
<text top="168" left="105" width="175" height="15" font="7"><b>Medical Subject Headings </b></text>
<text top="188" left="105" width="102" height="15" font="7"><b>(MeSH) Terms  </b></text>
<text top="168" left="328" width="76" height="15" font="7"><b>Key Words </b></text>
<text top="208" left="105" width="162" height="14" font="13">TERMS MAY HAVE BEEN </text>
<text top="228" left="105" width="80" height="14" font="13">EMPLOYED  </text>
<text top="248" left="105" width="4" height="14" font="13"> </text>
<text top="248" left="328" width="4" height="14" font="13"> </text>
<text top="268" left="105" width="4" height="14" font="13"> </text>
<text top="268" left="328" width="72" height="14" font="13">Team care </text>
<text top="289" left="105" width="4" height="14" font="13"> </text>
<text top="289" left="328" width="122" height="14" font="13">Collaborative care </text>
<text top="309" left="105" width="4" height="14" font="13"> </text>
<text top="309" left="328" width="116" height="14" font="13">Multidisciplinary  </text>
<text top="329" left="105" width="4" height="14" font="13"> </text>
<text top="329" left="328" width="93" height="14" font="13">“team based” </text>
<text top="350" left="105" width="4" height="14" font="13"> </text>
<text top="350" left="328" width="116" height="14" font="13">“team approach” </text>
<text top="370" left="105" width="4" height="14" font="13"> </text>
<text top="370" left="328" width="75" height="14" font="13">prevention </text>
<text top="390" left="105" width="4" height="14" font="13"> </text>
<text top="390" left="328" width="130" height="14" font="13">Primary prevention </text>
<text top="411" left="105" width="4" height="14" font="13"> </text>
<text top="411" left="328" width="156" height="14" font="13">Cardiovascular disease, </text>
<text top="431" left="105" width="4" height="14" font="13"> </text>
<text top="431" left="328" width="78" height="14" font="13">Cholesterol </text>
<text top="451" left="105" width="4" height="14" font="13"> </text>
<text top="451" left="328" width="49" height="14" font="13">Aspirin </text>
<text top="472" left="105" width="4" height="14" font="13"> </text>
<text top="472" left="328" width="59" height="14" font="13">Smoking </text>
<text top="492" left="105" width="4" height="14" font="13"> </text>
<text top="492" left="328" width="54" height="14" font="13">Obesity </text>
<text top="512" left="105" width="4" height="14" font="13"> </text>
<text top="512" left="328" width="92" height="14" font="13">Heart disease </text>
<text top="533" left="105" width="4" height="14" font="13"> </text>
<text top="533" left="328" width="104" height="14" font="13">Atherosclerosis </text>
<text top="553" left="105" width="4" height="14" font="13"> </text>
<text top="553" left="328" width="45" height="14" font="13">stroke </text>
<text top="573" left="105" width="164" height="15" font="27"><i><b>Shared Decision Making </b></i></text>
<text top="595" left="105" width="467" height="14" font="13">Search limited to English, 1/1/2010-10/24/2018 (though earlier articles </text>
<text top="615" left="105" width="381" height="14" font="13">may have been identified through related articles search)  </text>
<text top="634" left="105" width="466" height="14" font="13">Related articles searches were also conducted where potentially highly </text>
<text top="654" left="105" width="185" height="14" font="13">relevant papers were found<b> </b></text>
<text top="674" left="105" width="200" height="14" font="13">NONE SPECIFIED, BUT DUE TO </text>
<text top="694" left="105" width="195" height="14" font="13">AUTOMATIC TERM MAPPING </text>
<text top="713" left="105" width="171" height="14" font="13">IN PUBMED, SOME MeSH </text>
<text top="733" left="105" width="162" height="14" font="13">TERMS MAY HAVE BEEN </text>
<text top="753" left="105" width="196" height="14" font="13">AUTOMATICALLY EMPLOYED  </text>
<text top="674" left="328" width="158" height="14" font="13">Shared decision making </text>
<text top="773" left="105" width="4" height="14" font="13"> </text>
<text top="773" left="328" width="75" height="14" font="13">Prevention </text>
<text top="793" left="105" width="4" height="14" font="13"> </text>
<text top="793" left="328" width="103" height="14" font="13">Cardiovascular  </text>
<text top="814" left="105" width="4" height="14" font="13"> </text>
<text top="814" left="328" width="104" height="14" font="13">Atherosclerosis </text>
<text top="834" left="105" width="4" height="14" font="13"> </text>
<text top="834" left="328" width="46" height="14" font="13">Stroke </text>
<text top="854" left="105" width="4" height="14" font="13"> </text>
<text top="854" left="328" width="44" height="14" font="13">Heart  </text>
<text top="875" left="105" width="4" height="14" font="13"> </text>
<text top="875" left="328" width="92" height="14" font="13">Hypertension </text>
<text top="895" left="105" width="4" height="14" font="13"> </text>
<text top="895" left="328" width="41" height="14" font="13">Lipids </text>
<text top="915" left="105" width="4" height="14" font="13"> </text>
<text top="915" left="328" width="78" height="14" font="13">Cholesterol </text>
<text top="936" left="105" width="4" height="14" font="13"> </text>
<text top="936" left="328" width="60" height="14" font="13">diabetes </text>
<text top="956" left="105" width="184" height="15" font="27"><i><b>Exercise &amp; Physical Activity</b></i> </text>
<text top="976" left="105" width="434" height="14" font="13">Search limits: Not ACP Journal Club OR Summaries for patients OR </text>
<text top="996" left="105" width="464" height="14" font="13">Editorial OR case-report OR letter OR letter OR abstract OR newspaper </text>
<text top="1016" left="105" width="444" height="14" font="13">article OR comment OR baseline characteristics OR study design OR </text>
<text top="1035" left="105" width="91" height="14" font="13">methodology </text>
<text top="1055" left="105" width="266" height="14" font="13">Terms to identify clinical trials/SRs/Mas: </text>
<text top="1074" left="105" width="442" height="14" font="13">Filters: Meta-Analysis, Systematic Reviews, Clinical Trial, Controlled </text>
</page>
<page number="57" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 55 of 101 </text>
<text top="168" left="105" width="175" height="15" font="7"><b>Medical Subject Headings </b></text>
<text top="188" left="105" width="102" height="15" font="7"><b>(MeSH) Terms  </b></text>
<text top="168" left="328" width="76" height="15" font="7"><b>Key Words </b></text>
<text top="208" left="105" width="416" height="14" font="13">Clinical Trial, Randomized Controlled Trial, From 2011/01/01 to </text>
<text top="228" left="105" width="309" height="14" font="13">2018/05/25, Humans, English, Adult: 19+ years </text>
<text top="247" left="105" width="262" height="14" font="13">Terms to identify observational studies: </text>
<text top="267" left="105" width="449" height="14" font="13">2011/01/01 to 2018/12/31, Humans, English, Epidemiologic Studies, </text>
<text top="287" left="105" width="405" height="14" font="13">Case-Control Studies, Cohort Studies, Cross-Sectional Studies, </text>
<text top="306" left="105" width="451" height="14" font="13">epidemiolog* AND stud*, case control, cohort stud*, cross sectional, </text>
<text top="326" left="105" width="392" height="14" font="13">cohort analys*, follow up stud*, longitudinal, retrospective, </text>
<text top="345" left="105" width="250" height="14" font="13">prospective, observational AND stud* </text>
<text top="365" left="105" width="158" height="14" font="13">Filters: Adult: 19+ years </text>
<text top="385" left="105" width="142" height="15" font="27"><i><b>Waist Circumference</b></i> </text>
<text top="406" left="105" width="430" height="14" font="13">Search limited to adult populations, 01/01/2010-10/3/18, English </text>
<text top="425" left="105" width="63" height="14" font="13">language </text>
<text top="446" left="105" width="175" height="14" font="13">Acute Coronary Syndrome </text>
<text top="446" left="328" width="179" height="14" font="13">Acute coronary syndromes </text>
<text top="466" left="105" width="111" height="14" font="13">Angina Unstable </text>
<text top="466" left="328" width="244" height="14" font="13">Unstable angina?, “Angina Unstable” </text>
<text top="486" left="105" width="144" height="14" font="13">Myocardial infarction </text>
<text top="486" left="328" width="150" height="14" font="13">Myocardial infarctions </text>
<text top="506" left="105" width="121" height="14" font="13">Shock cardiogenic </text>
<text top="506" left="328" width="133" height="14" font="13">“shock cardiogenic” </text>
<text top="527" left="105" width="138" height="14" font="13">Myocardial Stunning </text>
<text top="527" left="328" width="150" height="14" font="13">“myocardial stunning” </text>
<text top="547" left="105" width="163" height="14" font="13">No Reflow Phenomenon </text>
<text top="547" left="328" width="4" height="14" font="13"> </text>
<text top="568" left="105" width="84" height="14" font="13">Heart Arrest </text>
<text top="568" left="328" width="4" height="14" font="13"> </text>
<text top="588" left="105" width="157" height="14" font="13">St elevation myocardial </text>
<text top="607" left="105" width="67" height="14" font="13">infarction </text>
<text top="588" left="328" width="45" height="14" font="13">STEMI </text>
<text top="628" left="105" width="184" height="14" font="13">Non-st elevated myocardial </text>
<text top="647" left="105" width="67" height="14" font="13">infarction </text>
<text top="628" left="328" width="55" height="14" font="13">NSTEMI </text>
<text top="668" left="105" width="4" height="14" font="13"> </text>
<text top="668" left="328" width="160" height="14" font="13">“death/sudden cardiac” </text>
<text top="688" left="105" width="46" height="14" font="13">Stroke </text>
<text top="688" left="328" width="4" height="14" font="13"> </text>
<text top="708" left="105" width="105" height="14" font="13">Brain Infarction </text>
<text top="708" left="328" width="4" height="14" font="13"> </text>
<text top="729" left="105" width="148" height="14" font="13">Brain Stem Infarctions </text>
<text top="729" left="328" width="4" height="14" font="13"> </text>
<text top="749" left="105" width="196" height="14" font="13">Lateral Meduallary Syndrome </text>
<text top="749" left="328" width="4" height="14" font="13"> </text>
<text top="769" left="105" width="126" height="14" font="13">Cerebral Infarction </text>
<text top="769" left="328" width="4" height="14" font="13"> </text>
<text top="790" left="105" width="4" height="14" font="13"> </text>
<text top="790" left="328" width="138" height="14" font="13">Myocardial ischemia </text>
<text top="810" left="105" width="4" height="14" font="13"> </text>
<text top="810" left="328" width="166" height="14" font="13">“Dementia Multi infarct” </text>
<text top="830" left="105" width="4" height="14" font="13"> </text>
<text top="830" left="328" width="237" height="14" font="13">“infarction anterior cerebral artery” </text>
<text top="851" left="105" width="4" height="14" font="13"> </text>
<text top="851" left="328" width="230" height="14" font="13">“infarction middle cerebral artery” </text>
<text top="871" left="105" width="4" height="14" font="13"> </text>
<text top="871" left="328" width="244" height="14" font="13">“infarction posterior cerebral artery” </text>
<text top="892" left="105" width="191" height="14" font="13">Myocardial revascularization </text>
<text top="892" left="328" width="4" height="14" font="13"> </text>
<text top="912" left="105" width="4" height="14" font="13"> </text>
<text top="912" left="328" width="4" height="14" font="13"> </text>
<text top="932" left="105" width="155" height="14" font="13">Coronary artery bypass </text>
<text top="932" left="328" width="4" height="14" font="13"> </text>
<text top="952" left="105" width="187" height="14" font="13">Internal mammary coronary </text>
<text top="972" left="105" width="128" height="14" font="13">artery anastomosis </text>
<text top="952" left="328" width="4" height="14" font="13"> </text>
<text top="992" left="105" width="80" height="14" font="13">Angioplasty </text>
<text top="992" left="328" width="170" height="14" font="13">&#34;angioplasty transluminal </text>
<text top="1012" left="328" width="162" height="14" font="13">percutaneous coronary&#34; </text>
<text top="1032" left="105" width="86" height="14" font="13">Heart failure </text>
<text top="1032" left="328" width="4" height="14" font="13"> </text>
<text top="1053" left="105" width="101" height="14" font="13">Hospitalization </text>
<text top="1053" left="328" width="132" height="14" font="13">Hospitalization? OR </text>
<text top="1072" left="328" width="120" height="14" font="13">rehospitalization? </text>
</page>
<page number="58" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 56 of 101 </text>
<text top="168" left="105" width="175" height="15" font="7"><b>Medical Subject Headings </b></text>
<text top="188" left="105" width="102" height="15" font="7"><b>(MeSH) Terms  </b></text>
<text top="168" left="328" width="76" height="15" font="7"><b>Key Words </b></text>
<text top="208" left="105" width="4" height="14" font="13"> </text>
<text top="208" left="328" width="163" height="14" font="13">“atherectomy coronary” </text>
<text top="228" left="105" width="4" height="14" font="13"> </text>
<text top="228" left="328" width="101" height="14" font="13">Coronary stent </text>
<text top="249" left="105" width="4" height="14" font="13"> </text>
<text top="249" left="328" width="40" height="14" font="13">CABG </text>
<text top="269" left="105" width="4" height="14" font="13"> </text>
<text top="269" left="328" width="102" height="14" font="13">“bypass grafts” </text>
<text top="289" left="105" width="4" height="14" font="13"> </text>
<text top="289" left="328" width="65" height="14" font="13">“Carotid” </text>
<text top="310" left="105" width="4" height="14" font="13"> </text>
<text top="310" left="328" width="69" height="14" font="13">pathology </text>
<text top="330" left="105" width="4" height="14" font="13"> </text>
<text top="330" left="328" width="112" height="14" font="13">physiopathology </text>
<text top="350" left="105" width="4" height="14" font="13"> </text>
<text top="350" left="328" width="209" height="14" font="13">Non-coronary revascularization </text>
<text top="370" left="328" width="72" height="14" font="13">procedure </text>
<text top="390" left="105" width="4" height="14" font="13"> </text>
<text top="390" left="328" width="173" height="14" font="13">Carotid revascularization? </text>
<text top="411" left="105" width="4" height="14" font="13"> </text>
<text top="411" left="328" width="232" height="14" font="13">Lower extremity revascularization? </text>
<text top="431" left="105" width="4" height="14" font="13"> </text>
<text top="431" left="328" width="179" height="14" font="13">Percutaneous transluminal </text>
<text top="451" left="328" width="78" height="14" font="13">angioplast? </text>
<text top="471" left="105" width="4" height="14" font="13"> </text>
<text top="471" left="328" width="119" height="14" font="13">Stent placement? </text>
<text top="491" left="105" width="4" height="14" font="13"> </text>
<text top="491" left="328" width="234" height="14" font="13">Abdominal aortic aneurysm repair? </text>
<text top="512" left="105" width="4" height="14" font="13"> </text>
<text top="512" left="328" width="82" height="14" font="13">AAA repair? </text>
<text top="532" left="105" width="4" height="14" font="13"> </text>
<text top="532" left="328" width="94" height="14" font="13">complications </text>
<text top="552" left="105" width="4" height="14" font="13"> </text>
<text top="552" left="328" width="226" height="14" font="13">Event? OR outcome? OR episode? </text>
<text top="573" left="105" width="4" height="14" font="13"> </text>
<text top="573" left="328" width="68" height="14" font="13">Risk score </text>
<text top="593" left="105" width="4" height="14" font="13"> </text>
<text top="593" left="328" width="176" height="14" font="13">Coronary risk modification </text>
<text top="613" left="105" width="4" height="14" font="13"> </text>
<text top="613" left="328" width="4" height="14" font="13"> </text>
<text top="634" left="105" width="158" height="14" font="13">Cardiovascular diseases </text>
<text top="634" left="328" width="154" height="14" font="13">Cardiovascular OR CVD </text>
<text top="654" left="105" width="152" height="14" font="13">Cardiovascular disease </text>
<text top="654" left="328" width="4" height="14" font="13"> </text>
<text top="674" left="105" width="116" height="14" font="13">Coronary disease </text>
<text top="674" left="328" width="62" height="14" font="13">coronary </text>
<text top="695" left="105" width="159" height="14" font="13">Coronary artery disease </text>
<text top="695" left="328" width="4" height="14" font="13"> </text>
<text top="715" left="105" width="144" height="14" font="13">Myocardial infarction </text>
<text top="715" left="328" width="4" height="14" font="13"> </text>
<text top="735" left="105" width="86" height="14" font="13">Heart failure </text>
<text top="735" left="328" width="85" height="14" font="13">CHF OR CHD </text>
<text top="756" left="105" width="174" height="14" font="13">Cerebrovascular disorders </text>
<text top="756" left="328" width="4" height="14" font="13"> </text>
<text top="776" left="105" width="4" height="14" font="13"> </text>
<text top="776" left="328" width="150" height="14" font="13">“dyspnea paroxysmal” </text>
<text top="796" left="105" width="4" height="14" font="13"> </text>
<text top="796" left="328" width="112" height="14" font="13">“edema cardiac” </text>
<text top="817" left="105" width="102" height="14" font="13">Physical fitness </text>
<text top="817" left="328" width="4" height="14" font="13"> </text>
<text top="837" left="105" width="96" height="14" font="13">Motor activity </text>
<text top="837" left="328" width="4" height="14" font="13"> </text>
<text top="857" left="105" width="122" height="14" font="13">Exercise tolerance </text>
<text top="857" left="328" width="4" height="14" font="13"> </text>
<text top="878" left="105" width="142" height="14" font="13">Metabolic equivalent </text>
<text top="878" left="328" width="142" height="14" font="13">Metabolic equivalent </text>
<text top="898" left="105" width="86" height="14" font="13">Exercise test </text>
<text top="898" left="328" width="184" height="14" font="13">Graded exercise test OR gxt </text>
<text top="918" left="105" width="133" height="14" font="13">Life style or lifestyle </text>
<text top="918" left="328" width="4" height="14" font="13"> </text>
<text top="939" left="105" width="57" height="14" font="13">Exercise </text>
<text top="939" left="328" width="4" height="14" font="13"> </text>
<text top="959" left="105" width="57" height="14" font="13">Training </text>
<text top="959" left="328" width="4" height="14" font="13"> </text>
<text top="979" left="105" width="56" height="14" font="13">Walking </text>
<text top="979" left="328" width="4" height="14" font="13"> </text>
<text top="1000" left="105" width="4" height="14" font="13"> </text>
<text top="1000" left="328" width="4" height="14" font="13"> </text>
<text top="1020" left="105" width="4" height="14" font="13"> </text>
<text top="1020" left="328" width="29" height="14" font="13">Vo2 </text>
<text top="1040" left="105" width="4" height="14" font="13"> </text>
<text top="1040" left="328" width="90" height="14" font="13">Maximal met </text>
<text top="1061" left="105" width="4" height="14" font="13"> </text>
<text top="1061" left="328" width="37" height="14" font="13">Mets </text>
<text top="1081" left="105" width="4" height="14" font="13"> </text>
<text top="1081" left="328" width="106" height="14" font="13">Physical activity </text>
</page>
<page number="59" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 57 of 101 </text>
<text top="168" left="105" width="175" height="15" font="7"><b>Medical Subject Headings </b></text>
<text top="188" left="105" width="102" height="15" font="7"><b>(MeSH) Terms  </b></text>
<text top="168" left="328" width="76" height="15" font="7"><b>Key Words </b></text>
<text top="208" left="105" width="4" height="14" font="13"> </text>
<text top="208" left="328" width="136" height="14" font="13">Maximal metabolic? </text>
<text top="228" left="105" width="175" height="14" font="13">Acute Coronary Syndrome </text>
<text top="228" left="328" width="179" height="14" font="13">Acute coronary syndromes </text>
<text top="249" left="105" width="111" height="14" font="13">Angina Unstable </text>
<text top="249" left="328" width="244" height="14" font="13">Unstable angina?, “Angina Unstable” </text>
<text top="269" left="105" width="144" height="14" font="13">Myocardial infarction </text>
<text top="269" left="328" width="150" height="14" font="13">Myocardial infarctions </text>
<text top="289" left="105" width="121" height="14" font="13">Shock cardiogenic </text>
<text top="289" left="328" width="133" height="14" font="13">“shock cardiogenic” </text>
<text top="310" left="105" width="138" height="14" font="13">Myocardial Stunning </text>
<text top="310" left="328" width="150" height="14" font="13">“myocardial stunning” </text>
<text top="330" left="105" width="163" height="14" font="13">No Reflow Phenomenon </text>
<text top="330" left="328" width="4" height="14" font="13"> </text>
<text top="350" left="105" width="84" height="14" font="13">Heart Arrest </text>
<text top="350" left="328" width="4" height="14" font="13"> </text>
<text top="371" left="105" width="157" height="14" font="13">St elevation myocardial </text>
<text top="390" left="105" width="67" height="14" font="13">infarction </text>
<text top="371" left="328" width="45" height="14" font="13">STEMI </text>
<text top="411" left="105" width="184" height="14" font="13">Non-st elevated myocardial </text>
<text top="430" left="105" width="67" height="14" font="13">infarction </text>
<text top="411" left="328" width="55" height="14" font="13">NSTEMI </text>
<text top="451" left="105" width="4" height="14" font="13"> </text>
<text top="451" left="328" width="160" height="14" font="13">“death/sudden cardiac” </text>
<text top="471" left="105" width="46" height="14" font="13">Stroke </text>
<text top="471" left="328" width="4" height="14" font="13"> </text>
<text top="491" left="105" width="105" height="14" font="13">Brain Infarction </text>
<text top="491" left="328" width="4" height="14" font="13"> </text>
<text top="512" left="105" width="148" height="14" font="13">Brain Stem Infarctions </text>
<text top="512" left="328" width="4" height="14" font="13"> </text>
<text top="532" left="105" width="196" height="14" font="13">Lateral Meduallary Syndrome </text>
<text top="532" left="328" width="4" height="14" font="13"> </text>
<text top="552" left="105" width="126" height="14" font="13">Cerebral Infarction </text>
<text top="552" left="328" width="4" height="14" font="13"> </text>
<text top="573" left="105" width="4" height="14" font="13"> </text>
<text top="573" left="328" width="138" height="14" font="13">Myocardial ischemia </text>
<text top="593" left="105" width="4" height="14" font="13"> </text>
<text top="593" left="328" width="166" height="14" font="13">“Dementia Multi infarct” </text>
<text top="613" left="105" width="4" height="14" font="13"> </text>
<text top="613" left="328" width="237" height="14" font="13">“infarction anterior cerebral artery” </text>
<text top="634" left="105" width="4" height="14" font="13"> </text>
<text top="634" left="328" width="230" height="14" font="13">“infarction middle cerebral artery” </text>
<text top="654" left="105" width="4" height="14" font="13"> </text>
<text top="654" left="328" width="244" height="14" font="13">“infarction posterior cerebral artery” </text>
<text top="674" left="105" width="191" height="14" font="13">Myocardial revascularization </text>
<text top="674" left="328" width="4" height="14" font="13"> </text>
<text top="695" left="105" width="4" height="14" font="13"> </text>
<text top="695" left="328" width="4" height="14" font="13"> </text>
<text top="715" left="105" width="155" height="14" font="13">Coronary artery bypass </text>
<text top="715" left="328" width="4" height="14" font="13"> </text>
<text top="735" left="105" width="187" height="14" font="13">Internal mammary coronary </text>
<text top="755" left="105" width="128" height="14" font="13">artery anastomosis </text>
<text top="735" left="328" width="4" height="14" font="13"> </text>
<text top="775" left="105" width="80" height="14" font="13">Angioplasty </text>
<text top="775" left="328" width="170" height="14" font="13">&#34;angioplasty transluminal </text>
<text top="795" left="328" width="162" height="14" font="13">percutaneous coronary&#34; </text>
<text top="815" left="105" width="86" height="14" font="13">Heart failure </text>
<text top="815" left="328" width="4" height="14" font="13"> </text>
<text top="836" left="105" width="101" height="14" font="13">Hospitalization </text>
<text top="836" left="328" width="132" height="14" font="13">Hospitalization? OR </text>
<text top="855" left="328" width="120" height="14" font="13">rehospitalization? </text>
<text top="875" left="105" width="4" height="14" font="13"> </text>
<text top="875" left="328" width="163" height="14" font="13">“atherectomy coronary” </text>
<text top="896" left="105" width="4" height="14" font="13"> </text>
<text top="896" left="328" width="101" height="14" font="13">Coronary stent </text>
<text top="916" left="105" width="4" height="14" font="13"> </text>
<text top="916" left="328" width="40" height="14" font="13">CABG </text>
<text top="937" left="105" width="4" height="14" font="13"> </text>
<text top="937" left="328" width="102" height="14" font="13">“bypass grafts” </text>
<text top="957" left="105" width="4" height="14" font="13"> </text>
<text top="957" left="328" width="65" height="14" font="13">“Carotid” </text>
<text top="977" left="105" width="4" height="14" font="13"> </text>
<text top="977" left="328" width="69" height="14" font="13">pathology </text>
<text top="998" left="105" width="4" height="14" font="13"> </text>
<text top="998" left="328" width="112" height="14" font="13">physiopathology </text>
<text top="1018" left="105" width="4" height="14" font="13"> </text>
<text top="1018" left="328" width="209" height="14" font="13">Non-coronary revascularization </text>
<text top="1037" left="328" width="72" height="14" font="13">procedure </text>
<text top="1058" left="105" width="4" height="14" font="13"> </text>
<text top="1058" left="328" width="173" height="14" font="13">Carotid revascularization? </text>
<text top="1078" left="105" width="4" height="14" font="13"> </text>
<text top="1078" left="328" width="232" height="14" font="13">Lower extremity revascularization? </text>
</page>
<page number="60" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 58 of 101 </text>
<text top="168" left="105" width="175" height="15" font="7"><b>Medical Subject Headings </b></text>
<text top="188" left="105" width="102" height="15" font="7"><b>(MeSH) Terms  </b></text>
<text top="168" left="328" width="76" height="15" font="7"><b>Key Words </b></text>
<text top="208" left="105" width="4" height="14" font="13"> </text>
<text top="208" left="328" width="179" height="14" font="13">Percutaneous transluminal </text>
<text top="228" left="328" width="78" height="14" font="13">angioplast? </text>
<text top="248" left="105" width="4" height="14" font="13"> </text>
<text top="248" left="328" width="119" height="14" font="13">Stent placement? </text>
<text top="268" left="105" width="4" height="14" font="13"> </text>
<text top="268" left="328" width="234" height="14" font="13">Abdominal aortic aneurysm repair? </text>
<text top="289" left="105" width="4" height="14" font="13"> </text>
<text top="289" left="328" width="82" height="14" font="13">AAA repair? </text>
<text top="309" left="105" width="4" height="14" font="13"> </text>
<text top="309" left="328" width="94" height="14" font="13">complications </text>
<text top="329" left="105" width="4" height="14" font="13"> </text>
<text top="329" left="328" width="226" height="14" font="13">Event? OR outcome? OR episode? </text>
<text top="350" left="105" width="4" height="14" font="13"> </text>
<text top="350" left="328" width="68" height="14" font="13">Risk score </text>
<text top="370" left="105" width="4" height="14" font="13"> </text>
<text top="370" left="328" width="176" height="14" font="13">Coronary risk modification </text>
<text top="390" left="105" width="4" height="14" font="13"> </text>
<text top="390" left="328" width="4" height="14" font="13"> </text>
<text top="411" left="105" width="158" height="14" font="13">Cardiovascular diseases </text>
<text top="411" left="328" width="154" height="14" font="13">Cardiovascular OR CVD </text>
<text top="431" left="105" width="152" height="14" font="13">Cardiovascular disease </text>
<text top="431" left="328" width="4" height="14" font="13"> </text>
<text top="451" left="105" width="116" height="14" font="13">Coronary disease </text>
<text top="451" left="328" width="62" height="14" font="13">coronary </text>
<text top="472" left="105" width="159" height="14" font="13">Coronary artery disease </text>
<text top="472" left="328" width="4" height="14" font="13"> </text>
<text top="492" left="105" width="144" height="14" font="13">Myocardial infarction </text>
<text top="492" left="328" width="4" height="14" font="13"> </text>
<text top="512" left="105" width="86" height="14" font="13">Heart failure </text>
<text top="512" left="328" width="85" height="14" font="13">CHF OR CHD </text>
<text top="533" left="105" width="174" height="14" font="13">Cerebrovascular disorders </text>
<text top="533" left="328" width="4" height="14" font="13"> </text>
<text top="553" left="105" width="4" height="14" font="13"> </text>
<text top="553" left="328" width="150" height="14" font="13">“dyspnea paroxysmal” </text>
<text top="573" left="105" width="4" height="14" font="13"> </text>
<text top="573" left="328" width="112" height="14" font="13">“edema cardiac” </text>
<text top="594" left="105" width="4" height="14" font="13"> </text>
<text top="594" left="328" width="4" height="14" font="13"> </text>
<text top="614" left="105" width="687" height="13" font="23">Because of automatic term mapping in PubMed, some MeSH terms may have been used even when not explicitly </text>
<text top="631" left="105" width="60" height="13" font="23">specified. </text>
</page>
<page number="61" position="absolute" top="0" left="0" height="892" width="1263">
	<fontspec id="31" size="52" family="Times" color="#e5e5e5"/>
	<fontspec id="32" size="13" family="Times" color="#ffffff"/>
	<fontspec id="33" size="14" family="Times" color="#000000"/>
	<fontspec id="34" size="14" family="Times" color="#000000"/>
	<fontspec id="35" size="12" family="Times" color="#000000"/>
	<fontspec id="36" size="21" family="Times" color="#000000"/>
	<fontspec id="37" size="14" family="Times" color="#000000"/>
	<fontspec id="38" size="14" family="Times" color="#000000"/>
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 59 of 101 </text>
<text top="142" left="159" width="922" height="21" font="36"><b>Appendix 2. Author Relationships With Industry and Other Entities (Relevant)—2019 ACC/AHA </b></text>
<text top="170" left="159" width="613" height="21" font="36"><b>Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="240" left="167" width="78" height="15" font="33"><b>Committee </b></text>
<text top="259" left="176" width="61" height="15" font="33"><b>Member </b></text>
<text top="259" left="336" width="89" height="15" font="33"><b>Employment </b></text>
<text top="259" left="515" width="76" height="15" font="33"><b>Consultant </b></text>
<text top="240" left="618" width="64" height="15" font="33"><b>Speakers </b></text>
<text top="259" left="625" width="52" height="15" font="33"><b>Bureau </b></text>
<text top="220" left="706" width="84" height="15" font="33"><b>Ownership/ </b></text>
<text top="240" left="703" width="88" height="15" font="33"><b>Partnership/ </b></text>
<text top="259" left="716" width="62" height="15" font="33"><b>Principal </b></text>
<text top="240" left="813" width="62" height="15" font="33"><b>Personal </b></text>
<text top="259" left="812" width="64" height="15" font="33"><b>Research </b></text>
<text top="201" left="910" width="90" height="15" font="33"><b>Institutional, </b></text>
<text top="220" left="902" width="106" height="15" font="33"><b>Organizational, </b></text>
<text top="240" left="924" width="61" height="15" font="33"><b>or Other </b></text>
<text top="259" left="897" width="115" height="15" font="33"><b>Financial Benefit </b></text>
<text top="240" left="1045" width="47" height="15" font="33"><b>Expert </b></text>
<text top="259" left="1039" width="57" height="15" font="33"><b>Witness </b></text>
<text top="292" left="159" width="63" height="14" font="37">Donna K. </text>
<text top="311" left="159" width="72" height="14" font="37">Arnett <i>(Co-</i></text>
<text top="331" left="159" width="43" height="14" font="38"><i>Chair)</i> </text>
<text top="292" left="266" width="219" height="14" font="37">University of Kentucky College of </text>
<text top="311" left="266" width="167" height="14" font="37">Public Health—Dean and </text>
<text top="331" left="266" width="174" height="14" font="37">Professor of Epidemiology </text>
<text top="292" left="506" width="39" height="14" font="37">None </text>
<text top="292" left="613" width="39" height="14" font="37">None </text>
<text top="292" left="700" width="39" height="14" font="37">None </text>
<text top="292" left="807" width="39" height="14" font="37">None </text>
<text top="292" left="894" width="39" height="14" font="37">None </text>
<text top="292" left="1028" width="39" height="14" font="37">None </text>
<text top="363" left="159" width="57" height="14" font="37">Roger S. </text>
<text top="382" left="159" width="79" height="14" font="37">Blumenthal </text>
<text top="402" left="159" width="69" height="14" font="38"><i>(Co-Chair)</i> </text>
<text top="363" left="266" width="177" height="14" font="37">Johns Hopkins University—</text>
<text top="382" left="266" width="175" height="14" font="37">Professor of Medicine and </text>
<text top="402" left="266" width="224" height="14" font="37">Director, Ciccarone Center for the </text>
<text top="422" left="266" width="186" height="14" font="37">Prevention of Heart Disease </text>
<text top="363" left="506" width="39" height="14" font="37">None </text>
<text top="363" left="613" width="39" height="14" font="37">None </text>
<text top="363" left="700" width="39" height="14" font="37">None </text>
<text top="363" left="807" width="39" height="14" font="37">None </text>
<text top="363" left="894" width="39" height="14" font="37">None </text>
<text top="363" left="1028" width="39" height="14" font="37">None </text>
<text top="454" left="159" width="77" height="14" font="37">Michelle A. </text>
<text top="473" left="159" width="44" height="14" font="37">Albert </text>
<text top="454" left="266" width="177" height="14" font="37">UCSF School of Medicine—</text>
<text top="473" left="266" width="175" height="14" font="37">Professor of Medicine and </text>
<text top="493" left="266" width="214" height="14" font="37">Director, UCSF NURTURE Center </text>
<text top="454" left="506" width="39" height="14" font="37">None </text>
<text top="454" left="613" width="39" height="14" font="37">None </text>
<text top="454" left="700" width="39" height="14" font="37">None </text>
<text top="454" left="807" width="39" height="14" font="37">None </text>
<text top="454" left="894" width="39" height="14" font="37">None </text>
<text top="454" left="1028" width="39" height="14" font="37">None </text>
<text top="525" left="159" width="72" height="14" font="37">Andrew B. </text>
<text top="544" left="159" width="56" height="14" font="37">Buroker </text>
<text top="525" left="266" width="222" height="14" font="37">Faegre Baker Daniels LLP, Partner </text>
<text top="525" left="506" width="39" height="14" font="37">None </text>
<text top="525" left="613" width="39" height="14" font="37">None </text>
<text top="525" left="700" width="39" height="14" font="37">None </text>
<text top="525" left="807" width="39" height="14" font="37">None </text>
<text top="525" left="894" width="43" height="14" font="37">None  </text>
<text top="525" left="1028" width="39" height="14" font="37">None </text>
<text top="577" left="159" width="72" height="14" font="37">Zachary D. </text>
<text top="596" left="159" width="78" height="14" font="37">Goldberger </text>
<text top="577" left="266" width="220" height="14" font="37">University of Wisconsin School of </text>
<text top="596" left="266" width="193" height="14" font="37">Medicine and Public Health—</text>
<text top="616" left="266" width="216" height="14" font="37">Associate Professor of Medicine, </text>
<text top="635" left="266" width="145" height="14" font="37">Division of Cardiology </text>
<text top="577" left="506" width="39" height="14" font="37">None </text>
<text top="577" left="613" width="39" height="14" font="37">None </text>
<text top="577" left="700" width="39" height="14" font="37">None </text>
<text top="577" left="807" width="39" height="14" font="37">None </text>
<text top="577" left="894" width="39" height="14" font="37">None </text>
<text top="577" left="1028" width="39" height="14" font="37">None </text>
</page>
<page number="62" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 60 of 101 </text>
<text top="154" left="167" width="78" height="15" font="33"><b>Committee </b></text>
<text top="173" left="176" width="61" height="15" font="33"><b>Member </b></text>
<text top="173" left="336" width="89" height="15" font="33"><b>Employment </b></text>
<text top="173" left="515" width="76" height="15" font="33"><b>Consultant </b></text>
<text top="154" left="618" width="64" height="15" font="33"><b>Speakers </b></text>
<text top="173" left="625" width="52" height="15" font="33"><b>Bureau </b></text>
<text top="134" left="706" width="84" height="15" font="33"><b>Ownership/ </b></text>
<text top="154" left="703" width="88" height="15" font="33"><b>Partnership/ </b></text>
<text top="173" left="716" width="62" height="15" font="33"><b>Principal </b></text>
<text top="154" left="813" width="62" height="15" font="33"><b>Personal </b></text>
<text top="173" left="812" width="64" height="15" font="33"><b>Research </b></text>
<text top="114" left="910" width="90" height="15" font="33"><b>Institutional, </b></text>
<text top="134" left="902" width="106" height="15" font="33"><b>Organizational, </b></text>
<text top="154" left="924" width="61" height="15" font="33"><b>or Other </b></text>
<text top="173" left="897" width="115" height="15" font="33"><b>Financial Benefit </b></text>
<text top="154" left="1045" width="47" height="15" font="33"><b>Expert </b></text>
<text top="173" left="1039" width="57" height="15" font="33"><b>Witness </b></text>
<text top="205" left="159" width="86" height="14" font="37">Ellen J. Hahn </text>
<text top="205" left="266" width="219" height="14" font="37">University of Kentucky College of </text>
<text top="225" left="266" width="206" height="14" font="37">Nursing—Professor &amp; Director, </text>
<text top="245" left="266" width="203" height="14" font="37">BREATHE, Deputy Director, UK-</text>
<text top="264" left="266" width="220" height="14" font="37">CARES &amp; Leader, and Community </text>
<text top="284" left="266" width="226" height="14" font="37">Engagement Core; Marcia A. Dake </text>
<text top="303" left="266" width="136" height="14" font="37">Professor of Nursing </text>
<text top="205" left="506" width="39" height="14" font="37">None </text>
<text top="205" left="613" width="39" height="14" font="37">None </text>
<text top="205" left="700" width="39" height="14" font="37">None </text>
<text top="205" left="807" width="39" height="14" font="37">None </text>
<text top="205" left="894" width="39" height="14" font="37">None </text>
<text top="205" left="1028" width="39" height="14" font="37">None </text>
<text top="335" left="159" width="63" height="14" font="37">Cheryl D. </text>
<text top="355" left="159" width="81" height="14" font="37">Himmelfarb </text>
<text top="335" left="266" width="161" height="14" font="37">Johns Hopkins School of </text>
<text top="355" left="266" width="200" height="14" font="37">Nursing—Professor; Associate </text>
<text top="375" left="266" width="223" height="14" font="37">Dean Research, Office for Science </text>
<text top="394" left="266" width="186" height="14" font="37">and Innovation; and Deputy </text>
<text top="414" left="266" width="216" height="14" font="37">Director, Johns Hopkins Institute </text>
<text top="433" left="266" width="189" height="14" font="37">for Clinical and Translational </text>
<text top="453" left="266" width="63" height="14" font="37">Research </text>
<text top="335" left="506" width="39" height="14" font="37">None </text>
<text top="335" left="613" width="39" height="14" font="37">None </text>
<text top="335" left="700" width="39" height="14" font="37">None </text>
<text top="335" left="807" width="39" height="14" font="37">None </text>
<text top="335" left="894" width="39" height="14" font="37">None </text>
<text top="335" left="1028" width="39" height="14" font="37">None </text>
<text top="485" left="159" width="77" height="14" font="37">Amit Khera </text>
<text top="485" left="266" width="181" height="14" font="37">UT Southwestern School of </text>
<text top="505" left="266" width="213" height="14" font="37">Medicine—Professor of Internal </text>
<text top="524" left="266" width="227" height="14" font="37">Medicine and Director, Preventive </text>
<text top="544" left="266" width="133" height="14" font="37">Cardiology Program </text>
<text top="485" left="506" width="39" height="14" font="37">None </text>
<text top="485" left="613" width="39" height="14" font="37">None </text>
<text top="485" left="700" width="39" height="14" font="37">None </text>
<text top="485" left="807" width="39" height="14" font="37">None </text>
<text top="485" left="894" width="39" height="14" font="37">None </text>
<text top="485" left="1028" width="39" height="14" font="37">None </text>
<text top="576" left="159" width="90" height="14" font="37">Donald Lloyd-</text>
<text top="595" left="159" width="40" height="14" font="37">Jones </text>
<text top="576" left="266" width="219" height="14" font="37">Northwestern University—Eileen </text>
<text top="595" left="266" width="171" height="14" font="37">M. Foell Professor; Senior </text>
<text top="615" left="266" width="204" height="14" font="37">Associate Dean for Clinical and </text>
<text top="635" left="266" width="197" height="14" font="37">Translational Research; Chair, </text>
<text top="654" left="266" width="174" height="14" font="37">Department of Preventive </text>
<text top="674" left="266" width="208" height="14" font="37">Medicine; and Director, Clinical </text>
<text top="694" left="266" width="175" height="14" font="37">and Translational Sciences </text>
<text top="713" left="266" width="59" height="14" font="37">Institute </text>
<text top="576" left="506" width="39" height="14" font="37">None </text>
<text top="576" left="613" width="39" height="14" font="37">None </text>
<text top="576" left="700" width="39" height="14" font="37">None </text>
<text top="576" left="807" width="39" height="14" font="37">None </text>
<text top="576" left="894" width="39" height="14" font="37">None </text>
<text top="576" left="1028" width="39" height="14" font="37">None </text>
</page>
<page number="63" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 61 of 101 </text>
<text top="154" left="167" width="78" height="15" font="33"><b>Committee </b></text>
<text top="173" left="176" width="61" height="15" font="33"><b>Member </b></text>
<text top="173" left="336" width="89" height="15" font="33"><b>Employment </b></text>
<text top="173" left="515" width="76" height="15" font="33"><b>Consultant </b></text>
<text top="154" left="618" width="64" height="15" font="33"><b>Speakers </b></text>
<text top="173" left="625" width="52" height="15" font="33"><b>Bureau </b></text>
<text top="134" left="706" width="84" height="15" font="33"><b>Ownership/ </b></text>
<text top="154" left="703" width="88" height="15" font="33"><b>Partnership/ </b></text>
<text top="173" left="716" width="62" height="15" font="33"><b>Principal </b></text>
<text top="154" left="813" width="62" height="15" font="33"><b>Personal </b></text>
<text top="173" left="812" width="64" height="15" font="33"><b>Research </b></text>
<text top="114" left="910" width="90" height="15" font="33"><b>Institutional, </b></text>
<text top="134" left="902" width="106" height="15" font="33"><b>Organizational, </b></text>
<text top="154" left="924" width="61" height="15" font="33"><b>or Other </b></text>
<text top="173" left="897" width="115" height="15" font="33"><b>Financial Benefit </b></text>
<text top="154" left="1045" width="47" height="15" font="33"><b>Expert </b></text>
<text top="173" left="1039" width="57" height="15" font="33"><b>Witness </b></text>
<text top="205" left="159" width="66" height="14" font="37">J. William </text>
<text top="225" left="159" width="55" height="14" font="37">McEvoy </text>
<text top="205" left="266" width="199" height="14" font="37">National University of Ireland, </text>
<text top="225" left="266" width="201" height="14" font="37">Galway Campus—Professor of </text>
<text top="245" left="266" width="210" height="14" font="37">Preventive Cardiology; National </text>
<text top="264" left="266" width="155" height="14" font="37">Institute for Preventive </text>
<text top="284" left="266" width="223" height="14" font="37">Cardiology, Galway—Medical and </text>
<text top="303" left="266" width="222" height="14" font="37">Research Director; and University </text>
<text top="323" left="266" width="174" height="14" font="37">Hospital Galway, Ireland—</text>
<text top="343" left="266" width="159" height="14" font="37">Consultant Cardiologist. </text>
<text top="205" left="506" width="39" height="14" font="37">None </text>
<text top="205" left="613" width="39" height="14" font="37">None </text>
<text top="205" left="700" width="39" height="14" font="37">None </text>
<text top="205" left="807" width="39" height="14" font="37">None </text>
<text top="205" left="894" width="39" height="14" font="37">None </text>
<text top="205" left="1028" width="39" height="14" font="37">None </text>
<text top="375" left="159" width="47" height="14" font="37">Erin D. </text>
<text top="394" left="159" width="51" height="14" font="37">Michos </text>
<text top="375" left="266" width="161" height="14" font="37">Johns Hopkins School of </text>
<text top="394" left="266" width="223" height="14" font="37">Medicine—Associate Professor of </text>
<text top="414" left="266" width="215" height="14" font="37">Medicine and Associate Director </text>
<text top="433" left="266" width="168" height="14" font="37">of Preventive Cardiology, </text>
<text top="453" left="266" width="163" height="14" font="37">Ciccarone Center for the </text>
<text top="472" left="266" width="190" height="14" font="37">Prevention of Heart Disease; </text>
<text top="492" left="266" width="219" height="14" font="37">Johns Hopkins Bloomberg School </text>
<text top="512" left="266" width="183" height="14" font="37">of Public Health—Associate </text>
<text top="531" left="266" width="174" height="14" font="37">Professor of Epidemiology </text>
<text top="375" left="506" width="39" height="14" font="37">None </text>
<text top="375" left="613" width="39" height="14" font="37">None </text>
<text top="375" left="700" width="39" height="14" font="37">None </text>
<text top="375" left="807" width="39" height="14" font="37">None </text>
<text top="375" left="894" width="39" height="14" font="37">None </text>
<text top="375" left="1028" width="39" height="14" font="37">None </text>
<text top="564" left="159" width="73" height="14" font="37">Michael D. </text>
<text top="583" left="159" width="66" height="14" font="37">Miedema </text>
<text top="564" left="266" width="194" height="14" font="37">Minneapolis Heart Institute—</text>
<text top="583" left="266" width="144" height="14" font="37">Research Cardiologist </text>
<text top="564" left="506" width="39" height="14" font="37">None </text>
<text top="564" left="613" width="39" height="14" font="37">None </text>
<text top="564" left="700" width="39" height="14" font="37">None </text>
<text top="564" left="807" width="39" height="14" font="37">None </text>
<text top="564" left="894" width="39" height="14" font="37">None </text>
<text top="564" left="1028" width="39" height="14" font="37">None </text>
<text top="615" left="159" width="305" height="14" font="37">Daniel Muñoz  Vanderbilt University Medical </text>
<text top="635" left="266" width="203" height="14" font="37">Center—Assistant Professor of </text>
<text top="654" left="266" width="217" height="14" font="37">Medicine, Division of Cardiology, </text>
<text top="674" left="266" width="190" height="14" font="37">Medical Director for Quality, </text>
<text top="694" left="266" width="186" height="14" font="37">Vanderbilt Heart &amp; Vascular </text>
<text top="713" left="266" width="212" height="14" font="37">Institute, and Associate Medical </text>
<text top="733" left="266" width="187" height="14" font="37">Director, Cardiovascular ICU </text>
<text top="615" left="506" width="39" height="14" font="37">None </text>
<text top="615" left="613" width="39" height="14" font="37">None </text>
<text top="615" left="700" width="39" height="14" font="37">None </text>
<text top="615" left="807" width="39" height="14" font="37">None </text>
<text top="615" left="894" width="39" height="14" font="37">None </text>
<text top="615" left="1028" width="39" height="14" font="37">None </text>
</page>
<page number="64" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 62 of 101 </text>
<text top="154" left="167" width="78" height="15" font="33"><b>Committee </b></text>
<text top="173" left="176" width="61" height="15" font="33"><b>Member </b></text>
<text top="173" left="336" width="89" height="15" font="33"><b>Employment </b></text>
<text top="173" left="515" width="76" height="15" font="33"><b>Consultant </b></text>
<text top="154" left="618" width="64" height="15" font="33"><b>Speakers </b></text>
<text top="173" left="625" width="52" height="15" font="33"><b>Bureau </b></text>
<text top="134" left="706" width="84" height="15" font="33"><b>Ownership/ </b></text>
<text top="154" left="703" width="88" height="15" font="33"><b>Partnership/ </b></text>
<text top="173" left="716" width="62" height="15" font="33"><b>Principal </b></text>
<text top="154" left="813" width="62" height="15" font="33"><b>Personal </b></text>
<text top="173" left="812" width="64" height="15" font="33"><b>Research </b></text>
<text top="114" left="910" width="90" height="15" font="33"><b>Institutional, </b></text>
<text top="134" left="902" width="106" height="15" font="33"><b>Organizational, </b></text>
<text top="154" left="924" width="61" height="15" font="33"><b>or Other </b></text>
<text top="173" left="897" width="115" height="15" font="33"><b>Financial Benefit </b></text>
<text top="154" left="1045" width="47" height="15" font="33"><b>Expert </b></text>
<text top="173" left="1039" width="57" height="15" font="33"><b>Witness </b></text>
<text top="205" left="159" width="63" height="14" font="37">Sidney C. </text>
<text top="225" left="159" width="60" height="14" font="37">Smith, Jr </text>
<text top="205" left="266" width="190" height="14" font="37">University of North Carolina, </text>
<text top="225" left="266" width="167" height="14" font="37">Chapel Hill—Professor of </text>
<text top="245" left="266" width="213" height="14" font="37">Medicine, Division of Cardiology </text>
<text top="205" left="506" width="39" height="14" font="37">None </text>
<text top="205" left="613" width="39" height="14" font="37">None </text>
<text top="205" left="700" width="39" height="14" font="37">None </text>
<text top="205" left="807" width="39" height="14" font="37">None </text>
<text top="205" left="894" width="39" height="14" font="37">None </text>
<text top="205" left="1028" width="39" height="14" font="37">None </text>
<text top="276" left="159" width="54" height="14" font="37">Salim S. </text>
<text top="296" left="159" width="42" height="14" font="37">Virani </text>
<text top="276" left="266" width="189" height="14" font="37">Baylor College of Medicine—</text>
<text top="296" left="266" width="138" height="14" font="37">Professor, Section of </text>
<text top="316" left="266" width="191" height="14" font="37">Cardiovascular Research and </text>
<text top="335" left="266" width="220" height="14" font="37">Director for Research, Cardiology </text>
<text top="355" left="266" width="194" height="14" font="37">Fellowship Training Program; </text>
<text top="375" left="266" width="209" height="14" font="37">Michael E. DeBakey VA Medical </text>
<text top="394" left="266" width="202" height="14" font="37">Center—Staff Cardiologist and </text>
<text top="414" left="266" width="178" height="14" font="37">Investigator, Health Policy, </text>
<text top="433" left="266" width="207" height="14" font="37">Quality &amp; Informatics Program, </text>
<text top="453" left="266" width="221" height="14" font="37">Center for Innovations in Quality, </text>
<text top="472" left="266" width="162" height="14" font="37">Effectiveness and Safety </text>
<text top="276" left="506" width="39" height="14" font="37">None </text>
<text top="276" left="613" width="39" height="14" font="37">None </text>
<text top="276" left="700" width="39" height="14" font="37">None </text>
<text top="276" left="807" width="39" height="14" font="37">None </text>
<text top="276" left="894" width="39" height="14" font="37">None </text>
<text top="276" left="1028" width="39" height="14" font="37">None </text>
<text top="505" left="159" width="46" height="14" font="37">Kim A. </text>
<text top="524" left="159" width="80" height="14" font="37">Williams, Sr </text>
<text top="505" left="266" width="214" height="14" font="37">Rush Medical College—James B. </text>
<text top="524" left="266" width="185" height="14" font="37">Herrick Professor and Chief, </text>
<text top="544" left="266" width="149" height="14" font="37">Division of Cardiology, </text>
<text top="564" left="266" width="220" height="14" font="37">Department of Internal Medicine </text>
<text top="505" left="506" width="39" height="14" font="37">None </text>
<text top="505" left="613" width="39" height="14" font="37">None </text>
<text top="505" left="700" width="39" height="14" font="37">None </text>
<text top="505" left="807" width="39" height="14" font="37">None </text>
<text top="505" left="894" width="39" height="14" font="37">None </text>
<text top="505" left="1028" width="39" height="14" font="37">None </text>
<text top="595" left="159" width="48" height="14" font="37">Joseph </text>
<text top="615" left="159" width="53" height="14" font="37">Yeboah </text>
<text top="595" left="266" width="193" height="14" font="37">Wake Forest Baptist Health—</text>
<text top="615" left="266" width="190" height="14" font="37">Associate Professor, Internal </text>
<text top="635" left="266" width="168" height="14" font="37">Medicine, Cardiovascular </text>
<text top="595" left="506" width="39" height="14" font="37">None </text>
<text top="595" left="613" width="39" height="14" font="37">None </text>
<text top="595" left="700" width="39" height="14" font="37">None </text>
<text top="595" left="807" width="39" height="14" font="37">None </text>
<text top="595" left="894" width="39" height="14" font="37">None </text>
<text top="595" left="1028" width="39" height="14" font="37">None </text>
<text top="667" left="159" width="51" height="14" font="37">Boback </text>
<text top="686" left="159" width="50" height="14" font="37">Ziaeian </text>
<text top="667" left="266" width="194" height="14" font="37">University of California at Los </text>
<text top="686" left="266" width="211" height="14" font="37">Angeles, David Geffen School of </text>
<text top="706" left="266" width="197" height="14" font="37">Medicine—Clinical Instructor, </text>
<text top="726" left="266" width="145" height="14" font="37">Division of Cardiology </text>
<text top="667" left="506" width="39" height="14" font="37">None </text>
<text top="667" left="613" width="39" height="14" font="37">None </text>
<text top="667" left="700" width="39" height="14" font="37">None </text>
<text top="667" left="807" width="39" height="14" font="37">None </text>
<text top="667" left="894" width="39" height="14" font="37">None </text>
<text top="667" left="1028" width="39" height="14" font="37">None </text>
</page>
<page number="65" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 63 of 101 </text>
<text top="114" left="159" width="909" height="14" font="37">This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this </text>
<text top="135" left="159" width="928" height="14" font="37">document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee </text>
<text top="156" left="159" width="949" height="14" font="37">during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person </text>
<text top="177" left="159" width="916" height="14" font="37">is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business </text>
<text top="198" left="159" width="949" height="14" font="37">entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed </text>
<text top="220" left="159" width="913" height="14" font="37">5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of </text>
<text top="241" left="159" width="506" height="14" font="37">transparency. Relationships in this table are modest unless otherwise noted.  </text>
<text top="274" left="159" width="929" height="14" font="37">According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, </text>
<text top="295" left="159" width="937" height="14" font="37">intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a </text>
<text top="316" left="159" width="924" height="14" font="37">drug, drug class, or device addressed in the document or makes a competing drug or device addressed in the document; or c) the person or a </text>
<text top="337" left="159" width="889" height="14" font="37">member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the </text>
<text top="358" left="159" width="286" height="14" font="37">issues/content addressed in the document. </text>
<text top="391" left="159" width="914" height="14" font="37">ACC indicated American College of Cardiology; AHA, American Heart Association; ICU, Intensive Care Unit; LLP, Limited Liability Partnership; </text>
<text top="411" left="159" width="618" height="14" font="37">UCSF, University of California, San Francisco; UT, University of Texas; and VA, Veterans Affairs. </text>
<text top="430" left="159" width="4" height="14" font="37"> </text>
<text top="430" left="369" width="4" height="14" font="37"> </text>
</page>
<page number="66" position="absolute" top="0" left="0" height="892" width="1263">
	<fontspec id="39" size="21" family="Times" color="#000000"/>
	<fontspec id="40" size="11" family="Times" color="#000000"/>
	<fontspec id="41" size="11" family="Times" color="#000000"/>
	<fontspec id="42" size="11" family="Symbol" color="#000000"/>
	<fontspec id="43" size="11" family="Helvetica" color="#000000"/>
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 64 of 101 </text>
<text top="116" left="159" width="913" height="21" font="36"><b>Appendix 3. Reviewer Relationships With Industry and Other Entities (Comprehensive)—2019 </b></text>
<text top="144" left="159" width="711" height="21" font="36"><b>ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease</b> </text>
<text top="238" left="141" width="54" height="12" font="40"><b>Reviewer </b></text>
<text top="238" left="224" width="87" height="12" font="40"><b>Representation </b></text>
<text top="238" left="336" width="72" height="12" font="40"><b>Employment </b></text>
<text top="238" left="451" width="62" height="12" font="40"><b>Consultant </b></text>
<text top="222" left="563" width="52" height="12" font="40"><b>Speakers </b></text>
<text top="238" left="568" width="42" height="12" font="40"><b>Bureau </b></text>
<text top="206" left="650" width="68" height="12" font="40"><b>Ownership/ </b></text>
<text top="222" left="648" width="72" height="12" font="40"><b>Partnership/ </b></text>
<text top="238" left="658" width="51" height="12" font="40"><b>Principal </b></text>
<text top="222" left="752" width="50" height="12" font="40"><b>Personal </b></text>
<text top="238" left="751" width="52" height="12" font="40"><b>Research </b></text>
<text top="174" left="842" width="73" height="12" font="40"><b>Institutional, </b></text>
<text top="190" left="836" width="86" height="12" font="40"><b>Organizational, </b></text>
<text top="206" left="854" width="49" height="12" font="40"><b>or Other </b></text>
<text top="222" left="853" width="51" height="12" font="40"><b>Financial </b></text>
<text top="238" left="858" width="43" height="12" font="40"><b>Benefit </b></text>
<text top="238" left="941" width="85" height="12" font="40"><b>Expert Witness </b></text>
<text top="238" left="1058" width="36" height="12" font="40"><b>Salary </b></text>
<text top="267" left="125" width="78" height="12" font="41">Amy Peterson </text>
<text top="267" left="224" width="40" height="12" font="41">Official </text>
<text top="283" left="224" width="62" height="12" font="41">Reviewer—</text>
<text top="299" left="224" width="27" height="12" font="41">AHA </text>
<text top="267" left="324" width="47" height="12" font="41">Hospital </text>
<text top="283" left="324" width="64" height="12" font="41">Affiliations: </text>
<text top="299" left="324" width="92" height="12" font="41">American Family </text>
<text top="315" left="324" width="56" height="12" font="41">Children’s </text>
<text top="331" left="324" width="50" height="12" font="41">Hospital; </text>
<text top="347" left="324" width="59" height="12" font="41">UnityPoint </text>
<text top="363" left="324" width="95" height="12" font="41">Health—Meriter; </text>
<text top="379" left="324" width="75" height="12" font="41">UW School of </text>
<text top="395" left="324" width="75" height="12" font="41">Medicine and </text>
<text top="411" left="324" width="73" height="12" font="41">Public Health </text>
<text top="427" left="324" width="82" height="12" font="41">Department of </text>
<text top="443" left="324" width="55" height="12" font="41">Pediatrics </text>
<text top="267" left="434" width="32" height="12" font="41">None </text>
<text top="267" left="544" width="32" height="12" font="41">None </text>
<text top="267" left="648" width="32" height="12" font="41">None </text>
<text top="267" left="733" width="32" height="12" font="41">None </text>
<text top="267" left="834" width="32" height="12" font="41">None </text>
<text top="267" left="936" width="32" height="12" font="41">None </text>
<text top="267" left="1043" width="32" height="12" font="41">None </text>
<text top="460" left="125" width="82" height="12" font="41">Kim K. Birtcher </text>
<text top="460" left="224" width="40" height="12" font="41">Official </text>
<text top="476" left="224" width="62" height="12" font="41">Reviewer—</text>
<text top="492" left="224" width="80" height="12" font="41">ACC/AHA Task </text>
<text top="508" left="224" width="50" height="12" font="41">Force on </text>
<text top="524" left="224" width="86" height="12" font="41">Clinical Practice </text>
<text top="540" left="224" width="59" height="12" font="41">Guidelines </text>
<text top="556" left="224" width="81" height="12" font="41">Lead Reviewer </text>
<text top="460" left="324" width="71" height="12" font="41">University of </text>
<text top="476" left="324" width="94" height="12" font="41">Houston, College </text>
<text top="492" left="324" width="73" height="12" font="41">of Pharmacy, </text>
<text top="508" left="324" width="94" height="12" font="41">Clinical Professor </text>
<text top="457" left="434" width="6" height="17" font="42">•</text>
<text top="461" left="440" width="4" height="12" font="43"> </text>
<text top="461" left="448" width="45" height="12" font="41">Jones &amp; </text>
<text top="476" left="448" width="44" height="12" font="41">Bartlett </text>
<text top="493" left="448" width="49" height="12" font="41">Learning </text>
<text top="460" left="544" width="32" height="12" font="41">None </text>
<text top="460" left="648" width="32" height="12" font="41">None </text>
<text top="460" left="733" width="32" height="12" font="41">None </text>
<text top="457" left="834" width="6" height="17" font="42">•</text>
<text top="461" left="840" width="4" height="12" font="43"> </text>
<text top="461" left="849" width="74" height="12" font="41">Accreditation </text>
<text top="476" left="849" width="61" height="12" font="41">Council for </text>
<text top="493" left="849" width="41" height="12" font="41">Clinical </text>
<text top="509" left="849" width="57" height="12" font="41">Lipidology </text>
<text top="525" left="849" width="38" height="12" font="41">(Other </text>
<text top="541" left="849" width="60" height="12" font="41">category)† </text>
<text top="460" left="936" width="32" height="12" font="41">None </text>
<text top="460" left="1043" width="32" height="12" font="41">None </text>
<text top="585" left="125" width="79" height="12" font="41">Sanjay Gandhi </text>
<text top="585" left="224" width="40" height="12" font="41">Official </text>
<text top="600" left="224" width="86" height="12" font="41">Reviewer—ACC </text>
<text top="585" left="324" width="75" height="12" font="41">Metro Health </text>
<text top="600" left="324" width="84" height="12" font="41">Medical Center </text>
<text top="617" left="324" width="58" height="12" font="41">Cleveland, </text>
<text top="632" left="324" width="54" height="12" font="41">Associate </text>
<text top="649" left="324" width="85" height="12" font="41">Professor, Case </text>
<text top="664" left="324" width="94" height="12" font="41">Western Reserve </text>
<text top="681" left="324" width="95" height="12" font="41">University School </text>
<text top="697" left="324" width="66" height="12" font="41">of Medicine </text>
<text top="585" left="434" width="32" height="12" font="41">None </text>
<text top="585" left="544" width="32" height="12" font="41">None </text>
<text top="585" left="648" width="32" height="12" font="41">None </text>
<text top="581" left="733" width="6" height="17" font="42">•</text>
<text top="585" left="739" width="4" height="12" font="43"> </text>
<text top="585" left="747" width="55" height="12" font="41">Cleveland </text>
<text top="601" left="747" width="55" height="12" font="41">Heart Lab </text>
<text top="614" left="733" width="6" height="17" font="42">•</text>
<text top="618" left="739" width="4" height="12" font="43"> </text>
<text top="618" left="747" width="49" height="12" font="41">Juventas </text>
<text top="581" left="834" width="6" height="17" font="42">•</text>
<text top="585" left="840" width="4" height="12" font="43"> </text>
<text top="585" left="849" width="49" height="12" font="41">Athersys </text>
<text top="601" left="849" width="68" height="12" font="41">(Data Safety </text>
<text top="617" left="849" width="63" height="12" font="41">Monitoring </text>
<text top="633" left="849" width="39" height="12" font="41">Board) </text>
<text top="646" left="834" width="6" height="17" font="42">•</text>
<text top="650" left="840" width="4" height="12" font="43"> </text>
<text top="650" left="849" width="49" height="12" font="41">Tendyne </text>
<text top="666" left="849" width="38" height="12" font="41">(Other </text>
<text top="682" left="849" width="53" height="12" font="41">category) </text>
<text top="585" left="936" width="32" height="12" font="41">None </text>
<text top="585" left="1043" width="32" height="12" font="41">None </text>
</page>
<page number="67" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 65 of 101 </text>
<text top="114" left="125" width="71" height="12" font="41">Andrea Price </text>
<text top="114" left="224" width="40" height="12" font="41">Official </text>
<text top="130" left="224" width="86" height="12" font="41">Reviewer—ACC </text>
<text top="146" left="224" width="66" height="12" font="41">Science and </text>
<text top="162" left="224" width="41" height="12" font="41">Quality </text>
<text top="178" left="224" width="63" height="12" font="41">Committee </text>
<text top="114" left="324" width="41" height="12" font="41">Quality </text>
<text top="130" left="324" width="72" height="12" font="41">Databases at </text>
<text top="146" left="324" width="42" height="12" font="41">Indiana </text>
<text top="162" left="324" width="57" height="12" font="41">University </text>
<text top="178" left="324" width="88" height="12" font="41">Health, Director </text>
<text top="114" left="434" width="32" height="12" font="41">None </text>
<text top="114" left="544" width="32" height="12" font="41">None </text>
<text top="114" left="648" width="32" height="12" font="41">None </text>
<text top="114" left="733" width="32" height="12" font="41">None </text>
<text top="111" left="834" width="6" height="17" font="42">•</text>
<text top="115" left="840" width="4" height="12" font="43"> </text>
<text top="115" left="849" width="31" height="12" font="41">ACC* </text>
<text top="114" left="936" width="32" height="12" font="41">None </text>
<text top="114" left="1043" width="32" height="12" font="41">None </text>
<text top="207" left="125" width="58" height="12" font="41">Jennifer E. </text>
<text top="223" left="125" width="40" height="12" font="41">Sanner </text>
<text top="239" left="125" width="66" height="12" font="41">Beauchamp </text>
<text top="207" left="224" width="46" height="12" font="41">Content </text>
<text top="223" left="224" width="62" height="12" font="41">Reviewer—</text>
<text top="239" left="224" width="27" height="12" font="41">AHA </text>
<text top="207" left="324" width="71" height="12" font="41">University of </text>
<text top="223" left="324" width="71" height="12" font="41">Texas Health </text>
<text top="239" left="324" width="85" height="12" font="41">Science Center, </text>
<text top="255" left="324" width="79" height="12" font="41">Cizik School of </text>
<text top="271" left="324" width="47" height="12" font="41">Nursing, </text>
<text top="287" left="324" width="54" height="12" font="41">Associate </text>
<text top="303" left="324" width="54" height="12" font="41">Professor </text>
<text top="207" left="434" width="32" height="12" font="41">None </text>
<text top="207" left="544" width="32" height="12" font="41">None </text>
<text top="207" left="648" width="32" height="12" font="41">None </text>
<text top="207" left="733" width="32" height="12" font="41">None </text>
<text top="207" left="834" width="32" height="12" font="41">None </text>
<text top="207" left="936" width="32" height="12" font="41">None </text>
<text top="207" left="1043" width="32" height="12" font="41">None </text>
<text top="331" left="125" width="49" height="12" font="41">Glenn N. </text>
<text top="347" left="125" width="38" height="12" font="41">Levine </text>
<text top="331" left="224" width="46" height="12" font="41">Content </text>
<text top="347" left="224" width="62" height="12" font="41">Reviewer—</text>
<text top="363" left="224" width="80" height="12" font="41">ACC/AHA Task </text>
<text top="379" left="224" width="50" height="12" font="41">Force on </text>
<text top="395" left="224" width="86" height="12" font="41">Clinical Practice </text>
<text top="411" left="224" width="59" height="12" font="41">Guidelines </text>
<text top="331" left="324" width="68" height="12" font="41">Professor of </text>
<text top="347" left="324" width="66" height="12" font="41">Medicine at </text>
<text top="363" left="324" width="93" height="12" font="41">Baylor College of </text>
<text top="379" left="324" width="65" height="12" font="41">Medicine in </text>
<text top="395" left="324" width="85" height="12" font="41">Houston, Texas </text>
<text top="331" left="434" width="32" height="12" font="41">None </text>
<text top="331" left="544" width="32" height="12" font="41">None </text>
<text top="331" left="648" width="32" height="12" font="41">None </text>
<text top="331" left="733" width="32" height="12" font="41">None </text>
<text top="331" left="834" width="32" height="12" font="41">None </text>
<text top="328" left="936" width="6" height="17" font="42">•</text>
<text top="332" left="942" width="4" height="12" font="43"> </text>
<text top="332" left="951" width="37" height="12" font="41">Out of </text>
<text top="348" left="951" width="45" height="12" font="41">hospital </text>
<text top="364" left="951" width="74" height="12" font="41">cardiopulmon</text>
<text top="380" left="951" width="54" height="12" font="41">ary arrest </text>
<text top="396" left="951" width="29" height="12" font="41">2017 </text>
<text top="412" left="951" width="74" height="12" font="41">(Defendant)* </text>
<text top="425" left="936" width="6" height="17" font="42">•</text>
<text top="429" left="942" width="4" height="12" font="43"> </text>
<text top="429" left="951" width="37" height="12" font="41">Out of </text>
<text top="445" left="951" width="79" height="12" font="41">hospital death </text>
<text top="461" left="951" width="29" height="12" font="41">2018 </text>
<text top="477" left="951" width="74" height="12" font="41">(Defendant)* </text>
<text top="331" left="1043" width="32" height="12" font="41">None </text>
<text top="494" left="125" width="52" height="12" font="41">Patrick T. </text>
<text top="510" left="125" width="40" height="12" font="41">O’Gara </text>
<text top="494" left="224" width="46" height="12" font="41">Content </text>
<text top="510" left="224" width="62" height="12" font="41">Reviewer—</text>
<text top="526" left="224" width="80" height="12" font="41">ACC/AHA Task </text>
<text top="542" left="224" width="50" height="12" font="41">Force on </text>
<text top="558" left="224" width="86" height="12" font="41">Clinical Practice </text>
<text top="574" left="224" width="59" height="12" font="41">Guidelines </text>
<text top="494" left="324" width="61" height="12" font="41">Director of </text>
<text top="510" left="324" width="50" height="12" font="41">Strategic </text>
<text top="526" left="324" width="88" height="12" font="41">Planning for the </text>
<text top="542" left="324" width="81" height="12" font="41">Cardiovascular </text>
<text top="558" left="324" width="59" height="12" font="41">Division at </text>
<text top="574" left="324" width="70" height="12" font="41">Brigham and </text>
<text top="590" left="324" width="54" height="12" font="41">Women’s </text>
<text top="606" left="324" width="71" height="12" font="41">Hospital, the </text>
<text top="622" left="324" width="84" height="12" font="41">Watkins Family </text>
<text top="638" left="324" width="75" height="12" font="41">Distinguished </text>
<text top="654" left="324" width="43" height="12" font="41">Chair in </text>
<text top="670" left="324" width="83" height="12" font="41">Cardiology and </text>
<text top="686" left="324" width="68" height="12" font="41">Professor of </text>
<text top="702" left="324" width="66" height="12" font="41">Medicine at </text>
<text top="718" left="324" width="91" height="12" font="41">Harvard Medical </text>
<text top="735" left="324" width="38" height="12" font="41">School </text>
<text top="494" left="434" width="32" height="12" font="41">None </text>
<text top="494" left="544" width="32" height="12" font="41">None </text>
<text top="494" left="648" width="32" height="12" font="41">None </text>
<text top="494" left="733" width="32" height="12" font="41">None </text>
<text top="491" left="834" width="6" height="17" font="42">•</text>
<text top="494" left="840" width="4" height="12" font="43"> </text>
<text top="494" left="849" width="49" height="12" font="41">Edwards </text>
<text top="511" left="849" width="51" height="12" font="41">Scientific </text>
<text top="526" left="849" width="49" height="12" font="41">(Other)† </text>
<text top="540" left="834" width="6" height="17" font="42">•</text>
<text top="543" left="840" width="4" height="12" font="43"> </text>
<text top="543" left="849" width="59" height="12" font="41">Medtronic </text>
<text top="559" left="849" width="42" height="12" font="41">(Other) </text>
<text top="572" left="834" width="6" height="17" font="42">•</text>
<text top="576" left="840" width="4" height="12" font="43"> </text>
<text top="576" left="849" width="72" height="12" font="41">NIH (Other)* </text>
<text top="494" left="936" width="32" height="12" font="41">None </text>
<text top="494" left="1043" width="32" height="12" font="41">None </text>
</page>
<page number="68" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 66 of 101 </text>
<text top="114" left="125" width="53" height="12" font="41">Joshua A. </text>
<text top="130" left="125" width="52" height="12" font="41">Beckman </text>
<text top="114" left="224" width="46" height="12" font="41">Content </text>
<text top="130" left="224" width="62" height="12" font="41">Reviewer—</text>
<text top="146" left="224" width="80" height="12" font="41">ACC/AHA Task </text>
<text top="162" left="224" width="50" height="12" font="41">Force on </text>
<text top="178" left="224" width="86" height="12" font="41">Clinical Practice </text>
<text top="194" left="224" width="59" height="12" font="41">Guidelines </text>
<text top="114" left="324" width="50" height="12" font="41">Director, </text>
<text top="130" left="324" width="48" height="12" font="41">Vascular </text>
<text top="146" left="324" width="56" height="12" font="41">Medicine; </text>
<text top="162" left="324" width="68" height="12" font="41">Professor of </text>
<text top="178" left="324" width="66" height="12" font="41">Medicine at </text>
<text top="194" left="324" width="59" height="12" font="41">Vanderbilt </text>
<text top="210" left="324" width="57" height="12" font="41">University </text>
<text top="111" left="434" width="6" height="17" font="42">•</text>
<text top="115" left="440" width="4" height="12" font="43"> </text>
<text top="115" left="448" width="36" height="12" font="41">Aralez </text>
<text top="131" left="448" width="80" height="12" font="41">Pharmaceutica</text>
<text top="147" left="448" width="18" height="12" font="41">ls* </text>
<text top="160" left="434" width="6" height="17" font="42">•</text>
<text top="164" left="440" width="4" height="12" font="43"> </text>
<text top="164" left="448" width="72" height="12" font="41">Astra Zeneca </text>
<text top="180" left="448" width="80" height="12" font="41">Pharmaceutica</text>
<text top="196" left="448" width="18" height="12" font="41">ls* </text>
<text top="208" left="434" width="6" height="17" font="42">•</text>
<text top="212" left="440" width="4" height="12" font="43"> </text>
<text top="212" left="448" width="44" height="12" font="41">Janssen </text>
<text top="228" left="448" width="51" height="12" font="41">Scientific </text>
<text top="244" left="448" width="44" height="12" font="41">Affairs* </text>
<text top="257" left="434" width="6" height="17" font="42">•</text>
<text top="261" left="440" width="4" height="12" font="43"> </text>
<text top="261" left="448" width="68" height="12" font="41">ER Squibb &amp; </text>
<text top="277" left="448" width="28" height="12" font="41">Sons </text>
<text top="290" left="434" width="6" height="17" font="42">•</text>
<text top="294" left="440" width="4" height="12" font="43"> </text>
<text top="294" left="448" width="62" height="12" font="41">Boehringer </text>
<text top="310" left="448" width="56" height="12" font="41">Ingelheim </text>
<text top="326" left="448" width="80" height="12" font="41">Pharmaceutica</text>
<text top="342" left="448" width="18" height="12" font="41">ls* </text>
<text top="355" left="434" width="6" height="17" font="42">•</text>
<text top="359" left="440" width="4" height="12" font="43"> </text>
<text top="359" left="448" width="37" height="12" font="41">Merck </text>
<text top="372" left="434" width="6" height="17" font="42">•</text>
<text top="375" left="440" width="4" height="12" font="43"> </text>
<text top="375" left="448" width="36" height="12" font="41">Sanofi </text>
<text top="111" left="544" width="6" height="17" font="42">•</text>
<text top="115" left="550" width="4" height="12" font="43"> </text>
<text top="115" left="558" width="69" height="12" font="41">AstraZeneca </text>
<text top="131" left="558" width="73" height="12" font="41">Pharmaceutic</text>
<text top="147" left="558" width="17" height="12" font="41">als </text>
<text top="114" left="648" width="32" height="12" font="41">None </text>
<text top="111" left="733" width="6" height="17" font="42">•</text>
<text top="115" left="739" width="4" height="12" font="43"> </text>
<text top="115" left="747" width="38" height="12" font="41">Bristol-</text>
<text top="131" left="747" width="36" height="12" font="41">Myers </text>
<text top="147" left="747" width="46" height="12" font="41">Squibb* </text>
<text top="111" left="834" width="6" height="17" font="42">•</text>
<text top="115" left="840" width="4" height="12" font="43"> </text>
<text top="115" left="847" width="66" height="12" font="41">Bayer (Data </text>
<text top="131" left="847" width="36" height="12" font="41">Safety </text>
<text top="147" left="847" width="63" height="12" font="41">Monitoring </text>
<text top="163" left="847" width="45" height="12" font="41">Board)* </text>
<text top="176" left="834" width="6" height="17" font="42">•</text>
<text top="180" left="840" width="4" height="12" font="43"> </text>
<text top="180" left="847" width="48" height="12" font="41">Novartis </text>
<text top="196" left="847" width="67" height="12" font="41">Corporation </text>
<text top="212" left="847" width="68" height="12" font="41">(Data Safety </text>
<text top="228" left="847" width="63" height="12" font="41">Monitoring </text>
<text top="244" left="847" width="39" height="12" font="41">Board) </text>
<text top="257" left="834" width="6" height="17" font="42">•</text>
<text top="260" left="840" width="4" height="12" font="43"> </text>
<text top="260" left="847" width="48" height="12" font="41">Vascular </text>
<text top="277" left="847" width="73" height="12" font="41">Interventiona</text>
<text top="292" left="847" width="60" height="12" font="41">l Advances </text>
<text top="309" left="847" width="47" height="12" font="41">(Officer, </text>
<text top="325" left="847" width="50" height="12" font="41">Director, </text>
<text top="341" left="847" width="61" height="12" font="41">Trustee, or </text>
<text top="357" left="847" width="32" height="12" font="41">other </text>
<text top="373" left="847" width="51" height="12" font="41">Fiduciary </text>
<text top="389" left="847" width="37" height="12" font="41">Role)* </text>
<text top="402" left="834" width="6" height="17" font="42">•</text>
<text top="405" left="840" width="4" height="12" font="43"> </text>
<text top="405" left="847" width="34" height="12" font="41">EMX† </text>
<text top="418" left="834" width="6" height="17" font="42">•</text>
<text top="422" left="840" width="4" height="12" font="43"> </text>
<text top="422" left="847" width="58" height="12" font="41">JanaCare† </text>
<text top="114" left="936" width="32" height="12" font="41">None </text>
<text top="114" left="1043" width="32" height="12" font="41">None </text>
</page>
<page number="69" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 67 of 101 </text>
<text top="114" left="125" width="73" height="12" font="41">Anita Deswal </text>
<text top="114" left="224" width="46" height="12" font="41">Content </text>
<text top="130" left="224" width="62" height="12" font="41">Reviewer—</text>
<text top="146" left="224" width="80" height="12" font="41">ACC/AHA Task </text>
<text top="162" left="224" width="50" height="12" font="41">Force on </text>
<text top="178" left="224" width="86" height="12" font="41">Clinical Practice </text>
<text top="194" left="224" width="59" height="12" font="41">Guidelines </text>
<text top="114" left="324" width="97" height="12" font="41">Chief, Cardiology, </text>
<text top="130" left="324" width="58" height="12" font="41">Michael E. </text>
<text top="146" left="324" width="67" height="12" font="41">DeBakey VA </text>
<text top="162" left="324" width="96" height="12" font="41">Medical Center &amp; </text>
<text top="178" left="324" width="93" height="12" font="41">Baylor College of </text>
<text top="194" left="324" width="56" height="12" font="41">Medicine, </text>
<text top="210" left="324" width="94" height="12" font="41">Professor, Baylor </text>
<text top="226" left="324" width="56" height="12" font="41">College of </text>
<text top="242" left="324" width="53" height="12" font="41">Medicine </text>
<text top="114" left="434" width="32" height="12" font="41">None </text>
<text top="114" left="544" width="32" height="12" font="41">None </text>
<text top="114" left="648" width="32" height="12" font="41">None </text>
<text top="111" left="733" width="6" height="17" font="42">•</text>
<text top="115" left="739" width="4" height="12" font="43"> </text>
<text top="115" left="745" width="29" height="12" font="41">NIH* </text>
<text top="111" left="834" width="6" height="17" font="42">•</text>
<text top="115" left="840" width="4" height="12" font="43"> </text>
<text top="115" left="847" width="53" height="12" font="41">ACC/AHA </text>
<text top="131" left="847" width="42" height="12" font="41">(Other) </text>
<text top="144" left="834" width="6" height="17" font="42">•</text>
<text top="147" left="840" width="4" height="12" font="43"> </text>
<text top="147" left="847" width="48" height="12" font="41">Novartis </text>
<text top="164" left="847" width="67" height="12" font="41">Corporation </text>
<text top="180" left="847" width="49" height="12" font="41">(Other)† </text>
<text top="192" left="834" width="6" height="17" font="42">•</text>
<text top="196" left="840" width="4" height="12" font="43"> </text>
<text top="196" left="847" width="48" height="12" font="41">AHA Get </text>
<text top="212" left="847" width="52" height="12" font="41">With The </text>
<text top="228" left="847" width="59" height="12" font="41">Guidelines </text>
<text top="244" left="847" width="47" height="12" font="41">Steering </text>
<text top="260" left="847" width="63" height="12" font="41">Committee </text>
<text top="277" left="847" width="49" height="12" font="41">(Other)† </text>
<text top="289" left="834" width="6" height="17" font="42">•</text>
<text top="293" left="840" width="4" height="12" font="43"> </text>
<text top="293" left="847" width="72" height="12" font="41">Heart Failure </text>
<text top="309" left="847" width="56" height="12" font="41">Society of </text>
<text top="325" left="847" width="47" height="12" font="41">America </text>
<text top="341" left="847" width="49" height="12" font="41">(Other)† </text>
<text top="354" left="834" width="6" height="17" font="42">•</text>
<text top="358" left="840" width="4" height="12" font="43"> </text>
<text top="358" left="847" width="61" height="12" font="41">Immediate </text>
<text top="374" left="847" width="56" height="12" font="41">Past Chair </text>
<text top="390" left="847" width="76" height="12" font="41">and Member, </text>
<text top="406" left="847" width="26" height="12" font="41">AHA </text>
<text top="422" left="847" width="63" height="12" font="41">Committee </text>
<text top="438" left="847" width="50" height="12" font="41">on Heart </text>
<text top="454" left="847" width="62" height="12" font="41">Failure and </text>
<text top="470" left="847" width="70" height="12" font="41">Transplantati</text>
<text top="486" left="847" width="65" height="12" font="41">on (Other)† </text>
<text top="499" left="834" width="6" height="17" font="42">•</text>
<text top="503" left="840" width="4" height="12" font="43"> </text>
<text top="503" left="847" width="72" height="12" font="41">NIH (Other)† </text>
<text top="114" left="936" width="32" height="12" font="41">None </text>
<text top="114" left="1043" width="32" height="12" font="41">None </text>
<text top="520" left="125" width="49" height="12" font="41">Federico </text>
<text top="536" left="125" width="42" height="12" font="41">Gentile </text>
<text top="520" left="224" width="46" height="12" font="41">Content </text>
<text top="536" left="224" width="62" height="12" font="41">Reviewer—</text>
<text top="552" left="224" width="80" height="12" font="41">ACC/AHA Task </text>
<text top="568" left="224" width="50" height="12" font="41">Force on </text>
<text top="584" left="224" width="86" height="12" font="41">Clinical Practice </text>
<text top="600" left="224" width="59" height="12" font="41">Guidelines </text>
<text top="520" left="324" width="83" height="12" font="41">Centro Medico </text>
<text top="536" left="324" width="74" height="12" font="41">Diagnostico—</text>
<text top="552" left="324" width="50" height="12" font="41">Director, </text>
<text top="568" left="324" width="81" height="12" font="41">Cardiovascular </text>
<text top="584" left="324" width="44" height="12" font="41">Disease </text>
<text top="520" left="434" width="32" height="12" font="41">None </text>
<text top="520" left="544" width="32" height="12" font="41">None </text>
<text top="520" left="648" width="32" height="12" font="41">None </text>
<text top="520" left="733" width="32" height="12" font="41">None </text>
<text top="520" left="834" width="32" height="12" font="41">None </text>
<text top="520" left="936" width="32" height="12" font="41">None </text>
<text top="520" left="1043" width="32" height="12" font="41">None </text>
<text top="628" left="125" width="74" height="12" font="41">José A. Joglar </text>
<text top="628" left="224" width="46" height="12" font="41">Content </text>
<text top="645" left="224" width="62" height="12" font="41">Reviewer—</text>
<text top="661" left="224" width="80" height="12" font="41">ACC/AHA Task </text>
<text top="677" left="224" width="50" height="12" font="41">Force on </text>
<text top="693" left="224" width="86" height="12" font="41">Clinical Practice </text>
<text top="709" left="224" width="59" height="12" font="41">Guidelines </text>
<text top="628" left="324" width="49" height="12" font="41">Program </text>
<text top="645" left="324" width="91" height="12" font="41">Director, Clinical </text>
<text top="661" left="324" width="43" height="12" font="41">Cardiac </text>
<text top="677" left="324" width="97" height="12" font="41">Electrophysiology </text>
<text top="693" left="324" width="60" height="12" font="41">Fellowship </text>
<text top="709" left="324" width="52" height="12" font="41">Program; </text>
<text top="725" left="324" width="75" height="12" font="41">Professor, UT </text>
<text top="741" left="324" width="77" height="12" font="41">Southwestern </text>
<text top="757" left="324" width="85" height="12" font="41">Medical Center </text>
<text top="628" left="434" width="32" height="12" font="41">None </text>
<text top="628" left="544" width="32" height="12" font="41">None </text>
<text top="628" left="648" width="32" height="12" font="41">None </text>
<text top="628" left="733" width="32" height="12" font="41">None </text>
<text top="628" left="834" width="32" height="12" font="41">None </text>
<text top="628" left="936" width="32" height="12" font="41">None </text>
<text top="628" left="1043" width="32" height="12" font="41">None </text>
</page>
<page number="70" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 68 of 101 </text>
<text top="114" left="125" width="66" height="12" font="41">Duminda N. </text>
<text top="130" left="125" width="77" height="12" font="41">Wijeysundera </text>
<text top="114" left="224" width="46" height="12" font="41">Content </text>
<text top="130" left="224" width="62" height="12" font="41">Reviewer—</text>
<text top="146" left="224" width="80" height="12" font="41">ACC/AHA Task </text>
<text top="162" left="224" width="50" height="12" font="41">Force on </text>
<text top="178" left="224" width="86" height="12" font="41">Clinical Practice </text>
<text top="194" left="224" width="59" height="12" font="41">Guidelines </text>
<text top="114" left="324" width="54" height="12" font="41">Associate </text>
<text top="130" left="324" width="54" height="12" font="41">Professor </text>
<text top="146" left="324" width="65" height="12" font="41">Anesthesia, </text>
<text top="162" left="324" width="71" height="12" font="41">University of </text>
<text top="178" left="324" width="46" height="12" font="41">Toronto </text>
<text top="114" left="434" width="32" height="12" font="41">None </text>
<text top="114" left="544" width="32" height="12" font="41">None </text>
<text top="114" left="648" width="32" height="12" font="41">None </text>
<text top="111" left="733" width="6" height="17" font="42">•</text>
<text top="115" left="739" width="4" height="12" font="43"> </text>
<text top="115" left="745" width="52" height="12" font="41">Canadian </text>
<text top="131" left="745" width="67" height="12" font="41">Institutes of </text>
<text top="147" left="745" width="38" height="12" font="41">Health </text>
<text top="163" left="745" width="58" height="12" font="41">Research* </text>
<text top="176" left="733" width="6" height="17" font="42">•</text>
<text top="180" left="739" width="4" height="12" font="43"> </text>
<text top="180" left="745" width="61" height="12" font="41">Ministry of </text>
<text top="196" left="745" width="61" height="12" font="41">Health and </text>
<text top="212" left="745" width="54" height="12" font="41">Longterm </text>
<text top="228" left="745" width="41" height="12" font="41">Care of </text>
<text top="244" left="745" width="44" height="12" font="41">Ontario </text>
<text top="260" left="745" width="57" height="12" font="41">(Canada)* </text>
<text top="273" left="733" width="6" height="17" font="42">•</text>
<text top="277" left="739" width="4" height="12" font="43"> </text>
<text top="277" left="745" width="29" height="12" font="41">NIH* </text>
<text top="111" left="834" width="6" height="17" font="42">•</text>
<text top="115" left="840" width="4" height="12" font="43"> </text>
<text top="115" left="847" width="68" height="12" font="41">PCORI (Data </text>
<text top="131" left="847" width="36" height="12" font="41">Safety </text>
<text top="147" left="847" width="63" height="12" font="41">Monitoring </text>
<text top="163" left="847" width="45" height="12" font="41">Board)† </text>
<text top="114" left="936" width="32" height="12" font="41">None </text>
<text top="111" left="1043" width="6" height="17" font="42">•</text>
<text top="115" left="1049" width="4" height="12" font="43"> </text>
<text top="115" left="1056" width="52" height="12" font="41">Canadian </text>
<text top="131" left="1056" width="45" height="12" font="41">Institute</text>
<text top="147" left="1056" width="22" height="12" font="41">s of </text>
<text top="163" left="1056" width="38" height="12" font="41">Health </text>
<text top="179" left="1056" width="52" height="12" font="41">Research </text>
<text top="195" left="1056" width="50" height="12" font="41">(Ottawa, </text>
<text top="211" left="1056" width="47" height="12" font="41">Ontario, </text>
<text top="227" left="1056" width="44" height="12" font="41">Canada)</text>
<text top="243" left="1056" width="10" height="12" font="41">* </text>
</page>
<page number="71" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 69 of 101 </text>
<text top="114" left="125" width="53" height="12" font="41">Eileen M. </text>
<text top="130" left="125" width="56" height="12" font="41">Handberg </text>
<text top="114" left="224" width="46" height="12" font="41">Content </text>
<text top="130" left="224" width="86" height="12" font="41">Reviewer—ACC </text>
<text top="114" left="324" width="52" height="12" font="41">Research </text>
<text top="130" left="324" width="68" height="12" font="41">Professor of </text>
<text top="146" left="324" width="56" height="12" font="41">Medicine; </text>
<text top="162" left="324" width="91" height="12" font="41">Director, Clinical </text>
<text top="178" left="324" width="84" height="12" font="41">Trials Program; </text>
<text top="194" left="324" width="49" height="12" font="41">Program </text>
<text top="210" left="324" width="90" height="12" font="41">Director, Florida </text>
<text top="226" left="324" width="96" height="12" font="41">CARES, UF Health </text>
<text top="111" left="434" width="6" height="17" font="42">•</text>
<text top="115" left="440" width="4" height="12" font="43"> </text>
<text top="115" left="446" width="75" height="12" font="41">Bristol-Myers </text>
<text top="131" left="446" width="39" height="12" font="41">Squibb </text>
<text top="147" left="446" width="54" height="12" font="41">Company </text>
<text top="114" left="544" width="32" height="12" font="41">None </text>
<text top="114" left="648" width="32" height="12" font="41">None </text>
<text top="111" left="733" width="6" height="17" font="42">•</text>
<text top="115" left="739" width="4" height="12" font="43"> </text>
<text top="115" left="745" width="49" height="12" font="41">Aastrom </text>
<text top="131" left="745" width="71" height="12" font="41">Biosciences* </text>
<text top="144" left="733" width="6" height="17" font="42">•</text>
<text top="147" left="739" width="4" height="12" font="43"> </text>
<text top="147" left="745" width="58" height="12" font="41">Amorcyte, </text>
<text top="164" left="745" width="25" height="12" font="41">Inc* </text>
<text top="176" left="733" width="6" height="17" font="42">•</text>
<text top="180" left="739" width="4" height="12" font="43"> </text>
<text top="180" left="745" width="56" height="12" font="41">Biocardia, </text>
<text top="196" left="745" width="25" height="12" font="41">Inc* </text>
<text top="209" left="733" width="6" height="17" font="42">•</text>
<text top="213" left="739" width="4" height="12" font="43"> </text>
<text top="213" left="745" width="70" height="12" font="41">Brigham and </text>
<text top="229" left="745" width="54" height="12" font="41">Women's </text>
<text top="245" left="745" width="53" height="12" font="41">Hospital* </text>
<text top="258" left="733" width="6" height="17" font="42">•</text>
<text top="262" left="739" width="4" height="12" font="43"> </text>
<text top="262" left="745" width="54" height="12" font="41">Capricor* </text>
<text top="275" left="733" width="6" height="17" font="42">•</text>
<text top="279" left="739" width="4" height="12" font="43"> </text>
<text top="279" left="745" width="35" height="12" font="41">Cytori </text>
<text top="295" left="745" width="75" height="12" font="41">Therapeutics, </text>
<text top="311" left="745" width="25" height="12" font="41">Inc* </text>
<text top="324" left="733" width="6" height="17" font="42">•</text>
<text top="328" left="739" width="4" height="12" font="43"> </text>
<text top="328" left="745" width="68" height="12" font="41">Department </text>
<text top="343" left="745" width="67" height="12" font="41">of Defense* </text>
<text top="356" left="733" width="6" height="17" font="42">•</text>
<text top="360" left="739" width="4" height="12" font="43"> </text>
<text top="360" left="745" width="63" height="12" font="41">Direct Flow </text>
<text top="376" left="745" width="52" height="12" font="41">Medical* </text>
<text top="389" left="733" width="6" height="17" font="42">•</text>
<text top="393" left="739" width="4" height="12" font="43"> </text>
<text top="393" left="745" width="71" height="12" font="41">Duke Clinical </text>
<text top="409" left="745" width="52" height="12" font="41">Research </text>
<text top="425" left="745" width="54" height="12" font="41">Institute* </text>
<text top="438" left="733" width="6" height="17" font="42">•</text>
<text top="442" left="739" width="4" height="12" font="43"> </text>
<text top="442" left="745" width="72" height="12" font="41">East Carolina </text>
<text top="458" left="745" width="63" height="12" font="41">University* </text>
<text top="471" left="733" width="6" height="17" font="42">•</text>
<text top="474" left="739" width="4" height="12" font="43"> </text>
<text top="474" left="745" width="69" height="12" font="41">Everyfit Inc* </text>
<text top="487" left="733" width="6" height="17" font="42">•</text>
<text top="491" left="739" width="4" height="12" font="43"> </text>
<text top="491" left="745" width="76" height="12" font="41">MEDTRONIC* </text>
<text top="504" left="733" width="6" height="17" font="42">•</text>
<text top="508" left="739" width="4" height="12" font="43"> </text>
<text top="508" left="745" width="72" height="12" font="41">Merck &amp; Co., </text>
<text top="524" left="745" width="29" height="12" font="41">Inc.* </text>
<text top="537" left="733" width="6" height="17" font="42">•</text>
<text top="541" left="739" width="4" height="12" font="43"> </text>
<text top="541" left="745" width="59" height="12" font="41">Mesoblast </text>
<text top="557" left="745" width="25" height="12" font="41">Inc* </text>
<text top="570" left="733" width="6" height="17" font="42">•</text>
<text top="574" left="739" width="4" height="12" font="43"> </text>
<text top="574" left="745" width="29" height="12" font="41">NIH* </text>
<text top="586" left="733" width="6" height="17" font="42">•</text>
<text top="590" left="739" width="4" height="12" font="43"> </text>
<text top="590" left="745" width="42" height="12" font="41">PCORI* </text>
<text top="603" left="733" width="6" height="17" font="42">•</text>
<text top="607" left="739" width="4" height="12" font="43"> </text>
<text top="607" left="745" width="36" height="12" font="41">Sanofi </text>
<text top="623" left="745" width="49" height="12" font="41">Aventis* </text>
<text top="111" left="834" width="6" height="17" font="42">•</text>
<text top="115" left="840" width="4" height="12" font="43"> </text>
<text top="115" left="847" width="41" height="12" font="41">Amgen </text>
<text top="131" left="847" width="42" height="12" font="41">(Other) </text>
<text top="144" left="834" width="6" height="17" font="42">•</text>
<text top="147" left="840" width="4" height="12" font="43"> </text>
<text top="147" left="847" width="69" height="12" font="41">AstraZeneca </text>
<text top="164" left="847" width="42" height="12" font="41">(Other) </text>
<text top="176" left="834" width="6" height="17" font="42">•</text>
<text top="180" left="840" width="4" height="12" font="43"> </text>
<text top="180" left="847" width="62" height="12" font="41">Boehringer </text>
<text top="196" left="847" width="56" height="12" font="41">Ingelheim </text>
<text top="212" left="847" width="42" height="12" font="41">(Other) </text>
<text top="225" left="834" width="6" height="17" font="42">•</text>
<text top="229" left="840" width="4" height="12" font="43"> </text>
<text top="229" left="847" width="39" height="12" font="41">Daiichi </text>
<text top="245" left="847" width="41" height="12" font="41">Sankyo </text>
<text top="261" left="847" width="42" height="12" font="41">(Other) </text>
<text top="274" left="834" width="6" height="17" font="42">•</text>
<text top="278" left="840" width="4" height="12" font="43"> </text>
<text top="278" left="847" width="37" height="12" font="41">Gilead </text>
<text top="294" left="847" width="74" height="12" font="41">Sciences, Inc. </text>
<text top="310" left="847" width="42" height="12" font="41">(Other) </text>
<text top="323" left="834" width="6" height="17" font="42">•</text>
<text top="327" left="840" width="4" height="12" font="43"> </text>
<text top="327" left="847" width="70" height="12" font="41">Ionis (Other) </text>
<text top="340" left="834" width="6" height="17" font="42">•</text>
<text top="343" left="840" width="4" height="12" font="43"> </text>
<text top="343" left="847" width="44" height="12" font="41">Relypsa </text>
<text top="360" left="847" width="42" height="12" font="41">(Other) </text>
<text top="114" left="936" width="32" height="12" font="41">None </text>
<text top="114" left="1043" width="32" height="12" font="41">None </text>
<text top="640" left="125" width="71" height="12" font="41">Prem Soman </text>
<text top="640" left="224" width="46" height="12" font="41">Content </text>
<text top="656" left="224" width="86" height="12" font="41">Reviewer—ACC </text>
<text top="640" left="324" width="54" height="12" font="41">Associate </text>
<text top="656" left="324" width="68" height="12" font="41">Professor of </text>
<text top="672" left="324" width="52" height="12" font="41">Medicine </text>
<text top="688" left="324" width="71" height="12" font="41">(Cardiology), </text>
<text top="704" left="324" width="94" height="12" font="41">Director, Nuclear </text>
<text top="720" left="324" width="63" height="12" font="41">Cardiology, </text>
<text top="736" left="324" width="36" height="12" font="41">UPMC </text>
<text top="637" left="434" width="6" height="17" font="42">•</text>
<text top="641" left="440" width="4" height="12" font="43"> </text>
<text top="641" left="446" width="46" height="12" font="41">Alnylam </text>
<text top="657" left="446" width="44" height="12" font="41">Pharma </text>
<text top="640" left="544" width="32" height="12" font="41">None </text>
<text top="637" left="648" width="6" height="17" font="42">•</text>
<text top="641" left="654" width="4" height="12" font="43"> </text>
<text top="641" left="660" width="54" height="12" font="41">American </text>
<text top="657" left="660" width="56" height="12" font="41">Society of </text>
<text top="673" left="660" width="44" height="12" font="41">Nuclear </text>
<text top="689" left="660" width="51" height="12" font="41">Cardiolog</text>
<text top="705" left="660" width="15" height="12" font="41">y* </text>
<text top="637" left="733" width="6" height="17" font="42">•</text>
<text top="641" left="739" width="4" height="12" font="43"> </text>
<text top="641" left="745" width="44" height="12" font="41">Astellas </text>
<text top="657" left="745" width="71" height="12" font="41">Pharma US*  </text>
<text top="640" left="834" width="32" height="12" font="41">None </text>
<text top="640" left="936" width="32" height="12" font="41">None </text>
<text top="640" left="1043" width="32" height="12" font="41">None </text>
</page>
<page number="72" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 70 of 101 </text>
<text top="114" left="125" width="65" height="12" font="41">Eric Stecker </text>
<text top="114" left="224" width="46" height="12" font="41">Content </text>
<text top="130" left="224" width="86" height="12" font="41">Reviewer—ACC </text>
<text top="114" left="324" width="54" height="12" font="41">Associate </text>
<text top="130" left="324" width="68" height="12" font="41">Professor of </text>
<text top="146" left="324" width="56" height="12" font="41">Medicine, </text>
<text top="162" left="324" width="59" height="12" font="41">Division of </text>
<text top="178" left="324" width="81" height="12" font="41">Cardiovascular </text>
<text top="194" left="324" width="91" height="12" font="41">Medicine School </text>
<text top="210" left="324" width="70" height="12" font="41">of Medicine, </text>
<text top="226" left="324" width="34" height="12" font="41">OHSU </text>
<text top="114" left="434" width="32" height="12" font="41">None </text>
<text top="114" left="544" width="32" height="12" font="41">None </text>
<text top="111" left="648" width="6" height="17" font="42">•</text>
<text top="115" left="654" width="4" height="12" font="43"> </text>
<text top="115" left="660" width="47" height="12" font="41">Hygeia / </text>
<text top="131" left="660" width="55" height="12" font="41">Desi MD* </text>
<text top="111" left="733" width="6" height="17" font="42">•</text>
<text top="115" left="739" width="4" height="12" font="43"> </text>
<text top="115" left="745" width="54" height="12" font="41">American </text>
<text top="131" left="745" width="33" height="12" font="41">Heart </text>
<text top="147" left="745" width="70" height="12" font="41">Association* </text>
<text top="160" left="733" width="6" height="17" font="42">•</text>
<text top="164" left="739" width="4" height="12" font="43"> </text>
<text top="164" left="745" width="45" height="12" font="41">Medical </text>
<text top="180" left="745" width="52" height="12" font="41">Research </text>
<text top="196" left="745" width="64" height="12" font="41">Foundation </text>
<text top="212" left="745" width="63" height="12" font="41">of Oregon* </text>
<text top="114" left="834" width="32" height="12" font="41">None </text>
<text top="114" left="936" width="32" height="12" font="41">None </text>
<text top="114" left="1043" width="32" height="12" font="41">None </text>
<text top="255" left="125" width="81" height="12" font="41">Pamela Morris </text>
<text top="255" left="224" width="46" height="12" font="41">Content </text>
<text top="271" left="224" width="86" height="12" font="41">Reviewer—ACC </text>
<text top="255" left="324" width="57" height="12" font="41">Professor, </text>
<text top="271" left="324" width="45" height="12" font="41">Medical </text>
<text top="287" left="324" width="71" height="12" font="41">University of </text>
<text top="303" left="324" width="81" height="12" font="41">South Carolina </text>
<text top="252" left="434" width="6" height="17" font="42">•</text>
<text top="256" left="440" width="4" height="12" font="43"> </text>
<text top="256" left="446" width="63" height="12" font="41">Amgen Inc. </text>
<text top="268" left="434" width="6" height="17" font="42">•</text>
<text top="272" left="440" width="4" height="12" font="43"> </text>
<text top="272" left="446" width="36" height="12" font="41">Sanofi </text>
<text top="285" left="434" width="6" height="17" font="42">•</text>
<text top="289" left="440" width="4" height="12" font="43"> </text>
<text top="289" left="446" width="61" height="12" font="41">Regeneron </text>
<text top="255" left="544" width="32" height="12" font="41">None </text>
<text top="255" left="648" width="32" height="12" font="41">None </text>
<text top="255" left="733" width="32" height="12" font="41">None </text>
<text top="255" left="834" width="32" height="12" font="41">None </text>
<text top="255" left="936" width="32" height="12" font="41">None </text>
<text top="255" left="1043" width="32" height="12" font="41">None </text>
<text top="331" left="125" width="45" height="12" font="41">Andrew </text>
<text top="347" left="125" width="50" height="12" font="41">Freeman </text>
<text top="331" left="224" width="46" height="12" font="41">Content </text>
<text top="347" left="224" width="86" height="12" font="41">Reviewer—ACC </text>
<text top="331" left="324" width="91" height="12" font="41">Director, Clinical </text>
<text top="347" left="324" width="83" height="12" font="41">Cardiology and </text>
<text top="363" left="324" width="84" height="12" font="41">Operations; Co-</text>
<text top="379" left="324" width="94" height="12" font="41">Director, Nuclear </text>
<text top="395" left="324" width="63" height="12" font="41">Cardiology, </text>
<text top="411" left="324" width="86" height="12" font="41">National Jewish </text>
<text top="428" left="324" width="38" height="12" font="41">Health </text>
<text top="331" left="434" width="32" height="12" font="41">None </text>
<text top="328" left="544" width="6" height="17" font="42">•</text>
<text top="332" left="550" width="4" height="12" font="43"> </text>
<text top="332" left="557" width="62" height="12" font="41">Boehringer </text>
<text top="348" left="557" width="62" height="12" font="41">Ingelheim* </text>
<text top="331" left="648" width="32" height="12" font="41">None </text>
<text top="331" left="733" width="32" height="12" font="41">None </text>
<text top="331" left="834" width="32" height="12" font="41">None </text>
<text top="331" left="936" width="32" height="12" font="41">None </text>
<text top="331" left="1043" width="32" height="12" font="41">None </text>
<text top="456" left="125" width="65" height="12" font="41">Carl J. Lavie </text>
<text top="456" left="224" width="46" height="12" font="41">Content </text>
<text top="472" left="224" width="86" height="12" font="41">Reviewer—ACC </text>
<text top="456" left="324" width="95" height="12" font="41">Medical Director, </text>
<text top="472" left="324" width="43" height="12" font="41">Cardiac </text>
<text top="488" left="324" width="78" height="12" font="41">Rehabilitation </text>
<text top="504" left="324" width="88" height="12" font="41">and Prevention, </text>
<text top="520" left="324" width="79" height="12" font="41">Ochsner Clinic </text>
<text top="536" left="324" width="64" height="12" font="41">Foundation </text>
<text top="456" left="434" width="32" height="12" font="41">None </text>
<text top="453" left="544" width="6" height="17" font="42">•</text>
<text top="457" left="550" width="4" height="12" font="43"> </text>
<text top="457" left="557" width="47" height="12" font="41">Amgen* </text>
<text top="470" left="544" width="6" height="17" font="42">•</text>
<text top="474" left="550" width="4" height="12" font="43"> </text>
<text top="474" left="557" width="68" height="12" font="41">ER Squibb &amp; </text>
<text top="489" left="557" width="28" height="12" font="41">Sons </text>
<text top="502" left="544" width="6" height="17" font="42">•</text>
<text top="506" left="550" width="4" height="12" font="43"> </text>
<text top="506" left="557" width="40" height="12" font="41">Pfizer* </text>
<text top="519" left="544" width="6" height="17" font="42">•</text>
<text top="523" left="550" width="4" height="12" font="43"> </text>
<text top="523" left="557" width="36" height="12" font="41">Aralez </text>
<text top="539" left="557" width="73" height="12" font="41">Pharmaceutic</text>
<text top="555" left="557" width="17" height="12" font="41">als </text>
<text top="568" left="544" width="6" height="17" font="42">•</text>
<text top="572" left="550" width="4" height="12" font="43"> </text>
<text top="572" left="557" width="42" height="12" font="41">Amarin </text>
<text top="588" left="557" width="44" height="12" font="41">Pharma </text>
<text top="601" left="544" width="6" height="17" font="42">•</text>
<text top="605" left="550" width="4" height="12" font="43"> </text>
<text top="605" left="557" width="36" height="12" font="41">Sanofi </text>
<text top="621" left="557" width="49" height="12" font="41">Aventis* </text>
<text top="456" left="648" width="32" height="12" font="41">None </text>
<text top="456" left="733" width="32" height="12" font="41">None </text>
<text top="456" left="834" width="32" height="12" font="41">None </text>
<text top="456" left="936" width="32" height="12" font="41">None </text>
<text top="456" left="1043" width="32" height="12" font="41">None </text>
</page>
<page number="73" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 71 of 101 </text>
<text top="114" left="125" width="66" height="12" font="41">James Stein </text>
<text top="114" left="224" width="46" height="12" font="41">Content </text>
<text top="130" left="224" width="86" height="12" font="41">Reviewer—ACC </text>
<text top="114" left="324" width="73" height="12" font="41">Director, UW </text>
<text top="130" left="324" width="38" height="12" font="41">Health </text>
<text top="146" left="324" width="60" height="12" font="41">Preventive </text>
<text top="162" left="324" width="60" height="12" font="41">Cardiology </text>
<text top="178" left="324" width="92" height="12" font="41">Program, Robert </text>
<text top="194" left="324" width="87" height="12" font="41">Turell Professor </text>
<text top="210" left="324" width="94" height="12" font="41">in Cardiovascular </text>
<text top="226" left="324" width="78" height="12" font="41">Research, UW </text>
<text top="242" left="324" width="52" height="12" font="41">School of </text>
<text top="258" left="324" width="75" height="12" font="41">Medicine and </text>
<text top="274" left="324" width="73" height="12" font="41">Public Health </text>
<text top="111" left="434" width="6" height="17" font="42">•</text>
<text top="115" left="440" width="4" height="12" font="43"> </text>
<text top="115" left="446" width="62" height="12" font="41">Eli Lilly and </text>
<text top="131" left="446" width="54" height="12" font="41">Company </text>
<text top="147" left="446" width="43" height="12" font="41">(DSMB) </text>
<text top="114" left="544" width="32" height="12" font="41">None </text>
<text top="114" left="648" width="32" height="12" font="41">None </text>
<text top="114" left="733" width="32" height="12" font="41">None </text>
<text top="111" left="834" width="6" height="17" font="42">•</text>
<text top="115" left="840" width="4" height="12" font="43"> </text>
<text top="115" left="847" width="63" height="12" font="41">Up To Date </text>
<text top="131" left="847" width="42" height="12" font="41">(Other) </text>
<text top="144" left="834" width="6" height="17" font="42">•</text>
<text top="147" left="840" width="4" height="12" font="43"> </text>
<text top="147" left="847" width="57" height="12" font="41">Wisconsin </text>
<text top="164" left="847" width="41" height="12" font="41">Alumni </text>
<text top="180" left="847" width="52" height="12" font="41">Research </text>
<text top="196" left="847" width="64" height="12" font="41">Foundation </text>
<text top="212" left="847" width="42" height="12" font="41">(Other) </text>
<text top="114" left="936" width="32" height="12" font="41">None </text>
<text top="114" left="1043" width="32" height="12" font="41">None </text>
<text top="303" left="125" width="46" height="12" font="41">Heather </text>
<text top="319" left="125" width="47" height="12" font="41">Johnson </text>
<text top="303" left="224" width="46" height="12" font="41">Content </text>
<text top="319" left="224" width="86" height="12" font="41">Reviewer—ACC </text>
<text top="303" left="324" width="54" height="12" font="41">Associate </text>
<text top="319" left="324" width="87" height="12" font="41">Professor in the </text>
<text top="335" left="324" width="59" height="12" font="41">Division of </text>
<text top="351" left="324" width="81" height="12" font="41">Cardiovascular </text>
<text top="367" left="324" width="87" height="12" font="41">Medicine at the </text>
<text top="383" left="324" width="71" height="12" font="41">University of </text>
<text top="399" left="324" width="96" height="12" font="41">Wisconsin School </text>
<text top="415" left="324" width="90" height="12" font="41">of Medicine and </text>
<text top="431" left="324" width="73" height="12" font="41">Public Health </text>
<text top="303" left="434" width="32" height="12" font="41">None </text>
<text top="303" left="544" width="32" height="12" font="41">None </text>
<text top="303" left="648" width="32" height="12" font="41">None </text>
<text top="303" left="733" width="32" height="12" font="41">None </text>
<text top="300" left="834" width="6" height="17" font="42">•</text>
<text top="303" left="840" width="4" height="12" font="43"> </text>
<text top="303" left="847" width="33" height="12" font="41">Pfizer </text>
<text top="303" left="936" width="32" height="12" font="41">None </text>
<text top="303" left="1043" width="32" height="12" font="41">None </text>
<text top="460" left="125" width="46" height="12" font="41">Nanette </text>
<text top="476" left="125" width="45" height="12" font="41">Wenger </text>
<text top="460" left="224" width="46" height="12" font="41">Content </text>
<text top="476" left="224" width="62" height="12" font="41">Reviewer—</text>
<text top="492" left="224" width="27" height="12" font="41">AHA </text>
<text top="460" left="324" width="68" height="12" font="41">Professor of </text>
<text top="476" left="324" width="56" height="12" font="41">Medicine, </text>
<text top="492" left="324" width="59" height="12" font="41">Division of </text>
<text top="508" left="324" width="63" height="12" font="41">Cardiology, </text>
<text top="524" left="324" width="94" height="12" font="41">Emory University </text>
<text top="540" left="324" width="52" height="12" font="41">School of </text>
<text top="556" left="324" width="56" height="12" font="41">Medicine. </text>
<text top="457" left="434" width="6" height="17" font="42">•</text>
<text top="460" left="440" width="4" height="12" font="43"> </text>
<text top="460" left="446" width="44" height="12" font="41">Janssen </text>
<text top="476" left="446" width="80" height="12" font="41">Pharmaceutica</text>
<text top="492" left="446" width="40" height="12" font="41">ls, Inc* </text>
<text top="505" left="434" width="6" height="17" font="42">•</text>
<text top="509" left="440" width="4" height="12" font="43"> </text>
<text top="509" left="446" width="41" height="12" font="41">Amgen </text>
<text top="522" left="434" width="6" height="17" font="42">•</text>
<text top="526" left="440" width="4" height="12" font="43"> </text>
<text top="526" left="446" width="69" height="12" font="41">AstraZeneca </text>
<text top="539" left="434" width="6" height="17" font="42">•</text>
<text top="543" left="440" width="4" height="12" font="43"> </text>
<text top="543" left="446" width="37" height="12" font="41">Gilead </text>
<text top="559" left="446" width="48" height="12" font="41">Sciences </text>
<text top="572" left="434" width="6" height="17" font="42">•</text>
<text top="575" left="440" width="4" height="12" font="43"> </text>
<text top="575" left="446" width="37" height="12" font="41">Merck </text>
<text top="460" left="544" width="32" height="12" font="41">None </text>
<text top="460" left="648" width="32" height="12" font="41">None </text>
<text top="457" left="733" width="6" height="17" font="42">•</text>
<text top="460" left="739" width="4" height="12" font="43"> </text>
<text top="460" left="745" width="37" height="12" font="41">Gilead </text>
<text top="476" left="745" width="55" height="12" font="41">Sciences* </text>
<text top="489" left="733" width="6" height="17" font="42">•</text>
<text top="493" left="739" width="4" height="12" font="43"> </text>
<text top="493" left="745" width="42" height="12" font="41">NHLBI* </text>
<text top="506" left="733" width="6" height="17" font="42">•</text>
<text top="510" left="739" width="4" height="12" font="43"> </text>
<text top="510" left="745" width="40" height="12" font="41">Pfizer* </text>
<text top="523" left="733" width="6" height="17" font="42">•</text>
<text top="526" left="739" width="4" height="12" font="43"> </text>
<text top="526" left="745" width="60" height="12" font="41">Society for </text>
<text top="543" left="745" width="54" height="12" font="41">Women’s </text>
<text top="559" left="745" width="38" height="12" font="41">Health </text>
<text top="575" left="745" width="58" height="12" font="41">Research* </text>
<text top="460" left="834" width="32" height="12" font="41">None </text>
<text top="460" left="936" width="32" height="12" font="41">None </text>
<text top="460" left="1043" width="32" height="12" font="41">None </text>
</page>
<page number="74" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 72 of 101 </text>
<text top="114" left="125" width="78" height="12" font="41">Michael Blaha </text>
<text top="114" left="224" width="46" height="12" font="41">Content </text>
<text top="130" left="224" width="62" height="12" font="41">Reviewer—</text>
<text top="146" left="224" width="27" height="12" font="41">AHA </text>
<text top="114" left="324" width="61" height="12" font="41">Director of </text>
<text top="130" left="324" width="95" height="12" font="41">Clinical Research, </text>
<text top="146" left="324" width="94" height="12" font="41">Ciccarone Center </text>
<text top="162" left="324" width="39" height="12" font="41">for the </text>
<text top="178" left="324" width="75" height="12" font="41">Prevention of </text>
<text top="194" left="324" width="77" height="12" font="41">Heart Disease </text>
<text top="210" left="324" width="54" height="12" font="41">Associate </text>
<text top="226" left="324" width="68" height="12" font="41">Professor of </text>
<text top="242" left="324" width="89" height="12" font="41">Medicine, Johns </text>
<text top="258" left="324" width="46" height="12" font="41">Hopkins </text>
<text top="274" left="324" width="53" height="12" font="41">Medicine </text>
<text top="111" left="434" width="6" height="17" font="42">•</text>
<text top="115" left="440" width="4" height="12" font="43"> </text>
<text top="115" left="446" width="41" height="12" font="41">Ferring </text>
<text top="131" left="446" width="80" height="12" font="41">Pharmaceutica</text>
<text top="147" left="446" width="11" height="12" font="41">ls </text>
<text top="160" left="434" width="6" height="17" font="42">•</text>
<text top="164" left="440" width="4" height="12" font="43"> </text>
<text top="164" left="446" width="61" height="12" font="41">Regeneron </text>
<text top="180" left="446" width="80" height="12" font="41">Pharmaceutica</text>
<text top="196" left="446" width="11" height="12" font="41">ls </text>
<text top="208" left="434" width="6" height="17" font="42">•</text>
<text top="212" left="440" width="4" height="12" font="43"> </text>
<text top="212" left="446" width="37" height="12" font="41">Sanofi-</text>
<text top="228" left="446" width="49" height="12" font="41">Aventis* </text>
<text top="241" left="434" width="6" height="17" font="42">•</text>
<text top="245" left="440" width="4" height="12" font="43"> </text>
<text top="245" left="446" width="41" height="12" font="41">Amgen </text>
<text top="258" left="434" width="6" height="17" font="42">•</text>
<text top="262" left="440" width="4" height="12" font="43"> </text>
<text top="262" left="446" width="35" height="12" font="41">Akcea </text>
<text top="275" left="434" width="6" height="17" font="42">•</text>
<text top="279" left="440" width="4" height="12" font="43"> </text>
<text top="279" left="446" width="72" height="12" font="41">MedImmune </text>
<text top="291" left="434" width="6" height="17" font="42">•</text>
<text top="295" left="440" width="4" height="12" font="43"> </text>
<text top="295" left="446" width="48" height="12" font="41">Novartis </text>
<text top="308" left="434" width="6" height="17" font="42">•</text>
<text top="312" left="440" width="4" height="12" font="43"> </text>
<text top="312" left="446" width="75" height="12" font="41">Novo Nordisk </text>
<text top="325" left="434" width="6" height="17" font="42">•</text>
<text top="329" left="440" width="4" height="12" font="43"> </text>
<text top="329" left="446" width="54" height="12" font="41">Siemens* </text>
<text top="342" left="434" width="6" height="17" font="42">•</text>
<text top="346" left="440" width="4" height="12" font="43"> </text>
<text top="346" left="446" width="25" height="12" font="41">ACC </text>
<text top="114" left="544" width="32" height="12" font="41">None </text>
<text top="114" left="648" width="32" height="12" font="41">None </text>
<text top="111" left="733" width="6" height="17" font="42">•</text>
<text top="115" left="739" width="4" height="12" font="43"> </text>
<text top="115" left="745" width="41" height="12" font="41">Aetna† </text>
<text top="128" left="733" width="6" height="17" font="42">•</text>
<text top="132" left="739" width="4" height="12" font="43"> </text>
<text top="132" left="745" width="47" height="12" font="41">Amgen† </text>
<text top="144" left="733" width="6" height="17" font="42">•</text>
<text top="148" left="739" width="4" height="12" font="43"> </text>
<text top="148" left="745" width="33" height="12" font="41">AHA† </text>
<text top="161" left="733" width="6" height="17" font="42">•</text>
<text top="165" left="739" width="4" height="12" font="43"> </text>
<text top="165" left="745" width="31" height="12" font="41">FDA† </text>
<text top="178" left="733" width="6" height="17" font="42">•</text>
<text top="182" left="739" width="4" height="12" font="43"> </text>
<text top="182" left="745" width="29" height="12" font="41">NIH† </text>
<text top="114" left="834" width="32" height="12" font="41">None </text>
<text top="114" left="936" width="32" height="12" font="41">None </text>
<text top="114" left="1043" width="32" height="12" font="41">None </text>
<text top="362" left="125" width="52" height="12" font="41">Laurence </text>
<text top="378" left="125" width="46" height="12" font="41">Sperling </text>
<text top="362" left="224" width="46" height="12" font="41">Content </text>
<text top="378" left="224" width="62" height="12" font="41">Reviewer—</text>
<text top="394" left="224" width="56" height="12" font="41">ACC/AHA  </text>
<text top="362" left="324" width="71" height="12" font="41">Founder and </text>
<text top="378" left="324" width="61" height="12" font="41">Director of </text>
<text top="394" left="324" width="60" height="12" font="41">Preventive </text>
<text top="410" left="324" width="94" height="12" font="41">Cardiology at the </text>
<text top="427" left="324" width="90" height="12" font="41">Emory Clinic, Co-</text>
<text top="443" left="324" width="81" height="12" font="41">Director of the </text>
<text top="459" left="324" width="81" height="12" font="41">Cardiovascular </text>
<text top="475" left="324" width="44" height="12" font="41">Disease </text>
<text top="491" left="324" width="60" height="12" font="41">Fellowship </text>
<text top="507" left="324" width="63" height="12" font="41">Program at </text>
<text top="523" left="324" width="94" height="12" font="41">Emory, Professor </text>
<text top="539" left="324" width="66" height="12" font="41">of Medicine </text>
<text top="555" left="324" width="81" height="12" font="41">(Cardiology) at </text>
<text top="571" left="324" width="58" height="12" font="41">the Emory </text>
<text top="587" left="324" width="95" height="12" font="41">University School </text>
<text top="603" left="324" width="66" height="12" font="41">of Medicine </text>
<text top="362" left="434" width="32" height="12" font="41">None </text>
<text top="362" left="544" width="32" height="12" font="41">None </text>
<text top="362" left="648" width="32" height="12" font="41">None </text>
<text top="362" left="733" width="32" height="12" font="41">None </text>
<text top="362" left="834" width="32" height="12" font="41">None </text>
<text top="362" left="936" width="32" height="12" font="41">None </text>
<text top="362" left="1043" width="32" height="12" font="41">None </text>
</page>
<page number="75" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 73 of 101 </text>
<text top="114" left="125" width="66" height="12" font="41">Seth Martin </text>
<text top="114" left="224" width="46" height="12" font="41">Content </text>
<text top="130" left="224" width="62" height="12" font="41">Reviewer—</text>
<text top="146" left="224" width="53" height="12" font="41">ACC/AHA </text>
<text top="114" left="324" width="50" height="12" font="41">Director, </text>
<text top="130" left="324" width="84" height="12" font="41">Advanced Lipid </text>
<text top="146" left="324" width="54" height="12" font="41">Disorders </text>
<text top="162" left="324" width="84" height="12" font="41">Program of the </text>
<text top="178" left="324" width="55" height="12" font="41">Ciccarone </text>
<text top="194" left="324" width="96" height="12" font="41">Center; Associate </text>
<text top="210" left="324" width="68" height="12" font="41">Professor of </text>
<text top="226" left="324" width="66" height="12" font="41">Medicine at </text>
<text top="242" left="324" width="79" height="12" font="41">Johns Hopkins </text>
<text top="258" left="324" width="53" height="12" font="41">Medicine </text>
<text top="111" left="434" width="6" height="17" font="42">•</text>
<text top="115" left="440" width="4" height="12" font="43"> </text>
<text top="115" left="446" width="41" height="12" font="41">Amgen </text>
<text top="128" left="434" width="6" height="17" font="42">•</text>
<text top="132" left="440" width="4" height="12" font="43"> </text>
<text top="132" left="446" width="35" height="12" font="41">Akcea </text>
<text top="147" left="446" width="72" height="12" font="41">Therapeutics </text>
<text top="160" left="434" width="6" height="17" font="42">•</text>
<text top="164" left="440" width="4" height="12" font="43"> </text>
<text top="164" left="446" width="35" height="12" font="41">Quest </text>
<text top="180" left="446" width="64" height="12" font="41">Diagnostics </text>
<text top="193" left="434" width="6" height="17" font="42">•</text>
<text top="197" left="440" width="4" height="12" font="43"> </text>
<text top="197" left="446" width="37" height="12" font="41">Sanofi-</text>
<text top="213" left="446" width="61" height="12" font="41">Regeneron </text>
<text top="226" left="434" width="6" height="17" font="42">•</text>
<text top="230" left="440" width="4" height="12" font="43"> </text>
<text top="230" left="446" width="49" height="12" font="41">Esperion </text>
<text top="243" left="434" width="6" height="17" font="42">•</text>
<text top="247" left="440" width="4" height="12" font="43"> </text>
<text top="247" left="446" width="75" height="12" font="41">Novo Nordisk </text>
<text top="114" left="544" width="32" height="12" font="41">None </text>
<text top="114" left="648" width="32" height="12" font="41">None </text>
<text top="111" left="733" width="6" height="17" font="42">•</text>
<text top="115" left="739" width="4" height="12" font="43"> </text>
<text top="115" left="745" width="34" height="12" font="41">Aetna </text>
<text top="131" left="745" width="71" height="12" font="41">Foundation* </text>
<text top="144" left="733" width="6" height="17" font="42">•</text>
<text top="147" left="739" width="4" height="12" font="43"> </text>
<text top="147" left="745" width="40" height="12" font="41">Apple* </text>
<text top="160" left="733" width="6" height="17" font="42">•</text>
<text top="164" left="739" width="4" height="12" font="43"> </text>
<text top="164" left="745" width="47" height="12" font="41">Google* </text>
<text top="177" left="733" width="6" height="17" font="42">•</text>
<text top="181" left="739" width="4" height="12" font="43"> </text>
<text top="181" left="745" width="48" height="12" font="41">iHealth* </text>
<text top="194" left="733" width="6" height="17" font="42">•</text>
<text top="198" left="739" width="4" height="12" font="43"> </text>
<text top="198" left="745" width="54" height="12" font="41">Maryland </text>
<text top="214" left="745" width="60" height="12" font="41">Innovation </text>
<text top="230" left="745" width="56" height="12" font="41">Initiative* </text>
<text top="243" left="733" width="6" height="17" font="42">•</text>
<text top="247" left="739" width="4" height="12" font="43"> </text>
<text top="247" left="745" width="33" height="12" font="41">AHA* </text>
<text top="111" left="834" width="6" height="17" font="42">•</text>
<text top="115" left="840" width="4" height="12" font="43"> </text>
<text top="115" left="847" width="74" height="12" font="41">Corrie Health </text>
<text top="131" left="847" width="47" height="12" font="41">(Officer, </text>
<text top="147" left="847" width="50" height="12" font="41">Director, </text>
<text top="163" left="847" width="61" height="12" font="41">Trustee, or </text>
<text top="179" left="847" width="32" height="12" font="41">other </text>
<text top="195" left="847" width="51" height="12" font="41">Fiduciary </text>
<text top="211" left="847" width="37" height="12" font="41">Role)† </text>
<text top="224" left="834" width="6" height="17" font="42">•</text>
<text top="228" left="840" width="4" height="12" font="43"> </text>
<text top="228" left="847" width="66" height="12" font="41">Co-inventor </text>
<text top="244" left="847" width="63" height="12" font="41">on pending </text>
<text top="260" left="847" width="65" height="12" font="41">patent filed </text>
<text top="276" left="847" width="49" height="12" font="41">by Johns </text>
<text top="292" left="847" width="46" height="12" font="41">Hopkins </text>
<text top="308" left="847" width="75" height="12" font="41">University for </text>
<text top="324" left="847" width="59" height="12" font="41">method of </text>
<text top="340" left="847" width="33" height="12" font="41">LDL-C </text>
<text top="356" left="847" width="60" height="12" font="41">estimation </text>
<text top="372" left="847" width="49" height="12" font="41">(Other)† </text>
<text top="114" left="936" width="32" height="12" font="41">None </text>
<text top="114" left="1043" width="32" height="12" font="41">None </text>
</page>
<page number="76" position="absolute" top="0" left="0" height="892" width="1263">
	<fontspec id="44" size="11" family="Times" color="#000000"/>
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 74 of 101 </text>
<text top="114" left="125" width="67" height="12" font="41">Samia Mora </text>
<text top="114" left="224" width="46" height="12" font="41">Content </text>
<text top="130" left="224" width="62" height="12" font="41">Reviewer—</text>
<text top="146" left="224" width="53" height="12" font="41">ACC/AHA </text>
<text top="114" left="324" width="54" height="12" font="41">Associate </text>
<text top="130" left="324" width="68" height="12" font="41">Professor of </text>
<text top="146" left="324" width="56" height="12" font="41">Medicine, </text>
<text top="162" left="324" width="45" height="12" font="41">Harvard </text>
<text top="178" left="324" width="91" height="12" font="41">Medicine School </text>
<text top="194" left="324" width="89" height="12" font="41">Director, Center </text>
<text top="210" left="324" width="47" height="12" font="41">for Lipid </text>
<text top="226" left="324" width="83" height="12" font="41">Metabolomics, </text>
<text top="242" left="324" width="70" height="12" font="41">Brigham and </text>
<text top="258" left="324" width="54" height="12" font="41">Women’s </text>
<text top="274" left="324" width="47" height="12" font="41">Hospital </text>
<text top="111" left="434" width="6" height="17" font="42">•</text>
<text top="115" left="440" width="4" height="12" font="43"> </text>
<text top="115" left="446" width="53" height="12" font="41">Pri-Med* </text>
<text top="128" left="434" width="6" height="17" font="42">•</text>
<text top="132" left="440" width="4" height="12" font="43"> </text>
<text top="132" left="446" width="33" height="12" font="41">Pfizer </text>
<text top="144" left="434" width="6" height="17" font="42">•</text>
<text top="148" left="440" width="4" height="12" font="43"> </text>
<text top="148" left="446" width="35" height="12" font="41">Quest </text>
<text top="164" left="446" width="64" height="12" font="41">Diagnostics </text>
<text top="114" left="544" width="32" height="12" font="41">None </text>
<text top="114" left="648" width="32" height="12" font="41">None </text>
<text top="114" left="733" width="32" height="12" font="41">None </text>
<text top="111" left="834" width="6" height="17" font="42">•</text>
<text top="115" left="840" width="4" height="12" font="43"> </text>
<text top="115" left="847" width="17" height="12" font="41">C3 </text>
<text top="131" left="847" width="64" height="12" font="41">Conference </text>
<text top="147" left="847" width="42" height="12" font="41">(Other) </text>
<text top="160" left="834" width="6" height="17" font="42">•</text>
<text top="164" left="840" width="4" height="12" font="43"> </text>
<text top="164" left="847" width="54" height="12" font="41">European </text>
<text top="180" left="847" width="69" height="12" font="41">Atherosclero</text>
<text top="196" left="847" width="58" height="12" font="41">sis Society </text>
<text top="212" left="847" width="42" height="12" font="41">(Other) </text>
<text top="225" left="834" width="6" height="17" font="42">•</text>
<text top="228" left="840" width="4" height="12" font="43"> </text>
<text top="228" left="847" width="29" height="12" font="41">FEBS </text>
<text top="244" left="847" width="52" height="12" font="41">Congress </text>
<text top="260" left="847" width="42" height="12" font="41">(Other) </text>
<text top="273" left="834" width="6" height="17" font="42">•</text>
<text top="277" left="840" width="4" height="12" font="43"> </text>
<text top="277" left="847" width="43" height="12" font="41">Oregon </text>
<text top="293" left="847" width="50" height="12" font="41">Health &amp; </text>
<text top="309" left="847" width="43" height="12" font="41">Science </text>
<text top="325" left="847" width="57" height="12" font="41">University </text>
<text top="341" left="847" width="42" height="12" font="41">(Other) </text>
<text top="354" left="834" width="6" height="17" font="42">•</text>
<text top="358" left="840" width="4" height="12" font="43"> </text>
<text top="358" left="847" width="48" height="12" font="41">Vascular </text>
<text top="374" left="847" width="42" height="12" font="41">Biology </text>
<text top="390" left="847" width="48" height="12" font="41">Working </text>
<text top="406" left="847" width="36" height="12" font="41">Group </text>
<text top="422" left="847" width="48" height="12" font="41">Meeting </text>
<text top="438" left="847" width="45" height="12" font="41">(Other)  </text>
<text top="451" left="834" width="6" height="17" font="42">•</text>
<text top="455" left="840" width="4" height="12" font="43"> </text>
<text top="455" left="847" width="63" height="12" font="41">Atherotech </text>
<text top="471" left="847" width="70" height="12" font="41">Diagnostics* </text>
<text top="484" left="834" width="6" height="17" font="42">•</text>
<text top="488" left="840" width="4" height="12" font="43"> </text>
<text top="488" left="847" width="40" height="12" font="41">Pfizer* </text>
<text top="501" left="834" width="6" height="17" font="42">•</text>
<text top="505" left="840" width="4" height="12" font="43"> </text>
<text top="505" left="847" width="35" height="12" font="41">Quest </text>
<text top="520" left="847" width="70" height="12" font="41">Diagnostics* </text>
<text top="534" left="834" width="6" height="17" font="42">•</text>
<text top="537" left="840" width="4" height="12" font="43"> </text>
<text top="537" left="847" width="45" height="12" font="41">NHLBI*  </text>
<text top="550" left="834" width="6" height="17" font="42">•</text>
<text top="554" left="840" width="4" height="12" font="43"> </text>
<text top="554" left="847" width="44" height="12" font="41">NIDDK* </text>
<text top="114" left="936" width="32" height="12" font="41">None </text>
<text top="114" left="1043" width="32" height="12" font="41">None </text>
<text top="571" left="125" width="66" height="12" font="41">Clyde Yancy </text>
<text top="571" left="224" width="46" height="12" font="41">Content </text>
<text top="587" left="224" width="62" height="12" font="41">Reviewer—</text>
<text top="603" left="224" width="53" height="12" font="41">ACC/AHA </text>
<text top="571" left="324" width="44" height="12" font="41">Chief of </text>
<text top="587" left="324" width="93" height="12" font="41">Cardiology in the </text>
<text top="603" left="324" width="82" height="12" font="41">Department of </text>
<text top="619" left="324" width="56" height="12" font="41">Medicine, </text>
<text top="635" left="324" width="78" height="12" font="41">Northwestern </text>
<text top="651" left="324" width="53" height="12" font="41">Medicine </text>
<text top="571" left="434" width="32" height="12" font="41">None </text>
<text top="571" left="544" width="32" height="12" font="41">None </text>
<text top="571" left="648" width="32" height="12" font="41">None </text>
<text top="571" left="733" width="32" height="12" font="41">None </text>
<text top="568" left="834" width="6" height="17" font="42">•</text>
<text top="572" left="840" width="4" height="12" font="43"> </text>
<text top="572" left="847" width="34" height="12" font="44"><i>JAMA </i></text>
<text top="587" left="847" width="60" height="12" font="44"><i>Cardiology</i> </text>
<text top="604" left="847" width="49" height="12" font="41">(Other)* </text>
<text top="571" left="936" width="32" height="12" font="41">None </text>
<text top="571" left="1043" width="32" height="12" font="41">None </text>
<text top="679" left="125" width="63" height="12" font="41">Quinn Pack </text>
<text top="679" left="224" width="47" height="12" font="41">AACVPR </text>
<text top="679" left="324" width="51" height="12" font="41">Assistant </text>
<text top="696" left="324" width="68" height="12" font="41">Professor of </text>
<text top="711" left="324" width="66" height="12" font="41">Medicine at </text>
<text top="728" left="324" width="71" height="12" font="41">University of </text>
<text top="744" left="324" width="82" height="12" font="41">Massachusetts </text>
<text top="760" left="324" width="84" height="12" font="41">Medical School </text>
<text top="679" left="434" width="32" height="12" font="41">None </text>
<text top="679" left="544" width="32" height="12" font="41">None </text>
<text top="679" left="648" width="32" height="12" font="41">None </text>
<text top="679" left="733" width="32" height="12" font="41">None </text>
<text top="679" left="834" width="32" height="12" font="41">None </text>
<text top="679" left="936" width="32" height="12" font="41">None </text>
<text top="679" left="1043" width="32" height="12" font="41">None </text>
</page>
<page number="77" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 75 of 101 </text>
<text top="114" left="125" width="65" height="12" font="41">Frank Sacks </text>
<text top="114" left="224" width="25" height="12" font="41">ASN </text>
<text top="114" left="324" width="68" height="12" font="41">Professor of </text>
<text top="130" left="324" width="81" height="12" font="41">Cardiovascular </text>
<text top="146" left="324" width="44" height="12" font="41">Disease </text>
<text top="162" left="324" width="65" height="12" font="41">Prevention, </text>
<text top="178" left="324" width="84" height="12" font="41">Harvard School </text>
<text top="194" left="324" width="87" height="12" font="41">of Public Health </text>
<text top="111" left="434" width="6" height="17" font="42">•</text>
<text top="115" left="440" width="4" height="12" font="43"> </text>
<text top="115" left="446" width="41" height="12" font="41">Amgen </text>
<text top="128" left="434" width="6" height="17" font="42">•</text>
<text top="132" left="440" width="4" height="12" font="43"> </text>
<text top="132" left="446" width="40" height="12" font="41">Pfizer* </text>
<text top="144" left="434" width="6" height="17" font="42">•</text>
<text top="148" left="440" width="4" height="12" font="43"> </text>
<text top="148" left="446" width="76" height="12" font="41">AstraZeneca* </text>
<text top="114" left="544" width="32" height="12" font="41">None </text>
<text top="114" left="648" width="32" height="12" font="41">None </text>
<text top="114" left="733" width="32" height="12" font="41">None </text>
<text top="114" left="834" width="32" height="12" font="41">None </text>
<text top="114" left="936" width="32" height="12" font="41">None </text>
<text top="114" left="1043" width="32" height="12" font="41">None </text>
<text top="223" left="125" width="53" height="12" font="41">Salvatore </text>
<text top="239" left="125" width="56" height="12" font="41">Lacagnina </text>
<text top="223" left="224" width="36" height="12" font="41">ACPM </text>
<text top="223" left="324" width="87" height="12" font="41">System Medical </text>
<text top="239" left="324" width="61" height="12" font="41">Director of </text>
<text top="255" left="324" width="63" height="12" font="41">Wellness &amp; </text>
<text top="271" left="324" width="97" height="12" font="41">Employee Health, </text>
<text top="287" left="324" width="60" height="12" font="41">Lee Health </text>
<text top="223" left="434" width="32" height="12" font="41">None </text>
<text top="223" left="544" width="32" height="12" font="41">None </text>
<text top="223" left="648" width="32" height="12" font="41">None </text>
<text top="223" left="733" width="32" height="12" font="41">None </text>
<text top="223" left="834" width="32" height="12" font="41">None </text>
<text top="223" left="936" width="32" height="12" font="41">None </text>
<text top="223" left="1043" width="32" height="12" font="41">None </text>
</page>
<page number="78" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 76 of 101 </text>
<text top="114" left="125" width="82" height="12" font="41">Ron Blankstein </text>
<text top="114" left="224" width="31" height="12" font="41">ASPC </text>
<text top="114" left="324" width="68" height="12" font="41">Co-Director, </text>
<text top="130" left="324" width="81" height="12" font="41">Cardiovascular </text>
<text top="146" left="324" width="92" height="12" font="41">Imaging Training </text>
<text top="162" left="324" width="52" height="12" font="41">Program, </text>
<text top="178" left="324" width="54" height="12" font="41">Associate </text>
<text top="194" left="324" width="56" height="12" font="41">Physician, </text>
<text top="210" left="324" width="60" height="12" font="41">Preventive </text>
<text top="226" left="324" width="63" height="12" font="41">Cardiology, </text>
<text top="242" left="324" width="92" height="12" font="41">Director, Cardiac </text>
<text top="258" left="324" width="59" height="12" font="41">Computed </text>
<text top="274" left="324" width="74" height="12" font="41">Tomography, </text>
<text top="290" left="324" width="89" height="12" font="41">Brigham Health, </text>
<text top="306" left="324" width="54" height="12" font="41">Associate </text>
<text top="322" left="324" width="67" height="12" font="41">Professor in </text>
<text top="339" left="324" width="75" height="12" font="41">Medicine and </text>
<text top="355" left="324" width="59" height="12" font="41">Radiology, </text>
<text top="371" left="324" width="91" height="12" font="41">Harvard Medical </text>
<text top="387" left="324" width="38" height="12" font="41">School </text>
<text top="111" left="434" width="6" height="17" font="42">•</text>
<text top="115" left="440" width="4" height="12" font="43"> </text>
<text top="115" left="446" width="28" height="12" font="41">Ekos </text>
<text top="131" left="446" width="67" height="12" font="41">Corporation </text>
<text top="144" left="434" width="6" height="17" font="42">•</text>
<text top="147" left="440" width="4" height="12" font="43"> </text>
<text top="147" left="446" width="41" height="12" font="41">Amgen </text>
<text top="114" left="544" width="32" height="12" font="41">None </text>
<text top="114" left="648" width="32" height="12" font="41">None </text>
<text top="111" left="733" width="6" height="17" font="42">•</text>
<text top="115" left="739" width="4" height="12" font="43"> </text>
<text top="115" left="745" width="47" height="12" font="41">Amgen† </text>
<text top="128" left="733" width="6" height="17" font="42">•</text>
<text top="132" left="739" width="4" height="12" font="43"> </text>
<text top="132" left="745" width="51" height="12" font="41">Astellas† </text>
<text top="144" left="733" width="6" height="17" font="42">•</text>
<text top="148" left="739" width="4" height="12" font="43"> </text>
<text top="148" left="745" width="37" height="12" font="41">Sanofi-</text>
<text top="164" left="745" width="49" height="12" font="41">AvenƟs† </text>
<text top="111" left="834" width="6" height="17" font="42">•</text>
<text top="115" left="840" width="4" height="12" font="43"> </text>
<text top="115" left="847" width="54" height="12" font="41">American </text>
<text top="131" left="847" width="56" height="12" font="41">Society of </text>
<text top="147" left="847" width="44" height="12" font="41">Nuclear </text>
<text top="163" left="847" width="60" height="12" font="41">Cardiology </text>
<text top="179" left="847" width="47" height="12" font="41">(Officer, </text>
<text top="195" left="847" width="50" height="12" font="41">Director, </text>
<text top="211" left="847" width="61" height="12" font="41">Trustee, or </text>
<text top="227" left="847" width="32" height="12" font="41">other </text>
<text top="243" left="847" width="51" height="12" font="41">Fiduciary </text>
<text top="259" left="847" width="37" height="12" font="41">Role)† </text>
<text top="272" left="834" width="6" height="17" font="42">•</text>
<text top="276" left="840" width="4" height="12" font="43"> </text>
<text top="276" left="847" width="70" height="12" font="41">Intersocietal </text>
<text top="292" left="847" width="74" height="12" font="41">Accreditation </text>
<text top="308" left="847" width="68" height="12" font="41">Commission </text>
<text top="324" left="847" width="19" height="12" font="41">for </text>
<text top="340" left="847" width="59" height="12" font="41">Computed </text>
<text top="356" left="847" width="71" height="12" font="41">Tomography </text>
<text top="372" left="847" width="47" height="12" font="41">(Officer, </text>
<text top="388" left="847" width="50" height="12" font="41">Director, </text>
<text top="404" left="847" width="61" height="12" font="41">Trustee, or </text>
<text top="420" left="847" width="32" height="12" font="41">other </text>
<text top="436" left="847" width="51" height="12" font="41">Fiduciary </text>
<text top="452" left="847" width="37" height="12" font="41">Role)† </text>
<text top="465" left="834" width="6" height="17" font="42">•</text>
<text top="469" left="840" width="4" height="12" font="43"> </text>
<text top="469" left="847" width="56" height="12" font="41">Society of </text>
<text top="485" left="847" width="68" height="12" font="41">Cardiovascul</text>
<text top="501" left="847" width="73" height="12" font="41">ar Computed </text>
<text top="517" left="847" width="71" height="12" font="41">Tomography </text>
<text top="533" left="847" width="47" height="12" font="41">(Officer, </text>
<text top="549" left="847" width="50" height="12" font="41">Director, </text>
<text top="565" left="847" width="61" height="12" font="41">Trustee, or </text>
<text top="581" left="847" width="32" height="12" font="41">other </text>
<text top="597" left="847" width="51" height="12" font="41">Fiduciary </text>
<text top="613" left="847" width="37" height="12" font="41">Role)† </text>
<text top="114" left="936" width="32" height="12" font="41">None </text>
<text top="114" left="1043" width="32" height="12" font="41">None </text>
<text top="630" left="125" width="40" height="12" font="41">Jo-Ann </text>
<text top="646" left="125" width="55" height="12" font="41">Eastwood </text>
<text top="630" left="224" width="33" height="12" font="41">PCNA </text>
<text top="630" left="324" width="54" height="12" font="41">Associate </text>
<text top="646" left="324" width="88" height="12" font="41">Professor, UCLA </text>
<text top="662" left="324" width="97" height="12" font="41">School of Nursing </text>
<text top="630" left="434" width="32" height="12" font="41">None </text>
<text top="630" left="544" width="32" height="12" font="41">None </text>
<text top="630" left="648" width="32" height="12" font="41">None </text>
<text top="630" left="733" width="32" height="12" font="41">None </text>
<text top="630" left="834" width="32" height="12" font="41">None </text>
<text top="630" left="936" width="32" height="12" font="41">None </text>
<text top="630" left="1043" width="32" height="12" font="41">None </text>
</page>
<page number="79" position="absolute" top="0" left="0" height="892" width="1263">
	<fontspec id="45" size="12" family="Times" color="#000000"/>
	<fontspec id="46" size="12" family="Times" color="#000000"/>
<text top="410" left="647" width="29" height="71" font="31">M</text>
<text top="375" left="674" width="46" height="71" font="31">AN</text>
<text top="315" left="720" width="42" height="71" font="31">US</text>
<text top="256" left="767" width="46" height="71" font="31">CR</text>
<text top="194" left="814" width="28" height="71" font="31">IP</text>
<text top="154" left="846" width="20" height="71" font="31">T</text>
<text top="421" left="639" width="8" height="71" font="31"> </text>
<text top="654" left="458" width="44" height="71" font="31">AC</text>
<text top="594" left="504" width="44" height="71" font="31">CE</text>
<text top="535" left="550" width="42" height="71" font="31">PT</text>
<text top="480" left="592" width="46" height="71" font="31">ED</text>
<text top="12" left="539" width="186" height="21" font="32">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="84" height="15" font="33"><b>Arnett et al. </b></text>
<text top="76" left="159" width="525" height="15" font="33"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="95" left="159" width="4" height="15" font="34"> </text>
<text top="827" left="588" width="91" height="13" font="35">Page 77 of 101 </text>
<text top="114" left="125" width="75" height="12" font="41">Stuart Haines </text>
<text top="114" left="224" width="46" height="12" font="41">Content </text>
<text top="130" left="224" width="62" height="12" font="41">Reviewer—</text>
<text top="146" left="224" width="53" height="12" font="41">ACC/AHA </text>
<text top="114" left="324" width="68" height="12" font="41">Professor of </text>
<text top="130" left="324" width="56" height="12" font="41">Pharmacy </text>
<text top="146" left="324" width="49" height="12" font="41">Practice, </text>
<text top="162" left="324" width="71" height="12" font="41">University of </text>
<text top="178" left="324" width="61" height="12" font="41">Mississippi </text>
<text top="114" left="434" width="32" height="12" font="41">None </text>
<text top="114" left="544" width="32" height="12" font="41">None </text>
<text top="111" left="648" width="6" height="17" font="42">•</text>
<text top="115" left="654" width="4" height="12" font="43"> </text>
<text top="115" left="663" width="16" height="12" font="41">Rx </text>
<text top="131" left="663" width="51" height="12" font="41">Instructio</text>
<text top="147" left="663" width="19" height="12" font="41">nal </text>
<text top="163" left="663" width="53" height="12" font="41">Systems* </text>
<text top="114" left="733" width="32" height="12" font="41">None </text>
<text top="111" left="834" width="6" height="17" font="42">•</text>
<text top="115" left="840" width="4" height="12" font="43"> </text>
<text top="115" left="850" width="54" height="12" font="41">American </text>
<text top="131" left="850" width="64" height="12" font="41">Association </text>
<text top="147" left="850" width="61" height="12" font="41">of Colleges </text>
<text top="163" left="850" width="70" height="12" font="41">of Pharmacy </text>
<text top="179" left="850" width="46" height="12" font="41">(Officer, </text>
<text top="195" left="850" width="50" height="12" font="41">Director, </text>
<text top="211" left="850" width="61" height="12" font="41">Trustee, or </text>
<text top="227" left="850" width="32" height="12" font="41">other </text>
<text top="243" left="850" width="51" height="12" font="41">Fiduciary </text>
<text top="259" left="850" width="37" height="12" font="41">Role)† </text>
<text top="114" left="936" width="32" height="12" font="41">None </text>
<text top="114" left="1043" width="32" height="12" font="41">None </text>
<text top="276" left="125" width="71" height="12" font="41">Michael Rich </text>
<text top="276" left="224" width="25" height="12" font="41">AGS </text>
<text top="276" left="324" width="68" height="12" font="41">Professor of </text>
<text top="292" left="324" width="56" height="12" font="41">Medicine, </text>
<text top="308" left="324" width="67" height="12" font="41">Washington </text>
<text top="324" left="324" width="95" height="12" font="41">University School </text>
<text top="340" left="324" width="96" height="12" font="41">of Medicine in St. </text>
<text top="356" left="324" width="30" height="12" font="41">Louis </text>
<text top="276" left="434" width="32" height="12" font="41">None </text>
<text top="276" left="544" width="32" height="12" font="41">None </text>
<text top="276" left="648" width="32" height="12" font="41">None </text>
<text top="276" left="733" width="32" height="12" font="41">None </text>
<text top="276" left="834" width="32" height="12" font="41">None </text>
<text top="276" left="936" width="32" height="12" font="41">None </text>
<text top="276" left="1043" width="32" height="12" font="41">None </text>
<text top="385" left="126" width="1061" height="13" font="45">This table represents all relationships of reviewers with industry and other entities that were reported at the time of peer review, including those not deemed to be relevant to </text>
<text top="402" left="126" width="1061" height="13" font="45">this document, at the time this document was under review. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to </text>
<text top="420" left="126" width="1061" height="13" font="45">have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market </text>
<text top="438" left="126" width="1061" height="13" font="45">value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist </text>
<text top="456" left="126" width="1061" height="13" font="45">with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order </text>
<text top="474" left="126" width="1061" height="13" font="45">within  each  category  of  review.  Please  refer  to  http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy  for  definitions  of </text>
<text top="492" left="126" width="651" height="13" font="45">disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees. </text>
<text top="509" left="126" width="3" height="13" font="45"> </text>
<text top="527" left="126" width="150" height="13" font="45">*Significant relationship. </text>
<text top="545" left="126" width="131" height="13" font="45">†No ﬁnancial beneﬁt. </text>
<text top="563" left="126" width="3" height="13" font="45"> </text>
<text top="581" left="126" width="1061" height="13" font="45">AACVPR indicates American Association of Cardiovascular and Pulmonary Rehabilitation; ACC, American College of Cardiology; ACPM, American College of Preventive Medicine; </text>
<text top="599" left="126" width="1061" height="13" font="45">AGS,  American  Geriatrics  Society;  AHA,  American  Heart  Association;  ASN,  American  Society  for  Nutrition;  American  Society  of  Preventive  Cardiology;  DSMB,  Data  and  Safety </text>
<text top="617" left="126" width="1058" height="13" font="45">Monitoring Board; FDA, U.S. Food and Drug Administration; FEBS, Federation of European Biochemical Societies; <i>JAMA, Journal of the American Medical Association</i>; LDL-C, low-</text>
<text top="634" left="126" width="1061" height="13" font="45">density lipoprotein cholesterol; NHLBI, National Heart, Lung, and Blood Institute; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; NIH, National Institutes </text>
<text top="652" left="126" width="1061" height="13" font="45">of  Health;  OHSU,  Oregon  Health  &amp;  Science  University;  PCNA,  Preventive  Cardiovascular  Nurses  Association;  PCORI,  Patient-Centered  Outcomes  Research  Institute;  UCLA, </text>
<text top="670" left="126" width="1061" height="13" font="45">University  of  California,  Los  Angeles;  UF,  University  of  Florida;  UPMC,  University  of  Pittsburgh  Medical  Center;  UT,  University  of  Texas;  UW,  University  of  Wisconsin;  and  VA, </text>
<text top="688" left="126" width="102" height="13" font="45">Veterans Affairs. </text>
</page>
<page number="80" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="47" size="12" family="Helvetica" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 78 of 101 </text>
<text top="195" left="105" width="113" height="21" font="10"><b>References </b></text>
<text top="228" left="105" width="141" height="20" font="20"><b>1. Introduction </b></text>
<text top="253" left="105" width="30" height="13" font="23">S1-1.</text>
<text top="253" left="135" width="4" height="13" font="47"> </text>
<text top="253" left="164" width="627" height="13" font="23">Weir HK, Anderson RN, Coleman King SM, et al. Heart disease and cancer deaths—trends and projections </text>
<text top="271" left="164" width="387" height="13" font="23">in the United States, 1969-2020. Prev Chronic Dis. 2016;13:E157. </text>
<text top="289" left="105" width="30" height="13" font="23">S1-2.</text>
<text top="289" left="135" width="4" height="13" font="47"> </text>
<text top="289" left="164" width="590" height="13" font="23">Johnson NB, Hayes LD, Brown K, et al. CDC National Health Report: leading causes of morbidity and </text>
<text top="307" left="164" width="590" height="13" font="23">mortality and associated behavioral risk and protective factors—United States, 2005-2013. MMWR </text>
<text top="324" left="164" width="126" height="13" font="23">Suppl. 2014;63:3-27. </text>
<text top="342" left="105" width="30" height="13" font="23">S1-3.</text>
<text top="342" left="135" width="4" height="13" font="47"> </text>
<text top="342" left="164" width="600" height="13" font="23">Xu J, Murphy SL, Kochanek KD, et al. Mortality in the United States, 2015. NCHS Data Brief. 2016;1-8. </text>
<text top="360" left="105" width="30" height="13" font="23">S1-4.</text>
<text top="360" left="135" width="4" height="13" font="47"> </text>
<text top="360" left="164" width="616" height="13" font="23">Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary </text>
<text top="378" left="164" width="271" height="13" font="23">heart disease events. JAMA. 2003;290:891-7. </text>
<text top="395" left="105" width="30" height="13" font="23">S1-5.</text>
<text top="395" left="135" width="4" height="13" font="47"> </text>
<text top="395" left="164" width="613" height="13" font="23">Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health </text>
<text top="413" left="164" width="618" height="13" font="23">promotion and disease reduction: the American Heart Association’s Strategic Impact Goal through 2020 </text>
<text top="431" left="164" width="264" height="13" font="23">and beyond. Circulation. 2010;121:586-613. </text>
<text top="449" left="105" width="30" height="13" font="23">S1-6.</text>
<text top="449" left="135" width="4" height="13" font="47"> </text>
<text top="449" left="164" width="618" height="13" font="23">Turco JV, Inal-Veith A, Fuster V. Cardiovascular health promotion: an issue that can no longer wait. J Am </text>
<text top="467" left="164" width="175" height="13" font="23">Coll Cardiol. 2018;72:908-13. </text>
<text top="485" left="105" width="30" height="13" font="23">S1-7.</text>
<text top="485" left="135" width="4" height="13" font="47"> </text>
<text top="485" left="164" width="575" height="13" font="23">Younus A, Aneni EC, Spatz ES, et al. A systematic review of the prevalence and outcomes of ideal </text>
<text top="503" left="164" width="510" height="13" font="23">cardiovascular health in US and non-US populations. Mayo Clin Proc. 2016;91:649-70. </text>
<text top="530" left="105" width="339" height="19" font="15"><b>1.1. Methodology and Evidence Review </b></text>
<text top="554" left="105" width="41" height="13" font="23">S1.1-1.</text>
<text top="554" left="146" width="4" height="13" font="47"> </text>
<text top="554" left="164" width="284" height="13" font="23">Whelton PK, Carey RM, Aronow WS, et al. 2017 </text>
<text top="572" left="164" width="615" height="13" font="23">ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, </text>
<text top="590" left="164" width="584" height="13" font="23">evaluation, and management of high blood pressure in adults: a report of the American College of </text>
<text top="608" left="164" width="574" height="13" font="23">Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. </text>
<text top="625" left="164" width="108" height="13" font="23">2018;71:e13-115. </text>
<text top="643" left="105" width="41" height="13" font="23">S1.1-2.</text>
<text top="643" left="146" width="4" height="13" font="47"> </text>
<text top="643" left="164" width="258" height="13" font="23">Grundy SM, Stone NJ, Bailey AL, et al. 2018 </text>
<text top="661" left="164" width="624" height="13" font="23">AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of </text>
<text top="679" left="164" width="625" height="13" font="23">blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force </text>
<text top="697" left="164" width="600" height="13" font="23">on Clinical Practice Guidelines [published online ahead of print November 10, 2018]. Circulation. doi: </text>
<text top="714" left="164" width="199" height="13" font="23">10.1161/CIR.0000000000000625 </text>
<text top="742" left="105" width="448" height="19" font="15"><b>1.5. Class of Recommendation and Level of Evidence </b></text>
<text top="766" left="105" width="41" height="13" font="23">S1.5-1.</text>
<text top="766" left="146" width="4" height="13" font="47"> </text>
<text top="766" left="164" width="613" height="13" font="23">Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/AHA clinical practice guideline </text>
<text top="784" left="164" width="612" height="13" font="23">recommendation classification system: a report of the American College of Cardiology/American Heart </text>
<text top="802" left="164" width="500" height="13" font="23">Association Task Force on Clinical Practice Guidelines. Circulation. 2016;133:1426-8. </text>
<text top="829" left="105" width="606" height="19" font="15"><b>2.1. Patient-Centered Approaches for Providing Comprehensive ASCVD </b></text>
<text top="854" left="105" width="98" height="19" font="15"><b>Prevention </b></text>
<text top="878" left="105" width="41" height="13" font="23">S2.1-1.</text>
<text top="878" left="146" width="4" height="13" font="47"> </text>
<text top="878" left="171" width="592" height="13" font="23">Carter BL, Rogers M, Daly J, et al. The potency of team-based care interventions for hypertension: a </text>
<text top="896" left="171" width="309" height="13" font="23">meta-analysis. Arch Intern Med. 2009;169:1748-55. </text>
<text top="914" left="105" width="41" height="13" font="23">S2.1-2.</text>
<text top="914" left="146" width="4" height="13" font="47"> </text>
<text top="914" left="171" width="594" height="13" font="23">Chisholm-Burns MA, Kim Lee J, Spivey CA, et al. US pharmacists’ effect as team members on patient </text>
<text top="932" left="171" width="426" height="13" font="23">care: systematic review and meta-analyses. Med Care. 2010;48:923-33. </text>
<text top="949" left="105" width="41" height="13" font="23">S2.1-3.</text>
<text top="949" left="146" width="4" height="13" font="47"> </text>
<text top="949" left="171" width="610" height="13" font="23">Fazel MT, Bagalagel A, Lee JK, et al. Impact of diabetes care by pharmacists as part of health care team </text>
<text top="967" left="171" width="601" height="13" font="23">in ambulatory settings: a systematic review and meta-analysis. Ann Pharmacother. 2017;51:890-907. </text>
<text top="985" left="105" width="41" height="13" font="23">S2.1-4.</text>
<text top="985" left="146" width="4" height="13" font="47"> </text>
<text top="985" left="171" width="591" height="13" font="23">Mills KT, Obst KM, Shen W, et al. Comparative effectiveness of implementation strategies for blood </text>
<text top="1003" left="171" width="586" height="13" font="23">pressure control in hypertensive patients: a systematic review and meta-analysis. Ann Intern Med. </text>
<text top="1021" left="171" width="108" height="13" font="23">2018;168:110-20. </text>
<text top="1039" left="105" width="41" height="13" font="23">S2.1-5.</text>
<text top="1039" left="146" width="4" height="13" font="47"> </text>
<text top="1039" left="171" width="611" height="13" font="23">Proia KK, Thota AB, Njie GJ, et al. Team-based care and improved blood pressure control: a community </text>
<text top="1056" left="171" width="339" height="13" font="23">guide systematic review. Am J Prev Med. 2014;47:86-99. </text>
<text top="1074" left="105" width="41" height="13" font="23">S2.1-6.</text>
<text top="1074" left="146" width="4" height="13" font="47"> </text>
<text top="1074" left="171" width="598" height="13" font="23">Chen Z, Ernst ME, Ardery G, et al. Physician-pharmacist co-management and 24-hour blood pressure </text>
</page>
<page number="81" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 79 of 101 </text>
<text top="167" left="171" width="328" height="13" font="23">control. J Clin Hypertens (Greenwich). 2013;15:337-43. </text>
<text top="185" left="105" width="41" height="13" font="23">S2.1-7.</text>
<text top="185" left="146" width="4" height="13" font="47"> </text>
<text top="185" left="171" width="611" height="13" font="23">Hirsch JD, Steers N, Adler DS, et al. Primary care-based, pharmacist-physician collaborative medication-</text>
<text top="203" left="171" width="583" height="13" font="23">therapy management of hypertension: a randomized, pragmatic trial. Clin Ther. 2014;36:1244-54. </text>
<text top="221" left="105" width="41" height="13" font="23">S2.1-8.</text>
<text top="220" left="146" width="4" height="13" font="47"> </text>
<text top="221" left="171" width="580" height="13" font="23">Hunt JS, Siemienczuk J, Pape G, et al. A randomized controlled trial of team-based care: impact of </text>
<text top="238" left="171" width="612" height="13" font="23">physician-pharmacist collaboration on uncontrolled hypertension. J Gen Intern Med. 2008;23:1966-72. </text>
<text top="256" left="105" width="41" height="13" font="23">S2.1-9.</text>
<text top="256" left="146" width="4" height="13" font="47"> </text>
<text top="256" left="171" width="585" height="13" font="23">Isetts BJ, Buffington DE, Carter BL, et al. Evaluation of pharmacists’ work in a physician-pharmacist </text>
<text top="274" left="171" width="562" height="13" font="23">collaborative model for the management of hypertension. Pharmacotherapy. 2016;36:374-84. </text>
<text top="292" left="105" width="48" height="13" font="23">S2.1-10.</text>
<text top="292" left="153" width="4" height="13" font="47"> </text>
<text top="292" left="171" width="604" height="13" font="23">McLean DL, McAlister FA, Johnson JA, et al. A randomized trial of the effect of community pharmacist </text>
<text top="310" left="171" width="603" height="13" font="23">and nurse care on improving blood pressure management in patients with diabetes mellitus: study of </text>
<text top="328" left="171" width="550" height="13" font="23">cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med. </text>
<text top="345" left="171" width="115" height="13" font="23">2008;168:2355-61. </text>
<text top="363" left="105" width="48" height="13" font="23">S2.1-11.</text>
<text top="363" left="153" width="4" height="13" font="47"> </text>
<text top="363" left="171" width="559" height="13" font="23">Polgreen LA, Han J, Carter BL, et al. Cost-effectiveness of a physician-pharmacist collaboration </text>
<text top="381" left="171" width="482" height="13" font="23">intervention to improve blood pressure control. Hypertension. 2015;66:1145-51. </text>
<text top="399" left="105" width="48" height="13" font="23">S2.1-12.</text>
<text top="399" left="153" width="4" height="13" font="47"> </text>
<text top="399" left="171" width="617" height="13" font="23">Chen EH, Thom DH, Hessler DM, et al. Using the Teamlet Model to improve chronic care in an academic </text>
<text top="417" left="171" width="394" height="13" font="23">primary care practice. J Gen Intern Med. 2010;25(suppl 4):S610-4. </text>
<text top="434" left="105" width="48" height="13" font="23">S2.1-13.</text>
<text top="434" left="153" width="4" height="13" font="47"> </text>
<text top="434" left="171" width="619" height="13" font="23">Kravetz JD, Walsh RF. Team-based hypertension management to improve blood pressure control. J Prim </text>
<text top="452" left="171" width="235" height="13" font="23">Care Community Health. 2016;7:272-5. </text>
<text top="470" left="105" width="48" height="13" font="23">S2.1-14.</text>
<text top="470" left="153" width="4" height="13" font="47"> </text>
<text top="470" left="171" width="620" height="13" font="23">Wan EYF, Fung CSC, Jiao27 FF, et al. Five-year effectiveness of the Multidisciplinary Risk Assessment and </text>
<text top="488" left="171" width="611" height="13" font="23">Management Programme-Diabetes Mellitus (RAMP-DM) on diabetes-related complications and health </text>
<text top="506" left="171" width="617" height="13" font="23">service uses—a population-based and propensity-matched cohort study. Diabetes Care. 2018;41:49-59. </text>
<text top="524" left="105" width="48" height="13" font="23">S2.1-15.</text>
<text top="524" left="153" width="4" height="13" font="47"> </text>
<text top="524" left="171" width="610" height="13" font="23">Buhse S, Mühlhauser I, Heller T, et al. Informed shared decision-making programme on the prevention </text>
<text top="541" left="171" width="608" height="13" font="23">of myocardial infarction in type 2 diabetes: a randomised controlled trial. BMJ Open. 2015;5:e009116. </text>
<text top="559" left="105" width="48" height="13" font="23">S2.1-16.</text>
<text top="559" left="153" width="4" height="13" font="47"> </text>
<text top="559" left="171" width="566" height="13" font="23">Cooper LA, Roter DL, Carson KA, et al. A randomized trial to improve patient-centered care and </text>
<text top="577" left="171" width="579" height="13" font="23">hypertension control in underserved primary care patients. J Gen Intern Med. 2011;26:1297-304. </text>
<text top="595" left="105" width="48" height="13" font="23">S2.1-17.</text>
<text top="595" left="153" width="4" height="13" font="47"> </text>
<text top="595" left="171" width="592" height="13" font="23">Olomu A, Hart-Davidson W, Luo Z, et al. Implementing shared decision making in federally qualified </text>
<text top="613" left="171" width="590" height="13" font="23">health centers, a quasi-experimental design study: the Office-Guidelines Applied to Practice (Office-</text>
<text top="631" left="171" width="318" height="13" font="23">GAP) program. BMC Health S24erv Res. 2016;16:334. </text>
<text top="648" left="105" width="48" height="13" font="23">S2.1-18.</text>
<text top="648" left="153" width="4" height="13" font="47"> </text>
<text top="648" left="171" width="575" height="13" font="23">Parchman ML, Zeber JE, Palmer RF. Participatory decision making, patient activation, medication </text>
<text top="666" left="171" width="590" height="13" font="23">adherence, and intermediate clinical outcomes in type 2 diabetes: a STARNet study. Ann Fam Med. </text>
<text top="684" left="171" width="86" height="13" font="23">2010;8:410-7. </text>
<text top="702" left="105" width="48" height="13" font="23">S2.1-19.</text>
<text top="702" left="153" width="4" height="13" font="47"> </text>
<text top="702" left="171" width="604" height="13" font="23">Havranek EP, Mujahid MS, Barr DA, et al. Social determinants of risk and outcomes for cardiovascular </text>
<text top="720" left="171" width="587" height="13" font="23">disease: a scientific statement from the American Heart Association. Circulation. 2015;132:873-98. </text>
<text top="737" left="105" width="48" height="13" font="23">S2.1-20.</text>
<text top="737" left="153" width="4" height="13" font="47"> </text>
<text top="737" left="171" width="588" height="13" font="23">Vilhelmsson A, Östergren P-O. Reducing health inequalities with interventions targeting behavioral </text>
<text top="755" left="171" width="609" height="13" font="23">factors among individuals with low levels of education—a rapid review. PLoS ONE. 2018;13:e0195774. </text>
<text top="773" left="105" width="48" height="13" font="23">S2.1-21.</text>
<text top="773" left="153" width="4" height="13" font="47"> </text>
<text top="773" left="171" width="598" height="13" font="23">Schultz WM, Kelli HM, Lisko JC, et al. Socioeconomic status and cardiovascular outcomes: challenges </text>
<text top="791" left="171" width="298" height="13" font="23">and interventions. Circulation. 2018;137:2166-78. </text>
<text top="809" left="105" width="48" height="13" font="23">S2.1-22.</text>
<text top="809" left="153" width="4" height="13" font="47"> </text>
<text top="809" left="171" width="584" height="13" font="23">Backholer K, Peters SAE, Bots SH, et al. Sex differences in the relationship between socioeconomic </text>
<text top="827" left="171" width="582" height="13" font="23">status and cardiovascular disease: a systematic review and meta-analysis. J Epidemiol Community </text>
<text top="844" left="171" width="140" height="13" font="23">Health. 2017;71:550-7. </text>
<text top="862" left="105" width="48" height="13" font="23">S2.1-23.</text>
<text top="862" left="153" width="4" height="13" font="47"> </text>
<text top="862" left="171" width="607" height="13" font="23">Beauchamp A, Peeters A, Tonkin A, et al. Best practice for prevention and treatment of cardiovascular </text>
<text top="880" left="171" width="533" height="13" font="23">disease through an equity lens: a review. Eur J Cardiovasc Prev Rehabil. 2010;17:599-606. </text>
<text top="898" left="105" width="48" height="13" font="23">S2.1-24.</text>
<text top="898" left="153" width="4" height="13" font="47"> </text>
<text top="898" left="171" width="617" height="13" font="23">Khaing W, Vallibhakara SA, Attia J, et al. Effects of education and income on cardiovascular outcomes: a </text>
<text top="916" left="171" width="442" height="13" font="23">systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24:1032-42. </text>
<text top="933" left="105" width="48" height="13" font="23">S2.1-25.</text>
<text top="933" left="153" width="4" height="13" font="47"> </text>
<text top="933" left="171" width="579" height="13" font="23">Pollitt RA, Rose KM, Kaufman JS. Evaluating the evidence for models of life course socioeconomic </text>
<text top="951" left="171" width="525" height="13" font="23">factors and cardiovascular outcomes: a systematic review. BMC Public Health. 2005;5:7. </text>
<text top="969" left="105" width="48" height="13" font="23">S2.1-26.</text>
<text top="969" left="153" width="4" height="13" font="47"> </text>
<text top="969" left="171" width="609" height="13" font="23">Schottenfeld L, Petersen D, Peikes D, et al. Creating Patient-centered Team-based Primary Care. AHRQ </text>
<text top="987" left="171" width="550" height="13" font="23">Publication No. 16-0002-EF. Rockville, MD: Agency for Healthcare Research and Quality, U.S. </text>
<text top="1005" left="171" width="602" height="13" font="23">Department of Health and Human Services; 2016. Available at: https://pcmh.ahrq.gov/page/creating-</text>
<text top="1023" left="171" width="421" height="13" font="23">patient-centered-team-based-primary-care. Accessed January 3, 2019. </text>
<text top="1040" left="105" width="48" height="13" font="23">S2.1-27.</text>
<text top="1040" left="153" width="4" height="13" font="47"> </text>
<text top="1040" left="171" width="619" height="13" font="23">Brush JE Jr, Handberg EM, Biga C, et al. 2015 ACC health policy statement on cardiovascular team-based </text>
<text top="1058" left="171" width="508" height="13" font="23">care and the role of advanced practice providers. J Am Coll Cardiol. 2015;65:2118-36. </text>
<text top="1076" left="105" width="48" height="13" font="23">S2.1-28.</text>
<text top="1076" left="153" width="4" height="13" font="47"> </text>
<text top="1076" left="171" width="566" height="13" font="23">Fentanes E, Vande Hei AG, Holuby RS, et al. Treatment in a preventive cardiology clinic utilizing </text>
</page>
<page number="82" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 80 of 101 </text>
<text top="167" left="171" width="611" height="13" font="23">advanced practice providers effectively closes atherosclerotic cardiovascular disease risk-management </text>
<text top="185" left="171" width="579" height="13" font="23">gaps among a primary-prevention population compared with a propensity-matched primary-care </text>
<text top="203" left="171" width="613" height="13" font="23">cohort: a team-based care model and its impact on lipid and blood pressure management. Clin Cardiol. </text>
<text top="221" left="171" width="101" height="13" font="23">2018;41:817-24. </text>
<text top="238" left="105" width="48" height="13" font="23">S2.1-29.</text>
<text top="238" left="153" width="4" height="13" font="47"> </text>
<text top="238" left="171" width="587" height="13" font="23">Billioux A, Verlander K, Anthony S, et al. Standardized Screening for Health-Related Social Needs in </text>
<text top="256" left="171" width="498" height="13" font="23">Clinical Settings: The Accountable Health Communities Screening Tool. Available at: </text>
<text top="274" left="171" width="586" height="13" font="23">https://nam.edu/wp-content/uploads/2017/05/Standardized-Screening-for-Health-Related-Social-</text>
<text top="292" left="171" width="339" height="13" font="23">Needs-in-Clinical-Settings.pdf. Accessed January 5, 2019. </text>
<text top="310" left="105" width="48" height="13" font="23">S2.1-30.</text>
<text top="310" left="153" width="4" height="13" font="47"> </text>
<text top="310" left="171" width="556" height="13" font="23">Malambo P, Kengne AP, De Villiers A, et al. Built environment, selected risk factors and major </text>
<text top="328" left="171" width="509" height="13" font="23">cardiovascular disease outcomes: a systematic review. PLoS ONE. 2016;11:e0166846. </text>
<text top="345" left="105" width="48" height="13" font="23">S2.1-31.</text>
<text top="345" left="153" width="4" height="13" font="47"> </text>
<text top="345" left="171" width="549" height="13" font="23">DeFilippis AP, Young R, McEvoy JW, et al. Risk score overestimation: the impact of individual </text>
<text top="363" left="171" width="566" height="13" font="23">cardiovascular risk factors and preventive therapies on the performance of the American Heart </text>
<text top="381" left="171" width="579" height="13" font="23">Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a </text>
<text top="399" left="171" width="352" height="13" font="23">modern multi-ethnic cohort. Eur Heart J. 2017;38:598-608. </text>
<text top="417" left="105" width="48" height="13" font="23">S2.1-32.</text>
<text top="417" left="153" width="4" height="13" font="47"> </text>
<text top="417" left="171" width="604" height="13" font="23">Berkowitz SA, Hulberg AC, Standish S, et al. Addressing unmet basic resource needs as part of chronic </text>
<text top="434" left="171" width="452" height="13" font="23">cardiometabolic disease management. JAMA Intern Med. 2017;177:244-52. </text>
<text top="452" left="105" width="48" height="13" font="23">S2.1-33.</text>
<text top="452" left="153" width="4" height="13" font="47"> </text>
<text top="452" left="171" width="614" height="13" font="23">Carnethon MR, Pu J, Howard G, et al. Cardiovascular health in African Americans: a scientific statement </text>
<text top="470" left="171" width="421" height="13" font="23">from the American Heart Association. Circulation. 2017;136:e393-423. </text>
<text top="488" left="105" width="48" height="13" font="23">S2.1-34.</text>
<text top="488" left="153" width="4" height="13" font="47"> </text>
<text top="488" left="171" width="528" height="13" font="23">Rodriguez CJ, Allison M, Daviglus ML, et al. Status of cardiovascular disease and stroke in </text>
<text top="506" left="171" width="569" height="13" font="23">Hispanics/Latinos in the United States: a science advisory from the American Heart Association. </text>
<text top="524" left="171" width="186" height="13" font="23">Circulation. 2014;130:593-625. </text>
<text top="541" left="105" width="48" height="13" font="23">S2.1-35.</text>
<text top="541" left="153" width="4" height="13" font="47"> </text>
<text top="541" left="171" width="612" height="13" font="23">Volgman AS, Palaniappan LS, Aggarwal NT, et al. Atherosclerotic cardiovascular disease in South Asians </text>
<text top="559" left="171" width="569" height="13" font="23">in the United States: epidemiology, risk factors, and treatments: a scientific statement from the </text>
<text top="577" left="171" width="343" height="13" font="23">American Heart Association. Circulation. 2018;138:e1-34. </text>
<text top="595" left="105" width="48" height="13" font="23">S2.1-36.</text>
<text top="595" left="153" width="4" height="13" font="47"> </text>
<text top="595" left="171" width="602" height="13" font="23">Magnani JW, Mujahid MS, Aronow HD, et al. Health literacy and cardiovascular disease: fundamental </text>
<text top="613" left="171" width="571" height="13" font="23">relevance to primary and secondary prevention: a scientific statement from the American Heart </text>
<text top="631" left="171" width="254" height="13" font="23">Association. Circulation. 2018;138:e48-74. </text>
<text top="648" left="105" width="48" height="13" font="23">S2.1-37.</text>
<text top="648" left="153" width="4" height="13" font="47"> </text>
<text top="648" left="171" width="594" height="13" font="23">Powell TM, de Lemos JA, Banks K, et al. Body size misperception: a novel determinant in the obesity </text>
<text top="666" left="171" width="274" height="13" font="23">epidemic. Arch Intern Med. 2010;170:1695-7. </text>
<text top="684" left="105" width="48" height="13" font="23">S2.1-38.</text>
<text top="684" left="153" width="4" height="13" font="47"> </text>
<text top="684" left="171" width="611" height="13" font="23">Padgett J, Biro FM. Different shapes in different cultures: body dissatisfaction, overweight, and obesity </text>
<text top="702" left="171" width="521" height="13" font="23">in African-American and caucasian females. J Pediatr Adolesc Gynecol. 2003;16:349-54. </text>
<text top="720" left="105" width="48" height="13" font="23">S2.1-39.</text>
<text top="720" left="153" width="4" height="13" font="47"> </text>
<text top="720" left="171" width="614" height="13" font="23">U.S. Department of Health and Human Services. Healthy People 2020. Washington, DC: 2010. Available </text>
<text top="737" left="171" width="375" height="13" font="23">at: https://www.healthypeople.gov. Accessed January 3, 2019. </text>
<text top="755" left="105" width="48" height="13" font="23">S2.1-40.</text>
<text top="755" left="153" width="4" height="13" font="47"> </text>
<text top="755" left="171" width="583" height="13" font="23">Bird EL, Ige JO, Pilkington P, et al. Built and natural environment planning principles for promoting </text>
<text top="773" left="171" width="365" height="13" font="23">health: an umbrella review. BMC Public Health. 2018;18:930. </text>
<text top="791" left="105" width="48" height="13" font="23">S2.1-41.</text>
<text top="791" left="153" width="4" height="13" font="47"> </text>
<text top="791" left="171" width="615" height="13" font="23">Kaiser P, Diez Roux AV, Mujahid M, et al. Neighborhood environments and incident hypertension in the </text>
<text top="809" left="171" width="433" height="13" font="23">Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2016;183:988-97. </text>
<text top="827" left="105" width="48" height="13" font="23">S2.1-42.</text>
<text top="827" left="153" width="4" height="13" font="47"> </text>
<text top="827" left="171" width="611" height="13" font="23">Kumanyika SK, Gary TL, Lancaster KJ, et al. Achieving healthy weight in African-American communities: </text>
<text top="844" left="171" width="388" height="13" font="23">research perspectives and priorities. Obes Res. 2005;13:2037-47. </text>
<text top="862" left="105" width="48" height="13" font="23">S2.1-43.</text>
<text top="862" left="153" width="4" height="13" font="47"> </text>
<text top="862" left="171" width="605" height="13" font="23">Grandner MA. Addressing sleep disturbances: an opportunity to prevent cardiometabolic disease? Int </text>
<text top="880" left="171" width="193" height="13" font="23">Rev Psychiatry. 2014;26:155-76. </text>
<text top="898" left="105" width="48" height="13" font="23">S2.1-44.</text>
<text top="898" left="153" width="4" height="13" font="47"> </text>
<text top="898" left="171" width="556" height="13" font="23">Knutson KL. Sociodemographic and cultural determinants of sleep deficiency: implications for </text>
<text top="916" left="171" width="338" height="13" font="23">cardiometabolic disease risk. Soc Sci Med. 2013;79:7-15. </text>
<text top="933" left="105" width="48" height="13" font="23">S2.1-45.</text>
<text top="933" left="153" width="4" height="13" font="47"> </text>
<text top="933" left="171" width="593" height="13" font="23">Ismail K, Winkley K, Rabe-Hesketh S. Systematic review and meta-analysis of randomised controlled </text>
<text top="951" left="171" width="584" height="13" font="23">trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. </text>
<text top="969" left="171" width="162" height="13" font="23">Lancet. 2004;363:1589-97. </text>
<text top="987" left="105" width="48" height="13" font="23">S2.1-46.</text>
<text top="987" left="153" width="4" height="13" font="47"> </text>
<text top="987" left="171" width="580" height="13" font="23">Alam R, Sturt J, Lall R, et al. An updated meta-analysis to assess the effectiveness of psychological </text>
<text top="1005" left="171" width="620" height="13" font="23">interventions delivered by psychological specialists and generalist clinicians on glycaemic control and on </text>
<text top="1023" left="171" width="340" height="13" font="23">psychological status. Patient Educ Couns. 2009;75:25-36. </text>
<text top="1040" left="105" width="48" height="13" font="23">S2.1-47.</text>
<text top="1040" left="153" width="4" height="13" font="47"> </text>
<text top="1040" left="171" width="616" height="13" font="23">Bolen SD, Chandar A, Falck-Ytter C, et al. Effectiveness and safety of patient activation interventions for </text>
<text top="1058" left="171" width="609" height="13" font="23">adults with type 2 diabetes: systematic review, meta-analysis, and meta-regression. J Gen Intern Med. </text>
<text top="1076" left="171" width="108" height="13" font="23">2014;29:1166-76. </text>
</page>
<page number="83" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 81 of 101 </text>
<text top="167" left="105" width="48" height="13" font="23">S2.1-48.</text>
<text top="167" left="153" width="4" height="13" font="47"> </text>
<text top="167" left="171" width="580" height="13" font="23">Gonzalez JS, Tanenbaum ML, Commissariat PV. Psychosocial factors in medication adherence and </text>
<text top="185" left="171" width="572" height="13" font="23">diabetes self-management: Implications for research and practice. Am Psychol. 2016;71:539-51. </text>
<text top="203" left="105" width="48" height="13" font="23">S2.1-49.</text>
<text top="203" left="153" width="4" height="13" font="47"> </text>
<text top="203" left="171" width="538" height="13" font="23">Javaheri S, Redline S. Insomnia and risk of cardiovascular disease. Chest. 2017;152:435-44. </text>
<text top="221" left="105" width="48" height="13" font="23">S2.1-50.</text>
<text top="220" left="153" width="4" height="13" font="47"> </text>
<text top="221" left="171" width="566" height="13" font="23">Samuel LJ, Dennison Himmelfarb CR, Szklo M, et al. Social engagement and chronic disease risk </text>
<text top="238" left="171" width="465" height="13" font="23">behaviors: the Multi-Ethnic Study of Atherosclerosis. Prev Med. 2015;71:61-6. </text>
<text top="256" left="105" width="48" height="13" font="23">S2.1-51.</text>
<text top="256" left="153" width="4" height="13" font="47"> </text>
<text top="256" left="171" width="612" height="13" font="23">Verbiest M, Brakema E, van der Kleij R, et al. National guidelines for smoking cessation in primary care: </text>
<text top="274" left="171" width="476" height="13" font="23">a literature review and evidence analysis. NPJ Prim Care Respir Med. 2017;27:2. </text>
<text top="302" left="105" width="332" height="19" font="15"><b>2.2. Assessment of Cardiovascular Risk </b></text>
<text top="326" left="105" width="41" height="13" font="23">S2.2-1.</text>
<text top="326" left="146" width="4" height="13" font="47"> </text>
<text top="326" left="174" width="545" height="13" font="23">Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of </text>
<text top="343" left="174" width="595" height="13" font="23">cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task </text>
<text top="361" left="174" width="389" height="13" font="23">Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2935-59. </text>
<text top="379" left="105" width="41" height="13" font="23">S2.2-2.</text>
<text top="379" left="146" width="4" height="13" font="47"> </text>
<text top="379" left="174" width="575" height="13" font="23">American College of Cardiology, American Heart Association. ASCVD Risk Estimator. Available at: </text>
<text top="397" left="174" width="603" height="13" font="23">https://tools.acc.org/ldl/ascvd_risk_estimator/index.html#!/calulate/estimator. Accessed September </text>
<text top="415" left="174" width="58" height="13" font="23">21, 2018. </text>
<text top="433" left="105" width="41" height="13" font="23">S2.2-3.</text>
<text top="433" left="146" width="4" height="13" font="47"> </text>
<text top="433" left="174" width="573" height="13" font="23">Ference BA, Graham I, Tokgozoglu L, et al. Impact of lipids on cardiovascular health: JACC Health </text>
<text top="450" left="174" width="323" height="13" font="23">Promotion Series. J Am Coll Cardiol. 2018;72:1141-56. </text>
<text top="468" left="105" width="41" height="13" font="23">S2.2-4.</text>
<text top="468" left="146" width="4" height="13" font="47"> </text>
<text top="468" left="174" width="258" height="13" font="23">Grundy SM, Stone NJ, Bailey AL, et al. 2018 </text>
<text top="486" left="174" width="609" height="13" font="23">AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management </text>
<text top="504" left="174" width="604" height="13" font="23">of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task </text>
<text top="522" left="174" width="610" height="13" font="23">Force on Clinical Practice Guidelines [published online ahead of print November 10, 2018]. Circulation. </text>
<text top="539" left="174" width="224" height="13" font="23">doi: 10.1161/CIR.0000000000000625 </text>
<text top="557" left="105" width="41" height="13" font="23">S2.2-5.</text>
<text top="557" left="146" width="4" height="13" font="47"> </text>
<text top="557" left="174" width="568" height="13" font="23">Patel J, Al Rifai M, Scheuner MT, et al. Basic vs more complex definitions of family history in the </text>
<text top="575" left="174" width="568" height="13" font="23">prediction of coronary heart disease: the Multi-Ethnic Study of Atherosclerosis. Mayo Clin Proc. </text>
<text top="593" left="174" width="108" height="13" font="23">2018;93:1213-23. </text>
<text top="611" left="105" width="41" height="13" font="23">S2.2-6.</text>
<text top="611" left="146" width="4" height="13" font="47"> </text>
<text top="611" left="174" width="583" height="13" font="23">del Rincón ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid </text>
<text top="629" left="174" width="587" height="13" font="23">arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737-45. </text>
<text top="646" left="105" width="41" height="13" font="23">S2.2-7.</text>
<text top="646" left="146" width="4" height="13" font="47"> </text>
<text top="646" left="174" width="613" height="13" font="23">Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in </text>
<text top="664" left="174" width="606" height="13" font="23">women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. </text>
<text top="682" left="174" width="108" height="13" font="23">1997;145:408-15. </text>
<text top="700" left="105" width="41" height="13" font="23">S2.2-8.</text>
<text top="700" left="146" width="4" height="13" font="47"> </text>
<text top="700" left="174" width="585" height="13" font="23">Wu P, Haththotuwa R, Kwok CS, et al. Preeclampsia and future cardiovascular health: a systematic </text>
<text top="718" left="174" width="460" height="13" font="23">review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2017;10:e003497. </text>
<text top="735" left="105" width="41" height="13" font="23">S2.2-9.</text>
<text top="735" left="146" width="4" height="13" font="47"> </text>
<text top="735" left="174" width="613" height="13" font="23">Tanz LJ, Stuart JJ, Williams PL, et al. Preterm delivery and maternal cardiovascular disease in young and </text>
<text top="753" left="174" width="342" height="13" font="23">middle-aged adult women. Circulation. 2017;135:578-89. </text>
<text top="771" left="105" width="48" height="13" font="23">S2.2-10.</text>
<text top="771" left="153" width="4" height="13" font="47"> </text>
<text top="771" left="174" width="607" height="13" font="23">Wellons M, Ouyang P, Schreiner PJ, et al. Early menopause predicts future coronary heart disease and </text>
<text top="789" left="174" width="473" height="13" font="23">stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause. 2012;19:1081-7. </text>
<text top="807" left="105" width="48" height="13" font="23">S2.2-11.</text>
<text top="807" left="153" width="4" height="13" font="47"> </text>
<text top="807" left="174" width="595" height="13" font="23">Uddin SMI, Mirbolouk M, Dardari Z, et al. Erectile dysfunction as an independent predictor of future </text>
<text top="825" left="174" width="307" height="13" font="23">cardiovascular events. Circulation. 2018;138:540-2. </text>
<text top="842" left="105" width="48" height="13" font="23">S2.2-12.</text>
<text top="842" left="153" width="4" height="13" font="47"> </text>
<text top="842" left="174" width="587" height="13" font="23">Triant VA, Perez J, Regan S, et al. Cardiovascular risk prediction functions underestimate risk in HIV </text>
<text top="860" left="174" width="246" height="13" font="23">infection. Circulation. 2018;137:2203-14. </text>
<text top="878" left="105" width="48" height="13" font="23">S2.2-13.</text>
<text top="878" left="153" width="4" height="13" font="47"> </text>
<text top="878" left="174" width="612" height="13" font="23">Volgman AS, Palaniappan LS, Aggarwal NT, et al. Atherosclerotic cardiovascular disease in South Asians </text>
<text top="896" left="174" width="569" height="13" font="23">in the United States: epidemiology, risk factors, and treatments: a scientific statement from the </text>
<text top="914" left="174" width="343" height="13" font="23">American Heart Association. Circulation. 2018;138:e1-34. </text>
<text top="932" left="105" width="48" height="13" font="23">S2.2-14.</text>
<text top="931" left="153" width="4" height="13" font="47"> </text>
<text top="932" left="174" width="617" height="13" font="23">Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women </text>
<text top="949" left="174" width="404" height="13" font="23">with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207. </text>
<text top="967" left="105" width="48" height="13" font="23">S2.2-15.</text>
<text top="967" left="153" width="4" height="13" font="47"> </text>
<text top="967" left="174" width="611" height="13" font="23">DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple </text>
<text top="985" left="174" width="556" height="13" font="23">cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162:266-75. </text>
<text top="1003" left="105" width="48" height="13" font="23">S2.2-16.</text>
<text top="1003" left="153" width="4" height="13" font="47"> </text>
<text top="1003" left="174" width="609" height="13" font="23">Mahabadi AA, Möhlenkamp S, Lehmann N, et al. CAC score improves coronary and CV risk assessment </text>
<text top="1021" left="174" width="604" height="13" font="23">above statin indication by ESC and AHA/ACC primary prevention guidelines. JACC Cardiovasc Imaging. </text>
<text top="1039" left="174" width="101" height="13" font="23">2017;10:143-53. </text>
<text top="1056" left="105" width="48" height="13" font="23">S2.2-17.</text>
<text top="1056" left="153" width="4" height="13" font="47"> </text>
<text top="1056" left="174" width="617" height="13" font="23">Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic </text>
<text top="1074" left="174" width="603" height="13" font="23">cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA). Eur Heart J. </text>
</page>
<page number="84" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 82 of 101 </text>
<text top="167" left="174" width="101" height="13" font="23">2018;39:2401-8. </text>
<text top="185" left="105" width="48" height="13" font="23">S2.2-18.</text>
<text top="185" left="153" width="4" height="13" font="47"> </text>
<text top="185" left="174" width="589" height="13" font="23">McClelland RL, Jorgensen NW, Budoff M, et al. 10-year coronary heart disease risk prediction using </text>
<text top="203" left="174" width="580" height="13" font="23">coronary artery calcium and traditional risk factors: derivation in the MESA (Multi-Ethnic Study of </text>
<text top="221" left="174" width="581" height="13" font="23">Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) study and the DHS (Dallas Heart </text>
<text top="238" left="174" width="259" height="13" font="23">Study). J Am Coll Cardiol. 2015;66:1643-53. </text>
<text top="256" left="105" width="48" height="13" font="23">S2.2-19.</text>
<text top="256" left="153" width="4" height="13" font="47"> </text>
<text top="256" left="174" width="556" height="13" font="23">Kavousi M, Desai CS, Ayers C, et al. Prevalence and prognostic implications of coronary artery </text>
<text top="274" left="174" width="446" height="13" font="23">calcification in low-risk women: a meta-analysis. JAMA. 2016;316:2126-34. </text>
<text top="292" left="105" width="48" height="13" font="23">S2.2-20.</text>
<text top="292" left="153" width="4" height="13" font="47"> </text>
<text top="292" left="174" width="615" height="13" font="23">Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 to 46 years </text>
<text top="310" left="174" width="459" height="13" font="23">with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391-9. </text>
<text top="328" left="105" width="48" height="13" font="23">S2.2-21.</text>
<text top="328" left="153" width="4" height="13" font="47"> </text>
<text top="328" left="174" width="569" height="13" font="23">Mortensen MB, Fuster V, Muntendam P, et al. A simple disease-guided approach to personalize </text>
<text top="345" left="174" width="583" height="13" font="23">ACC/AHA-recommended statin allocation in elderly people: the BioImage Study. J Am Coll Cardiol. </text>
<text top="363" left="174" width="101" height="13" font="23">2016;68:881-91. </text>
<text top="381" left="105" width="48" height="13" font="23">S2.2-22.</text>
<text top="381" left="153" width="4" height="13" font="47"> </text>
<text top="381" left="174" width="587" height="13" font="23">Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of coronary artery calcium score of zero and </text>
<text top="399" left="174" width="575" height="13" font="23">other negative risk markers for cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis </text>
<text top="417" left="174" width="230" height="13" font="23">(MESA). Circulation. 2016;133:849-58. </text>
<text top="434" left="105" width="48" height="13" font="23">S2.2-23.</text>
<text top="434" left="153" width="4" height="13" font="47"> </text>
<text top="434" left="174" width="596" height="13" font="23">Patel J, Al Rifai M, Blaha MJ, et al. Coronary artery calcium improves risk assessment in adults with a </text>
<text top="452" left="174" width="536" height="13" font="23">family history of premature coronary heart disease: results from the Multi-Ethnic Study of </text>
<text top="470" left="174" width="349" height="13" font="23">Atherosclerosis. Circ Cardiovasc Imaging. 2015;8:e003186. </text>
<text top="488" left="105" width="48" height="13" font="23">S2.2-24.</text>
<text top="488" left="153" width="4" height="13" font="47"> </text>
<text top="488" left="174" width="580" height="13" font="23">Pursnani A, Massaro JM, D’Agostino RB Sr, et al. Guideline-based statin eligibility, coronary artery </text>
<text top="506" left="174" width="387" height="13" font="23">calcification, and cardiovascular events. JAMA. 2015;314:134-41. </text>
<text top="524" left="105" width="48" height="13" font="23">S2.2-25.</text>
<text top="524" left="153" width="4" height="13" font="47"> </text>
<text top="524" left="174" width="602" height="13" font="23">Valenti V, Ó Hartaigh B, Heo R, et al. A 15-year warranty period for asymptomatic individuals without </text>
<text top="541" left="174" width="567" height="13" font="23">coronary artery calcium: a prospective follow-up of 9,715 individuals. JACC Cardiovasc Imaging. </text>
<text top="559" left="174" width="86" height="13" font="23">2015;8:900-9. </text>
<text top="577" left="105" width="48" height="13" font="23">S2.2-26.</text>
<text top="577" left="153" width="4" height="13" font="47"> </text>
<text top="577" left="174" width="548" height="13" font="23">Yano Y, O’Donnell CJ, Kuller L, et al. Association of coronary artery calcium score vs age with </text>
<text top="595" left="174" width="576" height="13" font="23">cardiovascular risk in older adults: an analysis of pooled population-based studies. JAMA Cardiol. </text>
<text top="613" left="174" width="93" height="13" font="23">2017;2:986-94. </text>
<text top="631" left="105" width="48" height="13" font="23">S2.2-27.</text>
<text top="631" left="153" width="4" height="13" font="47"> </text>
<text top="631" left="174" width="563" height="13" font="23">Yeboah J, Young R, McClelland RL, et al. Utility of nontraditional risk markers in atherosclerotic </text>
<text top="648" left="174" width="442" height="13" font="23">cardiovascular disease risk assessment. J Am Coll Cardiol. 2016;67:139-47. </text>
<text top="666" left="105" width="48" height="13" font="23">S2.2-28.</text>
<text top="666" left="153" width="4" height="13" font="47"> </text>
<text top="666" left="174" width="578" height="13" font="23">Multi-Ethnic Study of Atherosclerosis. MESA 10-Year CHD Risk with Coronary Artery Calcification. </text>
<text top="684" left="174" width="588" height="13" font="23">Available at: https://www.mesa-nhlbi.org/MESACHDRisk/MesaRiskScore/RiskScore.aspx. Accessed </text>
<text top="702" left="174" width="127" height="13" font="23">September 21, 2018. </text>
<text top="720" left="105" width="48" height="13" font="23">S2.2-29.</text>
<text top="720" left="153" width="4" height="13" font="47"> </text>
<text top="720" left="174" width="608" height="13" font="23">Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM). 10-Year ASCVD Risk Calculator </text>
<text top="737" left="174" width="571" height="13" font="23">with Coronary Artery Calcium. Available at: http://astrocharm.org/calculator-working. Accessed </text>
<text top="755" left="174" width="127" height="13" font="23">September 21, 2018. </text>
<text top="773" left="105" width="48" height="13" font="23">S2.2-30.</text>
<text top="773" left="153" width="4" height="13" font="47"> </text>
<text top="773" left="174" width="582" height="13" font="23">Gupta A, Lau E, Varshney R, et al. The identification of calcified coronary plaque is associated with </text>
<text top="791" left="174" width="603" height="13" font="23">initiation and continuation of pharmacological and lifestyle preventive therapies: a systematic review </text>
<text top="809" left="174" width="368" height="13" font="23">and meta-analysis. JACC Cardiovasc Imaging. 2017;10:833-42. </text>
<text top="827" left="105" width="48" height="13" font="23">S2.2-31.</text>
<text top="827" left="153" width="4" height="13" font="47"> </text>
<text top="827" left="174" width="615" height="13" font="23">Shah RV, Spahillari A, Mwasongwe S, et al. Subclinical atherosclerosis, statin eligibility, and outcomes in </text>
<text top="844" left="174" width="505" height="13" font="23">African American individuals: the Jackson Heart Study. JAMA Cardiol. 2017;2:644-52. </text>
<text top="862" left="105" width="48" height="13" font="23">S2.2-32.</text>
<text top="862" left="153" width="4" height="13" font="47"> </text>
<text top="862" left="174" width="605" height="13" font="23">Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk </text>
<text top="880" left="174" width="368" height="13" font="23">factor burden at 50 years of age. Circulation. 2006;113:791-8. </text>
<text top="898" left="105" width="48" height="13" font="23">S2.2-33.</text>
<text top="898" left="153" width="4" height="13" font="47"> </text>
<text top="898" left="174" width="592" height="13" font="23">Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366:321-9. </text>
<text top="916" left="105" width="48" height="13" font="23">S2.2-34.</text>
<text top="916" left="153" width="4" height="13" font="47"> </text>
<text top="916" left="174" width="614" height="13" font="23">Wilkins JT, Ning H, Berry J, et al. Lifetime risk and years lived free of total cardiovascular disease. JAMA. </text>
<text top="933" left="174" width="123" height="13" font="23">2012;308:1795-801. </text>
<text top="951" left="105" width="48" height="13" font="23">S2.2-35.</text>
<text top="951" left="153" width="4" height="13" font="47"> </text>
<text top="951" left="174" width="599" height="13" font="23">Pencina MJ, D’Agostino RB Sr, Larson MG, et al. Predicting the 30-year risk of cardiovascular disease: </text>
<text top="969" left="174" width="365" height="13" font="23">the Framingham Heart Study. Circulation. 2009;119:3078-84. </text>
<text top="987" left="105" width="48" height="13" font="23">S2.2-36.</text>
<text top="987" left="153" width="4" height="13" font="47"> </text>
<text top="987" left="174" width="579" height="13" font="23">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood </text>
<text top="1005" left="174" width="605" height="13" font="23">cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of </text>
<text top="1023" left="174" width="612" height="13" font="23">Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1-45. </text>
<text top="1040" left="105" width="48" height="13" font="23">S2.2-37.</text>
<text top="1040" left="153" width="4" height="13" font="47"> </text>
<text top="1040" left="174" width="284" height="13" font="23">Whelton PK, Carey RM, Aronow WS, et al. 2017 </text>
<text top="1058" left="174" width="615" height="13" font="23">ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, </text>
<text top="1076" left="174" width="583" height="13" font="23">evaluation, and management of high blood pressure in adults: a report of the American College of </text>
</page>
<page number="85" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 83 of 101 </text>
<text top="167" left="174" width="574" height="13" font="23">Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. </text>
<text top="185" left="174" width="108" height="13" font="23">2018;71:e13-115. </text>
<text top="203" left="105" width="48" height="13" font="23">S2.2-38.</text>
<text top="203" left="153" width="4" height="13" font="47"> </text>
<text top="203" left="174" width="559" height="13" font="23">Pender A, Lloyd-Jones DM, Stone NJ, et al. Refining statin prescribing in lower-risk individuals: </text>
<text top="221" left="174" width="401" height="13" font="23">informing risk/benefit decisions. J Am Coll Cardiol. 2016;68:1690-7. </text>
<text top="238" left="105" width="48" height="13" font="23">S2.2-39.</text>
<text top="238" left="153" width="4" height="13" font="47"> </text>
<text top="238" left="174" width="612" height="13" font="23">Andersson C, Enserro D, Larson MG, et al. Implications of the US cholesterol guidelines on eligibility for </text>
<text top="256" left="174" width="584" height="13" font="23">statin th4erapy in the community: comparison of observed and predicted risks in the Framingham </text>
<text top="274" left="174" width="392" height="13" font="23">Heart Study Offspring Cohort. J Am Heart Assoc. 2015;4:e001888. </text>
<text top="292" left="105" width="48" height="13" font="23">S2.2-40.</text>
<text top="292" left="153" width="4" height="13" font="47"> </text>
<text top="292" left="174" width="615" height="13" font="23">Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult </text>
<text top="310" left="174" width="618" height="13" font="23">Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease </text>
<text top="328" left="174" width="356" height="13" font="23">prevention in a European cohort. JAMA. 2014;311:1416-23. </text>
<text top="345" left="105" width="48" height="13" font="23">S2.2-41.</text>
<text top="345" left="153" width="4" height="13" font="47"> </text>
<text top="345" left="174" width="608" height="13" font="23">Pylypchuk R, Wells S, Kerr A, et al. Cardiovascular disease risk prediction equations in 400 000 primary </text>
<text top="363" left="174" width="549" height="13" font="23">care patients in New Zealand: a derivation and validation study. Lancet. 2018;391:1897-907. </text>
<text top="381" left="105" width="48" height="13" font="23">S2.2-42.</text>
<text top="381" left="153" width="4" height="13" font="47"> </text>
<text top="381" left="174" width="549" height="13" font="23">DeFilippis AP, Young R, McEvoy JW, et al. Risk score overestimation: the impact of individual </text>
<text top="399" left="174" width="566" height="13" font="23">cardiovascular risk factors and preventive therapies on the performance of the American Heart </text>
<text top="417" left="174" width="579" height="13" font="23">Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a </text>
<text top="434" left="174" width="352" height="13" font="23">modern multi-ethnic cohort. Eur Heart J. 2017;38:598-608. </text>
<text top="452" left="105" width="48" height="13" font="23">S2.2-43.</text>
<text top="452" left="153" width="4" height="13" font="47"> </text>
<text top="452" left="174" width="589" height="13" font="23">Emdin CA, Khera AV, Natarajan P, et al. Evaluation of the pooled cohort equations for prediction of </text>
<text top="470" left="174" width="525" height="13" font="23">cardiovascular risk in a contemporary prospective cohort. Am J Cardiol. 2017;119:881-5. </text>
<text top="488" left="105" width="48" height="13" font="23">S2.2-44.</text>
<text top="488" left="153" width="4" height="13" font="47"> </text>
<text top="488" left="174" width="612" height="13" font="23">Rana JS, Tabada GH, Solomon MD, et al. Accuracy of the atherosclerotic cardiovascular risk equation in </text>
<text top="506" left="174" width="491" height="13" font="23">a large contemporary, multiethnic population. J Am Coll Cardiol. 2016;67:2118-30. </text>
<text top="524" left="105" width="48" height="13" font="23">S2.2-45.</text>
<text top="524" left="153" width="4" height="13" font="47"> </text>
<text top="524" left="174" width="562" height="13" font="23">Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: the roles of statins, </text>
<text top="541" left="174" width="555" height="13" font="23">revascularizations, and underascertainment in the Women’s Health Study. JAMA Intern Med. </text>
<text top="559" left="174" width="115" height="13" font="23">2014;174:1964-71. </text>
<text top="577" left="105" width="48" height="13" font="23">S2.2-46.</text>
<text top="577" left="153" width="4" height="13" font="47"> </text>
<text top="577" left="174" width="604" height="13" font="23">Sussman JB, Wiitala WL, Zawistowski M, et al. The veterans affairs cardiac risk score: recalibrating the </text>
<text top="595" left="174" width="525" height="13" font="23">atherosclerotic cardiovascular disease score for applied use. Med Care. 2017;55:864-70. </text>
<text top="613" left="105" width="48" height="13" font="23">S2.2-47.</text>
<text top="613" left="153" width="4" height="13" font="47"> </text>
<text top="613" left="174" width="572" height="13" font="23">Wolfson J, Vock DM, Bandyopadhyay S, et al. Use and customization of risk scores for predicting </text>
<text top="631" left="174" width="558" height="13" font="23">cardiovascular events using electronic health record data. J Am Heart Assoc. 2017;6:e003670. </text>
<text top="648" left="105" width="48" height="13" font="23">S2.2-48.</text>
<text top="648" left="153" width="4" height="13" font="47"> </text>
<text top="648" left="174" width="602" height="13" font="23">Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease </text>
<text top="666" left="174" width="333" height="13" font="23">pooled cohort risk equations. JAMA. 2014;311:1406-15. </text>
<text top="684" left="105" width="48" height="13" font="23">S2.2-49.</text>
<text top="684" left="153" width="4" height="13" font="47"> </text>
<text top="684" left="174" width="611" height="13" font="23">Colantonio LD, Richman JS, Carson AP, et al. Performance of the atherosclerotic cardiovascular disease </text>
<text top="702" left="174" width="554" height="13" font="23">pooled cohort risk equations by social deprivation status. J Am Heart Assoc. 2017;6:e005676. </text>
<text top="720" left="105" width="48" height="13" font="23">S2.2-50.</text>
<text top="720" left="153" width="4" height="13" font="47"> </text>
<text top="720" left="174" width="613" height="13" font="23">Crowson CS, Gabriel SE, Semb AG, et al. Rheumatoid arthritis-specific cardiovascular risk scores are not </text>
<text top="737" left="174" width="597" height="13" font="23">superior to general risk scores: a validation analysis of patients from seven countries. Rheumatology </text>
<text top="755" left="174" width="165" height="13" font="23">(Oxford). 2017;56:1102-10. </text>
<text top="773" left="105" width="48" height="13" font="23">S2.2-51.</text>
<text top="773" left="153" width="4" height="13" font="47"> </text>
<text top="773" left="174" width="538" height="13" font="23">Dalton JE, Perzynski AT, Zidar DA, et al. Accuracy of cardiovascular risk prediction varies by </text>
<text top="791" left="174" width="618" height="13" font="23">neighborhood socioeconomic position: a retrospective cohort study. Ann Intern Med. 2017;167:456-64. </text>
<text top="809" left="105" width="48" height="13" font="23">S2.2-52.</text>
<text top="809" left="153" width="4" height="13" font="47"> </text>
<text top="809" left="174" width="601" height="13" font="23">Mora S, Wenger NK, Cook NR, et al. Evaluation of the pooled cohort risk equations for cardiovascular </text>
<text top="827" left="174" width="555" height="13" font="23">risk prediction in a multiethnic cohort from the Women’s Health Initiative. JAMA Intern Med. </text>
<text top="844" left="174" width="115" height="13" font="23">2018;178:1231-40. </text>
<text top="862" left="105" width="48" height="13" font="23">S2.2-53.</text>
<text top="862" left="153" width="4" height="13" font="47"> </text>
<text top="862" left="174" width="613" height="13" font="23">Yang X, Li J, Hu D, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese </text>
<text top="880" left="174" width="611" height="13" font="23">population: the China-PAR project (Prediction for ASCVD Risk in China). Circulation. 2016;134:1430-40. </text>
<text top="898" left="105" width="48" height="13" font="23">S2.2-54.</text>
<text top="898" left="153" width="4" height="13" font="47"> </text>
<text top="898" left="174" width="596" height="13" font="23">Jung KJ, Jang Y, Oh DJ, et al. The ACC/AHA 2013 pooled cohort equations compared to a Korean Risk </text>
<text top="916" left="174" width="565" height="13" font="23">Prediction Model for atherosclerotic cardiovascular disease. Atherosclerosis. 2015;242:367-75. </text>
<text top="933" left="105" width="48" height="13" font="23">S2.2-55.</text>
<text top="933" left="153" width="4" height="13" font="47"> </text>
<text top="933" left="174" width="588" height="13" font="23">D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary </text>
<text top="951" left="174" width="390" height="13" font="23">care: the Framingham Heart Study. Circulation. 2008;117:743-53. </text>
<text top="969" left="105" width="48" height="13" font="23">S2.2-56.</text>
<text top="969" left="153" width="4" height="13" font="47"> </text>
<text top="969" left="174" width="564" height="13" font="23">Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the </text>
<text top="987" left="174" width="595" height="13" font="23">assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611-9. </text>
<text top="1005" left="105" width="48" height="13" font="23">S2.2-57.</text>
<text top="1005" left="153" width="4" height="13" font="47"> </text>
<text top="1005" left="174" width="545" height="13" font="23">Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global </text>
<text top="1023" left="174" width="583" height="13" font="23">cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118:2243-51, 4p </text>
<text top="1040" left="174" width="95" height="13" font="23">following 2251. </text>
<text top="1058" left="105" width="48" height="13" font="23">S2.2-58.</text>
<text top="1058" left="153" width="4" height="13" font="47"> </text>
<text top="1058" left="174" width="546" height="13" font="23">Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of </text>
<text top="1076" left="174" width="289" height="13" font="23">dyslipidaemias. Eur Heart J. 2016;37:2999-3058. </text>
</page>
<page number="86" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 84 of 101 </text>
<text top="167" left="105" width="48" height="13" font="23">S2.2-59.</text>
<text top="167" left="153" width="4" height="13" font="47"> </text>
<text top="167" left="174" width="597" height="13" font="23">JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular </text>
<text top="185" left="174" width="288" height="13" font="23">disease (JBS3). Heart. 2014;100(suppl 2):ii1-ii67. </text>
<text top="203" left="105" width="48" height="13" font="23">S2.2-60.</text>
<text top="203" left="153" width="4" height="13" font="47"> </text>
<text top="203" left="174" width="586" height="13" font="23">Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society guidelines for the </text>
<text top="221" left="174" width="597" height="13" font="23">management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. </text>
<text top="238" left="174" width="108" height="13" font="23">2016;32:1263-82. </text>
<text top="256" left="105" width="48" height="13" font="23">S2.2-61.</text>
<text top="256" left="153" width="4" height="13" font="47"> </text>
<text top="256" left="174" width="566" height="13" font="23">Downs JR, O’Malley PG. Management of dyslipidemia for cardiovascular disease risk reduction: </text>
<text top="274" left="174" width="580" height="13" font="23">synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical </text>
<text top="292" left="174" width="314" height="13" font="23">practice guideline. Ann Intern Med. 2015;163:291-7. </text>
<text top="310" left="105" width="48" height="13" font="23">S2.2-62.</text>
<text top="310" left="153" width="4" height="13" font="47"> </text>
<text top="310" left="174" width="581" height="13" font="23">Bibbins-Domingo K, U.S. Preventive Services Task Force. Aspirin use for the primary prevention of </text>
<text top="328" left="174" width="588" height="13" font="23">cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation </text>
<text top="345" left="174" width="277" height="13" font="23">statement. Ann Intern Med. 2016;164:836-45. </text>
<text top="363" left="105" width="48" height="13" font="23">S2.2-63.</text>
<text top="363" left="153" width="4" height="13" font="47"> </text>
<text top="363" left="174" width="609" height="13" font="23">U.S. Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Statin use for the primary </text>
<text top="381" left="174" width="613" height="13" font="23">prevention of cardiovascular disease in adults: U.S. Preventive Services Task Force Re64commendation </text>
<text top="399" left="174" width="241" height="13" font="23">Statement. JAMA. 2016;316:1997-2007. </text>
<text top="417" left="105" width="48" height="13" font="23">S2.2-64.</text>
<text top="417" left="153" width="4" height="13" font="47"> </text>
<text top="417" left="174" width="615" height="13" font="23">Karmali KN, Goff DC Jr, Ning H, et al. A systematic examination of the 2013 ACC/AHA pooled cohort risk </text>
<text top="434" left="174" width="558" height="13" font="23">assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64:959-68. </text>
<text top="452" left="105" width="48" height="13" font="23">S2.2-65.</text>
<text top="452" left="153" width="4" height="13" font="47"> </text>
<text top="452" left="174" width="612" height="13" font="23">Mortensen MB, Nordestgaard BG, Afzal S, et al. ACC/AHA guidelines superior to ESC/EAS guidelines for </text>
<text top="470" left="174" width="613" height="13" font="23">primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study. </text>
<text top="488" left="174" width="172" height="13" font="23">Eur Heart J. 2017;38:586-94. </text>
<text top="506" left="105" width="48" height="13" font="23">S2.2-66.</text>
<text top="506" left="153" width="4" height="13" font="47"> </text>
<text top="506" left="174" width="601" height="13" font="23">Mortensen MB, Afzal S, Nordestgaard BG, et al. Primary prevention with statins: ACC/AHA risk-based </text>
<text top="524" left="174" width="603" height="13" font="23">approach versus trial-based approaches to guide statin therapy. J Am Coll Cardiol. 2015;66:2699-709. </text>
<text top="541" left="105" width="48" height="13" font="23">S2.2-67.</text>
<text top="541" left="153" width="4" height="13" font="47"> </text>
<text top="541" left="174" width="567" height="13" font="23">Loprinzi PD, Addoh O. Predictive validity of the American College of Cardiology/American Heart </text>
<text top="559" left="174" width="564" height="13" font="23">Association pooled cohort equations in predicting all-cause and cardiovascular disease-specific </text>
<text top="577" left="174" width="561" height="13" font="23">mortality in a national prospective cohort study of adults in the United States. Mayo Clin Proc. </text>
<text top="595" left="174" width="93" height="13" font="23">2016;91:763-9. </text>
<text top="613" left="105" width="48" height="13" font="23">S2.2-68.</text>
<text top="613" left="153" width="4" height="13" font="47"> </text>
<text top="613" left="174" width="598" height="13" font="23">Yadlowsky S, Hayward RA, Sussman JB, et al. Clinical implications of revised pooled cohort equations </text>
<text top="631" left="174" width="537" height="13" font="23">for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med. 2018;169:20-9. </text>
<text top="648" left="105" width="48" height="13" font="23">S2.2-69.</text>
<text top="648" left="153" width="4" height="13" font="47"> </text>
<text top="648" left="174" width="599" height="13" font="23">Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coronary artery calcium testing among statin </text>
<text top="666" left="174" width="573" height="13" font="23">candidates according to American College of Cardiology/American Heart Association cholesterol </text>
<text top="684" left="174" width="529" height="13" font="23">management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. </text>
<text top="702" left="174" width="108" height="13" font="23">2015;66:1657-68. </text>
<text top="720" left="105" width="48" height="13" font="23">S2.2-70.</text>
<text top="720" left="153" width="4" height="13" font="47"> </text>
<text top="720" left="174" width="588" height="13" font="23">Miedema MD, Duprez DA, Misialek JR, et al. Use of coronary artery calcium testing to guide aspirin </text>
<text top="737" left="174" width="570" height="13" font="23">utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ </text>
<text top="755" left="174" width="259" height="13" font="23">Cardiovasc Qual Outcomes. 2014;7:453-60. </text>
<text top="773" left="105" width="48" height="13" font="23">S2.2-71.</text>
<text top="773" left="153" width="4" height="13" font="47"> </text>
<text top="773" left="174" width="579" height="13" font="23">Mitchell JD, Fergestrom N, Gage BF, et al. Impact of statins on cardiovascular outcomes following </text>
<text top="791" left="174" width="407" height="13" font="23">coronary artery calcium scoring. J Am Coll Cardiol. 2018;72:3233-42. </text>
<text top="819" left="105" width="195" height="19" font="15"><b>3.1. Nutrition and Diet </b></text>
<text top="842" left="105" width="41" height="13" font="23">S3.1-1.</text>
<text top="842" left="146" width="4" height="13" font="47"> </text>
<text top="842" left="174" width="539" height="13" font="23">Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a </text>
<text top="860" left="174" width="580" height="13" font="23">Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378:e34. </text>
<text top="878" left="105" width="41" height="13" font="23">S3.1-2.</text>
<text top="878" left="146" width="4" height="13" font="47"> </text>
<text top="878" left="174" width="600" height="13" font="23">Kim H, Caulfield LE, Rebholz CM. Healthy plant-based diets are associated with lower risk of all-cause </text>
<text top="896" left="174" width="285" height="13" font="23">mortality in US adults. J Nutr. 2018;148:624-31. </text>
<text top="914" left="105" width="41" height="13" font="23">S3.1-3.</text>
<text top="914" left="146" width="4" height="13" font="47"> </text>
<text top="914" left="174" width="589" height="13" font="23">Reedy J, Krebs-Smith SM, Miller PE, et al. Higher diet quality is associated with decreased risk of all-</text>
<text top="932" left="174" width="571" height="13" font="23">cause, cardiovascular disease, and cancer mortality among older adults. J Nutr. 2014;144:881-9. </text>
<text top="949" left="105" width="41" height="13" font="23">S3.1-4.</text>
<text top="949" left="146" width="4" height="13" font="47"> </text>
<text top="949" left="174" width="610" height="13" font="23">Satija A, Bhupathiraju SN, Spiegelman D, et al. Healthful and unhealthful plant-based diets and the risk </text>
<text top="967" left="174" width="438" height="13" font="23">of coronary heart disease in US adults. J Am Coll Cardiol. 2017;70:411-22. </text>
<text top="985" left="105" width="41" height="13" font="23">S3.1-5.</text>
<text top="985" left="146" width="4" height="13" font="47"> </text>
<text top="985" left="174" width="596" height="13" font="23">Sotos-Prieto M, Bhupathiraju SN, Mattei J, et al. Association of changes in diet quality with total and </text>
<text top="1003" left="174" width="339" height="13" font="23">cause-specific mortality. N Engl J Med. 2017;377:143-53. </text>
<text top="1021" left="105" width="41" height="13" font="23">S3.1-6.</text>
<text top="1021" left="146" width="4" height="13" font="47"> </text>
<text top="1021" left="174" width="570" height="13" font="23">Whalen KA, Judd S, McCullough ML, et al. Paleolithic and Mediterranean diet pattern scores are </text>
<text top="1039" left="174" width="584" height="13" font="23">inversely associated with all-cause and cause-specific mortality in adults. J Nutr. 2017;147:612-20. </text>
<text top="1056" left="105" width="41" height="13" font="23">S3.1-7.</text>
<text top="1056" left="146" width="4" height="13" font="47"> </text>
<text top="1056" left="174" width="591" height="13" font="23">Bao Y, Han J, Hu FB, et al. Association of nut consumption with total and cause-specific mortality. N </text>
<text top="1074" left="174" width="186" height="13" font="23">Engl J Med. 2013;369:2001-11. </text>
</page>
<page number="87" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 85 of 101 </text>
<text top="167" left="105" width="41" height="13" font="23">S3.1-8.</text>
<text top="167" left="146" width="4" height="13" font="47"> </text>
<text top="167" left="174" width="603" height="13" font="23">Bernstein AM, Sun Q, Hu FB, et al. Major dietary protein sources and risk of coronary heart disease in </text>
<text top="185" left="174" width="231" height="13" font="23">women. Circulation. 2010;122:876-83. </text>
<text top="203" left="105" width="41" height="13" font="23">S3.1-9.</text>
<text top="203" left="146" width="4" height="13" font="47"> </text>
<text top="203" left="174" width="605" height="13" font="23">Song M, Fung TT, Hu FB, et al. Association of animal and plant protein intake with all-cause and cause-</text>
<text top="221" left="174" width="336" height="13" font="23">specific mortality. JAMA Intern Med. 2016;176:1453-63. </text>
<text top="238" left="105" width="48" height="13" font="23">S3.1-10.</text>
<text top="238" left="153" width="4" height="13" font="47"> </text>
<text top="238" left="174" width="579" height="13" font="23">Tharrey M, Mariotti F, Mashchak A, et al. Patterns of plant and animal protein intake are strongly </text>
<text top="256" left="174" width="560" height="13" font="23">associated with cardiovascular mortality: the Adventist Health Study-2 cohort. Int J Epidemiol. </text>
<text top="274" left="174" width="108" height="13" font="23">2018;47:1603-12. </text>
<text top="292" left="105" width="48" height="13" font="23">S3.1-11.</text>
<text top="292" left="153" width="4" height="13" font="47"> </text>
<text top="292" left="174" width="609" height="13" font="23">Martínez-González MA, Sánchez-Tainta A, Corella D, et al. A provegetarian food pattern and reduction </text>
<text top="310" left="174" width="562" height="13" font="23">in total mortality in the Prevención con Dieta Mediterránea (PREDIMED) study. Am J Clin Nutr. </text>
<text top="328" left="174" width="166" height="13" font="23">2014;100(suppl 1):320S-8S. </text>
<text top="345" left="105" width="48" height="13" font="23">S3.1-12.</text>
<text top="345" left="153" width="4" height="13" font="47"> </text>
<text top="345" left="174" width="563" height="13" font="23">Wang DD, Li Y, Chiuve SE, et al. Association of specific dietary fats with total and cause-specific </text>
<text top="363" left="174" width="288" height="13" font="23">mortality. JAMA Intern Med. 2016;176:1134-45. </text>
<text top="381" left="105" width="48" height="13" font="23">S3.1-13.</text>
<text top="381" left="153" width="4" height="13" font="47"> </text>
<text top="381" left="174" width="606" height="13" font="23">Dehghan M, Mente A, Zhang X, et al. Associations of fats and carbohydrate intake with cardiovascular </text>
<text top="399" left="174" width="605" height="13" font="23">disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet. </text>
<text top="417" left="174" width="115" height="13" font="23">2017;390:2050-62. </text>
<text top="434" left="105" width="48" height="13" font="23">S3.1-14.</text>
<text top="434" left="153" width="4" height="13" font="47"> </text>
<text top="434" left="174" width="609" height="13" font="23">Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the </text>
<text top="452" left="174" width="607" height="13" font="23">Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N </text>
<text top="470" left="174" width="164" height="13" font="23">Engl J Med. 2001;344:3-10. </text>
<text top="488" left="105" width="48" height="13" font="23">S3.1-15.</text>
<text top="488" left="153" width="4" height="13" font="47"> </text>
<text top="488" left="174" width="614" height="13" font="23">Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular </text>
<text top="506" left="174" width="576" height="13" font="23">disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. </text>
<text top="524" left="174" width="101" height="13" font="23">2007;334:885-8. </text>
<text top="541" left="105" width="48" height="13" font="23">S3.1-16.</text>
<text top="541" left="153" width="4" height="13" font="47"> </text>
<text top="541" left="174" width="585" height="13" font="23">Micha R, Peñalvo JL, Cudhea F, et al. Association between dietary factors and mortality from heart </text>
<text top="559" left="174" width="489" height="13" font="23">disease, stroke, and type 2 diabetes in the United States. JAMA. 2017;317:912-24. </text>
<text top="577" left="105" width="48" height="13" font="23">S3.1-17.</text>
<text top="577" left="153" width="4" height="13" font="47"> </text>
<text top="577" left="174" width="592" height="13" font="23">Kiage JN, Merrill PD, Robinson CJ, et al. Intake of trans fat and all-cause mortality in the Reasons for </text>
<text top="595" left="174" width="579" height="13" font="23">Geographical and Racial Differences in Stroke (REGARDS) cohort. Am J Clin Nutr. 2013;97:1121-8. </text>
<text top="613" left="105" width="48" height="13" font="23">S3.1-18.</text>
<text top="613" left="153" width="4" height="13" font="47"> </text>
<text top="613" left="174" width="556" height="13" font="23">Löfvenborg JE, Andersson T, Carlsson P-O, et al. Sweetened beverage intake and risk of latent </text>
<text top="631" left="174" width="566" height="13" font="23">autoimmune diabetes in adults (LADA) and type 2 diabetes. Eur J Endocrinol. 2016;175:605-14. </text>
<text top="648" left="105" width="48" height="13" font="23">S3.1-19.</text>
<text top="648" left="153" width="4" height="13" font="47"> </text>
<text top="648" left="174" width="607" height="13" font="23">Yang Q, Zhang Z, Gregg EW, et al. Added sugar intake and cardiovascular diseases mortality among US </text>
<text top="666" left="174" width="262" height="13" font="23">adults. JAMA Intern Med. 2014;174:516-24. </text>
<text top="684" left="105" width="48" height="13" font="23">S3.1-20.</text>
<text top="684" left="153" width="4" height="13" font="47"> </text>
<text top="684" left="174" width="534" height="13" font="23">Johnson RK, Lichtenstein AH, Anderson CAM, et al. Low-calorie sweetened beverages and </text>
<text top="703" left="174" width="552" height="13" font="23">cardiometabolic health: a science advisory from the American Heart Association. Circulation. </text>
<text top="723" left="174" width="115" height="13" font="23">2018;138:e126-40. </text>
<text top="742" left="105" width="48" height="13" font="23">S3.1-21.</text>
<text top="742" left="153" width="4" height="13" font="47"> </text>
<text top="742" left="174" width="605" height="13" font="23">Shikany JM, Safford MM, Newby PK, et al. Southern dietary pattern is associated with hazard of acute </text>
<text top="759" left="174" width="579" height="13" font="23">coronary heart disease in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) </text>
<text top="777" left="174" width="219" height="13" font="23">study. Circulation. 2015;132:804-14. </text>
<text top="795" left="105" width="48" height="13" font="23">S3.1-22.</text>
<text top="795" left="153" width="4" height="13" font="47"> </text>
<text top="795" left="174" width="589" height="13" font="23">Seidelmann SB, Claggett B, Cheng S, et al. Dietary carbohydrate intake and mortality: a prospective </text>
<text top="813" left="174" width="421" height="13" font="23">cohort study and meta-analysis. Lancet Public Health. 2018;3:e419-28. </text>
<text top="831" left="105" width="48" height="13" font="23">S3.1-23.</text>
<text top="831" left="153" width="4" height="13" font="47"> </text>
<text top="831" left="174" width="595" height="13" font="23">Trichopoulou A, Psaltopoulou T, Orfanos P, et al. Low-carbohydrate-high-protein diet and long-term </text>
<text top="849" left="174" width="426" height="13" font="23">survival in a general population cohort. Eur J Clin Nutr. 2007;61:575-81. </text>
<text top="867" left="105" width="48" height="13" font="23">S3.1-24.</text>
<text top="867" left="153" width="4" height="13" font="47"> </text>
<text top="867" left="174" width="614" height="13" font="23">Noto H, Goto A, Tsujimoto T, et al. Low-carbohydrate diets and all-cause mortality: a systematic review </text>
<text top="884" left="174" width="420" height="13" font="23">and meta-analysis of observational studies. PLoS ONE. 2013;8:e55030. </text>
<text top="902" left="105" width="48" height="13" font="23">S3.1-25.</text>
<text top="902" left="153" width="4" height="13" font="47"> </text>
<text top="902" left="174" width="591" height="13" font="23">Brandt EJ, Myerson R, Perraillon MC, et al. Hospital admissions for myocardial infarction and stroke </text>
<text top="920" left="174" width="545" height="13" font="23">before and after the trans-fatty acid restrictions in New York. JAMA Cardiol. 2017;2:627-34. </text>
<text top="938" left="105" width="48" height="13" font="23">S3.1-26.</text>
<text top="938" left="153" width="4" height="13" font="47"> </text>
<text top="938" left="174" width="607" height="13" font="23">Micha R, Mozaffarian D. Trans fatty acids: effects on metabolic syndrome, heart disease and diabetes. </text>
<text top="955" left="174" width="214" height="13" font="23">Nat Rev Endocrinol. 2009;5:335-44. </text>
<text top="973" left="105" width="48" height="13" font="23">S3.1-27.</text>
<text top="973" left="153" width="4" height="13" font="47"> </text>
<text top="973" left="174" width="563" height="13" font="23">Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a </text>
<text top="991" left="174" width="328" height="13" font="23">comprehensive review. Circulation. 2016;133:187-225. </text>
<text top="1009" left="105" width="48" height="13" font="23">S3.1-28.</text>
<text top="1009" left="153" width="4" height="13" font="47"> </text>
<text top="1009" left="174" width="557" height="13" font="23">Weir HK, Anderson RN, Coleman King SM, et al. Heart disease and cancer deaths—trends and </text>
<text top="1027" left="174" width="457" height="13" font="23">projections in the United States, 1969-2020. Prev Chronic Dis. 2016;13:E157. </text>
<text top="1045" left="105" width="48" height="13" font="23">S3.1-29.</text>
<text top="1045" left="153" width="4" height="13" font="47"> </text>
<text top="1045" left="174" width="588" height="13" font="23">Van Horn L, Carson JAS, Appel LJ, et al. Recommended dietary pattern to achieve adherence to the </text>
<text top="1063" left="174" width="560" height="13" font="23">American Heart Association/American College of Cardiology (AHA/ACC) guidelines: a scientific </text>
<text top="1080" left="174" width="477" height="13" font="23">statement from the American Heart Association. Circulation. 2016;134:e505-29. </text>
</page>
<page number="88" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 86 of 101 </text>
<text top="167" left="105" width="48" height="13" font="23">S3.1-30.</text>
<text top="167" left="153" width="4" height="13" font="47"> </text>
<text top="167" left="174" width="543" height="13" font="23">Rimm EB, Appel LJ, Chiuve SE, et al. Seafood long-chain n-3 polyunsaturated fatty acids and </text>
<text top="185" left="174" width="548" height="13" font="23">cardiovascular disease: a science advisory from the American Heart Association. Circulation. </text>
<text top="203" left="174" width="108" height="13" font="23">2018;138:e35-47. </text>
<text top="221" left="105" width="48" height="13" font="23">S3.1-31.</text>
<text top="220" left="153" width="4" height="13" font="47"> </text>
<text top="221" left="174" width="602" height="13" font="23">Dehghan M, Mente A, Rangarajan S, et al. Association of dairy intake with cardiovascular disease and </text>
<text top="238" left="174" width="532" height="13" font="23">mortality in 21 countries from five continents (PURE): a prospective cohort study. Lancet. </text>
<text top="256" left="174" width="115" height="13" font="23">2018;392:2288-97. </text>
<text top="284" left="105" width="289" height="19" font="15"><b>3.2. Exercise and Physical Activity </b></text>
<text top="308" left="105" width="41" height="13" font="23">S3.2-1.</text>
<text top="308" left="146" width="4" height="13" font="47"> </text>
<text top="308" left="174" width="570" height="13" font="23">Orrow G, Kinmonth A-L, Sanderson S, et al. Effectiveness of physical activity promotion based in </text>
<text top="326" left="174" width="525" height="13" font="23">primary care: systematic review and meta-analysis of randomised controlled trials. BMJ. </text>
<text top="343" left="174" width="103" height="13" font="23">2012;344:e1389. </text>
<text top="361" left="105" width="41" height="13" font="23">S3.2-2.</text>
<text top="361" left="146" width="4" height="13" font="47"> </text>
<text top="361" left="174" width="575" height="13" font="23">Sanchez A, Bully P, Martinez C, et al. Effectiveness of physical activity promotion interventions in </text>
<text top="379" left="174" width="409" height="13" font="23">primary care: a review of reviews. Prev Med. 2015;76(suppl):S56-67. </text>
<text top="397" left="105" width="41" height="13" font="23">S3.2-3.</text>
<text top="397" left="146" width="4" height="13" font="47"> </text>
<text top="397" left="174" width="609" height="13" font="23">Ekelund U, Steene-Johannessen J, Brown WJ, et al. Does physical activity attenuate, or even eliminate, </text>
<text top="415" left="174" width="595" height="13" font="23">the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from </text>
<text top="433" left="174" width="389" height="13" font="23">more than 1 million men and women. Lancet. 2016;388:1302-10. </text>
<text top="450" left="105" width="41" height="13" font="23">S3.2-4.</text>
<text top="450" left="146" width="4" height="13" font="47"> </text>
<text top="450" left="174" width="612" height="13" font="23">Hamer M, Chida Y. Walking and primary prevention: a meta-analysis of prospective cohort studies. Br J </text>
<text top="468" left="174" width="176" height="13" font="23">Sports Med. 2008;42:238-43. </text>
<text top="486" left="105" width="41" height="13" font="23">S3.2-5.</text>
<text top="486" left="146" width="4" height="13" font="47"> </text>
<text top="486" left="174" width="578" height="13" font="23">Kyu HH, Bachman VF, Alexander LT, et al. Physical activity and risk of breast cancer, colon cancer, </text>
<text top="504" left="174" width="592" height="13" font="23">diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response </text>
<text top="522" left="174" width="486" height="13" font="23">meta-analysis for the Global Burden of Disease Study 2013. BMJ. 2016;354:i3857. </text>
<text top="539" left="105" width="41" height="13" font="23">S3.2-6.</text>
<text top="539" left="146" width="4" height="13" font="47"> </text>
<text top="539" left="174" width="590" height="13" font="23">Sattelmair J, Pertman J, Ding EL, et al. Dose response between physical activity and risk of coronary </text>
<text top="557" left="174" width="364" height="13" font="23">heart disease: a meta-analysis. Circulation. 2011;124:789-95. </text>
<text top="575" left="105" width="41" height="13" font="23">S3.2-7.</text>
<text top="575" left="146" width="4" height="13" font="47"> </text>
<text top="575" left="174" width="600" height="13" font="23">Zheng H, Orsini N, Amin J, et al. Quantifying the dose-response of walking in reducing coronary heart </text>
<text top="593" left="174" width="362" height="13" font="23">disease risk: meta-analysis. Eur J Epidemiol. 2009;24:181-92. </text>
<text top="611" left="105" width="41" height="13" font="23">S3.2-8.</text>
<text top="611" left="146" width="4" height="13" font="47"> </text>
<text top="611" left="174" width="561" height="13" font="23">Wahid A, Manek N, Nichols M, et al. Quantifying the association between physical activity and </text>
<text top="629" left="174" width="563" height="13" font="23">cardiovascular disease and diabetes: a systematic review and meta-analysis. J Am Heart Assoc. </text>
<text top="646" left="174" width="103" height="13" font="23">2016;5:e002495. </text>
<text top="664" left="105" width="41" height="13" font="23">S3.2-9.</text>
<text top="664" left="146" width="4" height="13" font="47"> </text>
<text top="664" left="174" width="600" height="13" font="23">Biswas A, Oh PI, Faulkner GE, et al. Sedentary time and its association with risk for disease incidence, </text>
<text top="682" left="174" width="571" height="13" font="23">mortality, and hospitalization in adults: a systematic review and meta-analysis. Ann Intern Med. </text>
<text top="700" left="174" width="108" height="13" font="23">2015;162:123-32. </text>
<text top="718" left="105" width="48" height="13" font="23">S3.2-10.</text>
<text top="718" left="153" width="4" height="13" font="47"> </text>
<text top="718" left="174" width="608" height="13" font="23">Chomistek AK, Manson JE, Stefanick ML, et al. Relationship of sedentary behavior and physical activity </text>
<text top="735" left="174" width="573" height="13" font="23">to incident cardiovascular disease: results from the Women’s Health Initiative. J Am Coll Cardiol. </text>
<text top="753" left="174" width="108" height="13" font="23">2013;61:2346-54. </text>
<text top="771" left="105" width="48" height="13" font="23">S3.2-11.</text>
<text top="771" left="153" width="4" height="13" font="47"> </text>
<text top="771" left="174" width="616" height="13" font="23">Patterson R, McNamara E, Tainio M, et al. Sedentary behaviour and risk of all-cause, cardiovascular and </text>
<text top="789" left="174" width="603" height="13" font="23">cancer mortality, and incident type 2 diabetes: a systematic review and dose response meta-analysis. </text>
<text top="807" left="174" width="198" height="13" font="23">Eur J Epidemiol. 2018;33:811-29. </text>
<text top="825" left="105" width="48" height="13" font="23">S3.2-12.</text>
<text top="825" left="153" width="4" height="13" font="47"> </text>
<text top="825" left="174" width="577" height="13" font="23">2018 Physical Activity Guidelines Advisory Committee. 2018 Physical Activity Guidelines Advisory </text>
<text top="842" left="174" width="601" height="13" font="23">Committee Scientific Report. Washington, DC: U.S. Department of Health and Human Services; 2018. </text>
<text top="860" left="174" width="568" height="13" font="23">Available at: https://health.gov/paguidelines/second-edition/report. Accessed January 3, 2019. </text>
<text top="878" left="105" width="48" height="13" font="23">S3.2-13.</text>
<text top="878" left="153" width="4" height="13" font="47"> </text>
<text top="878" left="174" width="602" height="13" font="23">Lee I-M, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases </text>
<text top="896" left="174" width="538" height="13" font="23">worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;380:219-29. </text>
<text top="914" left="105" width="48" height="13" font="23">S3.2-14.</text>
<text top="914" left="153" width="4" height="13" font="47"> </text>
<text top="914" left="174" width="577" height="13" font="23">Physical Activity Guidelines Steering Committee. 2008 Physical Activity Guidelines for Americans. </text>
<text top="932" left="174" width="471" height="13" font="23">Available at: https://health.gov/paguidelines/2008/. Accessed January 5, 2019. </text>
<text top="949" left="105" width="48" height="13" font="23">S3.2-15.</text>
<text top="949" left="153" width="4" height="13" font="47"> </text>
<text top="949" left="174" width="583" height="13" font="23">Milton K, Macniven R, Bauman A. Review of the epidemiological evidence for physical activity and </text>
<text top="967" left="174" width="493" height="13" font="23">health from low- and middle-income countries. Glob Public Health. 2014;9:369-81. </text>
<text top="985" left="105" width="48" height="13" font="23">S3.2-16.</text>
<text top="985" left="153" width="4" height="13" font="47"> </text>
<text top="985" left="174" width="573" height="13" font="23">Lobelo F, Rohm Young D, Sallis R, et al. Routine assessment and promotion of physical activity in </text>
<text top="1003" left="174" width="548" height="13" font="23">healthcare settings: a scientific statement from the American Heart Association. Circulation. </text>
<text top="1021" left="174" width="123" height="13" font="23">2018;137:e495-522. </text>
<text top="1039" left="105" width="48" height="13" font="23">S3.2-17.</text>
<text top="1039" left="153" width="4" height="13" font="47"> </text>
<text top="1039" left="174" width="561" height="13" font="23">Kraus WE, Bittner V, Appel L, et al. The National Physical Activity Plan: a call to action from the </text>
<text top="1056" left="174" width="580" height="13" font="23">American Heart Association: a science advisory from the American Heart Association. Circulation. </text>
<text top="1074" left="174" width="115" height="13" font="23">2015;131:1932-40. </text>
</page>
<page number="89" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 87 of 101 </text>
<text top="167" left="105" width="48" height="13" font="23">S3.2-18.</text>
<text top="167" left="153" width="4" height="13" font="47"> </text>
<text top="167" left="174" width="606" height="13" font="23">Diep L, Kwagyan J, Kurantsin-Mills J, et al. Association of physical activity level and stroke outcomes in </text>
<text top="185" left="174" width="486" height="13" font="23">men and women: a meta-analysis. J Womens Health (Larchmt). 2010;19:1815-22. </text>
<text top="203" left="105" width="48" height="13" font="23">S3.2-19.</text>
<text top="203" left="153" width="4" height="13" font="47"> </text>
<text top="203" left="174" width="563" height="13" font="23">Sofi F, Capalbo A, Cesari F, et al. Physical activity during leisure time and primary prevention of </text>
<text top="221" left="174" width="586" height="13" font="23">coronary heart disease: an updated meta-analysis of cohort studies. Eur J Cardiovasc Prev Rehabil. </text>
<text top="238" left="174" width="101" height="13" font="23">2008;15:247-57. </text>
<text top="256" left="105" width="48" height="13" font="23">S3.2-20.</text>
<text top="256" left="153" width="4" height="13" font="47"> </text>
<text top="256" left="174" width="590" height="13" font="23">Liu C-J, Latham NK. Progressive resistance strength training for improving physical function in older </text>
<text top="274" left="174" width="319" height="13" font="23">adults. Cochrane Database Syst Rev. 2009;CD002759. </text>
<text top="292" left="105" width="48" height="13" font="23">S3.2-21.</text>
<text top="292" left="153" width="4" height="13" font="47"> </text>
<text top="292" left="174" width="606" height="13" font="23">Sigal RJ, Kenny GP, Boulé NG, et al. Effects of aerobic training, resistance training, or both on glycemic </text>
<text top="310" left="174" width="483" height="13" font="23">control in type 2 diabetes: a randomized trial. Ann Intern Med. 2007;147:357-69. </text>
<text top="328" left="105" width="48" height="13" font="23">S3.2-22.</text>
<text top="328" left="153" width="4" height="13" font="47"> </text>
<text top="328" left="174" width="591" height="13" font="23">Carlson DJ, Dieberg G, Hess NC, et al. Isometric exercise training for blood pressure management: a </text>
<text top="345" left="174" width="421" height="13" font="23">systematic review and meta-analysis. Mayo Clin Proc. 2014;89:327-34. </text>
<text top="363" left="105" width="48" height="13" font="23">S3.2-23.</text>
<text top="363" left="153" width="4" height="13" font="47"> </text>
<text top="363" left="174" width="571" height="13" font="23">Goodman JM, Burr JF, Banks L, et al. The acute risks of exercise in apparently healthy adults and </text>
<text top="381" left="174" width="484" height="13" font="23">relevance for prevention of cardiovascular events. Can J Cardiol. 2016;32:523-32. </text>
<text top="399" left="105" width="48" height="13" font="23">S3.2-24.</text>
<text top="399" left="153" width="4" height="13" font="47"> </text>
<text top="399" left="174" width="604" height="13" font="23">Thompson PD, Franklin BA, Balady GJ, et al. Exercise and acute cardiovascular events placing the risks </text>
<text top="417" left="174" width="583" height="13" font="23">into perspective: a scientific statement from the American Heart Association Council on Nutrition, </text>
<text top="434" left="174" width="596" height="13" font="23">Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation. 2007;115:2358-</text>
<text top="452" left="174" width="22" height="13" font="23">68. </text>
<text top="470" left="105" width="48" height="13" font="23">S3.2-25.</text>
<text top="470" left="153" width="4" height="13" font="47"> </text>
<text top="470" left="174" width="605" height="13" font="23">Merghani A, Maestrini V, Rosmini S, et al. Prevalence of subclinical coronary artery disease in masters </text>
<text top="488" left="174" width="524" height="13" font="23">endurance athletes with a low atherosclerotic risk profile. Circulation. 2017;136:126-37. </text>
<text top="506" left="105" width="48" height="13" font="23">S3.2-26.</text>
<text top="506" left="153" width="4" height="13" font="47"> </text>
<text top="506" left="174" width="608" height="13" font="23">Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention </text>
<text top="524" left="174" width="612" height="13" font="23">in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies </text>
<text top="541" left="174" width="614" height="13" font="23">on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies </text>
<text top="559" left="174" width="575" height="13" font="23">and by invited experts). Developed with the special contribution of the European Association for </text>
<text top="577" left="174" width="493" height="13" font="23">Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J. 2016;37:2315-81. </text>
<text top="595" left="105" width="48" height="13" font="23">S3.2-27.</text>
<text top="595" left="153" width="4" height="13" font="47"> </text>
<text top="595" left="174" width="610" height="13" font="23">Saint-Maurice PF, Troiano RP, Matthews CE, et al. Moderate-to-vigorous physical activity and all-cause </text>
<text top="613" left="174" width="380" height="13" font="23">mortality: do bouts matter? J Am Heart Assoc. 2018;7:e007678. </text>
<text top="631" left="105" width="48" height="13" font="23">S3.2-28.</text>
<text top="631" left="153" width="4" height="13" font="47"> </text>
<text top="631" left="174" width="608" height="13" font="23">Vasankari V, Husu P, Vähä-Ypyä H, et al. Association of objectively measured sedentary behaviour and </text>
<text top="648" left="174" width="501" height="13" font="23">physical activity with cardiovascular disease risk. Eur J Prev Cardiol. 2017;24:1311-8. </text>
<text top="666" left="105" width="48" height="13" font="23">S3.2-29.</text>
<text top="666" left="153" width="4" height="13" font="47"> </text>
<text top="666" left="174" width="596" height="13" font="23">Pandey A, Garg S, Khunger M, et al. Dose-response relationship between physical activity and risk of </text>
<text top="684" left="174" width="366" height="13" font="23">heart failure: a meta-analysis. Circulation. 2015;132:1786-94. </text>
<text top="702" left="105" width="48" height="13" font="23">S3.2-30.</text>
<text top="702" left="153" width="4" height="13" font="47"> </text>
<text top="702" left="174" width="557" height="13" font="23">Young DR, Hivert M-F, Alhassan S, et al. Sedentary behavior and cardiovascular morbidity and </text>
<text top="720" left="174" width="585" height="13" font="23">mortality: a science advisory from the American Heart Association. Circulation. 2016;134:e262-79. </text>
<text top="737" left="105" width="48" height="13" font="23">S3.2-31.</text>
<text top="737" left="153" width="4" height="13" font="47"> </text>
<text top="737" left="174" width="617" height="13" font="23">Chastin SFM, De Craemer M, De Cocker K, et al. How does light-intensity physical activity associate with </text>
<text top="755" left="174" width="613" height="13" font="23">adult cardiometabolic health and mortality? Systematic review with meta-analysis of experimental and </text>
<text top="773" left="174" width="442" height="13" font="23">observational studies. Br J Sports Med. 2018 Apr 25 [Epub ahead of print]. </text>
<text top="801" left="105" width="299" height="19" font="15"><b>4.1. Obesity and Being Overweight </b></text>
<text top="825" left="105" width="41" height="13" font="23">S4.1-1.</text>
<text top="825" left="146" width="4" height="13" font="47"> </text>
<text top="825" left="174" width="594" height="13" font="23">LeBlanc EL, Patnode CD, Webber EM, et al. Draft evidence review for weight loss to prevent obesity-</text>
<text top="842" left="174" width="574" height="13" font="23">related morbidity and mortality in adults: behavioral interventions. Kaiser Permanente Research </text>
<text top="860" left="174" width="616" height="13" font="23">Affiliates Evidence-based Practice Center, Kaiser Permanente Center for Health Research: Portland, OR; </text>
<text top="878" left="174" width="339" height="13" font="23">2018. AHRQ Publication No. 18-05239-EF-1. Available at: </text>
<text top="896" left="174" width="591" height="13" font="23">https://www.uspreventiveservicestaskforce.org/Page/Document/draft-evidence-review/obesity-in-</text>
<text top="914" left="174" width="292" height="13" font="23">adults-interventions1. Accessed January 5, 2019. </text>
<text top="932" left="105" width="41" height="13" font="23">S4.1-2.</text>
<text top="931" left="146" width="4" height="13" font="47"> </text>
<text top="932" left="174" width="581" height="13" font="23">Ma C, Avenell A, Bolland M, et al. Effects of weight loss interventions for adults who are obese on </text>
<text top="949" left="174" width="530" height="13" font="23">mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ. </text>
<text top="967" left="174" width="100" height="13" font="23">2017;359:j4849. </text>
<text top="985" left="105" width="41" height="13" font="23">S4.1-3.</text>
<text top="985" left="146" width="4" height="13" font="47"> </text>
<text top="985" left="174" width="616" height="13" font="23">Canoy D, Cairns BJ, Balkwill A, et al. Coronary heart disease incidence in women by waist circumference </text>
<text top="1003" left="174" width="437" height="13" font="23">within categories of body mass index. Eur J Prev Cardiol. 2013;20:759-62. </text>
<text top="1021" left="105" width="41" height="13" font="23">S4.1-4.</text>
<text top="1021" left="146" width="4" height="13" font="47"> </text>
<text top="1021" left="174" width="541" height="13" font="23">Warren TY, Wilcox S, Dowda M, et al. Independent association of waist circumference with </text>
<text top="1039" left="174" width="601" height="13" font="23">hypertension and diabetes in African American women, South Carolina, 2007-2009. Prev Chronic Dis. </text>
<text top="1056" left="174" width="81" height="13" font="23">2012;9:E105. </text>
<text top="1074" left="105" width="41" height="13" font="23">S4.1-5.</text>
<text top="1074" left="146" width="4" height="13" font="47"> </text>
<text top="1074" left="174" width="589" height="13" font="23">Czernichow S, Kengne A-P, Stamatakis E, et al. Body mass index, waist circumference and waist-hip </text>
</page>
<page number="90" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 88 of 101 </text>
<text top="167" left="174" width="582" height="13" font="23">ratio: which is the better discriminator of cardiovascular disease mortality risk?: evidence from an </text>
<text top="185" left="174" width="563" height="13" font="23">individual-participant meta-analysis of 82 864 participants from nine cohort studies. Obes Rev. </text>
<text top="203" left="174" width="93" height="13" font="23">2011;12:680-7. </text>
<text top="221" left="105" width="41" height="13" font="23">S4.1-6.</text>
<text top="220" left="146" width="4" height="13" font="47"> </text>
<text top="221" left="174" width="593" height="13" font="23">Flint AJ, Rexrode KM, Hu FB, et al. Body mass index, waist circumference, and risk of coronary heart </text>
<text top="238" left="174" width="543" height="13" font="23">disease: a prospective study among men and women. Obes Res Clin Pract. 2010;4:e171-81. </text>
<text top="256" left="105" width="41" height="13" font="23">S4.1-7.</text>
<text top="256" left="146" width="4" height="13" font="47"> </text>
<text top="256" left="174" width="491" height="13" font="23">American Heart Association. Extreme Obesity, And What You Can Do. Available at: </text>
<text top="274" left="174" width="615" height="13" font="23">https://www.heart.org/en/healthy-living/healthy-eating/losing-weight/extreme-obesity-and-what-you-</text>
<text top="292" left="174" width="205" height="13" font="23">can-do. Accessed January 5, 2019. </text>
<text top="310" left="105" width="41" height="13" font="23">S4.1-8.</text>
<text top="310" left="146" width="4" height="13" font="47"> </text>
<text top="310" left="174" width="593" height="13" font="23">Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity among adults and youth: United States, </text>
<text top="328" left="174" width="233" height="13" font="23">2015-2016. NCHS Data Brief. 2017;1-8. </text>
<text top="345" left="105" width="41" height="13" font="23">S4.1-9.</text>
<text top="345" left="146" width="4" height="13" font="47"> </text>
<text top="345" left="174" width="586" height="13" font="23">Asad Z, Abbas M, Javed I, et al. Obesity is associated with incident atrial fibrillation independent of </text>
<text top="363" left="174" width="415" height="13" font="23">gender: a meta-analysis. J Cardiovasc Electrophysiol. 2018;29:725-32. </text>
<text top="381" left="105" width="48" height="13" font="23">S4.1-10.</text>
<text top="381" left="153" width="4" height="13" font="47"> </text>
<text top="381" left="174" width="561" height="13" font="23">Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of </text>
<text top="399" left="174" width="578" height="13" font="23">overweight and obesity in adults: a report of the American College of Cardiology/American Heart </text>
<text top="417" left="174" width="613" height="13" font="23">Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63:2985-</text>
<text top="434" left="174" width="37" height="13" font="23">3023. </text>
<text top="452" left="105" width="48" height="13" font="23">S4.1-11.</text>
<text top="452" left="153" width="4" height="13" font="47"> </text>
<text top="452" left="174" width="615" height="13" font="23">Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. </text>
<text top="470" left="174" width="101" height="13" font="23">2014;311:74-86. </text>
<text top="488" left="105" width="48" height="13" font="23">S4.1-12.</text>
<text top="488" left="153" width="4" height="13" font="47"> </text>
<text top="488" left="174" width="596" height="13" font="23">Golzarand M, Toolabi K, Farid R. The bariatric surgery and weight losing: a meta-analysis in the long- </text>
<text top="506" left="174" width="600" height="13" font="23">and very long-term effects of laparoscopic adjustable gastric banding, laparoscopic Roux-en-Y gastric </text>
<text top="524" left="174" width="597" height="13" font="23">bypass and laparoscopic sleeve gastrectomy on weight loss in adults. Surg Endosc. 2017;31:4331-45. </text>
<text top="541" left="105" width="48" height="13" font="23">S4.1-13.</text>
<text top="541" left="153" width="4" height="13" font="47"> </text>
<text top="541" left="174" width="599" height="13" font="23">Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the </text>
<text top="559" left="174" width="514" height="13" font="23">Health, Aging and Body Composition Study. Am J Clin Nutr. 2005;82:872-8; quiz 915-6. </text>
<text top="577" left="105" width="48" height="13" font="23">S4.1-14.</text>
<text top="577" left="153" width="4" height="13" font="47"> </text>
<text top="577" left="174" width="595" height="13" font="23">Zamboni M, Mazzali G, Zoico E, et al. Health consequences of obesity in the elderly: a review of four </text>
<text top="595" left="174" width="348" height="13" font="23">unresolved questions. Int J Obes (Lond). 2005;29:1011-29. </text>
<text top="613" left="105" width="48" height="13" font="23">S4.1-15.</text>
<text top="613" left="153" width="4" height="13" font="47"> </text>
<text top="613" left="174" width="582" height="13" font="23">Miller SL, Wolfe RR. The danger of weight loss in the elderly. J Nutr Health Aging. 2008;12:487-91. </text>
<text top="631" left="105" width="48" height="13" font="23">S4.1-16.</text>
<text top="631" left="153" width="4" height="13" font="47"> </text>
<text top="631" left="174" width="586" height="13" font="23">Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with </text>
<text top="648" left="174" width="412" height="13" font="23">lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. </text>
<text top="666" left="105" width="48" height="13" font="23">S4.1-17.</text>
<text top="666" left="153" width="4" height="13" font="47"> </text>
<text top="666" left="174" width="572" height="13" font="23">Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle </text>
<text top="684" left="174" width="381" height="13" font="23">intervention in type 2 diabetes. N Engl J Med. 2013;369:145-54. </text>
<text top="702" left="105" width="48" height="13" font="23">S4.1-18.</text>
<text top="702" left="153" width="4" height="13" font="47"> </text>
<text top="702" left="174" width="608" height="13" font="23">McTigue KM, Harris R, Hemphill B, et al. Screening and interventions for obesity in adults: summary of </text>
<text top="720" left="174" width="547" height="13" font="23">the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2003;139:933-49. </text>
<text top="737" left="105" width="48" height="13" font="23">S4.1-19.</text>
<text top="737" left="153" width="4" height="13" font="47"> </text>
<text top="737" left="174" width="597" height="13" font="23">Stegenga H, Haines A, Jones K, et al. Identification, assessment, and management of overweight and </text>
<text top="755" left="174" width="405" height="13" font="23">obesity: summary of updated NICE guidance. BMJ. 2014;349:g6608. </text>
<text top="773" left="105" width="48" height="13" font="23">S4.1-20.</text>
<text top="773" left="153" width="4" height="13" font="47"> </text>
<text top="773" left="174" width="606" height="13" font="23">WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for </text>
<text top="791" left="174" width="360" height="13" font="23">policy and intervention strategies. Lancet. 2004;363:157-63. </text>
<text top="809" left="105" width="48" height="13" font="23">S4.1-21.</text>
<text top="809" left="153" width="4" height="13" font="47"> </text>
<text top="809" left="174" width="586" height="13" font="23">Zhang P, Wang R, Gao C, et al. Prevalence of central obesity among adults with normal BMI and its </text>
<text top="827" left="174" width="513" height="13" font="23">association with metabolic diseases in northeast China. PLoS ONE. 2016;11:e0160402. </text>
<text top="844" left="105" width="48" height="13" font="23">S4.1-22.</text>
<text top="844" left="153" width="4" height="13" font="47"> </text>
<text top="844" left="174" width="604" height="13" font="23">Sharma S, Batsis JA, Coutinho T, et al. Normal-weight central obesity and mortality risk in older adults </text>
<text top="862" left="174" width="373" height="13" font="23">with coronary artery disease. Mayo Clin Proc. 2016;91:343-51. </text>
<text top="880" left="105" width="48" height="13" font="23">S4.1-23.</text>
<text top="880" left="153" width="4" height="13" font="47"> </text>
<text top="880" left="174" width="566" height="13" font="23">Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and </text>
<text top="898" left="174" width="577" height="13" font="23">American College of Endocrinology comprehensive clinical practice guidelines for medical care of </text>
<text top="916" left="174" width="359" height="13" font="23">patients with obesity. Endocr Pract. 2016;22(suppl 3):1-203. </text>
<text top="933" left="105" width="48" height="13" font="23">S4.1-24.</text>
<text top="933" left="153" width="4" height="13" font="47"> </text>
<text top="933" left="174" width="592" height="13" font="23">Balkau B, Deanfield JE, Després J-P, et al. International Day for the Evaluation of Abdominal Obesity </text>
<text top="951" left="174" width="568" height="13" font="23">(IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 </text>
<text top="969" left="174" width="412" height="13" font="23">primary care patients in 63 countries. Circulation. 2007;116:1942-51. </text>
<text top="987" left="105" width="48" height="13" font="23">S4.1-25.</text>
<text top="987" left="153" width="4" height="13" font="47"> </text>
<text top="987" left="174" width="588" height="13" font="23">NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of </text>
<text top="1005" left="174" width="595" height="13" font="23">Obesity in Adults. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight </text>
<text top="1023" left="174" width="587" height="13" font="23">and Obesity in Adults. Bethesda, MD: National Heart, Lung, and Blood Institute; 1998. Available at: </text>
<text top="1040" left="174" width="451" height="13" font="23">https://www.ncbi.nlm.nih.gov/books/NBK2003/. Accessed January 5, 2019. </text>
</page>
<page number="91" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 89 of 101 </text>
<text top="168" left="105" width="250" height="19" font="15"><b>4.2. Type 2 Diabetes Mellitus </b></text>
<text top="192" left="105" width="41" height="13" font="23">S4.2-1.</text>
<text top="192" left="146" width="4" height="13" font="47"> </text>
<text top="192" left="174" width="571" height="13" font="23">Huo R, Du T, Xu Y, et al. Effects of Mediterranean-style diet on glycemic control, weight loss and </text>
<text top="210" left="174" width="556" height="13" font="23">cardiovascular risk factors among type 2 diabetes individuals: a meta-analysis. Eur J Clin Nutr. </text>
<text top="228" left="174" width="101" height="13" font="23">2015;69:1200-8. </text>
<text top="246" left="105" width="41" height="13" font="23">S4.2-2.</text>
<text top="246" left="146" width="4" height="13" font="47"> </text>
<text top="246" left="174" width="611" height="13" font="23">Azadbakht L, Fard NRP, Karimi M, et al. Effects of the Dietary Approaches to Stop Hypertension (DASH) </text>
<text top="264" left="174" width="617" height="13" font="23">eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial. </text>
<text top="281" left="174" width="175" height="13" font="23">Diabetes Care. 2011;34:55-7. </text>
<text top="299" left="105" width="41" height="13" font="23">S4.2-3.</text>
<text top="299" left="146" width="4" height="13" font="47"> </text>
<text top="299" left="174" width="595" height="13" font="23">Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk </text>
<text top="317" left="174" width="608" height="13" font="23">factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care. 2006;29:2518-27. </text>
<text top="335" left="105" width="41" height="13" font="23">S4.2-4.</text>
<text top="335" left="146" width="4" height="13" font="47"> </text>
<text top="335" left="174" width="592" height="13" font="23">Church TS, Blair SN, Cocreham S, et al. Effects of aerobic and resistance training on hemoglobin A1c </text>
<text top="352" left="174" width="567" height="13" font="23">levels in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2010;304:2253-62. </text>
<text top="370" left="105" width="41" height="13" font="23">S4.2-5.</text>
<text top="370" left="146" width="4" height="13" font="47"> </text>
<text top="370" left="174" width="610" height="13" font="23">Effect of intensive blood-glucose control with metformin on complications in overweight patients with </text>
<text top="388" left="174" width="604" height="13" font="23">type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-65. </text>
<text top="406" left="105" width="41" height="13" font="23">S4.2-6.</text>
<text top="406" left="146" width="4" height="13" font="47"> </text>
<text top="406" left="174" width="594" height="13" font="23">Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based </text>
<text top="424" left="174" width="582" height="13" font="23">combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. </text>
<text top="442" left="174" width="108" height="13" font="23">2016;164:740-51. </text>
<text top="459" left="105" width="41" height="13" font="23">S4.2-7.</text>
<text top="459" left="146" width="4" height="13" font="47"> </text>
<text top="459" left="174" width="569" height="13" font="23">Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in </text>
<text top="477" left="174" width="546" height="13" font="23">patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36:1304-11. </text>
<text top="495" left="105" width="41" height="13" font="23">S4.2-8.</text>
<text top="495" left="146" width="4" height="13" font="47"> </text>
<text top="495" left="174" width="575" height="13" font="23">Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of </text>
<text top="513" left="174" width="506" height="13" font="23">randomised trials among people with type 2 diabetes. Diabetologia. 2017;60:1620-9. </text>
<text top="531" left="105" width="41" height="13" font="23">S4.2-9.</text>
<text top="531" left="146" width="4" height="13" font="47"> </text>
<text top="531" left="174" width="605" height="13" font="23">Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 </text>
<text top="548" left="174" width="257" height="13" font="23">diabetes. N Engl J Med. 2015;373:2117-28. </text>
<text top="566" left="105" width="48" height="13" font="23">S4.2-10.</text>
<text top="566" left="153" width="4" height="13" font="47"> </text>
<text top="566" left="174" width="584" height="13" font="23">Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 </text>
<text top="584" left="174" width="249" height="13" font="23">diabetes. N Engl J Med. 2017;377:644-57. </text>
<text top="602" left="105" width="48" height="13" font="23">S4.2-11.</text>
<text top="602" left="153" width="4" height="13" font="47"> </text>
<text top="602" left="174" width="580" height="13" font="23">Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 </text>
<text top="620" left="174" width="249" height="13" font="23">diabetes. N Engl J Med. 2016;375:311-22. </text>
<text top="638" left="105" width="48" height="13" font="23">S4.2-12.</text>
<text top="638" left="153" width="4" height="13" font="47"> </text>
<text top="638" left="174" width="592" height="13" font="23">Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N </text>
<text top="655" left="174" width="291" height="13" font="23">Engl J Med. 2018. doi:10.1056/NEJMoa1812389. </text>
<text top="673" left="105" width="48" height="13" font="23">S4.2-13.</text>
<text top="673" left="153" width="4" height="13" font="47"> </text>
<text top="673" left="174" width="589" height="13" font="23">Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients </text>
<text top="691" left="174" width="588" height="13" font="23">with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised </text>
<text top="709" left="174" width="308" height="13" font="23">placebo-controlled trial. Lancet. 2018;392:1519-29. </text>
<text top="727" left="105" width="48" height="13" font="23">S4.2-14.</text>
<text top="727" left="153" width="4" height="13" font="47"> </text>
<text top="727" left="174" width="598" height="13" font="23">Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 </text>
<text top="744" left="174" width="257" height="13" font="23">diabetes. N Engl J Med. 2016;375:1834-44. </text>
<text top="762" left="105" width="48" height="13" font="23">S4.2-15.</text>
<text top="762" left="153" width="4" height="13" font="47"> </text>
<text top="762" left="174" width="601" height="13" font="23">Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics—2018 update: a report </text>
<text top="780" left="174" width="413" height="13" font="23">from the American Heart Association. Circulation. 2018;137:e67-492. </text>
<text top="798" left="105" width="48" height="13" font="23">S4.2-16.</text>
<text top="798" left="153" width="4" height="13" font="47"> </text>
<text top="798" left="174" width="618" height="13" font="23">Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with </text>
<text top="816" left="174" width="290" height="13" font="23">type 2 diabetes. N Engl J Med. 2003;348:383-93. </text>
<text top="834" left="105" width="48" height="13" font="23">S4.2-17.</text>
<text top="834" left="153" width="4" height="13" font="47"> </text>
<text top="834" left="174" width="610" height="13" font="23">Liu G, Li Y, Hu Y, et al. Influence of lifestyle on incident cardiovascular disease and mortality in patients </text>
<text top="851" left="174" width="352" height="13" font="23">with diabetes mellitus. J Am Coll Cardiol. 2018;71:2867-76. </text>
<text top="869" left="105" width="48" height="13" font="23">S4.2-18.</text>
<text top="869" left="153" width="4" height="13" font="47"> </text>
<text top="869" left="174" width="608" height="13" font="23">Rejeski WJ, Ip EH, Bertoni AG, et al. Lifestyle change and mobility in obese adults with type 2 diabetes. </text>
<text top="887" left="174" width="199" height="13" font="23">N Engl J Med. 2012;366:1209-17. </text>
<text top="905" left="105" width="48" height="13" font="23">S4.2-19.</text>
<text top="905" left="153" width="4" height="13" font="47"> </text>
<text top="905" left="174" width="593" height="13" font="23">Burger KNJ, Beulens JWJ, van der Schouw YT, et al. Dietary fiber, carbohydrate quality and quantity, </text>
<text top="923" left="174" width="488" height="13" font="23">and mortality risk of individuals with diabetes mellitus. PLoS ONE. 2012;7:e43127. </text>
<text top="941" left="105" width="48" height="13" font="23">S4.2-20.</text>
<text top="940" left="153" width="4" height="13" font="47"> </text>
<text top="941" left="174" width="565" height="13" font="23">Micha R, Wallace SK, Mozaffarian D. Red and processed meat consumption and risk of incident </text>
<text top="959" left="174" width="556" height="13" font="23">coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. </text>
<text top="976" left="174" width="186" height="13" font="23">Circulation. 2010;121:2271-83. </text>
<text top="994" left="105" width="48" height="13" font="23">S4.2-21.</text>
<text top="994" left="153" width="4" height="13" font="47"> </text>
<text top="994" left="174" width="588" height="13" font="23">Pan A, Sun Q, Bernstein AM, et al. Changes in red meat consumption and subsequent risk of type 2 </text>
<text top="1012" left="174" width="561" height="13" font="23">diabetes mellitus: three cohorts of US men and women. JAMA Intern Med. 2013;173:1328-35. </text>
<text top="1030" left="105" width="48" height="13" font="23">S4.2-22.</text>
<text top="1030" left="153" width="4" height="13" font="47"> </text>
<text top="1030" left="174" width="599" height="13" font="23">Boulé NG, Haddad E, Kenny GP, et al. Effects of exercise on glycemic control and body mass in type 2 </text>
<text top="1047" left="174" width="520" height="13" font="23">diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286:1218-27. </text>
<text top="1065" left="105" width="48" height="13" font="23">S4.2-23.</text>
<text top="1065" left="153" width="4" height="13" font="47"> </text>
<text top="1065" left="174" width="595" height="13" font="23">Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of </text>
<text top="1083" left="174" width="591" height="13" font="23">intensive treatment of diabetes on the development and progression of long-term complications in </text>
</page>
<page number="92" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 90 of 101 </text>
<text top="167" left="174" width="411" height="13" font="23">insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86. </text>
<text top="185" left="105" width="48" height="13" font="23">S4.2-24.</text>
<text top="185" left="153" width="4" height="13" font="47"> </text>
<text top="185" left="174" width="608" height="13" font="23">Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment </text>
<text top="203" left="174" width="600" height="13" font="23">and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study </text>
<text top="221" left="174" width="251" height="13" font="23">(UKPDS) Group. Lancet. 1998;352:837-53. </text>
<text top="238" left="105" width="48" height="13" font="23">S4.2-25.</text>
<text top="238" left="153" width="4" height="13" font="47"> </text>
<text top="238" left="174" width="598" height="13" font="23">Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with </text>
<text top="256" left="174" width="290" height="13" font="23">type 2 diabetes. N Engl J Med. 2009;360:129-39. </text>
<text top="274" left="105" width="48" height="13" font="23">S4.2-26.</text>
<text top="274" left="153" width="4" height="13" font="47"> </text>
<text top="274" left="174" width="569" height="13" font="23">Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular </text>
<text top="292" left="174" width="615" height="13" font="23">outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. </text>
<text top="310" left="174" width="162" height="13" font="23">Lancet. 2009;373:1765-72. </text>
<text top="328" left="105" width="48" height="13" font="23">S4.2-27.</text>
<text top="328" left="153" width="4" height="13" font="47"> </text>
<text top="328" left="174" width="554" height="13" font="23">Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of </text>
<text top="345" left="174" width="569" height="13" font="23">cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of </text>
<text top="363" left="174" width="487" height="13" font="23">cardiovascular outcome trials. Lancet. 2018. doi:10.1016/S0140-6736(18)32590-X </text>
<text top="391" left="105" width="235" height="19" font="15"><b>4.3. High Blood Cholesterol </b></text>
<text top="415" left="105" width="41" height="13" font="23">S4.3-1.</text>
<text top="415" left="146" width="4" height="13" font="47"> </text>
<text top="415" left="174" width="258" height="13" font="23">Grundy SM, Stone NJ, Bailey AL, et al. 2018 </text>
<text top="433" left="174" width="609" height="13" font="23">AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management </text>
<text top="450" left="174" width="604" height="13" font="23">of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task </text>
<text top="468" left="174" width="610" height="13" font="23">Force on Clinical Practice Guidelines [published online ahead of print November 10, 2018]. Circulation. </text>
<text top="486" left="174" width="224" height="13" font="23">doi: 10.1161/CIR.0000000000000625 </text>
<text top="504" left="105" width="41" height="13" font="23">S4.3-2.</text>
<text top="504" left="146" width="4" height="13" font="47"> </text>
<text top="504" left="174" width="608" height="13" font="23">Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of </text>
<text top="522" left="174" width="590" height="13" font="23">more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 </text>
<text top="539" left="174" width="272" height="13" font="23">randomised trials. Lancet. 2010;376:1670-81. </text>
<text top="557" left="105" width="41" height="13" font="23">S4.3-3.</text>
<text top="557" left="146" width="4" height="13" font="47"> </text>
<text top="557" left="174" width="582" height="13" font="23">Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus </text>
<text top="575" left="174" width="608" height="13" font="23">ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised </text>
<text top="593" left="174" width="308" height="13" font="23">placebo-controlled trial. Lancet. 2011;377:2181-92. </text>
<text top="611" left="105" width="41" height="13" font="23">S4.3-4.</text>
<text top="611" left="146" width="4" height="13" font="47"> </text>
<text top="611" left="174" width="600" height="13" font="23">Cholesterol Treatment Trialists’ (CTT) Collaboration, Herrington W, Emberson J, et al. Impact of renal </text>
<text top="629" left="174" width="582" height="13" font="23">function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of </text>
<text top="646" left="174" width="581" height="13" font="23">individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016;4:829-39. </text>
<text top="664" left="105" width="41" height="13" font="23">S4.3-5.</text>
<text top="664" left="146" width="4" height="13" font="47"> </text>
<text top="664" left="174" width="580" height="13" font="23">Chou R, Dana T, Blazina I, et al. Statin use for the prevention of cardiovascular disease in adults: a </text>
<text top="682" left="174" width="617" height="13" font="23">systematic review for the U.S. Preventive Services Task Force. Report No. 14-05206-EF-2. Rockville, MD: </text>
<text top="700" left="174" width="408" height="13" font="23">U.S. Agency for Healthcare Research and Quality; 2016. Available at: </text>
<text top="718" left="174" width="454" height="13" font="23">http://www.ncbi.nlm.nih.gov/books/NBK396415. Accessed January 5, 2019. </text>
<text top="735" left="105" width="41" height="13" font="23">S4.3-6.</text>
<text top="735" left="146" width="4" height="13" font="47"> </text>
<text top="735" left="174" width="596" height="13" font="23">Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in </text>
<text top="753" left="174" width="615" height="13" font="23">men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary </text>
<text top="771" left="174" width="360" height="13" font="23">Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22. </text>
<text top="789" left="105" width="41" height="13" font="23">S4.3-7.</text>
<text top="789" left="146" width="4" height="13" font="47"> </text>
<text top="789" left="174" width="617" height="13" font="23">Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women </text>
<text top="807" left="174" width="404" height="13" font="23">with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207. </text>
<text top="825" left="105" width="41" height="13" font="23">S4.3-8.</text>
<text top="825" left="146" width="4" height="13" font="47"> </text>
<text top="825" left="174" width="605" height="13" font="23">Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. </text>
<text top="842" left="174" width="276" height="13" font="23">Cochrane Database Syst Rev. 2013;CD004816. </text>
<text top="860" left="105" width="41" height="13" font="23">S4.3-9.</text>
<text top="860" left="146" width="4" height="13" font="47"> </text>
<text top="860" left="174" width="552" height="13" font="23">Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without </text>
<text top="878" left="174" width="339" height="13" font="23">cardiovascular disease. N Engl J Med. 2016;374:2021-31. </text>
<text top="896" left="105" width="48" height="13" font="23">S4.3-10.</text>
<text top="896" left="153" width="4" height="13" font="47"> </text>
<text top="896" left="174" width="588" height="13" font="23">Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk </text>
<text top="914" left="174" width="594" height="13" font="23">reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. </text>
<text top="932" left="174" width="115" height="13" font="23">2016;316:1289-97. </text>
<text top="949" left="105" width="48" height="13" font="23">S4.3-11.</text>
<text top="949" left="153" width="4" height="13" font="47"> </text>
<text top="949" left="174" width="592" height="13" font="23">Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with </text>
<text top="967" left="174" width="601" height="13" font="23">atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre </text>
<text top="985" left="174" width="374" height="13" font="23">randomised placebo-controlled trial. Lancet. 2004;364:685-96. </text>
<text top="1003" left="105" width="48" height="13" font="23">S4.3-12.</text>
<text top="1003" left="153" width="4" height="13" font="47"> </text>
<text top="1003" left="174" width="583" height="13" font="23">Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with </text>
<text top="1021" left="174" width="527" height="13" font="23">simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. </text>
<text top="1039" left="174" width="115" height="13" font="23">2003;361:2005-16. </text>
<text top="1056" left="105" width="48" height="13" font="23">S4.3-13.</text>
<text top="1056" left="153" width="4" height="13" font="47"> </text>
<text top="1056" left="174" width="524" height="13" font="23">de Vries FM, Denig P, Pouwels KB, et al. Primary prevention of major cardiovascular and </text>
<text top="1074" left="174" width="582" height="13" font="23">cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs. 2012;72:2365-73. </text>
</page>
<page number="93" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 91 of 101 </text>
<text top="167" left="105" width="48" height="13" font="23">S4.3-14.</text>
<text top="167" left="153" width="4" height="13" font="47"> </text>
<text top="167" left="174" width="563" height="13" font="23">Knopp RH, d’Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of </text>
<text top="185" left="174" width="590" height="13" font="23">cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of </text>
<text top="203" left="174" width="608" height="13" font="23">Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. </text>
<text top="221" left="174" width="108" height="13" font="23">2006;29:1478-85. </text>
<text top="238" left="105" width="48" height="13" font="23">S4.3-15.</text>
<text top="238" left="153" width="4" height="13" font="47"> </text>
<text top="238" left="174" width="608" height="13" font="23">Mulnier HE, Seaman HE, Raleigh VS, et al. Risk of myocardial infarction in men and women with type 2 </text>
<text top="256" left="174" width="565" height="13" font="23">diabetes in the UK: a cohort study using the General Practice Research Database. Diabetologia. </text>
<text top="274" left="174" width="108" height="13" font="23">2008;51:1639-45. </text>
<text top="292" left="105" width="48" height="13" font="23">S4.3-16.</text>
<text top="292" left="153" width="4" height="13" font="47"> </text>
<text top="292" left="174" width="584" height="13" font="23">Rana JS, Liu JY, Moffet HH, et al. Diabetes and prior coronary heart disease are not necessarily risk </text>
<text top="310" left="174" width="522" height="13" font="23">equivalent for future coronary heart disease events. J Gen Intern Med. 2016;31:387-93. </text>
<text top="328" left="105" width="48" height="13" font="23">S4.3-17.</text>
<text top="328" left="153" width="4" height="13" font="47"> </text>
<text top="328" left="174" width="584" height="13" font="23">Sever PS, Poulter NR, Dahlöf B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 </text>
<text top="345" left="174" width="610" height="13" font="23">patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial—lipid-lowering arm (ASCOT-</text>
<text top="363" left="174" width="222" height="13" font="23">LLA). Diabetes Care. 2005;28:1151-7. </text>
<text top="381" left="105" width="48" height="13" font="23">S4.3-18.</text>
<text top="381" left="153" width="4" height="13" font="47"> </text>
<text top="381" left="174" width="597" height="13" font="23">Soedamah-Muthu SS, Fuller JH, Mulnier HE, et al. High risk of cardiovascular disease in patients with </text>
<text top="399" left="174" width="614" height="13" font="23">type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care. </text>
<text top="417" left="174" width="108" height="13" font="23">2006;29:798-804. </text>
<text top="434" left="105" width="48" height="13" font="23">S4.3-19.</text>
<text top="434" left="153" width="4" height="13" font="47"> </text>
<text top="434" left="174" width="583" height="13" font="23">Wong ND, Glovaci D, Wong K, et al. Global cardiovascular disease risk assessment in United States </text>
<text top="452" left="174" width="330" height="13" font="23">adults with diabetes. Diab Vasc Dis Res. 2012;9:146-52. </text>
<text top="470" left="105" width="48" height="13" font="23">S4.3-20.</text>
<text top="470" left="153" width="4" height="13" font="47"> </text>
<text top="470" left="174" width="592" height="13" font="23">Besseling J, Hovingh GK, Huijgen R, et al. Statins in familial hypercholesterolemia: consequences for </text>
<text top="488" left="174" width="492" height="13" font="23">coronary artery disease and all-cause mortality. J Am Coll Cardiol. 2016;68:252-60. </text>
<text top="506" left="105" width="48" height="13" font="23">S4.3-21.</text>
<text top="506" left="153" width="4" height="13" font="47"> </text>
<text top="506" left="174" width="563" height="13" font="23">Khera AV, Won H-H, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial </text>
<text top="524" left="174" width="552" height="13" font="23">hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol. </text>
<text top="541" left="174" width="108" height="13" font="23">2016;67:2578-89. </text>
<text top="559" left="105" width="48" height="13" font="23">S4.3-22.</text>
<text top="559" left="153" width="4" height="13" font="47"> </text>
<text top="559" left="174" width="594" height="13" font="23">Nanchen D, Gencer B, Muller O, et al. Prognosis of patients with familial hypercholesterolemia after </text>
<text top="577" left="174" width="351" height="13" font="23">acute coronary syndromes. Circulation. 2016;134:698-709. </text>
<text top="595" left="105" width="48" height="13" font="23">S4.3-23.</text>
<text top="595" left="153" width="4" height="13" font="47"> </text>
<text top="595" left="174" width="602" height="13" font="23">Perak AM, Ning H, de Ferranti SD, et al. Long-term risk of atherosclerotic cardiovascular disease in US </text>
<text top="613" left="174" width="508" height="13" font="23">adults with the familial hypercholesterolemia phenotype. Circulation. 2016;134:9-19. </text>
<text top="631" left="105" width="48" height="13" font="23">S4.3-24.</text>
<text top="631" left="153" width="4" height="13" font="47"> </text>
<text top="631" left="174" width="610" height="13" font="23">Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with </text>
<text top="648" left="174" width="531" height="13" font="23">hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. </text>
<text top="666" left="174" width="108" height="13" font="23">1995;333:1301-7. </text>
<text top="684" left="105" width="48" height="13" font="23">S4.3-25.</text>
<text top="684" left="153" width="4" height="13" font="47"> </text>
<text top="684" left="174" width="483" height="13" font="23">Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial </text>
<text top="702" left="174" width="432" height="13" font="23">hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423. </text>
<text top="720" left="105" width="48" height="13" font="23">S4.3-26.</text>
<text top="720" left="153" width="4" height="13" font="47"> </text>
<text top="720" left="174" width="569" height="13" font="23">Mortensen MB, Fuster V, Muntendam P, et al. A simple disease-guided approach to personalize </text>
<text top="737" left="174" width="583" height="13" font="23">ACC/AHA-recommended statin allocation in elderly people: the BioImage Study. J Am Coll Cardiol. </text>
<text top="755" left="174" width="101" height="13" font="23">2016;68:881-91. </text>
<text top="773" left="105" width="48" height="13" font="23">S4.3-27.</text>
<text top="773" left="153" width="4" height="13" font="47"> </text>
<text top="773" left="174" width="616" height="13" font="23">Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with </text>
<text top="791" left="174" width="608" height="13" font="23">lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014;64:851-60. </text>
<text top="809" left="105" width="48" height="13" font="23">S4.3-28.</text>
<text top="809" left="153" width="4" height="13" font="47"> </text>
<text top="809" left="174" width="599" height="13" font="23">Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coronary artery calcium testing among statin </text>
<text top="827" left="174" width="573" height="13" font="23">candidates according to American College of Cardiology/American Heart Association cholesterol </text>
<text top="844" left="174" width="529" height="13" font="23">management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. </text>
<text top="862" left="174" width="108" height="13" font="23">2015;66:1657-68. </text>
<text top="880" left="105" width="48" height="13" font="23">S4.3-29.</text>
<text top="880" left="153" width="4" height="13" font="47"> </text>
<text top="880" left="174" width="593" height="13" font="23">Ridker PM, Mora S, Rose L, et al. Percent reduction in LDL cholesterol following high-intensity statin </text>
<text top="898" left="174" width="574" height="13" font="23">therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering </text>
<text top="916" left="174" width="219" height="13" font="23">agents. Eur Heart J. 2016;37:1373-9. </text>
<text top="933" left="105" width="48" height="13" font="23">S4.3-30.</text>
<text top="933" left="153" width="4" height="13" font="47"> </text>
<text top="933" left="174" width="548" height="13" font="23">Yano Y, O’Donnell CJ, Kuller L, et al. Association of coronary artery calcium score vs age with </text>
<text top="951" left="174" width="576" height="13" font="23">cardiovascular risk in older adults: an analysis of pooled population-based studies. JAMA Cardiol. </text>
<text top="969" left="174" width="93" height="13" font="23">2017;2:986-94. </text>
<text top="987" left="105" width="48" height="13" font="23">S4.3-31.</text>
<text top="987" left="153" width="4" height="13" font="47"> </text>
<text top="987" left="174" width="573" height="13" font="23">Malik S, Zhao Y, Budoff M, et al. Coronary artery calcium score for long-term risk classification in </text>
<text top="1005" left="174" width="525" height="13" font="23">individuals with type 2 diabetes and metabolic syndrome from the Multi-Ethnic Study of </text>
<text top="1023" left="174" width="285" height="13" font="23">Atherosclerosis. JAMA Cardiol. 2017;2:1332-40. </text>
<text top="1040" left="105" width="48" height="13" font="23">S4.3-32.</text>
<text top="1040" left="153" width="4" height="13" font="47"> </text>
<text top="1040" left="174" width="585" height="13" font="23">Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterolemia phenotype: clinical diagnosis, </text>
<text top="1058" left="174" width="448" height="13" font="23">management, and emerging therapies. J Am Coll Cardiol. 2014;63:1935-47. </text>
<text top="1076" left="105" width="48" height="13" font="23">S4.3-33.</text>
<text top="1076" left="153" width="4" height="13" font="47"> </text>
<text top="1076" left="174" width="589" height="13" font="23">Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, </text>
</page>
<page number="94" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 92 of 101 </text>
<text top="167" left="174" width="600" height="13" font="23">non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ </text>
<text top="185" left="174" width="259" height="13" font="23">Cardiovasc Qual Outcomes. 2011;4:337-45. </text>
<text top="203" left="105" width="48" height="13" font="23">S4.3-34.</text>
<text top="203" left="153" width="4" height="13" font="47"> </text>
<text top="203" left="174" width="617" height="13" font="23">Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic </text>
<text top="221" left="174" width="600" height="13" font="23">cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). Eur Heart J. </text>
<text top="238" left="174" width="101" height="13" font="23">2018;39:2401-8. </text>
<text top="256" left="105" width="48" height="13" font="23">S4.3-35.</text>
<text top="256" left="153" width="4" height="13" font="47"> </text>
<text top="256" left="174" width="583" height="13" font="23">Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of </text>
<text top="274" left="174" width="607" height="13" font="23">lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of </text>
<text top="292" left="174" width="406" height="13" font="23">individual data from 27 randomised trials. Lancet. 2012;380:581-90. </text>
<text top="310" left="105" width="48" height="13" font="23">S4.3-36.</text>
<text top="310" left="153" width="4" height="13" font="47"> </text>
<text top="310" left="174" width="614" height="13" font="23">Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin </text>
<text top="328" left="174" width="555" height="13" font="23">in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155-63. </text>
<text top="345" left="105" width="48" height="13" font="23">S4.3-37.</text>
<text top="345" left="153" width="4" height="13" font="47"> </text>
<text top="345" left="174" width="600" height="13" font="23">Vallejo-Vaz AJ, Robertson M, Catapano AL, et al. Low-density lipoprotein cholesterol lowering for the </text>
<text top="363" left="174" width="575" height="13" font="23">primary prevention of cardiovascular disease among men with primary elevations of low-density </text>
<text top="381" left="174" width="599" height="13" font="23">lipoprotein cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland </text>
<text top="399" left="174" width="603" height="13" font="23">Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. Circulation. </text>
<text top="417" left="174" width="115" height="13" font="23">2017;136:1878-91. </text>
<text top="434" left="105" width="48" height="13" font="23">S4.3-38.</text>
<text top="434" left="153" width="4" height="13" font="47"> </text>
<text top="434" left="174" width="594" height="13" font="23">Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women </text>
<text top="452" left="174" width="601" height="13" font="23">with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the </text>
<text top="470" left="174" width="611" height="13" font="23">Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis </text>
<text top="488" left="174" width="437" height="13" font="23">of women from primary prevention trials. Circulation. 2010;121:1069-77. </text>
<text top="506" left="105" width="48" height="13" font="23">S4.3-39.</text>
<text top="506" left="153" width="4" height="13" font="47"> </text>
<text top="506" left="174" width="604" height="13" font="23">Samarasekera EJ, Neilson JM, Warren RB, et al. Incidence of cardiovascular disease in individuals with </text>
<text top="524" left="174" width="511" height="13" font="23">psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133:2340-6. </text>
<text top="541" left="105" width="48" height="13" font="23">S4.3-40.</text>
<text top="541" left="153" width="4" height="13" font="47"> </text>
<text top="541" left="174" width="599" height="13" font="23">Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refining myocardial infarction risk estimation </text>
<text top="559" left="174" width="564" height="13" font="23">among patients with human immunodeficiency virus: a study by the Centers for AIDS Research </text>
<text top="577" left="174" width="416" height="13" font="23">Network of Integrated Clinical Systems. JAMA Cardiol. 2017;2:155-62. </text>
<text top="595" left="105" width="48" height="13" font="23">S4.3-41.</text>
<text top="595" left="153" width="4" height="13" font="47"> </text>
<text top="595" left="174" width="611" height="13" font="23">DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple </text>
<text top="613" left="174" width="556" height="13" font="23">cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162:266-75. </text>
<text top="631" left="105" width="48" height="13" font="23">S4.3-42.</text>
<text top="631" left="153" width="4" height="13" font="47"> </text>
<text top="631" left="174" width="615" height="13" font="23">Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 to 46 years </text>
<text top="648" left="174" width="459" height="13" font="23">with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391-9. </text>
<text top="666" left="105" width="48" height="13" font="23">S4.3-43.</text>
<text top="666" left="153" width="4" height="13" font="47"> </text>
<text top="666" left="174" width="568" height="13" font="23">Fudim M, Zalawadiya S, Patel DK, et al. Data on coronary artery calcium score performance and </text>
<text top="684" left="174" width="544" height="13" font="23">cardiovascular risk reclassification across gender and ethnicities. Data Brief. 2016;6:578-81. </text>
<text top="702" left="105" width="48" height="13" font="23">S4.3-44.</text>
<text top="702" left="153" width="4" height="13" font="47"> </text>
<text top="702" left="174" width="582" height="13" font="23">Gupta A, Lau E, Varshney R, et al. The identification of calcified coronary plaque is associated with </text>
<text top="720" left="174" width="603" height="13" font="23">initiation and continuation of pharmacological and lifestyle preventive therapies: a systematic review </text>
<text top="737" left="174" width="368" height="13" font="23">and meta-analysis. JACC Cardiovasc Imaging. 2017;10:833-42. </text>
<text top="755" left="105" width="48" height="13" font="23">S4.3-45.</text>
<text top="755" left="153" width="4" height="13" font="47"> </text>
<text top="755" left="174" width="602" height="13" font="23">Han D, Ó Hartaigh B, Lee JH, et al. Assessment of coronary artery calcium scoring for statin treatment </text>
<text top="773" left="174" width="612" height="13" font="23">strategy according to ACC/AHA guidelines in asymptomatic Korean adults. Yonsei Med J. 2017;58:82-9. </text>
<text top="791" left="105" width="48" height="13" font="23">S4.3-46.</text>
<text top="791" left="153" width="4" height="13" font="47"> </text>
<text top="791" left="174" width="583" height="13" font="23">Hong JC, Blankstein R, Shaw LJ, et al. Implications of coronary artery calcium testing for treatment </text>
<text top="809" left="174" width="595" height="13" font="23">decisions among statin candidates according to the ACC/AHA cholesterol management guidelines: a </text>
<text top="827" left="174" width="418" height="13" font="23">cost-effectiveness analysis. JACC Cardiovasc Imaging. 2017;10:938-52. </text>
<text top="844" left="105" width="48" height="13" font="23">S4.3-47.</text>
<text top="844" left="153" width="4" height="13" font="47"> </text>
<text top="844" left="174" width="556" height="13" font="23">Kavousi M, Desai CS, Ayers C, et al. Prevalence and prognostic implications of coronary artery </text>
<text top="862" left="174" width="446" height="13" font="23">calcification in low-risk women: a meta-analysis. JAMA. 2016;316:2126-34. </text>
<text top="880" left="105" width="48" height="13" font="23">S4.3-48.</text>
<text top="880" left="153" width="4" height="13" font="47"> </text>
<text top="880" left="174" width="609" height="13" font="23">Mahabadi AA, Möhlenkamp S, Lehmann N, et al. CAC score improves coronary and CV risk assessment </text>
<text top="898" left="174" width="604" height="13" font="23">above statin indication by ESC and AHA/ACC primary prevention guidelines. JACC Cardiovasc Imaging. </text>
<text top="916" left="174" width="101" height="13" font="23">2017;10:143-53. </text>
<text top="933" left="105" width="48" height="13" font="23">S4.3-49.</text>
<text top="933" left="153" width="4" height="13" font="47"> </text>
<text top="933" left="174" width="589" height="13" font="23">McClelland RL, Jorgensen NW, Budoff M, et al. 10-year coronary heart disease risk prediction using </text>
<text top="951" left="174" width="580" height="13" font="23">coronary artery calcium and traditional risk factors: derivation in the MESA (Multi-Ethnic Study of </text>
<text top="969" left="174" width="581" height="13" font="23">Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) study and the DHS (Dallas Heart </text>
<text top="987" left="174" width="259" height="13" font="23">Study). J Am Coll Cardiol. 2015;66:1643-53. </text>
<text top="1005" left="105" width="48" height="13" font="23">S4.3-50.</text>
<text top="1005" left="153" width="4" height="13" font="47"> </text>
<text top="1005" left="174" width="580" height="13" font="23">Pursnani A, Massaro JM, D’Agostino RB Sr, et al. Guideline-based statin eligibility, coronary artery </text>
<text top="1023" left="174" width="387" height="13" font="23">calcification, and cardiovascular events. JAMA. 2015;314:134-41. </text>
<text top="1040" left="105" width="48" height="13" font="23">S4.3-51.</text>
<text top="1040" left="153" width="4" height="13" font="47"> </text>
<text top="1040" left="174" width="576" height="13" font="23">Qureshi WT, Rana JS, Yeboah J, et al. Risk stratification for primary prevention of coronary artery </text>
<text top="1058" left="174" width="568" height="13" font="23">disease: roles of C-reactive protein and coronary artery calcium. Curr Cardiol Rep. 2015;17:110. </text>
<text top="1076" left="105" width="48" height="13" font="23">S4.3-52.</text>
<text top="1076" left="153" width="4" height="13" font="47"> </text>
<text top="1076" left="174" width="615" height="13" font="23">Shah RV, Spahillari A, Mwasongwe S, et al. Subclinical atherosclerosis, statin eligibility, and outcomes in </text>
</page>
<page number="95" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 93 of 101 </text>
<text top="167" left="174" width="505" height="13" font="23">African American individuals: the Jackson Heart Study. JAMA Cardiol. 2017;2:644-52. </text>
<text top="185" left="105" width="48" height="13" font="23">S4.3-53.</text>
<text top="185" left="153" width="4" height="13" font="47"> </text>
<text top="185" left="174" width="593" height="13" font="23">Waheed S, Pollack S, Roth M, et al. Collective impact of conventional cardiovascular risk factors and </text>
<text top="203" left="174" width="613" height="13" font="23">coronary calcium score on clinical outcomes with or without statin therapy: The St Francis Heart Study. </text>
<text top="221" left="174" width="199" height="13" font="23">Atherosclerosis. 2016;255:193-9. </text>
<text top="238" left="105" width="48" height="13" font="23">S4.3-54.</text>
<text top="238" left="153" width="4" height="13" font="47"> </text>
<text top="238" left="174" width="601" height="13" font="23">Yeboah J, Polonsky TS, Young R, et al. Utility of nontraditional risk markers in individuals ineligible for </text>
<text top="256" left="174" width="578" height="13" font="23">statin therapy according to the 2013 American College of Cardiology/American Heart Association </text>
<text top="274" left="174" width="316" height="13" font="23">cholesterol guidelines. Circulation. 2015;132:916-22. </text>
<text top="292" left="105" width="48" height="13" font="23">S4.3-55.</text>
<text top="292" left="153" width="4" height="13" font="47"> </text>
<text top="292" left="174" width="563" height="13" font="23">Yeboah J, Young R, McClelland RL, et al. Utility of nontraditional risk markers in atherosclerotic </text>
<text top="310" left="174" width="442" height="13" font="23">cardiovascular disease risk assessment. J Am Coll Cardiol. 2016;67:139-47. </text>
<text top="328" left="105" width="48" height="13" font="23">S4.3-56.</text>
<text top="328" left="153" width="4" height="13" font="47"> </text>
<text top="328" left="174" width="432" height="13" font="23">Krumholz HM. Treatment of cholesterol in 2017. JAMA. 2017;318:417-8. </text>
<text top="345" left="105" width="48" height="13" font="23">S4.3-57.</text>
<text top="345" left="153" width="4" height="13" font="47"> </text>
<text top="345" left="174" width="530" height="13" font="23">Martin SS, Sperling LS, Blaha MJ, et al. Clinician-patient risk discussion for atherosclerotic </text>
<text top="363" left="174" width="600" height="13" font="23">cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA guidelines. J </text>
<text top="381" left="174" width="198" height="13" font="23">Am Coll Cardiol. 2015;65:1361-8. </text>
<text top="399" left="105" width="48" height="13" font="23">S4.3-58.</text>
<text top="399" left="153" width="4" height="13" font="47"> </text>
<text top="399" left="174" width="587" height="13" font="23">Cohen R, Budoff M, McClelland RL, et al. Significance of a positive family history for coronary heart </text>
<text top="417" left="174" width="550" height="13" font="23">disease in patients with a zero coronary artery calcium score (from the Multi-Ethnic Study of </text>
<text top="434" left="174" width="291" height="13" font="23">Atherosclerosis). Am J Cardiol. 2014;114:1210-4. </text>
<text top="452" left="105" width="48" height="13" font="23">S4.3-59.</text>
<text top="452" left="153" width="4" height="13" font="47"> </text>
<text top="452" left="174" width="610" height="13" font="23">Pandya A, Sy S, Cho S, et al. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy </text>
<text top="470" left="174" width="443" height="13" font="23">for primary prevention of cardiovascular disease. JAMA. 2015;314:142-50. </text>
<text top="488" left="105" width="48" height="13" font="23">S4.3-60.</text>
<text top="488" left="153" width="4" height="13" font="47"> </text>
<text top="488" left="174" width="604" height="13" font="23">Singh A, Collins BL, Gupta A, et al. Cardiovascular risk and statin eligibility of young adults after an MI: </text>
<text top="506" left="174" width="391" height="13" font="23">Partners YOUNG-MI Registry. J Am Coll Cardiol. 2018;71:292-302. </text>
<text top="524" left="105" width="48" height="13" font="23">S4.3-61.</text>
<text top="524" left="153" width="4" height="13" font="47"> </text>
<text top="524" left="174" width="617" height="13" font="23">Huo X, Gao L, Guo L, et al. Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type </text>
<text top="541" left="174" width="523" height="13" font="23">2 diabetes in China: a cross-sectional study. Lancet Diabetes Endocrinol. 2016;4:115-24. </text>
<text top="559" left="105" width="48" height="13" font="23">S4.3-62.</text>
<text top="559" left="153" width="4" height="13" font="47"> </text>
<text top="559" left="174" width="548" height="13" font="23">Svensson MK, Cederholm J, Eliasson B, et al. Albuminuria and renal function as predictors of </text>
<text top="577" left="174" width="561" height="13" font="23">cardiovascular events and mortality in a general population of patients with type 2 diabetes: a </text>
<text top="595" left="174" width="572" height="13" font="23">nationwide observational study from the Swedish National Diabetes Register. Diab Vasc Dis Res. </text>
<text top="613" left="174" width="93" height="13" font="23">2013;10:520-9. </text>
<text top="631" left="105" width="48" height="13" font="23">S4.3-63.</text>
<text top="631" left="153" width="4" height="13" font="47"> </text>
<text top="631" left="174" width="599" height="13" font="23">Guo VY, Cao B, Wu X, et al. Prospective association between diabetic retinopathy and cardiovascular </text>
<text top="648" left="174" width="546" height="13" font="23">disease—a systematic review and meta-analysis of cohort studies. J Stroke Cerebrovasc Dis. </text>
<text top="666" left="174" width="108" height="13" font="23">2016;25:1688-95. </text>
<text top="684" left="105" width="48" height="13" font="23">S4.3-64.</text>
<text top="684" left="153" width="4" height="13" font="47"> </text>
<text top="684" left="174" width="612" height="13" font="23">Brownrigg JRW, de Lusignan S, McGovern A, et al. Peripheral neuropathy and the risk of cardiovascular </text>
<text top="702" left="174" width="361" height="13" font="23">events in type 2 diabetes mellitus. Heart. 2014;100:1837-43. </text>
<text top="720" left="105" width="48" height="13" font="23">S4.3-65.</text>
<text top="720" left="153" width="4" height="13" font="47"> </text>
<text top="720" left="174" width="572" height="13" font="23">Ogren M, Hedblad B, Engström G, et al. Prevalence and prognostic significance of asymptomatic </text>
<text top="737" left="174" width="603" height="13" font="23">peripheral arterial disease in 68-year-old men with diabetes. Results from the population study “Men </text>
<text top="755" left="174" width="467" height="13" font="23">born in 1914” from Malmö, Sweden. Eur J Vasc Endovasc Surg. 2005;29:182-9. </text>
<text top="773" left="105" width="48" height="13" font="23">S4.3-66.</text>
<text top="773" left="153" width="4" height="13" font="47"> </text>
<text top="773" left="174" width="607" height="13" font="23">Pang X-H, Han J, Ye W-L, et al. Lower extremity peripheral arterial disease is an independent predictor </text>
<text top="791" left="174" width="573" height="13" font="23">of coronary heart disease and stroke risks in patients with type 2 diabetes mellitus in China. Int J </text>
<text top="809" left="174" width="196" height="13" font="23">Endocrinol. 2017;2017:9620513. </text>
<text top="837" left="105" width="354" height="19" font="15"><b>4.4. High Blood Pressure or Hypertension </b></text>
<text top="860" left="105" width="41" height="13" font="23">S4.4-1.</text>
<text top="860" left="146" width="4" height="13" font="47"> </text>
<text top="860" left="174" width="284" height="13" font="23">Whelton PK, Carey RM, Aronow WS, et al. 2017 </text>
<text top="878" left="174" width="615" height="13" font="23">ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, </text>
<text top="896" left="174" width="583" height="13" font="23">evaluation, and management of high blood pressure in adults: a report of the American College of </text>
<text top="914" left="174" width="592" height="13" font="23">Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. </text>
<text top="932" left="174" width="115" height="13" font="23">2018;71:e127-248. </text>
<text top="949" left="105" width="41" height="13" font="23">S4.4-2.</text>
<text top="949" left="146" width="4" height="13" font="47"> </text>
<text top="949" left="174" width="592" height="13" font="23">Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of </text>
<text top="967" left="174" width="362" height="13" font="23">randomized controlled trials. Hypertension. 2003;42:878-84. </text>
<text top="985" left="105" width="41" height="13" font="23">S4.4-3.</text>
<text top="985" left="146" width="4" height="13" font="47"> </text>
<text top="985" left="174" width="602" height="13" font="23">The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. </text>
<text top="1003" left="174" width="496" height="13" font="23">Results of the Trials of Hypertension Prevention, Phase I. JAMA. 1992;267:1213-20. </text>
<text top="1021" left="105" width="41" height="13" font="23">S4.4-4.</text>
<text top="1021" left="146" width="4" height="13" font="47"> </text>
<text top="1021" left="174" width="601" height="13" font="23">Whelton PK, Kumanyika SK, Cook NR, et al. Efficacy of nonpharmacologic interventions in adults with </text>
<text top="1039" left="174" width="591" height="13" font="23">high-normal blood pressure: results from phase 1 of the Trials of Hypertension Prevention. Trials of </text>
<text top="1056" left="174" width="548" height="13" font="23">Hypertension Prevention Collaborative Research Group. Am J Clin Nutr. 1997;65:652S-660S. </text>
<text top="1074" left="105" width="41" height="13" font="23">S4.4-5.</text>
<text top="1074" left="146" width="4" height="13" font="47"> </text>
<text top="1074" left="174" width="617" height="13" font="23">Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence </text>
</page>
<page number="96" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 94 of 101 </text>
<text top="167" left="174" width="614" height="13" font="23">in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. </text>
<text top="185" left="174" width="602" height="13" font="23">The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med. 1997;157:657-</text>
<text top="203" left="174" width="22" height="13" font="23">67. </text>
<text top="221" left="105" width="41" height="13" font="23">S4.4-6.</text>
<text top="220" left="146" width="4" height="13" font="47"> </text>
<text top="221" left="174" width="609" height="13" font="23">Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the </text>
<text top="238" left="174" width="607" height="13" font="23">Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N </text>
<text top="256" left="174" width="164" height="13" font="23">Engl J Med. 2001;344:3-10. </text>
<text top="274" left="105" width="41" height="13" font="23">S4.4-7.</text>
<text top="274" left="146" width="4" height="13" font="47"> </text>
<text top="274" left="174" width="566" height="13" font="23">Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood </text>
<text top="292" left="174" width="477" height="13" font="23">pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:1117-24. </text>
<text top="310" left="105" width="41" height="13" font="23">S4.4-8.</text>
<text top="310" left="146" width="4" height="13" font="47"> </text>
<text top="310" left="174" width="600" height="13" font="23">Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood </text>
<text top="328" left="174" width="507" height="13" font="23">pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083-93. </text>
<text top="345" left="105" width="41" height="13" font="23">S4.4-9.</text>
<text top="345" left="146" width="4" height="13" font="47"> </text>
<text top="345" left="174" width="599" height="13" font="23">Mozaffarian D, Fahimi S, Singh GM, et al. Global sodium consumption and death from cardiovascular </text>
<text top="363" left="174" width="238" height="13" font="23">causes. N Engl J Med. 2014;371:624-34. </text>
<text top="381" left="105" width="48" height="13" font="23">S4.4-10.</text>
<text top="381" left="153" width="4" height="13" font="47"> </text>
<text top="381" left="174" width="589" height="13" font="23">He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane </text>
<text top="399" left="174" width="479" height="13" font="23">systematic review and meta-analysis of randomised trials. BMJ. 2013;346:f1325. </text>
<text top="417" left="105" width="48" height="13" font="23">S4.4-11.</text>
<text top="417" left="153" width="4" height="13" font="47"> </text>
<text top="417" left="174" width="570" height="13" font="23">Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of </text>
<text top="434" left="174" width="609" height="13" font="23">hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the </text>
<text top="452" left="174" width="463" height="13" font="23">elderly (TONE). TONE Collaborative Research Group. JAMA. 1998;279:839-46. </text>
<text top="470" left="105" width="48" height="13" font="23">S4.4-12.</text>
<text top="470" left="153" width="4" height="13" font="47"> </text>
<text top="470" left="174" width="616" height="13" font="23">Aburto NJ, Ziolkovska A, Hooper L, et al. Effect of lower sodium intake on health: systematic review and </text>
<text top="488" left="174" width="225" height="13" font="23">meta-analyses. BMJ. 2013;346:f1326. </text>
<text top="506" left="105" width="48" height="13" font="23">S4.4-13.</text>
<text top="506" left="153" width="4" height="13" font="47"> </text>
<text top="506" left="174" width="590" height="13" font="23">Graudal NA, Hubeck-Graudal T, Jürgens G. Effects of low-sodium diet vs. high-sodium diet on blood </text>
<text top="524" left="174" width="593" height="13" font="23">pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am J </text>
<text top="541" left="174" width="154" height="13" font="23">Hypertens. 2012;25:1-15. </text>
<text top="559" left="105" width="48" height="13" font="23">S4.4-14.</text>
<text top="559" left="153" width="4" height="13" font="47"> </text>
<text top="559" left="174" width="566" height="13" font="23">Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure. Meta-analysis of </text>
<text top="577" left="174" width="375" height="13" font="23">randomized controlled clinical trials. JAMA. 1997;277:1624-32. </text>
<text top="595" left="105" width="48" height="13" font="23">S4.4-15.</text>
<text top="595" left="153" width="4" height="13" font="47"> </text>
<text top="595" left="174" width="585" height="13" font="23">Aburto NJ, Hanson S, Gutierrez H, et al. Effect of increased potassium intake on cardiovascular risk </text>
<text top="613" left="174" width="482" height="13" font="23">factors and disease: systematic review and meta-analyses. BMJ. 2013;346:f1378. </text>
<text top="631" left="105" width="48" height="13" font="23">S4.4-16.</text>
<text top="631" left="153" width="4" height="13" font="47"> </text>
<text top="631" left="174" width="617" height="13" font="23">Geleijnse JM, Kok FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: </text>
<text top="648" left="174" width="490" height="13" font="23">a metaregression analysis of randomised trials. J Hum Hypertens. 2003;17:471-80. </text>
<text top="666" left="105" width="48" height="13" font="23">S4.4-17.</text>
<text top="666" left="153" width="4" height="13" font="47"> </text>
<text top="666" left="174" width="599" height="13" font="23">World Health Association. Guideline: Potassium Intake for Adults and Children. Geneva, Switzerland: </text>
<text top="684" left="174" width="527" height="13" font="23">World Health Organization, Department of Nutrition for Health and Development; 2012. </text>
<text top="702" left="105" width="48" height="13" font="23">S4.4-18.</text>
<text top="702" left="153" width="4" height="13" font="47"> </text>
<text top="702" left="174" width="608" height="13" font="23">Whelton PK, He J. Health effects of sodium and potassium in humans. Curr Opin Lipidol. 2014;25:75-9. </text>
<text top="720" left="105" width="48" height="13" font="23">S4.4-19.</text>
<text top="720" left="153" width="4" height="13" font="47"> </text>
<text top="720" left="174" width="611" height="13" font="23">Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. </text>
<text top="737" left="174" width="212" height="13" font="23">J Am Heart Assoc. 2013;2:e004473. </text>
<text top="755" left="105" width="48" height="13" font="23">S4.4-20.</text>
<text top="755" left="153" width="4" height="13" font="47"> </text>
<text top="755" left="174" width="568" height="13" font="23">Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a meta-analysis of </text>
<text top="773" left="174" width="395" height="13" font="23">randomized, controlled trials. Ann Intern Med. 2002;136:493-503. </text>
<text top="791" left="105" width="48" height="13" font="23">S4.4-21.</text>
<text top="791" left="153" width="4" height="13" font="47"> </text>
<text top="791" left="174" width="591" height="13" font="23">Carlson DJ, Dieberg G, Hess NC, et al. Isometric exercise training for blood pressure management: a </text>
<text top="809" left="174" width="421" height="13" font="23">systematic review and meta-analysis. Mayo Clin Proc. 2014;89:327-34. </text>
<text top="827" left="105" width="48" height="13" font="23">S4.4-22.</text>
<text top="827" left="153" width="4" height="13" font="47"> </text>
<text top="827" left="174" width="589" height="13" font="23">García-Hermoso A, Saavedra JM, Escalante Y. Effects of exercise on resting blood pressure in obese </text>
<text top="844" left="174" width="504" height="13" font="23">children: a meta-analysis of randomized controlled trials. Obes Rev. 2013;14:919-28. </text>
<text top="862" left="105" width="48" height="13" font="23">S4.4-23.</text>
<text top="862" left="153" width="4" height="13" font="47"> </text>
<text top="862" left="174" width="593" height="13" font="23">Rossi AM, Moullec G, Lavoie KL, et al. The evolution of a Canadian Hypertension Education Program </text>
<text top="880" left="174" width="605" height="13" font="23">recommendation: the impact of resistance training on resting blood pressure in adults as an example. </text>
<text top="898" left="174" width="176" height="13" font="23">Can J Cardiol. 2013;29:622-7. </text>
<text top="916" left="105" width="48" height="13" font="23">S4.4-24.</text>
<text top="916" left="153" width="4" height="13" font="47"> </text>
<text top="916" left="174" width="606" height="13" font="23">Roerecke M, Kaczorowski J, Tobe SW, et al. The effect of a reduction in alcohol consumption on blood </text>
<text top="933" left="174" width="521" height="13" font="23">pressure: a systematic review and meta-analysis. Lancet Public Health. 2017;2:e108-20. </text>
<text top="951" left="105" width="48" height="13" font="23">S4.4-25.</text>
<text top="951" left="153" width="4" height="13" font="47"> </text>
<text top="951" left="174" width="570" height="13" font="23">Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure: a meta-analysis of </text>
<text top="969" left="174" width="362" height="13" font="23">randomized controlled trials. Hypertension. 2001;38:1112-7. </text>
<text top="987" left="105" width="48" height="13" font="23">S4.4-26.</text>
<text top="987" left="153" width="4" height="13" font="47"> </text>
<text top="987" left="174" width="566" height="13" font="23">Stewart SH, Latham PK, Miller PM, et al. Blood pressure reduction during treatment for alcohol </text>
<text top="1005" left="174" width="586" height="13" font="23">dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism </text>
<text top="1023" left="174" width="282" height="13" font="23">(COMBINE) study. Addiction. 2008;103:1622-8. </text>
<text top="1040" left="105" width="48" height="13" font="23">S4.4-27.</text>
<text top="1040" left="153" width="4" height="13" font="47"> </text>
<text top="1040" left="174" width="603" height="13" font="23">Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a </text>
<text top="1058" left="174" width="477" height="13" font="23">systematic review of randomized controlled trials. J Hypertens. 2006;24:215-33. </text>
<text top="1076" left="105" width="48" height="13" font="23">S4.4-28.</text>
<text top="1076" left="153" width="4" height="13" font="47"> </text>
<text top="1076" left="174" width="573" height="13" font="23">Wallace P, Cutler S, Haines A. Randomised controlled trial of general practitioner intervention in </text>
</page>
<page number="97" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 95 of 101 </text>
<text top="167" left="174" width="404" height="13" font="23">patients with excessive alcohol consumption. BMJ. 1988;297:663-8. </text>
<text top="185" left="105" width="48" height="13" font="23">S4.4-29.</text>
<text top="185" left="153" width="4" height="13" font="47"> </text>
<text top="185" left="174" width="598" height="13" font="23">Lang T, Nicaud V, Darné B, et al. Improving hypertension control among excessive alcohol drinkers: a </text>
<text top="203" left="174" width="610" height="13" font="23">randomised controlled trial in France. The WALPA Group. J Epidemiol Community Health. 1995;49:610-</text>
<text top="221" left="174" width="14" height="13" font="23">6. </text>
<text top="238" left="105" width="48" height="13" font="23">S4.4-30.</text>
<text top="238" left="153" width="4" height="13" font="47"> </text>
<text top="238" left="174" width="606" height="13" font="23">Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular </text>
<text top="256" left="174" width="569" height="13" font="23">disease: meta-analysis of 147 randomised trials in the context of expectations from prospective </text>
<text top="274" left="174" width="282" height="13" font="23">epidemiological studies. BMJ. 2009;338:b1665. </text>
<text top="292" left="105" width="48" height="13" font="23">S4.4-31.</text>
<text top="292" left="153" width="4" height="13" font="47"> </text>
<text top="292" left="174" width="600" height="13" font="23">Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease </text>
<text top="310" left="174" width="456" height="13" font="23">and death: a systematic review and meta-analysis. Lancet. 2016;387:957-67. </text>
<text top="328" left="105" width="48" height="13" font="23">S4.4-32.</text>
<text top="328" left="153" width="4" height="13" font="47"> </text>
<text top="328" left="174" width="582" height="13" font="23">Sundström J, Arima H, Jackson R, et al. Effects of blood pressure reduction in mild hypertension: a </text>
<text top="345" left="174" width="433" height="13" font="23">systematic review and meta-analysis. Ann Intern Med. 2015;162:184-91. </text>
<text top="363" left="105" width="48" height="13" font="23">S4.4-33.</text>
<text top="363" left="153" width="4" height="13" font="47"> </text>
<text top="363" left="174" width="580" height="13" font="23">Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal </text>
<text top="381" left="174" width="497" height="13" font="23">outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435-43. </text>
<text top="399" left="105" width="48" height="13" font="23">S4.4-34.</text>
<text top="399" left="153" width="4" height="13" font="47"> </text>
<text top="399" left="174" width="573" height="13" font="23">SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus </text>
<text top="417" left="174" width="398" height="13" font="23">standard blood-pressure control. N Engl J Med. 2015;373:2103-16. </text>
<text top="434" left="105" width="48" height="13" font="23">S4.4-35.</text>
<text top="434" left="153" width="4" height="13" font="47"> </text>
<text top="434" left="174" width="594" height="13" font="23">Czernichow S, Zanchetti A, Turnbull F, et al. The effects of blood pressure reduction and of different </text>
<text top="452" left="174" width="562" height="13" font="23">blood pressure-lowering regimens on major cardiovascular events according to baseline blood </text>
<text top="470" left="174" width="432" height="13" font="23">pressure: meta-analysis of randomized trials. J Hypertens. 2011;29:4-16. </text>
<text top="488" left="105" width="48" height="13" font="23">S4.4-36.</text>
<text top="488" left="153" width="4" height="13" font="47"> </text>
<text top="488" left="174" width="607" height="13" font="23">Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment based </text>
<text top="506" left="174" width="533" height="13" font="23">on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384:591-8. </text>
<text top="524" left="105" width="48" height="13" font="23">S4.4-37.</text>
<text top="524" left="153" width="4" height="13" font="47"> </text>
<text top="524" left="174" width="584" height="13" font="23">Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in </text>
<text top="541" left="174" width="606" height="13" font="23">hypertension: 2. Effects at different baseline and achieved blood pressure levels—overview and meta-</text>
<text top="559" left="174" width="371" height="13" font="23">analyses of randomized trials. J Hypertens. 2014;32:2296-304. </text>
<text top="577" left="105" width="48" height="13" font="23">S4.4-38.</text>
<text top="577" left="153" width="4" height="13" font="47"> </text>
<text top="577" left="174" width="606" height="13" font="23">Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of </text>
<text top="595" left="174" width="549" height="13" font="23">cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA. </text>
<text top="613" left="174" width="108" height="13" font="23">2011;305:913-22. </text>
<text top="631" left="105" width="48" height="13" font="23">S4.4-39.</text>
<text top="631" left="153" width="4" height="13" font="47"> </text>
<text top="631" left="174" width="584" height="13" font="23">Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in </text>
<text top="648" left="174" width="618" height="13" font="23">hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood </text>
<text top="666" left="174" width="608" height="13" font="23">pressure levels—updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34:613-</text>
<text top="684" left="174" width="22" height="13" font="23">22. </text>
<text top="702" left="105" width="48" height="13" font="23">S4.4-40.</text>
<text top="702" left="153" width="4" height="13" font="47"> </text>
<text top="702" left="174" width="596" height="13" font="23">Verdecchia P, Angeli F, Gentile G, et al. More versus less intensive blood pressure-lowering strategy: </text>
<text top="720" left="174" width="484" height="13" font="23">cumulative evidence and trial sequential analysis. Hypertension. 2016;68:642-53. </text>
<text top="737" left="105" width="48" height="13" font="23">S4.4-41.</text>
<text top="737" left="153" width="4" height="13" font="47"> </text>
<text top="737" left="174" width="610" height="13" font="23">Bangalore S, Toklu B, Gianos E, et al. Optimal systolic blood pressure target after SPRINT: insights from </text>
<text top="755" left="174" width="466" height="13" font="23">a network meta-analysis of randomized trials. Am J Med. 2017;130:707-19.e8. </text>
<text top="773" left="105" width="48" height="13" font="23">S4.4-42.</text>
<text top="773" left="153" width="4" height="13" font="47"> </text>
<text top="773" left="174" width="614" height="13" font="23">Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and </text>
<text top="791" left="174" width="529" height="13" font="23">mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775-81. </text>
<text top="809" left="105" width="48" height="13" font="23">S4.4-43.</text>
<text top="809" left="153" width="4" height="13" font="47"> </text>
<text top="809" left="174" width="603" height="13" font="23">Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-</text>
<text top="827" left="174" width="612" height="13" font="23">diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939-</text>
<text top="844" left="174" width="22" height="13" font="23">46. </text>
<text top="862" left="105" width="48" height="13" font="23">S4.4-44.</text>
<text top="862" left="153" width="4" height="13" font="47"> </text>
<text top="862" left="174" width="616" height="13" font="23">Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class </text>
<text top="880" left="174" width="601" height="13" font="23">on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-31. </text>
<text top="898" left="105" width="48" height="13" font="23">S4.4-45.</text>
<text top="898" left="153" width="4" height="13" font="47"> </text>
<text top="898" left="174" width="589" height="13" font="23">Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney </text>
<text top="916" left="174" width="474" height="13" font="23">disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541-8. </text>
<text top="933" left="105" width="48" height="13" font="23">S4.4-46.</text>
<text top="933" left="153" width="4" height="13" font="47"> </text>
<text top="933" left="174" width="600" height="13" font="23">Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure </text>
<text top="951" left="174" width="607" height="13" font="23">control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann </text>
<text top="969" left="174" width="182" height="13" font="23">Intern Med. 2003;139:244-52. </text>
<text top="987" left="105" width="48" height="13" font="23">S4.4-47.</text>
<text top="987" left="153" width="4" height="13" font="47"> </text>
<text top="987" left="174" width="602" height="13" font="23">Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of </text>
<text top="1005" left="174" width="523" height="13" font="23">chronic kidney disease: a systematic review and meta-analysis. CMAJ. 2013;185:949-57. </text>
<text top="1023" left="105" width="48" height="13" font="23">S4.4-48.</text>
<text top="1023" left="153" width="4" height="13" font="47"> </text>
<text top="1023" left="174" width="616" height="13" font="23">Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on </text>
<text top="1040" left="174" width="595" height="13" font="23">the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J </text>
<text top="1058" left="174" width="142" height="13" font="23">Med. 1994;330:877-84. </text>
<text top="1076" left="105" width="48" height="13" font="23">S4.4-49.</text>
<text top="1076" left="153" width="4" height="13" font="47"> </text>
<text top="1076" left="174" width="607" height="13" font="23">Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and </text>
</page>
<page number="98" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 96 of 101 </text>
<text top="167" left="174" width="238" height="13" font="23">meta-analysis. JAMA. 2015;313:603-15. </text>
<text top="185" left="105" width="48" height="13" font="23">S4.4-50.</text>
<text top="185" left="153" width="4" height="13" font="47"> </text>
<text top="185" left="174" width="578" height="13" font="23">Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes </text>
<text top="203" left="174" width="330" height="13" font="23">mellitus. Cochrane Database Syst Rev. 2013;CD008277. </text>
<text top="221" left="105" width="48" height="13" font="23">S4.4-51.</text>
<text top="220" left="153" width="4" height="13" font="47"> </text>
<text top="221" left="174" width="557" height="13" font="23">Margolis KL, O’Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor </text>
<text top="238" left="174" width="614" height="13" font="23">management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37:1721-</text>
<text top="256" left="174" width="14" height="13" font="23">8. </text>
<text top="274" left="105" width="48" height="13" font="23">S4.4-52.</text>
<text top="274" left="153" width="4" height="13" font="47"> </text>
<text top="274" left="174" width="586" height="13" font="23">Bress AP, Bellows BK, King JB, et al. Cost-effectiveness of intensive versus standard blood-pressure </text>
<text top="292" left="174" width="241" height="13" font="23">control. N Engl J Med. 2017;377:745-55. </text>
<text top="310" left="105" width="48" height="13" font="23">S4.4-53.</text>
<text top="310" left="153" width="4" height="13" font="47"> </text>
<text top="310" left="174" width="609" height="13" font="23">Soliman EZ, Byington RP, Bigger JT, et al. Effect of intensive blood pressure lowering on left ventricular </text>
<text top="328" left="174" width="611" height="13" font="23">hypertrophy in patients with diabetes mellitus: Action to Control Cardiovascular Risk in Diabetes blood </text>
<text top="345" left="174" width="273" height="13" font="23">pressure trial. Hypertension. 2015;66:1123-9. </text>
<text top="363" left="105" width="48" height="13" font="23">S4.4-54.</text>
<text top="363" left="153" width="4" height="13" font="47"> </text>
<text top="363" left="174" width="590" height="13" font="23">ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in </text>
<text top="381" left="174" width="347" height="13" font="23">type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85. </text>
<text top="399" left="105" width="48" height="13" font="23">S4.4-55.</text>
<text top="399" left="153" width="4" height="13" font="47"> </text>
<text top="399" left="174" width="586" height="13" font="23">Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular </text>
<text top="417" left="174" width="594" height="13" font="23">mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. </text>
<text top="434" left="174" width="115" height="13" font="23">2002;360:1903-13. </text>
<text top="452" left="105" width="48" height="13" font="23">S4.4-56.</text>
<text top="452" left="153" width="4" height="13" font="47"> </text>
<text top="452" left="174" width="590" height="13" font="23">Kassaï B, Boissel J-P, Cucherat M, et al. Treatment of high blood pressure and gain in event-free life </text>
<text top="470" left="174" width="308" height="13" font="23">expectancy. Vasc Health Risk Manag. 2005;1:163-9. </text>
<text top="488" left="105" width="48" height="13" font="23">S4.4-57.</text>
<text top="488" left="153" width="4" height="13" font="47"> </text>
<text top="488" left="174" width="569" height="13" font="23">van Dieren S, Kengne AP, Chalmers J, et al. Effects of blood pressure lowering on cardiovascular </text>
<text top="506" left="174" width="614" height="13" font="23">outcomes in different cardiovascular risk groups among participants with type 2 diabetes. Diabetes Res </text>
<text top="524" left="174" width="156" height="13" font="23">Clin Pract. 2012;98:83-90. </text>
<text top="541" left="105" width="48" height="13" font="23">S4.4-58.</text>
<text top="541" left="153" width="4" height="13" font="47"> </text>
<text top="541" left="174" width="596" height="13" font="23">Montgomery AA, Fahey T, Ben-Shlomo Y, et al. The influence of absolute cardiovascular risk, patient </text>
<text top="559" left="174" width="579" height="13" font="23">utilities, and costs on the decision to treat hypertension: a Markov decision analysis. J Hypertens. </text>
<text top="577" left="174" width="101" height="13" font="23">2003;21:1753-9. </text>
<text top="595" left="105" width="48" height="13" font="23">S4.4-59.</text>
<text top="595" left="153" width="4" height="13" font="47"> </text>
<text top="595" left="174" width="571" height="13" font="23">Lonn EM, Bosch J, López-Jaramillo P, et al. Blood-pressure lowering in intermediate-risk persons </text>
<text top="613" left="174" width="389" height="13" font="23">without cardiovascular disease. N Engl J Med. 2016;374:2009-20. </text>
<text top="631" left="105" width="48" height="13" font="23">S4.4-60.</text>
<text top="631" left="153" width="4" height="13" font="47"> </text>
<text top="631" left="174" width="562" height="13" font="23">Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. </text>
<text top="648" left="174" width="483" height="13" font="23">Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270:713-24. </text>
<text top="666" left="105" width="48" height="13" font="23">S4.4-61.</text>
<text top="666" left="153" width="4" height="13" font="47"> </text>
<text top="666" left="174" width="616" height="13" font="23">Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor </text>
<text top="684" left="174" width="250" height="13" font="23">blocker. N Engl J Med. 2006;354:1685-97. </text>
<text top="702" left="105" width="48" height="13" font="23">S4.4-62.</text>
<text top="702" left="153" width="4" height="13" font="47"> </text>
<text top="702" left="174" width="596" height="13" font="23">Lawes CMM, Bennett DA, Lewington S, et al. Blood pressure and coronary heart disease: a review of </text>
<text top="720" left="174" width="281" height="13" font="23">the evidence. Semin Vasc Med. 2002;2:355-68. </text>
<text top="737" left="105" width="48" height="13" font="23">S4.4-63.</text>
<text top="737" left="153" width="4" height="13" font="47"> </text>
<text top="737" left="174" width="556" height="13" font="23">Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States: </text>
<text top="755" left="174" width="517" height="13" font="23">comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. </text>
<text top="773" left="174" width="111" height="13" font="23">2009;6:e1000058. </text>
<text top="791" left="105" width="48" height="13" font="23">S4.4-64.</text>
<text top="791" left="153" width="4" height="13" font="47"> </text>
<text top="791" left="174" width="615" height="13" font="23">Muntner P, Carey RM, Gidding S, et al. Potential US population impact of the 2017 ACC/AHA high blood </text>
<text top="809" left="174" width="295" height="13" font="23">pressure guideline. Circulation. 2018;137:109-18. </text>
<text top="827" left="105" width="48" height="13" font="23">S4.4-65.</text>
<text top="827" left="153" width="4" height="13" font="47"> </text>
<text top="827" left="174" width="611" height="13" font="23">Blumenthal JA, Babyak MA, Hinderliter A, et al. Effects of the DASH diet alone and in combination with </text>
<text top="844" left="174" width="590" height="13" font="23">exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with </text>
<text top="862" left="174" width="453" height="13" font="23">high blood pressure: the ENCORE study. Arch Intern Med. 2010;170:126-35. </text>
<text top="880" left="105" width="48" height="13" font="23">S4.4-66.</text>
<text top="880" left="153" width="4" height="13" font="47"> </text>
<text top="880" left="174" width="453" height="13" font="23">Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 </text>
<text top="898" left="174" width="615" height="13" font="23">ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, </text>
<text top="916" left="174" width="583" height="13" font="23">evaluation, and management of high blood pressure in adults: a report of the American College of </text>
<text top="933" left="174" width="592" height="13" font="23">Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. </text>
<text top="951" left="174" width="108" height="13" font="23">2018;71:2176-98. </text>
<text top="969" left="105" width="48" height="13" font="23">S4.4-67.</text>
<text top="969" left="153" width="4" height="13" font="47"> </text>
<text top="969" left="174" width="557" height="13" font="23">Baker S, Priest P, Jackson R. Using thresholds based on risk of cardiovascular disease to target </text>
<text top="987" left="174" width="584" height="13" font="23">treatment for hypertension: modelling events averted and number treated. BMJ. 2000;320:680-5. </text>
<text top="1005" left="105" width="48" height="13" font="23">S4.4-68.</text>
<text top="1005" left="153" width="4" height="13" font="47"> </text>
<text top="1005" left="174" width="602" height="13" font="23">Eddy DM, Adler J, Patterson B, et al. Individualized guidelines: the potential for increasing quality and </text>
<text top="1023" left="174" width="301" height="13" font="23">reducing costs. Ann Intern Med. 2011;154:627-34. </text>
<text top="1040" left="105" width="48" height="13" font="23">S4.4-69.</text>
<text top="1040" left="153" width="4" height="13" font="47"> </text>
<text top="1040" left="174" width="551" height="13" font="23">Karmali KN, Lloyd-Jones DM. Global risk assessment to guide blood pressure management in </text>
<text top="1058" left="174" width="381" height="13" font="23">cardiovascular disease prevention. Hypertension. 2017;69:e2-9. </text>
<text top="1076" left="105" width="48" height="13" font="23">S4.4-70.</text>
<text top="1076" left="153" width="4" height="13" font="47"> </text>
<text top="1076" left="174" width="614" height="13" font="23">Muntner P, Whelton PK. Using predicted cardiovascular disease risk in conjunction with blood pressure </text>
</page>
<page number="99" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 97 of 101 </text>
<text top="167" left="174" width="507" height="13" font="23">to guide antihypertensive medication treatment. J Am Coll Cardiol. 2017;69:2446-56. </text>
<text top="185" left="105" width="48" height="13" font="23">S4.4-71.</text>
<text top="185" left="153" width="4" height="13" font="47"> </text>
<text top="185" left="174" width="589" height="13" font="23">Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in </text>
<text top="203" left="174" width="542" height="13" font="23">patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:i717. </text>
<text top="221" left="105" width="48" height="13" font="23">S4.4-72.</text>
<text top="220" left="153" width="4" height="13" font="47"> </text>
<text top="221" left="174" width="606" height="13" font="23">Appel LJ, Wright JT Jr, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney </text>
<text top="238" left="174" width="242" height="13" font="23">disease. N Engl J Med. 2010;363:918-29. </text>
<text top="256" left="105" width="48" height="13" font="23">S4.4-73.</text>
<text top="256" left="153" width="4" height="13" font="47"> </text>
<text top="256" left="174" width="570" height="13" font="23">Reboldi G, Gentile G, Angeli F, et al. Effects of intensive blood pressure reduction on myocardial </text>
<text top="274" left="174" width="593" height="13" font="23">infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens. 2011;29:1253-69. </text>
<text top="292" left="105" width="48" height="13" font="23">S4.4-74.</text>
<text top="292" left="153" width="4" height="13" font="47"> </text>
<text top="292" left="174" width="607" height="13" font="23">Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of </text>
<text top="310" left="174" width="471" height="13" font="23">intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59. </text>
<text top="328" left="105" width="48" height="13" font="23">S4.4-75.</text>
<text top="328" left="153" width="4" height="13" font="47"> </text>
<text top="328" left="174" width="608" height="13" font="23">Julius S, Kaciroti N, Egan BM, et al. TROPHY study: Outcomes based on the Seventh Report of the Joint </text>
<text top="345" left="174" width="596" height="13" font="23">National Committee on Hypertension definition of hypertension. J Am Soc Hypertens. 2008;2:39-43. </text>
<text top="363" left="105" width="48" height="13" font="23">S4.4-76.</text>
<text top="363" left="153" width="4" height="13" font="47"> </text>
<text top="363" left="174" width="549" height="13" font="23">Lüders S, Schrader J, Berger J, et al. The PHARAO study: prevention of hypertension with the </text>
<text top="381" left="174" width="571" height="13" font="23">angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a </text>
<text top="399" left="174" width="612" height="13" font="23">prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. </text>
<text top="417" left="174" width="108" height="13" font="23">2008;26:1487-96. </text>
<text top="434" left="105" width="48" height="13" font="23">S4.4-77.</text>
<text top="434" left="153" width="4" height="13" font="47"> </text>
<text top="434" left="174" width="588" height="13" font="23">Allen NB, Siddique J, Wilkins JT, et al. Blood pressure trajectories in early adulthood and subclinical </text>
<text top="452" left="174" width="321" height="13" font="23">atherosclerosis in middle age. JAMA. 2014;311:490-7. </text>
<text top="470" left="105" width="48" height="13" font="23">S4.4-78.</text>
<text top="470" left="153" width="4" height="13" font="47"> </text>
<text top="470" left="174" width="591" height="13" font="23">Inder JD, Carlson DJ, Dieberg G, et al. Isometric exercise training for blood pressure management: a </text>
<text top="488" left="174" width="527" height="13" font="23">systematic review and meta-analysis to optimize benefit. Hypertens Res. 2016;39:88-94. </text>
<text top="506" left="105" width="48" height="13" font="23">S4.4-79.</text>
<text top="506" left="153" width="4" height="13" font="47"> </text>
<text top="506" left="174" width="606" height="13" font="23">Roerecke M, Kaczorowski J, Tobe SW, et al. The effect of a reduction in alcohol consumption on blood </text>
<text top="524" left="174" width="521" height="13" font="23">pressure: a systematic review and meta-analysis. Lancet Public Health. 2017;2:e108-20. </text>
<text top="541" left="105" width="48" height="13" font="23">S4.4-80.</text>
<text top="541" left="153" width="4" height="13" font="47"> </text>
<text top="541" left="174" width="547" height="13" font="23">National Institute on Alcohol Abuse and Alcoholism. What Is A Standard Drink? Available at: </text>
<text top="559" left="174" width="576" height="13" font="23">https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/what-standard-drink. </text>
<text top="577" left="174" width="161" height="13" font="23">Accessed August 16, 2017. </text>
<text top="595" left="105" width="48" height="13" font="23">S4.4-81.</text>
<text top="595" left="153" width="4" height="13" font="47"> </text>
<text top="595" left="174" width="594" height="13" font="23">National Heart, Lung, and Blood Institute. Your Guide to Lowering Your Blood Pressure With DASH—</text>
<text top="613" left="174" width="237" height="13" font="23">How Do I Make the DASH? Available at: </text>
<text top="631" left="174" width="604" height="13" font="23">https://health.gov/dietaryguidelines/dga2005/toolkit/DASH/how_make_dash.htm. Accessed January </text>
<text top="648" left="174" width="51" height="13" font="23">6, 2019. </text>
<text top="666" left="105" width="48" height="13" font="23">S4.4-82.</text>
<text top="666" left="153" width="4" height="13" font="47"> </text>
<text top="666" left="174" width="610" height="13" font="23">Top 10 Dash Diet Tips. Available at: http://dashdiet.org/dash-diet-tips.html. Accessed January 6, 2019. </text>
<text top="694" left="105" width="148" height="19" font="15"><b>4.5. Tobacco Use </b></text>
<text top="718" left="105" width="41" height="13" font="23">S4.5-1.</text>
<text top="718" left="146" width="4" height="13" font="47"> </text>
<text top="718" left="174" width="617" height="13" font="23">Carson KV, Verbiest MEA, Crone MR, et al. Training health professionals in smoking cessation. Cochrane </text>
<text top="735" left="174" width="216" height="13" font="23">Database Syst Rev. 2012;CD000214. </text>
<text top="753" left="105" width="41" height="13" font="23">S4.5-2.</text>
<text top="753" left="146" width="4" height="13" font="47"> </text>
<text top="753" left="174" width="552" height="13" font="23">Patnode CD, Henderson JT, Thompson JH, et al. Behavioral counseling and pharmacotherapy </text>
<text top="771" left="174" width="598" height="13" font="23">interventions for tobacco cessation in adults, including pregnant women: a review of reviews for the </text>
<text top="789" left="174" width="424" height="13" font="23">U.S. Preventive Services Task Force. Ann Intern Med. 2015;163:608-21. </text>
<text top="807" left="105" width="41" height="13" font="23">S4.5-3.</text>
<text top="807" left="146" width="4" height="13" font="47"> </text>
<text top="807" left="174" width="604" height="13" font="23">Stead LF, Koilpillai P, Fanshawe TR1, et al. Combined pharmacotherapy and behavioural interventions </text>
<text top="825" left="174" width="423" height="13" font="23">for smoking cessation. Cochrane Database Syst Rev. 2016;3:CD008286. </text>
<text top="842" left="105" width="41" height="13" font="23">S4.5-4.</text>
<text top="842" left="146" width="4" height="13" font="47"> </text>
<text top="842" left="174" width="580" height="13" font="23">Pan A, Wang Y, Talaei M, et al. Relation of smoking with total mortality and cardiovascular events </text>
<text top="860" left="174" width="540" height="13" font="23">among patients with diabetes mellitus: a meta-analysis and systematic review. Circulation. </text>
<text top="878" left="174" width="123" height="13" font="23">2015;132:1795-804. </text>
<text top="896" left="105" width="41" height="13" font="23">S4.5-5.</text>
<text top="896" left="146" width="4" height="13" font="47"> </text>
<text top="896" left="174" width="586" height="13" font="23">Mons U, Müezzinler A, Gellert C, et al. Impact of smoking and smoking cessation on cardiovascular </text>
<text top="914" left="174" width="612" height="13" font="23">events and mortality among older adults: meta-analysis of individual participant data from prospective </text>
<text top="932" left="174" width="397" height="13" font="23">cohort studies of the CHANCES consortium. BMJ. 2015;350:h1551. </text>
<text top="949" left="105" width="41" height="13" font="23">S4.5-6.</text>
<text top="949" left="146" width="4" height="13" font="47"> </text>
<text top="949" left="174" width="617" height="13" font="23">Lv X, Sun J, Bi Y, et al. Risk of all-cause mortality and cardiovascular disease associated with secondhand </text>
<text top="967" left="174" width="523" height="13" font="23">smoke exposure: a systematic review and meta-analysis. Int J Cardiol. 2015;199:106-15. </text>
<text top="985" left="105" width="41" height="13" font="23">S4.5-7.</text>
<text top="985" left="146" width="4" height="13" font="47"> </text>
<text top="985" left="174" width="582" height="13" font="23">U.S. National Center for Chronic Disease Prevention and Health Promotion Office on Smoking and </text>
<text top="1003" left="174" width="610" height="13" font="23">Health. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. </text>
<text top="1021" left="174" width="478" height="13" font="23">Atlanta, GA: U.S. Centers for Disease Control and Prevention; 2014. Available at: </text>
<text top="1039" left="174" width="454" height="13" font="23">http://www.ncbi.nlm.nih.gov/books/NBK179276. Accessed January 5, 2019. </text>
<text top="1056" left="105" width="41" height="13" font="23">S4.5-8.</text>
<text top="1056" left="146" width="4" height="13" font="47"> </text>
<text top="1056" left="174" width="610" height="13" font="23">Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the </text>
<text top="1074" left="174" width="399" height="13" font="23">INTERHEART study: a case-control study. Lancet. 2006;368:647-58. </text>
</page>
<page number="100" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 98 of 101 </text>
<text top="167" left="105" width="41" height="13" font="23">S4.5-9.</text>
<text top="167" left="146" width="4" height="13" font="47"> </text>
<text top="167" left="174" width="614" height="13" font="23">U.S. Department of Health and Human Services. Healthy People 2020. Washington, DC: 2010. Available </text>
<text top="185" left="174" width="375" height="13" font="23">at: https://www.healthypeople.gov. Accessed January 3, 2019. </text>
<text top="203" left="105" width="48" height="13" font="23">S4.5-10.</text>
<text top="203" left="153" width="4" height="13" font="47"> </text>
<text top="203" left="174" width="600" height="13" font="23">Bhatnagar A, Whitsel LP, Ribisl KM, et al. Electronic cigarettes: a policy statement from the American </text>
<text top="221" left="174" width="298" height="13" font="23">Heart Association. Circulation. 2014;130:1418-36. </text>
<text top="238" left="105" width="48" height="13" font="23">S4.5-11.</text>
<text top="238" left="153" width="4" height="13" font="47"> </text>
<text top="238" left="174" width="545" height="13" font="23">Bhatnagar A. cardiovascular perspective of the promises and perils of e-cigarettes. Circ Res. </text>
<text top="256" left="174" width="108" height="13" font="23">2016;118:1872-5. </text>
<text top="274" left="105" width="48" height="13" font="23">S4.5-12.</text>
<text top="274" left="153" width="4" height="13" font="47"> </text>
<text top="274" left="174" width="616" height="13" font="23">Lippi G, Favaloro EJ, Meschi T, et al. E-cigarettes and cardiovascular risk: beyond science and mysticism. </text>
<text top="292" left="174" width="229" height="13" font="23">Semin Thromb Hemost. 2014;40:60-5. </text>
<text top="310" left="105" width="48" height="13" font="23">S4.5-13.</text>
<text top="310" left="153" width="4" height="13" font="47"> </text>
<text top="310" left="174" width="612" height="13" font="23">Moheimani RS, Bhetraratana M, Yin F, et al. Increased cardiac sympathetic activity and oxidative stress </text>
<text top="328" left="174" width="615" height="13" font="23">in habitual electronic cigarette users: implications for cardiovascular risk. JAMA Cardiol. 2017;2:278-84. </text>
<text top="345" left="105" width="48" height="13" font="23">S4.5-14.</text>
<text top="345" left="153" width="4" height="13" font="47"> </text>
<text top="345" left="174" width="617" height="13" font="23">A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. </text>
<text top="363" left="174" width="534" height="13" font="23">The Tobacco Use and Dependence Clinical Practice Guideline panel, staff, and consortium </text>
<text top="381" left="174" width="256" height="13" font="23">representatives. JAMA. 2000;283:3244-54. </text>
<text top="399" left="105" width="48" height="13" font="23">S4.5-15.</text>
<text top="399" left="153" width="4" height="13" font="47"> </text>
<text top="399" left="174" width="605" height="13" font="23">Tobacco Use and Dependence Guideline Panel. Treating Tobacco Use and Dependence: 2008 Update. </text>
<text top="417" left="174" width="427" height="13" font="23">Washington, DC: U.S. Department of Health and Human Services; 2008. </text>
<text top="434" left="105" width="48" height="13" font="23">S4.5-16.</text>
<text top="434" left="153" width="4" height="13" font="47"> </text>
<text top="434" left="174" width="612" height="13" font="23">Pbert L, Fletcher KE, Flint AJ, et al. Smoking prevention and cessation intervention delivery by pediatric </text>
<text top="452" left="174" width="484" height="13" font="23">providers, as assessed with patient exit interviews. Pediatrics. 2006;118:e810-24. </text>
<text top="470" left="105" width="48" height="13" font="23">S4.5-17.</text>
<text top="470" left="153" width="4" height="13" font="47"> </text>
<text top="470" left="174" width="614" height="13" font="23">Wang M, Wang J-W, Cao S-S, et al. Cigarette smoking and electronic cigarettes use: a meta-analysis. Int </text>
<text top="488" left="174" width="424" height="13" font="23">J Environ Res Public Health. 2016;13:120. doi: 10.3390/ijerph13010120 </text>
<text top="506" left="105" width="48" height="13" font="23">S4.5-18.</text>
<text top="506" left="153" width="4" height="13" font="47"> </text>
<text top="506" left="174" width="579" height="13" font="23">Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of </text>
<text top="524" left="174" width="375" height="13" font="23">cessation in the United States. N Engl J Med. 2013;368:341-50. </text>
<text top="541" left="105" width="48" height="13" font="23">S4.5-19.</text>
<text top="541" left="153" width="4" height="13" font="47"> </text>
<text top="541" left="174" width="587" height="13" font="23">Barua RS, Rigotti NA, Benowitz NL, et al. 2018 ACC Expert Consensus Decision Pathway on Tobacco </text>
<text top="559" left="174" width="585" height="13" font="23">Cessation Treatment: A Report of the American College of Cardiology Task Force on Clinical Expert </text>
<text top="577" left="174" width="355" height="13" font="23">Consensus Documents. J Am Coll Cardiol. 2018;72:3332-65. </text>
<text top="595" left="105" width="48" height="13" font="23">S4.5-20.</text>
<text top="595" left="153" width="4" height="13" font="47"> </text>
<text top="595" left="174" width="559" height="13" font="23">Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, </text>
<text top="613" left="174" width="598" height="13" font="23">bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-</text>
<text top="631" left="174" width="466" height="13" font="23">blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387:2507-20. </text>
<text top="648" left="105" width="48" height="13" font="23">S4.5-21.</text>
<text top="648" left="153" width="4" height="13" font="47"> </text>
<text top="648" left="174" width="610" height="13" font="23">Prochaska JJ, Benowitz NL. The past, present, and future of nicotine addiction therapy. Annu Rev Med. </text>
<text top="666" left="174" width="101" height="13" font="23">2016;67:467-86. </text>
<text top="684" left="105" width="48" height="13" font="23">S4.5-22.</text>
<text top="684" left="153" width="4" height="13" font="47"> </text>
<text top="684" left="174" width="582" height="13" font="23">Rigotti NA, Clair C, Munafo MR, et al. Interventions for smoking cessation in hospitalised patients. </text>
<text top="702" left="174" width="276" height="13" font="23">Cochrane Database Syst Rev. 2012;CD001837. </text>
<text top="720" left="105" width="48" height="13" font="23">S4.5-23.</text>
<text top="720" left="153" width="4" height="13" font="47"> </text>
<text top="720" left="174" width="606" height="13" font="23">U.S. Preventive Services Task Force. Final Recommendation Statement: Tobacco Smoking Cessation in </text>
<text top="737" left="174" width="615" height="13" font="23">Adults, Including Pregnant Women: Behavioral and Pharmacotherapy Interventions. 2017. Available at: </text>
<text top="755" left="174" width="613" height="13" font="23">https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/tob</text>
<text top="773" left="174" width="593" height="13" font="23">acco-use-in-adults-and-pregnant-women-counseling-and-interventions1. Accessed January 5, 2019. </text>
<text top="791" left="105" width="48" height="13" font="23">S4.5-24.</text>
<text top="791" left="153" width="4" height="13" font="47"> </text>
<text top="791" left="174" width="579" height="13" font="23">Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. Public </text>
<text top="809" left="174" width="339" height="13" font="23">Health Consequences of E-Cigarettes. 2018. Available at: </text>
<text top="827" left="174" width="596" height="13" font="23">http://nationalacademies.org/hmd/Reports/2018/public-health-consequences-of-e-cigarettes.aspx. </text>
<text top="844" left="174" width="158" height="13" font="23">Accessed January 5, 2019. </text>
<text top="862" left="105" width="48" height="13" font="23">S4.5-25.</text>
<text top="862" left="153" width="4" height="13" font="47"> </text>
<text top="862" left="174" width="613" height="13" font="23">Ahmed AA, Patel K, Nyaku MA, et al. Risk of heart failure and death after prolonged smoking cessation: </text>
<text top="880" left="174" width="467" height="13" font="23">role of amount and duration of prior smoking. Circ Heart Fail. 2015;8:694-701. </text>
<text top="898" left="105" width="48" height="13" font="23">S4.5-26.</text>
<text top="898" left="153" width="4" height="13" font="47"> </text>
<text top="898" left="174" width="590" height="13" font="23">Khan RJ, Stewart CP, Davis SK, et al. The risk and burden of smoking related heart disease mortality </text>
<text top="916" left="174" width="414" height="13" font="23">among young people in the United States. Tob Induc Dis. 2015;13:16. </text>
<text top="933" left="105" width="48" height="13" font="23">S4.5-27.</text>
<text top="933" left="153" width="4" height="13" font="47"> </text>
<text top="933" left="174" width="570" height="13" font="23">NAADAC, the Association for Addiction Professionals. National Certificate in Tobacco Treatment </text>
<text top="951" left="174" width="538" height="13" font="23">Practice (NCTTP). Available at: https://www.naadac.org/NCTTP. Accessed January 5, 2019. </text>
<text top="969" left="105" width="48" height="13" font="23">S4.5-28.</text>
<text top="969" left="153" width="4" height="13" font="47"> </text>
<text top="969" left="174" width="512" height="13" font="23">Association for the Treatment of Tobacco Use and Dependence (ATTUD). Available at: </text>
<text top="987" left="174" width="295" height="13" font="23">http://www.attud.org. Accessed January 5, 2019. </text>
<text top="1005" left="105" width="48" height="13" font="23">S4.5-29.</text>
<text top="1005" left="153" width="4" height="13" font="47"> </text>
<text top="1005" left="174" width="509" height="13" font="23">Council for Tobacco Treatment Training Programs. Accredited programs. Available at: </text>
<text top="1023" left="174" width="394" height="13" font="23">http://ctttp.org/accredited-programs. Accessed January 30, 2019. </text>
<text top="1040" left="105" width="48" height="13" font="23">S4.5-30.</text>
<text top="1040" left="153" width="4" height="13" font="47"> </text>
<text top="1040" left="174" width="602" height="13" font="23">Otsuka R, Watanabe H, Hirata K, et al. Acute effects of passive smoking on the coronary circulation in </text>
<text top="1058" left="174" width="280" height="13" font="23">healthy young adults. JAMA. 2001;286:436-41. </text>
<text top="1076" left="105" width="48" height="13" font="23">S4.5-31.</text>
<text top="1076" left="153" width="4" height="13" font="47"> </text>
<text top="1076" left="174" width="595" height="13" font="23">Oono IP, Mackay DF, Pell JP. Meta-analysis of the association between secondhand smoke exposure </text>
</page>
<page number="101" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="403" width="91" height="13" font="9">Page 99 of 101 </text>
<text top="167" left="174" width="304" height="13" font="23">and stroke. J Public Health (Oxf). 2011;33:496-502. </text>
<text top="185" left="105" width="48" height="13" font="23">S4.5-32.</text>
<text top="185" left="153" width="4" height="13" font="47"> </text>
<text top="185" left="174" width="588" height="13" font="23">U.S. Institute of Medicine Committee on Secondhand Smoke Exposure and Acute Coronary Events. </text>
<text top="203" left="174" width="604" height="13" font="23">Secondhand Smoke Exposure and Cardiovascular Effects: Making Sense of the Evidence. Washington, </text>
<text top="221" left="174" width="594" height="13" font="23">DC: National Academies Press; 2010. Available at: http://www.ncbi.nlm.nih.gov/books/NBK219565. </text>
<text top="238" left="174" width="158" height="13" font="23">Accessed January 5, 2019. </text>
<text top="256" left="105" width="48" height="13" font="23">S4.5-33.</text>
<text top="256" left="153" width="4" height="13" font="47"> </text>
<text top="256" left="174" width="584" height="13" font="23">U.S. Department of Health and Human Services. The health consequences of smoking--50 years of </text>
<text top="274" left="174" width="389" height="13" font="23">progress: A report of the Surgeon General. ed. Atlanta, GA: 2014. </text>
<text top="292" left="105" width="48" height="13" font="23">S4.5-34.</text>
<text top="292" left="153" width="4" height="13" font="47"> </text>
<text top="292" left="174" width="601" height="13" font="23">Tobacco Control Legal Consortium, Public Health Law Center. HUD’s rule to restrict smoking in public </text>
<text top="310" left="174" width="246" height="13" font="23">housing: an overview. 2017. Available at: </text>
<text top="328" left="174" width="592" height="13" font="23">https://publichealthlawcenter.org/sites/default/files/resources/HUD-Final-Rule-Smoke-Free-Public-</text>
<text top="345" left="174" width="270" height="13" font="23">Housing-2016.pdf. Accessed January 5, 2019. </text>
<text top="363" left="105" width="48" height="13" font="23">S4.5-35.</text>
<text top="363" left="153" width="4" height="13" font="47"> </text>
<text top="363" left="174" width="581" height="13" font="23">University of Southern California. Rx for change: clinician-assisted tobacco cessation. Available at: </text>
<text top="381" left="174" width="343" height="13" font="23">http://rxforchange.ucsf.edu/. Accessed January 30, 2019. </text>
<text top="409" left="105" width="137" height="19" font="15"><b>4.6. Aspirin Use </b></text>
<text top="433" left="105" width="41" height="13" font="23">S4.6-1.</text>
<text top="433" left="146" width="4" height="13" font="47"> </text>
<text top="433" left="174" width="584" height="13" font="23">Guirguis-Blake JM, Evans CV, Senger CA, et al. Aspirin for the primary prevention of cardiovascular </text>
<text top="450" left="174" width="583" height="13" font="23">events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. </text>
<text top="468" left="174" width="108" height="13" font="23">2016;164:804-13. </text>
<text top="486" left="105" width="41" height="13" font="23">S4.6-2.</text>
<text top="486" left="146" width="4" height="13" font="47"> </text>
<text top="486" left="174" width="583" height="13" font="23">Whitlock EP, Burda BU, Williams SB, et al. Bleeding risks with aspirin use for primary prevention in </text>
<text top="504" left="174" width="609" height="13" font="23">adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164:826-</text>
<text top="522" left="174" width="22" height="13" font="23">35. </text>
<text top="539" left="105" width="41" height="13" font="23">S4.6-3.</text>
<text top="539" left="146" width="4" height="13" font="47"> </text>
<text top="539" left="174" width="614" height="13" font="23">Lotrionte M, Biasucci LM, Peruzzi M, et al. Which aspirin dose and preparation is best for the long-term </text>
<text top="557" left="174" width="582" height="13" font="23">prevention of cardiovascular disease and cancer? Evidence from a systematic review and network </text>
<text top="575" left="174" width="320" height="13" font="23">meta-analysis. Prog Cardiovasc Dis. 2016;58:495-504. </text>
<text top="593" left="105" width="41" height="13" font="23">S4.6-4.</text>
<text top="593" left="146" width="4" height="13" font="47"> </text>
<text top="593" left="174" width="594" height="13" font="23">Raju N, Sobieraj-Teague M, Bosch J, et al. Updated meta-analysis of aspirin in primary prevention of </text>
<text top="611" left="174" width="306" height="13" font="23">cardiovascular disease. Am J Med. 2016;129:e35-6. </text>
<text top="629" left="105" width="41" height="13" font="23">S4.6-5.</text>
<text top="629" left="146" width="4" height="13" font="47"> </text>
<text top="629" left="174" width="607" height="13" font="23">Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic </text>
<text top="646" left="174" width="573" height="13" font="23">events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134-41. </text>
<text top="664" left="105" width="41" height="13" font="23">S4.6-6.</text>
<text top="664" left="146" width="4" height="13" font="47"> </text>
<text top="664" left="174" width="597" height="13" font="23">Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes </text>
<text top="682" left="174" width="597" height="13" font="23">(POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients </text>
<text top="700" left="174" width="494" height="13" font="23">with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840. </text>
<text top="718" left="105" width="41" height="13" font="23">S4.6-7.</text>
<text top="718" left="146" width="4" height="13" font="47"> </text>
<text top="718" left="174" width="605" height="13" font="23">Fowkes FGR, Price JF, Stewart MCW, et al. Aspirin for prevention of cardiovascular events in a general </text>
<text top="735" left="174" width="612" height="13" font="23">population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841-</text>
<text top="753" left="174" width="14" height="13" font="23">8. </text>
<text top="771" left="105" width="41" height="13" font="23">S4.6-8.</text>
<text top="771" left="146" width="4" height="13" font="47"> </text>
<text top="771" left="174" width="616" height="13" font="23">Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events </text>
<text top="789" left="174" width="581" height="13" font="23">in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. </text>
<text top="807" left="174" width="156" height="13" font="23">JAMA. 2014;312:2510-20. </text>
<text top="825" left="105" width="41" height="13" font="23">S4.6-9.</text>
<text top="825" left="146" width="4" height="13" font="47"> </text>
<text top="825" left="174" width="578" height="13" font="23">McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the </text>
<text top="842" left="174" width="294" height="13" font="23">healthy elderly. N Engl J Med. 2018;379:1509-18. </text>
<text top="860" left="105" width="48" height="13" font="23">S4.6-10.</text>
<text top="860" left="153" width="4" height="13" font="47"> </text>
<text top="860" left="174" width="580" height="13" font="23">García Rodríguez LA, Martín-Pérez M, Hennekens CH, et al. Bleeding risk with long-term low-dose </text>
<text top="878" left="174" width="499" height="13" font="23">aspirin: a systematic review of observational studies. PLoS ONE. 2016;11:e0160046. </text>
<text top="896" left="105" width="48" height="13" font="23">S4.6-11.</text>
<text top="896" left="153" width="4" height="13" font="47"> </text>
<text top="896" left="174" width="604" height="13" font="23">Capodanno D, Angiolillo DJ. Aspirin for primary cardiovascular risk prevention and beyond in diabetes </text>
<text top="914" left="174" width="241" height="13" font="23">mellitus. Circulation. 2016;134:1579-94. </text>
<text top="932" left="105" width="48" height="13" font="23">S4.6-12.</text>
<text top="931" left="153" width="4" height="13" font="47"> </text>
<text top="932" left="174" width="594" height="13" font="23">Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and </text>
<text top="949" left="174" width="591" height="13" font="23">secondary prevention of vascular disease: collaborative meta-analysis of individual participant data </text>
<text top="967" left="174" width="304" height="13" font="23">from randomised trials. Lancet. 2009;373:1849-60. </text>
<text top="985" left="105" width="48" height="13" font="23">S4.6-13.</text>
<text top="985" left="153" width="4" height="13" font="47"> </text>
<text top="985" left="174" width="610" height="13" font="23">Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention </text>
<text top="1003" left="174" width="614" height="13" font="23">in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies </text>
<text top="1021" left="174" width="614" height="13" font="23">on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies </text>
<text top="1039" left="174" width="575" height="13" font="23">and by invited experts). Developed with the special contribution of the European Association for </text>
<text top="1056" left="174" width="493" height="13" font="23">Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J. 2016;37:2315-81. </text>
<text top="1074" left="105" width="48" height="13" font="23">S4.6-14.</text>
<text top="1074" left="153" width="4" height="13" font="47"> </text>
<text top="1074" left="174" width="611" height="13" font="23">Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease </text>
</page>
<page number="102" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="399" width="99" height="13" font="9">Page 100 of 101 </text>
<text top="167" left="174" width="591" height="13" font="23">and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients </text>
<text top="185" left="174" width="538" height="13" font="23">without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106:388-91. </text>
<text top="203" left="105" width="48" height="13" font="23">S4.6-15.</text>
<text top="203" left="153" width="4" height="13" font="47"> </text>
<text top="203" left="174" width="581" height="13" font="23">Bibbins-Domingo K, U.S. Preventive Services Task Force. Aspirin use for the primary prevention of </text>
<text top="221" left="174" width="590" height="13" font="23">cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation </text>
<text top="238" left="174" width="278" height="13" font="23">Statement. Ann Intern Med. 2016;164:836-45. </text>
<text top="256" left="105" width="48" height="13" font="23">S4.6-16.</text>
<text top="256" left="153" width="4" height="13" font="47"> </text>
<text top="256" left="174" width="562" height="13" font="23">ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of aspirin for primary </text>
<text top="274" left="174" width="470" height="13" font="23">prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529-39. </text>
<text top="292" left="105" width="48" height="13" font="23">S4.6-17.</text>
<text top="292" left="153" width="4" height="13" font="47"> </text>
<text top="292" left="174" width="600" height="13" font="23">Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in </text>
<text top="310" left="174" width="586" height="13" font="23">patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-</text>
<text top="328" left="174" width="256" height="13" font="23">controlled trial. Lancet. 2018;392:1036-46. </text>
<text top="345" left="105" width="48" height="13" font="23">S4.6-18.</text>
<text top="345" left="153" width="4" height="13" font="47"> </text>
<text top="345" left="174" width="585" height="13" font="23">Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in </text>
<text top="363" left="174" width="617" height="13" font="23">people with diabetes: a position statement of the American Diabetes Association, a scientific statement </text>
<text top="381" left="174" width="584" height="13" font="23">of the American Heart Association, and an expert consensus document of the American College of </text>
<text top="399" left="174" width="335" height="13" font="23">Cardiology Foundation. Circulation. 2010;121:2694-701. </text>
<text top="417" left="105" width="48" height="13" font="23">S4.6-19.</text>
<text top="417" left="153" width="4" height="13" font="47"> </text>
<text top="417" left="174" width="555" height="13" font="23">Halvorsen S, Andreotti F, ten Berg JM, et al. Aspirin therapy in primary cardiovascular disease </text>
<text top="434" left="174" width="613" height="13" font="23">prevention: a position paper of the European Society of Cardiology working group on thrombosis. J Am </text>
<text top="452" left="174" width="175" height="13" font="23">Coll Cardiol. 2014;64:319-27. </text>
<text top="470" left="105" width="48" height="13" font="23">S4.6-20.</text>
<text top="470" left="153" width="4" height="13" font="47"> </text>
<text top="470" left="174" width="609" height="13" font="23">Mora S, Manson JE. Aspirin for primary prevention of atherosclerotic cardiovascular disease: advances </text>
<text top="488" left="174" width="400" height="13" font="23">in diagnosis and treatment. JAMA Intern Med. 2016;176:1195-204. </text>
<text top="506" left="105" width="48" height="13" font="23">S4.6-21.</text>
<text top="506" left="153" width="4" height="13" font="47"> </text>
<text top="506" left="174" width="588" height="13" font="23">Miedema MD, Duprez DA, Misialek JR, et al. Use of coronary artery calcium testing to guide aspirin </text>
<text top="524" left="174" width="570" height="13" font="23">utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ </text>
<text top="541" left="174" width="259" height="13" font="23">Cardiovasc Qual Outcomes. 2014;7:453-60. </text>
<text top="559" left="105" width="48" height="13" font="23">S4.6-22.</text>
<text top="559" left="153" width="4" height="13" font="47"> </text>
<text top="559" left="174" width="577" height="13" font="23">Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer </text>
<text top="577" left="174" width="602" height="13" font="23">according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. </text>
<text top="595" left="174" width="108" height="13" font="23">2018;392:387-99. </text>
<text top="613" left="105" width="48" height="13" font="23">S4.6-23.</text>
<text top="613" left="153" width="4" height="13" font="47"> </text>
<text top="613" left="174" width="561" height="13" font="23">Ridker PM. Should aspirin be used for primary prevention in the post-statin Era? N Engl J Med. </text>
<text top="631" left="174" width="108" height="13" font="23">2018;379:1572-4. </text>
<text top="658" left="105" width="283" height="19" font="15"><b>5. Cost and Value Considerations </b></text>
<text top="682" left="105" width="30" height="13" font="23">S5-1.</text>
<text top="682" left="135" width="4" height="13" font="47"> </text>
<text top="682" left="174" width="535" height="13" font="23">Weintraub WS, Daniels SR, Burke LE, et al. Value of primordial and primary prevention for </text>
<text top="700" left="174" width="550" height="13" font="23">cardiovascular disease: a policy statement from the American Heart Association. Circulation. </text>
<text top="718" left="174" width="108" height="13" font="23">2011;124:967-90. </text>
<text top="735" left="105" width="30" height="13" font="23">S5-2.</text>
<text top="735" left="135" width="4" height="13" font="47"> </text>
<text top="735" left="174" width="585" height="13" font="23">Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in </text>
<text top="753" left="174" width="541" height="13" font="23">clinical practice guidelines and performance measures: a report of the American College of </text>
<text top="771" left="174" width="573" height="13" font="23">Cardiology/American Heart Association Task Force on Performance Measures and Task Force on </text>
<text top="789" left="174" width="334" height="13" font="23">Practice Guidelines. J Am Coll Cardiol. 2014;63:2304-22. </text>
<text top="807" left="105" width="30" height="13" font="23">S5-3.</text>
<text top="807" left="135" width="4" height="13" font="47"> </text>
<text top="807" left="174" width="586" height="13" font="23">Bress AP, Bellows BK, King JB, et al. Cost-effectiveness of intensive versus standard blood-pressure </text>
<text top="825" left="174" width="241" height="13" font="23">control. N Engl J Med. 2017;377:745-55. </text>
<text top="842" left="105" width="30" height="13" font="23">S5-4.</text>
<text top="842" left="135" width="4" height="13" font="47"> </text>
<text top="842" left="174" width="610" height="13" font="23">Moran AE, Odden MC, Thanataveerat A, et al. Cost-effectiveness of hypertension therapy according to </text>
<text top="860" left="174" width="291" height="13" font="23">2014 guidelines. N Engl J Med. 2015;372:447-55. </text>
<text top="878" left="105" width="30" height="13" font="23">S5-5.</text>
<text top="878" left="135" width="4" height="13" font="47"> </text>
<text top="878" left="174" width="577" height="13" font="23">Park C, Wang G, Durthaler JM, et al. Cost-effectiveness analyses of antihypertensive medicines: a </text>
<text top="896" left="174" width="316" height="13" font="23">systematic review. Am J Prev Med. 2017;53:S131-42. </text>
<text top="914" left="105" width="30" height="13" font="23">S5-6.</text>
<text top="914" left="135" width="4" height="13" font="47"> </text>
<text top="914" left="174" width="534" height="13" font="23">Richman IB, Fairley M, Jørgensen ME, et al. Cost-effectiveness of intensive blood pressure </text>
<text top="932" left="174" width="258" height="13" font="23">management. JAMA Cardiol. 2016;1:872-9. </text>
<text top="949" left="105" width="30" height="13" font="23">S5-7.</text>
<text top="949" left="135" width="4" height="13" font="47"> </text>
<text top="949" left="174" width="558" height="13" font="23">Heller DJ, Coxson PG, Penko J, et al. Evaluating the impact and cost-effectiveness of statin use </text>
<text top="967" left="174" width="613" height="13" font="23">guidelines for primary prevention of coronary heart disease and stroke. Circulation. 2017;136:1087-98. </text>
<text top="985" left="105" width="30" height="13" font="23">S5-8.</text>
<text top="985" left="135" width="4" height="13" font="47"> </text>
<text top="985" left="174" width="578" height="13" font="23">Odden MC, Pletcher MJ, Coxson PG, et al. Cost-effectiveness and population impact of statins for </text>
<text top="1003" left="174" width="533" height="13" font="23">primary prevention in adults aged 75 years or older in the United States. Ann Intern Med. </text>
<text top="1021" left="174" width="108" height="13" font="23">2015;162:533-41. </text>
<text top="1039" left="105" width="30" height="13" font="23">S5-9.</text>
<text top="1039" left="135" width="4" height="13" font="47"> </text>
<text top="1039" left="174" width="614" height="13" font="23">Heart Protection Study Collaborative Group. Statin cost-effectiveness in the United States for people at </text>
<text top="1056" left="174" width="450" height="13" font="23">different vascular risk levels. Circ Cardiovasc Qual Outcomes. 2009;2:65-72. </text>
</page>
<page number="103" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="84" height="15" font="7"><b>Arnett et al. </b></text>
<text top="129" left="105" width="525" height="15" font="7"><b>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease </b></text>
<text top="149" left="105" width="4" height="15" font="8"> </text>
<text top="1144" left="399" width="99" height="13" font="9">Page 101 of 101 </text>
<text top="168" left="105" width="118" height="19" font="15"><b>6. Conclusion </b></text>
<text top="192" left="105" width="30" height="13" font="23">S6-1.</text>
<text top="192" left="135" width="4" height="13" font="47"> </text>
<text top="192" left="158" width="544" height="13" font="23">Lehr AL, Driver SL, Stone NJ. The ABCDs of lifestyle counseling. JAMA Cardiol. 2016;1:505-6. </text>
<text top="220" left="105" width="235" height="19" font="15"><b>Appendix 1. Search Criteria </b></text>
<text top="244" left="105" width="11" height="13" font="23">1.</text>
<text top="244" left="116" width="4" height="13" font="47"> </text>
<text top="244" left="131" width="658" height="13" font="23">Patnode CD, Evans CV, Senger CA, et al. Behavioral counseling to promote a healthful diet and physical activity </text>
<text top="261" left="131" width="634" height="13" font="23">for cardiovascular disease prevention in adults without known cardiovascular disease risk factors: updated </text>
<text top="279" left="131" width="633" height="13" font="23">evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2017;318:175-93. </text>
<text top="297" left="105" width="11" height="13" font="23">2.</text>
<text top="297" left="116" width="4" height="13" font="47"> </text>
<text top="297" left="131" width="626" height="13" font="23">LeBlanc ES, Patnode CD, Webber EM, et al. Behavioral and pharmacotherapy weight loss interventions to </text>
<text top="315" left="131" width="653" height="13" font="23">prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for </text>
<text top="333" left="131" width="387" height="13" font="23">the US Preventive Services Task Force. JAMA. 2018;320:1172-91. </text>
<text top="350" left="105" width="11" height="13" font="23">3.</text>
<text top="350" left="116" width="4" height="13" font="47"> </text>
<text top="350" left="131" width="651" height="13" font="23">Selph S, Dana T, Bougatsos C, et al. Screening for abnormal glucose and type 2 diabetes mellitus: a systematic </text>
<text top="368" left="131" width="646" height="13" font="23">review to update the 2008 U.S. Preventive Services Task Force Recommendation. Report No. 13-05190-EF-1. </text>
<text top="386" left="131" width="496" height="13" font="23">Rockville, MD: U.S. Agency for Healthcare Research and Quality; 2015. Available at: </text>
<text top="404" left="131" width="454" height="13" font="23">http://www.ncbi.nlm.nih.gov/books/NBK293871. Accessed January 5, 2019. </text>
<text top="422" left="105" width="11" height="13" font="23">4.</text>
<text top="422" left="116" width="4" height="13" font="47"> </text>
<text top="422" left="131" width="655" height="13" font="23">Patnode CD, Henderson JT, Thompson JH, et al. Behavioral counseling and pharmacotherapy interventions for </text>
<text top="440" left="131" width="640" height="13" font="23">tobacco cessation in adults, including pregnant women: a review of reviews for the U.S. Preventive Services </text>
<text top="457" left="131" width="279" height="13" font="23">Task Force. Ann Intern Med. 2015;163:608-21. </text>
<text top="475" left="105" width="11" height="13" font="23">5.</text>
<text top="475" left="116" width="4" height="13" font="47"> </text>
<text top="475" left="131" width="641" height="13" font="23">Guirguis-Blake JM, Evans CV, Senger CA, et al. Aspirin for the primary prevention of cardiovascular events: a </text>
<text top="493" left="131" width="634" height="13" font="23">systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164:804-13. </text>
<text top="511" left="105" width="3" height="13" font="23"> </text>
<text top="541" left="105" width="4" height="14" font="13"> </text>
</page>
</pdf2xml>
